ticker,date,open,high,low,close,news
ISRG,2000-06-16,2.01,2.06,2.0,2.03,
ISRG,2000-06-19,2.03,2.06,2.0,2.0,
ISRG,2000-06-20,2.01,2.18,1.75,2.08,
ISRG,2000-06-21,2.22,2.47,2.14,2.44,
ISRG,2000-06-22,2.46,2.47,2.12,2.19,
ISRG,2000-06-23,2.26,2.36,2.22,2.31,
ISRG,2000-06-26,2.33,2.36,2.17,2.22,
ISRG,2000-06-27,2.22,2.32,2.0,2.11,
ISRG,2000-06-28,2.14,2.19,2.03,2.14,
ISRG,2000-06-29,2.19,2.19,2.0,2.0,
ISRG,2000-06-30,2.07,2.14,2.03,2.1,
ISRG,2000-07-03,2.17,2.17,2.11,2.14,
ISRG,2000-07-05,2.17,2.22,2.11,2.22,
ISRG,2000-07-06,2.22,2.24,2.1,2.17,
ISRG,2000-07-07,2.23,2.58,2.12,2.28,
ISRG,2000-07-10,2.46,2.94,2.32,2.79,
ISRG,2000-07-11,3.01,3.17,2.64,2.83,
ISRG,2000-07-12,3.1,3.43,2.82,3.33,
ISRG,2000-07-13,4.0,4.03,3.58,3.72,
ISRG,2000-07-14,3.92,3.94,3.31,3.44,
ISRG,2000-07-17,3.56,3.58,3.39,3.47,
ISRG,2000-07-18,3.49,3.54,3.19,3.22,
ISRG,2000-07-19,3.19,3.22,2.92,3.11,
ISRG,2000-07-20,3.07,3.69,3.03,3.53,
ISRG,2000-07-21,3.53,3.81,3.47,3.81,
ISRG,2000-07-24,3.78,3.94,3.57,3.72,
ISRG,2000-07-25,3.75,3.83,3.44,3.58,
ISRG,2000-07-26,3.58,3.89,3.14,3.86,
ISRG,2000-07-27,3.72,4.22,3.67,3.81,
ISRG,2000-07-28,3.81,3.82,3.44,3.61,
ISRG,2000-07-31,3.56,4.24,3.31,4.19,
ISRG,2000-08-01,3.99,4.03,3.86,3.88,
ISRG,2000-08-02,3.89,4.04,3.78,3.79,
ISRG,2000-08-03,3.78,4.0,3.67,3.9,
ISRG,2000-08-04,4.0,4.01,3.75,3.79,
ISRG,2000-08-07,3.78,3.86,3.44,3.56,
ISRG,2000-08-08,3.72,3.72,3.44,3.5,
ISRG,2000-08-09,3.49,3.54,3.22,3.26,
ISRG,2000-08-10,3.28,3.47,3.25,3.28,
ISRG,2000-08-11,3.18,3.28,2.93,3.11,
ISRG,2000-08-14,3.26,3.26,3.11,3.11,
ISRG,2000-08-15,3.1,3.11,2.81,2.81,
ISRG,2000-08-16,2.83,3.15,2.83,3.04,
ISRG,2000-08-17,3.11,3.22,3.03,3.22,
ISRG,2000-08-18,3.23,3.25,3.11,3.11,
ISRG,2000-08-21,3.09,3.1,2.94,3.01,
ISRG,2000-08-22,2.94,3.01,2.92,2.94,
ISRG,2000-08-23,2.89,2.92,2.78,2.9,
ISRG,2000-08-24,2.86,2.89,2.78,2.86,
ISRG,2000-08-25,2.84,3.36,2.78,3.36,
ISRG,2000-08-28,3.35,3.36,3.14,3.19,
ISRG,2000-08-29,3.4,3.42,3.14,3.19,
ISRG,2000-08-30,3.23,3.36,3.23,3.33,
ISRG,2000-08-31,3.39,3.39,3.11,3.22,
ISRG,2000-09-01,3.23,3.31,3.08,3.08,
ISRG,2000-09-05,3.11,3.17,3.0,3.1,
ISRG,2000-09-06,3.08,3.11,3.0,3.06,
ISRG,2000-09-07,3.06,3.11,3.0,3.08,
ISRG,2000-09-08,3.1,3.21,3.06,3.11,
ISRG,2000-09-11,3.12,3.15,3.07,3.15,
ISRG,2000-09-12,3.18,3.32,3.17,3.32,
ISRG,2000-09-13,3.31,3.31,3.11,3.12,
ISRG,2000-09-14,3.22,3.28,3.11,3.24,
ISRG,2000-09-15,3.16,3.24,2.94,3.0,
ISRG,2000-09-18,3.06,3.11,2.78,2.89,
ISRG,2000-09-19,2.83,2.89,2.83,2.83,
ISRG,2000-09-20,2.86,2.89,2.58,2.58,
ISRG,2000-09-21,2.58,2.72,2.33,2.44,
ISRG,2000-09-22,2.4,2.67,2.36,2.65,
ISRG,2000-09-25,2.67,2.97,2.61,2.64,
ISRG,2000-09-26,2.65,2.67,2.61,2.64,
ISRG,2000-09-27,2.64,2.72,2.56,2.58,
ISRG,2000-09-28,2.72,2.72,2.61,2.61,
ISRG,2000-09-29,2.56,2.72,2.54,2.61,
ISRG,2000-10-02,2.61,2.72,2.58,2.62,
ISRG,2000-10-03,2.78,2.78,2.57,2.58,
ISRG,2000-10-04,2.57,2.58,2.44,2.56,
ISRG,2000-10-05,2.56,2.58,2.46,2.46,
ISRG,2000-10-06,2.51,2.56,2.29,2.31,
ISRG,2000-10-09,2.33,2.39,2.22,2.25,
ISRG,2000-10-10,2.24,2.28,2.1,2.1,
ISRG,2000-10-11,2.1,2.22,2.04,2.17,
ISRG,2000-10-12,2.19,2.19,1.86,2.17,
ISRG,2000-10-13,2.16,2.25,2.0,2.11,
ISRG,2000-10-16,2.14,2.28,2.06,2.28,
ISRG,2000-10-17,2.28,2.36,2.25,2.33,
ISRG,2000-10-18,2.2,2.22,2.03,2.11,
ISRG,2000-10-19,2.19,2.22,2.11,2.11,
ISRG,2000-10-20,2.14,2.25,2.11,2.22,
ISRG,2000-10-23,2.27,2.28,2.22,2.25,
ISRG,2000-10-24,2.31,2.38,2.22,2.33,
ISRG,2000-10-25,2.37,2.64,2.22,2.58,
ISRG,2000-10-26,2.61,2.78,2.53,2.75,
ISRG,2000-10-27,2.93,3.08,2.89,3.04,
ISRG,2000-10-30,3.06,3.35,3.06,3.28,
ISRG,2000-10-31,3.33,3.33,2.92,3.03,
ISRG,2000-11-01,3.09,3.19,2.78,2.83,
ISRG,2000-11-02,2.94,2.94,2.56,2.78,
ISRG,2000-11-03,2.82,3.07,2.81,3.03,
ISRG,2000-11-06,2.92,3.06,2.86,2.89,
ISRG,2000-11-07,2.99,2.99,2.86,2.89,
ISRG,2000-11-08,2.78,2.89,2.69,2.81,
ISRG,2000-11-09,2.7,3.11,2.7,3.11,
ISRG,2000-11-10,3.06,3.11,2.56,3.08,
ISRG,2000-11-13,3.11,3.11,2.85,2.94,
ISRG,2000-11-14,3.0,3.08,2.92,2.99,
ISRG,2000-11-15,3.08,3.08,2.92,2.94,
ISRG,2000-11-16,3.04,3.11,2.9,3.03,
ISRG,2000-11-17,3.08,3.11,2.94,3.0,
ISRG,2000-11-20,2.92,3.03,2.81,2.85,
ISRG,2000-11-21,2.81,2.94,2.44,2.94,
ISRG,2000-11-22,2.79,2.79,2.29,2.53,
ISRG,2000-11-24,2.58,2.67,2.28,2.28,
ISRG,2000-11-27,2.44,2.65,2.39,2.65,
ISRG,2000-11-28,2.67,2.67,2.39,2.39,
ISRG,2000-11-29,2.36,2.44,2.31,2.33,
ISRG,2000-11-30,2.33,2.75,2.32,2.61,
ISRG,2000-12-01,2.61,2.64,2.56,2.61,
ISRG,2000-12-04,2.46,2.5,2.36,2.36,
ISRG,2000-12-05,2.39,2.47,2.33,2.35,
ISRG,2000-12-06,2.25,2.39,2.0,2.0,
ISRG,2000-12-07,1.97,2.06,1.81,2.03,
ISRG,2000-12-08,2.06,2.17,1.99,2.12,
ISRG,2000-12-11,1.56,1.97,1.44,1.86,
ISRG,2000-12-12,1.83,1.9,1.79,1.9,
ISRG,2000-12-13,1.89,1.92,1.68,1.68,
ISRG,2000-12-14,1.76,1.81,1.61,1.68,
ISRG,2000-12-15,1.67,1.69,1.5,1.58,
ISRG,2000-12-18,1.6,1.64,1.54,1.57,
ISRG,2000-12-19,1.57,1.57,1.29,1.33,
ISRG,2000-12-20,1.31,1.36,1.19,1.31,
ISRG,2000-12-21,1.31,1.42,1.28,1.35,
ISRG,2000-12-22,1.4,1.44,1.36,1.42,
ISRG,2000-12-26,1.42,1.56,1.36,1.39,
ISRG,2000-12-27,1.49,1.58,1.38,1.44,
ISRG,2000-12-28,1.4,1.78,1.39,1.64,
ISRG,2000-12-29,1.75,1.94,1.72,1.89,
ISRG,2001-01-02,1.81,1.91,1.79,1.81,
ISRG,2001-01-03,1.9,1.94,1.78,1.94,
ISRG,2001-01-04,1.87,1.9,1.65,1.76,
ISRG,2001-01-05,1.76,1.76,1.69,1.72,
ISRG,2001-01-08,1.76,1.76,1.64,1.67,
ISRG,2001-01-09,1.67,1.74,1.64,1.74,
ISRG,2001-01-10,1.69,1.72,1.36,1.5,
ISRG,2001-01-11,1.5,1.83,1.47,1.81,
ISRG,2001-01-12,1.8,1.81,1.64,1.64,
ISRG,2001-01-16,1.65,1.79,1.65,1.78,
ISRG,2001-01-17,1.79,1.81,1.75,1.75,
ISRG,2001-01-18,1.78,1.92,1.75,1.78,
ISRG,2001-01-19,1.82,1.92,1.78,1.79,
ISRG,2001-01-22,1.78,1.81,1.51,1.61,
ISRG,2001-01-23,1.72,1.75,1.56,1.75,
ISRG,2001-01-24,1.74,1.81,1.72,1.79,
ISRG,2001-01-25,1.79,1.82,1.75,1.78,
ISRG,2001-01-26,1.79,1.81,1.72,1.76,
ISRG,2001-01-29,1.79,1.79,1.67,1.78,
ISRG,2001-01-30,1.78,1.88,1.69,1.74,
ISRG,2001-01-31,1.73,1.94,1.72,1.86,
ISRG,2001-02-01,1.83,1.93,1.72,1.91,
ISRG,2001-02-02,1.89,1.92,1.72,1.86,
ISRG,2001-02-05,1.82,1.92,1.78,1.86,
ISRG,2001-02-06,1.91,1.94,1.78,1.92,
ISRG,2001-02-07,1.88,1.94,1.83,1.88,
ISRG,2001-02-08,1.86,2.03,1.86,2.01,
ISRG,2001-02-09,1.93,2.0,1.64,1.64,
ISRG,2001-02-12,1.72,1.75,1.58,1.64,
ISRG,2001-02-13,1.63,1.67,1.53,1.58,
ISRG,2001-02-14,1.56,1.78,1.56,1.78,
ISRG,2001-02-15,1.75,1.89,1.72,1.81,
ISRG,2001-02-16,1.72,1.78,1.69,1.78,
ISRG,2001-02-20,1.78,1.92,1.75,1.89,
ISRG,2001-02-21,1.85,1.97,1.83,1.93,
ISRG,2001-02-22,1.9,1.93,1.89,1.92,
ISRG,2001-02-23,1.89,1.92,1.76,1.78,
ISRG,2001-02-26,1.78,1.85,1.78,1.78,
ISRG,2001-02-27,1.81,1.82,1.61,1.67,
ISRG,2001-02-28,1.69,1.69,1.58,1.61,
ISRG,2001-03-01,1.59,1.78,1.5,1.61,
ISRG,2001-03-02,1.58,1.64,1.56,1.64,
ISRG,2001-03-05,1.67,1.86,1.67,1.78,
ISRG,2001-03-06,1.86,1.88,1.61,1.72,
ISRG,2001-03-07,1.75,1.78,1.71,1.75,
ISRG,2001-03-08,1.75,1.78,1.67,1.72,
ISRG,2001-03-09,1.72,1.76,1.67,1.73,
ISRG,2001-03-12,1.76,1.76,1.53,1.54,
ISRG,2001-03-13,1.53,1.57,1.5,1.5,
ISRG,2001-03-14,1.51,1.56,1.47,1.56,
ISRG,2001-03-15,1.58,1.69,1.53,1.67,
ISRG,2001-03-16,1.64,1.72,1.62,1.67,
ISRG,2001-03-19,1.68,1.68,1.44,1.64,
ISRG,2001-03-20,1.56,1.64,1.56,1.56,
ISRG,2001-03-21,1.56,1.56,1.42,1.43,
ISRG,2001-03-22,1.33,1.36,1.22,1.26,
ISRG,2001-03-23,1.29,1.36,1.29,1.31,
ISRG,2001-03-26,1.35,1.43,1.31,1.33,
ISRG,2001-03-27,1.39,1.39,1.32,1.32,
ISRG,2001-03-28,1.33,1.33,1.19,1.19,
ISRG,2001-03-29,1.25,1.25,1.08,1.11,
ISRG,2001-03-30,1.08,1.14,1.08,1.08,
ISRG,2001-04-02,1.01,1.04,0.9,0.9,
ISRG,2001-04-03,0.94,0.96,0.67,0.94,
ISRG,2001-04-04,0.97,1.0,0.93,0.99,
ISRG,2001-04-05,0.99,1.07,0.94,1.0,
ISRG,2001-04-06,1.0,1.03,0.96,0.97,
ISRG,2001-04-09,0.96,1.0,0.83,0.87,
ISRG,2001-04-10,0.89,0.89,0.78,0.8,"Stocks to watch: E-Trade, Motorola and more CARBO Ceramics posted first-quarter net income of $6.2 million, or 41 cents a share, beating the consensus estimate by 7 cents a share. In the year-ago period, the company earned 17 cents a share. Revenue for the quarter totaled $34 million, a 55 percent increase over last year. Based on recent results and the strong backlog of jobs its customers have in hand, the company believes sales volume for 2001 can exceed last year's total by at least 25 percent. Shares closed up $2.68 to $37.20 ahead of the news. See full story."
ISRG,2001-04-11,0.81,0.81,0.72,0.74,
ISRG,2001-04-12,0.8,0.82,0.76,0.82,
ISRG,2001-04-16,0.82,0.9,0.82,0.9,
ISRG,2001-04-17,0.92,1.0,0.92,0.99,
ISRG,2001-04-18,1.08,1.14,1.07,1.1,
ISRG,2001-04-19,1.09,1.13,1.07,1.13,
ISRG,2001-04-20,1.13,1.17,1.12,1.17,
ISRG,2001-04-23,1.15,1.33,1.12,1.31,
ISRG,2001-04-24,1.3,1.54,1.3,1.54,
ISRG,2001-04-25,1.51,1.51,1.33,1.38,
ISRG,2001-04-26,1.4,1.56,1.39,1.47,
ISRG,2001-04-27,1.56,1.56,1.44,1.44,
ISRG,2001-04-30,1.53,1.53,1.37,1.47,
ISRG,2001-05-01,1.5,1.5,1.25,1.33,
ISRG,2001-05-02,1.34,1.39,1.19,1.22,
ISRG,2001-05-03,1.34,1.34,1.22,1.32,
ISRG,2001-05-04,1.33,1.33,1.3,1.32,
ISRG,2001-05-07,1.36,1.5,1.33,1.43,
ISRG,2001-05-08,1.5,1.5,1.33,1.38,
ISRG,2001-05-09,1.39,1.39,1.06,1.14,
ISRG,2001-05-10,1.29,1.31,1.21,1.26,
ISRG,2001-05-11,1.44,1.44,1.32,1.34,
ISRG,2001-05-14,1.36,1.38,1.33,1.34,
ISRG,2001-05-15,1.39,1.39,1.34,1.36,
ISRG,2001-05-16,1.36,1.4,1.33,1.39,
ISRG,2001-05-17,1.4,1.42,1.38,1.4,
ISRG,2001-05-18,1.38,1.4,1.33,1.39,
ISRG,2001-05-21,1.4,1.4,1.36,1.39,
ISRG,2001-05-22,1.38,1.4,1.33,1.39,
ISRG,2001-05-23,1.4,1.42,1.39,1.41,
ISRG,2001-05-24,1.41,1.42,1.39,1.4,
ISRG,2001-05-25,1.39,1.42,1.38,1.4,
ISRG,2001-05-29,1.4,1.42,1.37,1.4,
ISRG,2001-05-30,1.35,1.42,1.33,1.37,
ISRG,2001-05-31,1.4,1.44,1.38,1.43,
ISRG,2001-06-01,1.43,1.56,1.37,1.56,
ISRG,2001-06-04,1.56,1.88,1.54,1.82,"Stocks to Watch: Amazon.com, Comverse, Niku, more Amazon.com will hold its analyst meeting on Tuesday in Seattle, where the e-tailer is headquartered. Shares of Amazon.com ended the day down 4 cents to $13.93. See Net Stocks."
ISRG,2001-06-05,1.64,1.8,1.64,1.78,
ISRG,2001-06-06,1.77,1.79,1.69,1.77,
ISRG,2001-06-07,1.77,1.86,1.76,1.78,
ISRG,2001-06-08,1.78,2.01,1.77,1.96,
ISRG,2001-06-11,2.03,2.44,2.01,2.4,
ISRG,2001-06-12,2.35,2.6,2.28,2.48,
ISRG,2001-06-13,2.61,2.62,2.42,2.51,
ISRG,2001-06-14,2.56,2.56,2.4,2.47,
ISRG,2001-06-15,2.44,2.49,2.4,2.46,
ISRG,2001-06-18,2.45,2.46,2.39,2.43,
ISRG,2001-06-19,2.48,2.48,2.43,2.46,
ISRG,2001-06-20,2.45,2.77,2.44,2.68,
ISRG,2001-06-21,2.82,2.82,2.59,2.66,
ISRG,2001-06-22,2.61,2.62,2.3,2.34,
ISRG,2001-06-25,2.4,2.4,2.31,2.36,
ISRG,2001-06-26,2.37,2.57,2.29,2.5,
ISRG,2001-06-27,2.55,2.92,2.54,2.92,
ISRG,2001-06-28,2.95,3.11,2.87,2.98,
ISRG,2001-06-29,3.04,3.28,2.89,3.0,
ISRG,2001-07-02,2.96,2.99,2.88,2.96,
ISRG,2001-07-03,2.96,3.09,2.93,3.06,
ISRG,2001-07-05,3.09,3.09,2.94,2.97,
ISRG,2001-07-06,2.97,3.03,2.91,2.94,
ISRG,2001-07-09,2.91,3.14,2.91,3.1,
ISRG,2001-07-10,3.06,3.11,3.04,3.06,
ISRG,2001-07-11,3.07,3.07,2.72,2.89,
ISRG,2001-07-12,2.84,3.06,2.83,2.93,
ISRG,2001-07-13,2.94,3.11,2.93,3.07,
ISRG,2001-07-16,3.06,3.11,2.98,2.99,
ISRG,2001-07-17,3.0,3.08,2.97,3.01,
ISRG,2001-07-18,3.02,3.02,2.88,2.89,
ISRG,2001-07-19,2.92,2.93,2.7,2.72,
ISRG,2001-07-20,2.71,2.73,2.5,2.73,
ISRG,2001-07-23,2.77,2.83,2.72,2.73,
ISRG,2001-07-24,2.73,2.73,2.37,2.39,
ISRG,2001-07-25,2.43,2.5,2.37,2.43,
ISRG,2001-07-26,2.46,2.46,2.43,2.45,
ISRG,2001-07-27,2.24,2.24,1.95,2.01,"NetObjects, Pumatech, UAL, and more The U.S. Food & Drug Administration panel has chosen not to recommend approval of Aviron's flu vaccine, FluMist, citing safety issues. American Home Products , which has the rights to market FluMist through its Wyeth-Ayerst Laboratories division, closed down 87 cents at $58.06. The Vaccine and Related Biological Products Advisory Committee of the FDA voted 10 to 4 against giving the OK on safety issues, saying there was not enough information to issue an approval. FluMist passed on efficacy, however. Aviron's stock has been halted since before the Thursday open, when the committee meeting at the Holiday Inn in Gaithersburg, Md., began. See full story."
ISRG,2001-07-30,1.99,2.03,1.98,2.02,
ISRG,2001-07-31,2.0,2.16,1.98,2.04,
ISRG,2001-08-01,2.18,2.2,2.01,2.04,
ISRG,2001-08-02,2.04,2.1,1.98,2.07,
ISRG,2001-08-03,2.0,2.04,1.94,1.98,
ISRG,2001-08-06,1.99,2.0,1.94,1.96,
ISRG,2001-08-07,2.0,2.01,1.96,1.99,
ISRG,2001-08-08,1.98,2.04,1.98,2.01,
ISRG,2001-08-09,2.02,2.04,1.99,2.03,
ISRG,2001-08-10,2.04,2.04,2.01,2.02,
ISRG,2001-08-13,2.02,2.02,2.0,2.02,
ISRG,2001-08-14,2.02,2.09,2.01,2.07,
ISRG,2001-08-15,2.08,2.18,2.06,2.16,
ISRG,2001-08-16,2.05,2.06,1.99,2.02,
ISRG,2001-08-17,2.0,2.05,1.98,2.04,
ISRG,2001-08-20,2.02,2.06,1.98,2.04,
ISRG,2001-08-21,2.0,2.04,1.99,2.01,
ISRG,2001-08-22,2.0,2.08,2.0,2.08,
ISRG,2001-08-23,2.07,2.11,2.02,2.04,
ISRG,2001-08-24,2.06,2.1,2.0,2.03,
ISRG,2001-08-27,2.02,2.1,2.02,2.04,
ISRG,2001-08-28,2.04,2.08,2.02,2.06,
ISRG,2001-08-29,2.05,2.07,2.02,2.06,
ISRG,2001-08-30,2.03,2.04,1.94,2.04,
ISRG,2001-08-31,2.04,2.05,1.98,2.02,
ISRG,2001-09-04,2.02,2.04,1.98,2.0,
ISRG,2001-09-05,2.01,2.03,1.96,2.02,
ISRG,2001-09-06,2.03,2.03,1.84,1.84,
ISRG,2001-09-07,1.92,1.92,1.51,1.67,
ISRG,2001-09-10,1.57,1.6,1.46,1.51,
ISRG,2001-09-17,1.44,1.59,1.4,1.43,
ISRG,2001-09-18,1.46,1.52,1.42,1.46,
ISRG,2001-09-19,1.48,1.49,1.34,1.45,
ISRG,2001-09-20,1.41,1.46,1.3,1.31,
ISRG,2001-09-21,1.11,1.32,1.11,1.2,
ISRG,2001-09-24,1.18,1.32,1.14,1.2,
ISRG,2001-09-25,1.23,1.3,1.2,1.24,
ISRG,2001-09-26,1.29,1.29,1.22,1.24,
ISRG,2001-09-27,1.27,1.39,1.23,1.39,
ISRG,2001-09-28,1.36,1.44,1.33,1.39,
ISRG,2001-10-01,1.37,1.52,1.34,1.44,
ISRG,2001-10-02,1.51,1.51,1.42,1.43,
ISRG,2001-10-03,1.44,1.53,1.4,1.48,
ISRG,2001-10-04,1.49,1.83,1.49,1.78,
ISRG,2001-10-05,1.81,1.86,1.56,1.77,
ISRG,2001-10-08,1.76,1.82,1.7,1.78,
ISRG,2001-10-09,1.81,1.81,1.75,1.78,
ISRG,2001-10-10,1.78,1.85,1.77,1.81,
ISRG,2001-10-11,1.84,1.99,1.8,1.98,
ISRG,2001-10-12,1.98,2.06,1.94,2.01,
ISRG,2001-10-15,2.05,2.07,2.0,2.06,
ISRG,2001-10-16,2.07,2.09,2.02,2.09,
ISRG,2001-10-17,2.09,2.09,2.0,2.01,
ISRG,2001-10-18,2.01,2.03,1.93,2.0,
ISRG,2001-10-19,2.0,2.05,1.9,1.98,
ISRG,2001-10-22,2.0,2.07,1.96,2.0,
ISRG,2001-10-23,1.98,2.09,1.94,1.99,
ISRG,2001-10-24,1.95,2.02,1.95,2.0,
ISRG,2001-10-25,2.0,2.03,1.98,2.02,
ISRG,2001-10-26,2.01,2.14,1.98,2.08,
ISRG,2001-10-29,2.07,2.39,2.06,2.22,
ISRG,2001-10-30,2.01,2.15,1.92,2.0,
ISRG,2001-10-31,2.05,2.1,1.96,2.04,
ISRG,2001-11-01,2.03,2.04,1.89,1.95,
ISRG,2001-11-02,1.94,1.97,1.91,1.92,
ISRG,2001-11-05,1.94,1.94,1.83,1.86,
ISRG,2001-11-06,1.85,1.96,1.76,1.93,
ISRG,2001-11-07,1.96,2.02,1.92,1.92,
ISRG,2001-11-08,1.98,2.02,1.88,1.92,
ISRG,2001-11-09,1.87,2.27,1.87,2.06,
ISRG,2001-11-12,2.13,2.13,2.04,2.11,
ISRG,2001-11-13,2.1,2.21,2.09,2.19,
ISRG,2001-11-14,2.17,2.18,2.09,2.1,
ISRG,2001-11-15,2.11,2.12,1.92,1.94,
ISRG,2001-11-16,1.93,2.01,1.93,2.0,
ISRG,2001-11-19,2.03,2.03,2.0,2.02,
ISRG,2001-11-20,2.03,2.04,2.01,2.01,
ISRG,2001-11-21,2.04,2.04,2.0,2.0,
ISRG,2001-11-23,2.03,2.09,2.0,2.0,
ISRG,2001-11-26,2.01,2.07,2.01,2.03,
ISRG,2001-11-27,2.03,2.1,2.02,2.03,
ISRG,2001-11-28,2.04,2.04,2.01,2.01,
ISRG,2001-11-29,2.01,2.12,2.0,2.12,
ISRG,2001-11-30,2.11,2.13,2.08,2.12,
ISRG,2001-12-03,2.09,2.12,2.03,2.09,
ISRG,2001-12-04,2.09,2.1,1.98,2.09,
ISRG,2001-12-05,2.04,2.15,2.02,2.12,
ISRG,2001-12-06,2.09,2.22,2.09,2.18,
ISRG,2001-12-07,2.13,2.16,2.06,2.16,
ISRG,2001-12-10,2.17,2.18,2.04,2.14,
ISRG,2001-12-11,2.13,2.15,2.09,2.12,
ISRG,2001-12-12,2.12,2.14,2.03,2.08,
ISRG,2001-12-13,2.08,2.13,2.06,2.11,
ISRG,2001-12-14,2.11,2.11,2.0,2.1,
ISRG,2001-12-17,2.1,2.13,2.07,2.12,
ISRG,2001-12-18,2.12,2.12,2.1,2.1,
ISRG,2001-12-19,2.08,2.09,2.0,2.05,
ISRG,2001-12-20,2.05,2.05,1.95,2.01,
ISRG,2001-12-21,2.03,2.15,1.96,2.14,
ISRG,2001-12-24,2.07,2.16,2.06,2.06,
ISRG,2001-12-26,2.07,2.15,2.06,2.13,
ISRG,2001-12-27,2.12,2.28,2.12,2.26,
ISRG,2001-12-28,2.25,2.32,2.22,2.23,
ISRG,2001-12-31,2.3,2.3,2.12,2.23,
ISRG,2002-01-02,2.18,2.2,1.97,2.17,
ISRG,2002-01-03,2.1,2.11,2.04,2.04,
ISRG,2002-01-04,2.04,2.07,2.0,2.01,
ISRG,2002-01-07,2.01,2.04,1.97,1.97,
ISRG,2002-01-08,2.01,2.02,1.97,2.0,
ISRG,2002-01-09,2.01,2.01,1.94,2.0,
ISRG,2002-01-10,1.99,2.02,1.94,2.0,
ISRG,2002-01-11,1.94,1.97,1.94,1.96,
ISRG,2002-01-14,1.98,2.06,1.96,2.04,
ISRG,2002-01-15,2.06,2.08,1.96,1.99,
ISRG,2002-01-16,1.98,1.99,1.96,1.96,
ISRG,2002-01-17,1.94,1.97,1.91,1.93,
ISRG,2002-01-18,1.93,1.99,1.8,1.86,
ISRG,2002-01-22,1.88,2.0,1.88,1.94,
ISRG,2002-01-23,1.97,1.99,1.93,1.98,
ISRG,2002-01-24,1.98,1.99,1.92,1.94,
ISRG,2002-01-25,1.95,1.96,1.83,1.96,
ISRG,2002-01-28,1.96,1.96,1.93,1.96,
ISRG,2002-01-29,1.94,1.98,1.93,1.94,
ISRG,2002-01-30,1.94,1.94,1.87,1.89,
ISRG,2002-01-31,1.91,2.07,1.91,2.06,
ISRG,2002-02-01,2.14,2.28,2.13,2.25,
ISRG,2002-02-04,2.22,2.33,2.09,2.23,
ISRG,2002-02-05,2.22,2.28,2.2,2.22,
ISRG,2002-02-06,2.23,2.23,2.19,2.2,
ISRG,2002-02-07,2.2,2.21,2.04,2.13,
ISRG,2002-02-08,2.12,2.12,1.94,2.01,
ISRG,2002-02-11,2.04,2.04,1.84,1.91,
ISRG,2002-02-12,1.89,2.12,1.89,2.04,
ISRG,2002-02-13,2.09,2.27,2.06,2.19,
ISRG,2002-02-14,2.19,2.19,2.12,2.13,
ISRG,2002-02-15,2.16,2.16,1.98,1.99,
ISRG,2002-02-19,2.0,2.02,1.98,2.0,
ISRG,2002-02-20,1.99,2.01,1.96,1.99,
ISRG,2002-02-21,2.0,2.0,1.91,1.92,
ISRG,2002-02-22,1.95,2.07,1.93,2.07,
ISRG,2002-02-25,2.07,2.07,1.97,2.04,
ISRG,2002-02-26,1.99,2.08,1.99,2.08,
ISRG,2002-02-27,2.08,2.1,2.02,2.03,
ISRG,2002-02-28,2.04,2.12,2.02,2.04,
ISRG,2002-03-01,2.08,2.08,2.0,2.02,
ISRG,2002-03-04,2.04,2.05,2.0,2.04,
ISRG,2002-03-05,2.04,2.11,2.02,2.11,
ISRG,2002-03-06,2.06,2.08,2.03,2.07,
ISRG,2002-03-07,2.06,2.07,2.0,2.04,
ISRG,2002-03-08,2.02,2.06,2.02,2.03,
ISRG,2002-03-11,2.01,2.07,1.99,2.02,
ISRG,2002-03-12,2.04,2.09,2.04,2.06,
ISRG,2002-03-13,2.06,2.09,2.02,2.06,
ISRG,2002-03-14,2.07,2.11,2.04,2.09,
ISRG,2002-03-15,2.06,2.1,2.01,2.1,
ISRG,2002-03-18,2.1,2.14,2.07,2.13,
ISRG,2002-03-19,2.14,2.22,2.13,2.19,
ISRG,2002-03-20,2.19,2.22,2.17,2.2,
ISRG,2002-03-21,2.2,2.26,2.14,2.22,
ISRG,2002-03-22,2.22,2.22,2.11,2.19,
ISRG,2002-03-25,2.19,2.19,2.14,2.16,
ISRG,2002-03-26,2.16,2.19,2.06,2.09,
ISRG,2002-03-27,2.11,2.11,2.0,2.06,
ISRG,2002-03-28,2.06,2.11,2.03,2.09,
ISRG,2002-04-01,2.11,2.12,2.0,2.08,
ISRG,2002-04-02,2.05,2.13,2.02,2.06,
ISRG,2002-04-03,2.1,2.1,2.02,2.03,
ISRG,2002-04-04,2.04,2.09,2.03,2.09,
ISRG,2002-04-05,2.05,2.1,2.04,2.05,
ISRG,2002-04-08,2.08,2.1,2.03,2.06,
ISRG,2002-04-09,2.04,2.06,2.01,2.04,
ISRG,2002-04-10,2.06,2.06,2.02,2.03,
ISRG,2002-04-11,2.03,2.07,2.03,2.06,
ISRG,2002-04-12,2.04,2.14,2.04,2.13,
ISRG,2002-04-15,2.13,2.2,2.1,2.19,
ISRG,2002-04-16,2.19,2.24,2.18,2.24,
ISRG,2002-04-17,2.24,2.31,2.21,2.23,
ISRG,2002-04-18,2.27,2.3,2.18,2.21,
ISRG,2002-04-19,2.25,2.25,2.18,2.21,
ISRG,2002-04-22,2.21,2.28,2.14,2.14,
ISRG,2002-04-23,2.2,2.28,2.13,2.27,
ISRG,2002-04-24,2.29,2.5,2.27,2.42,
ISRG,2002-04-25,2.43,2.43,2.24,2.33,
ISRG,2002-04-26,2.34,2.34,2.2,2.28,
ISRG,2002-04-29,2.3,2.39,2.17,2.24,
ISRG,2002-04-30,2.22,2.3,2.18,2.26,
ISRG,2002-05-01,2.27,2.27,2.2,2.22,
ISRG,2002-05-02,2.22,2.24,2.2,2.22,
ISRG,2002-05-03,2.22,2.24,2.18,2.24,
ISRG,2002-05-06,2.23,2.24,2.08,2.13,
ISRG,2002-05-07,2.12,2.15,1.98,2.0,
ISRG,2002-05-08,2.02,2.11,1.98,2.09,
ISRG,2002-05-09,2.05,2.11,1.94,1.94,
ISRG,2002-05-10,1.94,2.0,1.61,1.91,
ISRG,2002-05-13,1.92,2.04,1.92,1.99,
ISRG,2002-05-14,1.98,2.02,1.98,1.99,
ISRG,2002-05-15,1.96,2.0,1.95,2.0,
ISRG,2002-05-16,1.97,2.03,1.97,2.03,
ISRG,2002-05-17,2.03,2.03,1.98,2.0,
ISRG,2002-05-20,1.99,1.99,1.94,1.99,
ISRG,2002-05-21,1.97,2.0,1.96,1.99,
ISRG,2002-05-22,1.97,2.0,1.97,2.0,
ISRG,2002-05-23,1.99,2.06,1.99,2.04,
ISRG,2002-05-24,2.05,2.06,2.0,2.0,
ISRG,2002-05-28,2.0,2.05,1.99,2.04,
ISRG,2002-05-29,2.0,2.04,2.0,2.03,
ISRG,2002-05-30,2.0,2.06,2.0,2.05,
ISRG,2002-05-31,2.06,2.11,2.03,2.1,
ISRG,2002-06-03,2.03,2.07,2.0,2.03,
ISRG,2002-06-04,2.01,2.04,1.97,2.02,
ISRG,2002-06-05,2.0,2.02,1.89,2.0,
ISRG,2002-06-06,2.0,2.0,1.97,1.97,
ISRG,2002-06-07,1.96,1.98,1.96,1.98,
ISRG,2002-06-10,1.92,1.97,1.92,1.94,
ISRG,2002-06-11,1.93,1.98,1.87,1.9,
ISRG,2002-06-12,1.91,1.91,1.7,1.76,
ISRG,2002-06-13,1.73,1.9,1.73,1.82,
ISRG,2002-06-14,1.79,1.9,1.69,1.84,
ISRG,2002-06-17,1.78,1.92,1.78,1.9,
ISRG,2002-06-18,1.9,1.92,1.88,1.89,
ISRG,2002-06-19,1.81,1.92,1.75,1.83,
ISRG,2002-06-20,1.89,1.93,1.82,1.83,
ISRG,2002-06-21,1.91,1.91,1.82,1.87,
ISRG,2002-06-24,1.87,1.93,1.8,1.93,
ISRG,2002-06-25,1.94,1.94,1.81,1.86,
ISRG,2002-06-26,1.84,1.88,1.78,1.88,
ISRG,2002-06-27,1.88,1.89,1.82,1.89,
ISRG,2002-06-28,1.83,1.89,1.83,1.88,
ISRG,2002-07-01,1.84,1.87,1.8,1.82,
ISRG,2002-07-02,1.81,1.84,1.75,1.76,
ISRG,2002-07-03,1.76,1.79,1.69,1.75,
ISRG,2002-07-05,1.74,1.82,1.74,1.8,
ISRG,2002-07-08,1.77,1.83,1.7,1.7,
ISRG,2002-07-09,1.7,1.77,1.66,1.76,
ISRG,2002-07-10,1.71,1.76,1.7,1.75,
ISRG,2002-07-11,1.77,1.78,1.7,1.77,
ISRG,2002-07-12,1.71,1.74,1.67,1.71,
ISRG,2002-07-15,1.68,1.68,1.44,1.64,
ISRG,2002-07-16,1.64,1.71,1.53,1.56,
ISRG,2002-07-17,1.53,1.73,1.48,1.73,
ISRG,2002-07-18,1.7,1.73,1.5,1.54,
ISRG,2002-07-19,1.54,1.57,1.48,1.48,
ISRG,2002-07-22,1.47,1.52,1.42,1.43,
ISRG,2002-07-23,1.43,1.48,1.24,1.28,
ISRG,2002-07-24,1.26,1.35,1.24,1.34,
ISRG,2002-07-25,1.34,1.4,1.29,1.38,
ISRG,2002-07-26,1.39,1.43,1.33,1.43,
ISRG,2002-07-29,1.43,1.43,1.34,1.39,
ISRG,2002-07-30,1.38,1.56,1.28,1.55,
ISRG,2002-07-31,1.58,1.72,1.56,1.56,
ISRG,2002-08-01,1.59,1.6,1.54,1.56,
ISRG,2002-08-02,1.56,1.72,1.56,1.67,
ISRG,2002-08-05,1.68,1.69,1.58,1.64,
ISRG,2002-08-06,1.66,1.79,1.63,1.78,
ISRG,2002-08-07,1.78,1.78,1.68,1.76,
ISRG,2002-08-08,1.76,1.78,1.7,1.78,
ISRG,2002-08-09,1.76,1.78,1.75,1.77,
ISRG,2002-08-12,1.73,1.77,1.69,1.74,
ISRG,2002-08-13,1.72,1.72,1.67,1.67,
ISRG,2002-08-14,1.67,1.74,1.62,1.73,
ISRG,2002-08-15,1.68,1.71,1.66,1.67,
ISRG,2002-08-16,1.67,1.78,1.67,1.76,
ISRG,2002-08-19,1.76,1.78,1.72,1.78,
ISRG,2002-08-20,1.73,1.73,1.67,1.67,
ISRG,2002-08-21,1.67,1.74,1.67,1.74,
ISRG,2002-08-22,1.74,1.78,1.66,1.66,
ISRG,2002-08-23,1.7,1.83,1.61,1.78,
ISRG,2002-08-26,1.84,1.86,1.78,1.85,
ISRG,2002-08-27,1.86,1.88,1.63,1.66,
ISRG,2002-08-28,1.71,1.72,1.61,1.61,
ISRG,2002-08-29,1.66,1.71,1.62,1.7,
ISRG,2002-08-30,1.71,1.76,1.62,1.64,
ISRG,2002-09-03,1.6,1.69,1.57,1.64,
ISRG,2002-09-04,1.6,1.72,1.58,1.72,
ISRG,2002-09-05,1.72,1.75,1.61,1.68,
ISRG,2002-09-06,1.7,1.76,1.67,1.7,
ISRG,2002-09-09,1.69,1.74,1.66,1.69,
ISRG,2002-09-10,1.67,1.7,1.66,1.69,
ISRG,2002-09-11,1.71,1.71,1.67,1.67,
ISRG,2002-09-12,1.67,1.73,1.64,1.73,
ISRG,2002-09-13,1.73,1.81,1.63,1.8,
ISRG,2002-09-16,1.76,1.81,1.71,1.73,
ISRG,2002-09-17,1.73,1.78,1.71,1.73,
ISRG,2002-09-18,1.73,1.74,1.69,1.74,
ISRG,2002-09-19,1.74,1.78,1.68,1.78,
ISRG,2002-09-20,1.74,1.75,1.67,1.7,
ISRG,2002-09-23,1.68,1.7,1.65,1.68,
ISRG,2002-09-24,1.66,1.69,1.66,1.67,
ISRG,2002-09-25,1.63,1.7,1.63,1.69,
ISRG,2002-09-26,1.72,1.77,1.66,1.76,
ISRG,2002-09-27,1.7,1.78,1.67,1.67,
ISRG,2002-09-30,1.6,1.78,1.56,1.78,
ISRG,2002-10-01,1.73,1.73,1.66,1.67,
ISRG,2002-10-02,1.66,1.76,1.6,1.68,
ISRG,2002-10-03,1.69,1.72,1.66,1.66,
ISRG,2002-10-04,1.66,1.66,1.59,1.62,
ISRG,2002-10-07,1.66,1.66,1.61,1.63,
ISRG,2002-10-08,1.61,1.66,1.57,1.64,
ISRG,2002-10-09,1.6,1.62,1.52,1.52,
ISRG,2002-10-10,1.56,1.56,1.29,1.35,
ISRG,2002-10-11,1.31,1.67,1.29,1.66,
ISRG,2002-10-14,1.6,1.69,1.59,1.62,
ISRG,2002-10-15,1.64,1.69,1.61,1.69,
ISRG,2002-10-16,1.7,1.7,1.62,1.63,
ISRG,2002-10-17,1.62,1.68,1.53,1.66,
ISRG,2002-10-18,1.67,1.75,1.64,1.71,
ISRG,2002-10-21,1.68,1.72,1.62,1.72,
ISRG,2002-10-22,1.73,1.76,1.67,1.72,
ISRG,2002-10-23,1.71,1.84,1.68,1.81,
ISRG,2002-10-24,1.81,1.85,1.74,1.75,
ISRG,2002-10-25,1.75,1.8,1.51,1.58,
ISRG,2002-10-28,1.58,1.6,1.52,1.54,
ISRG,2002-10-29,1.51,1.53,1.42,1.47,
ISRG,2002-10-30,1.48,1.48,1.4,1.45,
ISRG,2002-10-31,1.48,1.49,1.44,1.49,
ISRG,2002-11-01,1.45,1.49,1.4,1.49,
ISRG,2002-11-04,1.49,1.54,1.48,1.49,
ISRG,2002-11-05,1.55,1.55,1.47,1.49,
ISRG,2002-11-06,1.49,1.51,1.43,1.48,
ISRG,2002-11-07,1.44,1.47,1.43,1.44,
ISRG,2002-11-08,1.46,1.48,1.34,1.45,
ISRG,2002-11-11,1.49,1.52,1.4,1.42,
ISRG,2002-11-12,1.42,1.5,1.36,1.48,
ISRG,2002-11-13,1.56,1.61,1.43,1.47,
ISRG,2002-11-14,1.5,1.56,1.47,1.55,
ISRG,2002-11-15,1.49,1.56,1.49,1.54,
ISRG,2002-11-18,1.53,1.57,1.5,1.5,
ISRG,2002-11-19,1.53,1.56,1.49,1.51,
ISRG,2002-11-20,1.55,1.59,1.5,1.53,
ISRG,2002-11-21,1.53,1.58,1.51,1.58,
ISRG,2002-11-22,1.59,1.6,1.55,1.6,
ISRG,2002-11-25,1.59,1.72,1.56,1.66,
ISRG,2002-11-26,1.7,1.7,1.56,1.58,
ISRG,2002-11-27,1.56,1.67,1.56,1.64,
ISRG,2002-11-29,1.62,1.74,1.62,1.62,
ISRG,2002-12-02,1.66,1.67,1.6,1.64,
ISRG,2002-12-03,1.66,1.67,1.61,1.62,
ISRG,2002-12-04,1.62,1.66,1.6,1.6,
ISRG,2002-12-05,1.6,1.67,1.59,1.6,
ISRG,2002-12-06,1.62,1.66,1.59,1.6,
ISRG,2002-12-09,1.63,1.63,1.47,1.51,
ISRG,2002-12-10,1.5,1.71,1.44,1.52,
ISRG,2002-12-11,1.56,1.63,1.5,1.53,
ISRG,2002-12-12,1.52,1.58,1.52,1.52,
ISRG,2002-12-13,1.54,1.54,1.44,1.45,
ISRG,2002-12-16,1.44,1.49,1.44,1.48,
ISRG,2002-12-17,1.48,1.5,1.44,1.47,
ISRG,2002-12-18,1.51,1.52,1.34,1.38,
ISRG,2002-12-19,1.34,1.42,1.33,1.38,
ISRG,2002-12-20,1.36,1.39,1.3,1.38,
ISRG,2002-12-23,1.38,1.46,1.34,1.46,
ISRG,2002-12-24,1.45,1.46,1.42,1.44,
ISRG,2002-12-26,1.48,1.48,1.36,1.42,
ISRG,2002-12-27,1.44,1.44,1.38,1.4,
ISRG,2002-12-30,1.4,1.46,1.37,1.37,
ISRG,2002-12-31,1.35,1.44,1.35,1.37,
ISRG,2003-01-02,1.37,1.38,1.33,1.36,
ISRG,2003-01-03,1.35,1.43,1.34,1.36,
ISRG,2003-01-06,1.38,1.41,1.34,1.36,
ISRG,2003-01-07,1.35,1.37,1.31,1.32,
ISRG,2003-01-08,1.31,1.34,1.28,1.29,
ISRG,2003-01-09,1.3,1.31,1.28,1.3,
ISRG,2003-01-10,1.3,1.36,1.3,1.34,
ISRG,2003-01-13,1.35,1.41,1.29,1.3,
ISRG,2003-01-14,1.34,1.34,1.3,1.33,
ISRG,2003-01-15,1.31,1.32,1.2,1.29,
ISRG,2003-01-16,1.28,1.44,1.27,1.44,
ISRG,2003-01-17,1.44,1.45,1.4,1.44,
ISRG,2003-01-21,1.46,1.5,1.44,1.49,
ISRG,2003-01-22,1.49,1.49,1.43,1.46,
ISRG,2003-01-23,1.47,1.51,1.46,1.5,
ISRG,2003-01-24,1.47,1.51,1.46,1.47,
ISRG,2003-01-27,1.43,1.44,1.36,1.36,
ISRG,2003-01-28,1.4,1.4,1.36,1.36,
ISRG,2003-01-29,1.36,1.39,1.34,1.36,
ISRG,2003-01-30,1.39,1.46,1.38,1.43,
ISRG,2003-01-31,1.45,1.5,1.4,1.42,
ISRG,2003-02-03,1.44,1.44,1.26,1.29,
ISRG,2003-02-04,1.29,1.33,1.29,1.33,
ISRG,2003-02-05,1.34,1.34,1.3,1.3,
ISRG,2003-02-06,1.33,1.33,1.28,1.29,
ISRG,2003-02-07,1.28,1.34,1.28,1.31,
ISRG,2003-02-10,1.33,1.36,1.27,1.33,
ISRG,2003-02-11,1.28,1.28,1.06,1.19,"Bob Evans Farms, SuperGen and more Stocks making significant moves in Tuesday's U.S. equity trading."
ISRG,2003-02-12,1.12,1.17,1.06,1.07,
ISRG,2003-02-13,1.06,1.07,1.01,1.03,
ISRG,2003-02-14,1.02,1.08,0.94,1.05,
ISRG,2003-02-18,1.05,1.06,1.01,1.03,
ISRG,2003-02-19,1.06,1.06,1.01,1.02,
ISRG,2003-02-20,1.02,1.04,1.0,1.0,
ISRG,2003-02-21,1.0,1.02,0.94,0.98,
ISRG,2003-02-24,1.0,1.0,0.89,0.93,
ISRG,2003-02-25,0.96,0.96,0.89,0.94,
ISRG,2003-02-26,0.88,0.92,0.86,0.89,
ISRG,2003-02-27,0.89,0.91,0.86,0.87,
ISRG,2003-02-28,0.82,0.91,0.82,0.84,
ISRG,2003-03-03,0.83,0.98,0.83,0.98,
ISRG,2003-03-04,0.99,1.06,0.98,1.05,
ISRG,2003-03-05,1.06,1.11,1.01,1.1,
ISRG,2003-03-06,1.1,1.1,0.97,0.98,
ISRG,2003-03-07,1.0,1.0,0.91,0.93,
ISRG,2003-03-10,0.97,1.11,0.97,1.07,
ISRG,2003-03-11,1.07,1.18,1.03,1.13,
ISRG,2003-03-12,1.13,1.14,1.04,1.07,
ISRG,2003-03-13,1.07,1.07,1.0,1.02,
ISRG,2003-03-14,1.06,1.06,0.96,0.96,
ISRG,2003-03-17,0.97,1.06,0.92,1.05,
ISRG,2003-03-18,1.06,1.09,1.03,1.07,
ISRG,2003-03-19,1.07,1.16,1.06,1.16,
ISRG,2003-03-20,1.12,1.18,1.12,1.17,
ISRG,2003-03-21,1.12,1.23,1.11,1.22,
ISRG,2003-03-24,1.21,1.23,1.13,1.2,
ISRG,2003-03-25,1.2,1.33,1.18,1.26,
ISRG,2003-03-26,1.27,1.32,1.23,1.28,
ISRG,2003-03-27,1.3,1.3,1.26,1.28,
ISRG,2003-03-28,1.33,1.56,1.29,1.5,
ISRG,2003-03-31,1.56,1.64,1.4,1.44,
ISRG,2003-04-01,1.46,1.52,1.44,1.52,
ISRG,2003-04-02,1.53,1.57,1.48,1.55,
ISRG,2003-04-03,1.59,1.59,1.51,1.52,
ISRG,2003-04-04,1.51,1.54,1.46,1.47,
ISRG,2003-04-07,1.53,1.58,1.5,1.52,
ISRG,2003-04-08,1.52,1.53,1.49,1.5,
ISRG,2003-04-09,1.51,1.51,1.38,1.48,
ISRG,2003-04-10,1.47,1.5,1.35,1.37,
ISRG,2003-04-11,1.36,1.48,1.35,1.41,
ISRG,2003-04-14,1.41,1.41,1.35,1.38,
ISRG,2003-04-15,1.37,1.4,1.36,1.37,
ISRG,2003-04-16,1.37,1.37,1.29,1.31,
ISRG,2003-04-17,1.31,1.32,1.19,1.22,
ISRG,2003-04-21,1.21,1.23,1.19,1.22,
ISRG,2003-04-22,1.23,1.33,1.2,1.3,
ISRG,2003-04-23,1.33,1.38,1.31,1.34,
ISRG,2003-04-24,1.34,1.37,1.32,1.34,
ISRG,2003-04-25,1.34,1.4,1.34,1.36,
ISRG,2003-04-28,1.4,1.42,1.37,1.41,
ISRG,2003-04-29,1.42,1.44,1.32,1.37,
ISRG,2003-04-30,1.35,1.42,1.35,1.37,
ISRG,2003-05-01,1.37,1.41,1.36,1.38,
ISRG,2003-05-02,1.38,1.4,1.33,1.37,
ISRG,2003-05-05,1.38,1.4,1.36,1.37,
ISRG,2003-05-06,1.37,1.39,1.37,1.39,
ISRG,2003-05-07,1.39,1.4,1.36,1.38,
ISRG,2003-05-08,1.38,1.41,1.36,1.38,
ISRG,2003-05-09,1.41,1.44,1.39,1.41,
ISRG,2003-05-12,1.46,1.47,1.36,1.41,
ISRG,2003-05-13,1.41,1.42,1.37,1.39,
ISRG,2003-05-14,1.39,1.42,1.37,1.4,
ISRG,2003-05-15,1.4,1.51,1.4,1.49,
ISRG,2003-05-16,1.52,1.6,1.49,1.56,
ISRG,2003-05-19,1.6,1.62,1.56,1.61,
ISRG,2003-05-20,1.63,1.63,1.5,1.51,
ISRG,2003-05-21,1.58,1.6,1.5,1.58,
ISRG,2003-05-22,1.6,1.86,1.56,1.83,
ISRG,2003-05-23,1.87,1.92,1.79,1.9,
ISRG,2003-05-27,1.89,1.94,1.81,1.91,
ISRG,2003-05-28,1.91,1.99,1.81,1.94,
ISRG,2003-05-29,1.91,1.96,1.84,1.93,
ISRG,2003-05-30,1.96,2.04,1.9,1.95,
ISRG,2003-06-02,1.96,2.02,1.88,1.89,
ISRG,2003-06-03,1.88,1.93,1.86,1.91,
ISRG,2003-06-04,1.89,2.0,1.89,1.95,
ISRG,2003-06-05,1.96,2.04,1.91,2.02,
ISRG,2003-06-06,2.03,2.03,1.91,1.92,
ISRG,2003-06-09,1.96,1.96,1.85,1.88,
ISRG,2003-06-10,1.85,1.91,1.78,1.86,
ISRG,2003-06-11,1.81,1.89,1.79,1.89,
ISRG,2003-06-12,1.89,1.91,1.79,1.85,
ISRG,2003-06-13,1.83,1.89,1.73,1.8,
ISRG,2003-06-16,1.77,1.8,1.63,1.7,
ISRG,2003-06-17,1.73,1.77,1.67,1.76,
ISRG,2003-06-18,1.78,1.83,1.72,1.81,
ISRG,2003-06-19,1.8,1.91,1.77,1.81,
ISRG,2003-06-20,1.87,1.88,1.76,1.8,
ISRG,2003-06-23,1.82,1.83,1.7,1.73,
ISRG,2003-06-24,1.76,1.78,1.69,1.71,
ISRG,2003-06-25,1.76,1.81,1.7,1.7,
ISRG,2003-06-26,1.78,1.86,1.71,1.86,
ISRG,2003-06-27,1.81,1.86,1.74,1.75,
ISRG,2003-06-30,1.76,1.81,1.62,1.66,
ISRG,2003-07-01,1.61,1.64,1.61,1.63,
ISRG,2003-07-02,1.63,1.69,1.63,1.68,
ISRG,2003-07-03,1.68,1.69,1.65,1.67,
ISRG,2003-07-07,1.67,1.69,1.5,1.56,
ISRG,2003-07-08,1.58,1.63,1.54,1.63,
ISRG,2003-07-09,1.63,1.64,1.57,1.61,
ISRG,2003-07-10,1.6,1.62,1.5,1.56,
ISRG,2003-07-11,1.56,1.59,1.5,1.5,
ISRG,2003-07-14,1.5,1.54,1.47,1.49,
ISRG,2003-07-15,1.47,1.49,1.39,1.43,
ISRG,2003-07-16,1.12,1.39,1.11,1.38,
ISRG,2003-07-17,1.41,1.41,1.34,1.35,
ISRG,2003-07-18,1.33,1.34,1.29,1.34,
ISRG,2003-07-21,1.35,1.43,1.32,1.4,
ISRG,2003-07-22,1.43,1.49,1.39,1.48,
ISRG,2003-07-23,1.45,1.64,1.45,1.58,
ISRG,2003-07-24,1.63,1.7,1.62,1.66,
ISRG,2003-07-25,1.65,1.69,1.52,1.54,
ISRG,2003-07-28,1.53,1.59,1.53,1.54,
ISRG,2003-07-29,1.56,1.61,1.53,1.59,
ISRG,2003-07-30,1.61,1.78,1.58,1.72,
ISRG,2003-07-31,1.7,1.73,1.65,1.67,
ISRG,2003-08-01,1.66,1.72,1.65,1.7,
ISRG,2003-08-04,1.72,1.73,1.61,1.71,
ISRG,2003-08-05,1.7,1.71,1.61,1.64,
ISRG,2003-08-06,1.63,1.65,1.59,1.64,
ISRG,2003-08-07,1.65,1.65,1.59,1.61,
ISRG,2003-08-08,1.67,1.72,1.63,1.68,
ISRG,2003-08-11,1.71,1.73,1.67,1.7,
ISRG,2003-08-12,1.7,1.72,1.67,1.72,
ISRG,2003-08-13,1.7,1.71,1.65,1.67,
ISRG,2003-08-14,1.66,1.68,1.64,1.65,
ISRG,2003-08-15,1.65,1.67,1.65,1.67,
ISRG,2003-08-18,1.67,1.68,1.65,1.68,
ISRG,2003-08-19,1.68,1.69,1.63,1.67,
ISRG,2003-08-20,1.67,1.7,1.67,1.7,
ISRG,2003-08-21,1.68,1.74,1.68,1.71,
ISRG,2003-08-22,1.72,1.76,1.64,1.66,
ISRG,2003-08-25,1.67,1.69,1.65,1.68,
ISRG,2003-08-26,1.69,1.7,1.64,1.69,
ISRG,2003-08-27,1.67,1.7,1.64,1.69,
ISRG,2003-08-28,1.68,1.68,1.64,1.67,
ISRG,2003-08-29,1.67,1.69,1.65,1.68,
ISRG,2003-09-02,1.68,1.69,1.65,1.68,
ISRG,2003-09-03,1.68,1.69,1.66,1.69,
ISRG,2003-09-04,1.66,1.69,1.65,1.68,
ISRG,2003-09-05,1.66,1.69,1.66,1.67,
ISRG,2003-09-08,1.66,1.7,1.66,1.7,
ISRG,2003-09-09,1.69,1.71,1.67,1.68,
ISRG,2003-09-10,1.67,1.7,1.67,1.68,
ISRG,2003-09-11,1.68,1.7,1.67,1.68,
ISRG,2003-09-12,1.68,1.69,1.66,1.67,
ISRG,2003-09-15,1.66,1.69,1.66,1.69,
ISRG,2003-09-16,1.69,1.7,1.68,1.7,
ISRG,2003-09-17,1.7,1.8,1.68,1.78,
ISRG,2003-09-18,1.78,1.93,1.75,1.89,
ISRG,2003-09-19,1.93,1.93,1.78,1.84,
ISRG,2003-09-22,1.87,1.91,1.82,1.91,
ISRG,2003-09-23,1.91,2.07,1.87,2.01,
ISRG,2003-09-24,2.02,2.02,1.97,1.97,
ISRG,2003-09-25,1.98,1.98,1.81,1.83,
ISRG,2003-09-26,1.83,1.95,1.81,1.88,
ISRG,2003-09-29,1.87,1.91,1.83,1.87,
ISRG,2003-09-30,1.85,1.9,1.83,1.85,
ISRG,2003-10-01,1.85,1.94,1.85,1.9,
ISRG,2003-10-02,1.91,1.94,1.86,1.91,
ISRG,2003-10-03,1.87,1.98,1.87,1.97,
ISRG,2003-10-06,1.94,1.99,1.92,1.93,
ISRG,2003-10-07,1.96,2.0,1.91,1.99,
ISRG,2003-10-08,1.98,2.0,1.92,1.95,
ISRG,2003-10-09,1.95,1.96,1.81,1.88,
ISRG,2003-10-10,1.88,1.89,1.83,1.87,
ISRG,2003-10-13,1.86,1.89,1.83,1.86,
ISRG,2003-10-14,1.86,1.87,1.83,1.86,
ISRG,2003-10-15,1.84,1.87,1.82,1.85,
ISRG,2003-10-16,1.86,1.87,1.83,1.85,
ISRG,2003-10-17,1.85,1.88,1.81,1.85,
ISRG,2003-10-20,1.84,1.86,1.75,1.8,
ISRG,2003-10-21,1.81,1.84,1.77,1.79,
ISRG,2003-10-22,1.79,1.79,1.74,1.76,
ISRG,2003-10-23,1.76,1.78,1.73,1.74,
ISRG,2003-10-24,1.72,1.85,1.69,1.85,
ISRG,2003-10-27,1.85,1.86,1.8,1.81,
ISRG,2003-10-28,1.83,1.83,1.79,1.82,
ISRG,2003-10-29,1.8,1.81,1.72,1.73,
ISRG,2003-10-30,1.72,1.74,1.67,1.68,
ISRG,2003-10-31,1.7,1.72,1.56,1.61,
ISRG,2003-11-03,1.61,1.76,1.61,1.76,
ISRG,2003-11-04,1.66,1.77,1.65,1.69,
ISRG,2003-11-05,1.7,1.71,1.65,1.69,
ISRG,2003-11-06,1.7,1.74,1.66,1.66,
ISRG,2003-11-07,1.68,1.7,1.66,1.67,
ISRG,2003-11-10,1.7,1.7,1.65,1.67,
ISRG,2003-11-11,1.67,1.68,1.61,1.63,
ISRG,2003-11-12,1.63,1.65,1.61,1.63,
ISRG,2003-11-13,1.63,1.64,1.61,1.64,
ISRG,2003-11-14,1.64,1.64,1.59,1.6,
ISRG,2003-11-17,1.6,1.61,1.56,1.59,
ISRG,2003-11-18,1.6,1.6,1.53,1.56,
ISRG,2003-11-19,1.56,1.57,1.51,1.57,
ISRG,2003-11-20,1.57,1.58,1.53,1.58,
ISRG,2003-11-21,1.55,1.58,1.52,1.55,
ISRG,2003-11-24,1.54,1.64,1.54,1.61,
ISRG,2003-11-25,1.6,1.62,1.59,1.61,
ISRG,2003-11-26,1.62,1.72,1.6,1.72,
ISRG,2003-11-28,1.71,1.71,1.67,1.7,
ISRG,2003-12-01,1.71,1.76,1.7,1.74,
ISRG,2003-12-02,1.76,1.76,1.67,1.75,
ISRG,2003-12-03,1.76,1.76,1.69,1.71,
ISRG,2003-12-04,1.71,1.72,1.64,1.68,
ISRG,2003-12-05,1.68,1.74,1.68,1.73,
ISRG,2003-12-08,1.72,1.76,1.71,1.74,
ISRG,2003-12-09,1.76,1.78,1.74,1.78,
ISRG,2003-12-10,1.75,1.77,1.67,1.72,
ISRG,2003-12-11,1.69,1.73,1.68,1.71,
ISRG,2003-12-12,1.71,1.77,1.68,1.77,
ISRG,2003-12-15,1.78,1.78,1.75,1.76,
ISRG,2003-12-16,1.75,1.88,1.74,1.88,
ISRG,2003-12-17,1.84,1.94,1.84,1.91,
ISRG,2003-12-18,1.92,1.93,1.9,1.91,
ISRG,2003-12-19,1.89,1.91,1.81,1.88,
ISRG,2003-12-22,1.88,1.89,1.85,1.88,
ISRG,2003-12-23,1.88,1.89,1.82,1.89,
ISRG,2003-12-24,1.89,1.89,1.83,1.83,
ISRG,2003-12-26,1.84,1.86,1.84,1.85,
ISRG,2003-12-29,1.87,1.9,1.84,1.89,
ISRG,2003-12-30,1.89,1.9,1.86,1.89,
ISRG,2003-12-31,1.86,1.9,1.86,1.9,
ISRG,2004-01-02,1.9,1.91,1.82,1.88,
ISRG,2004-01-05,1.87,1.89,1.86,1.89,
ISRG,2004-01-06,1.89,1.91,1.83,1.86,
ISRG,2004-01-07,1.83,1.89,1.82,1.88,
ISRG,2004-01-08,1.89,1.89,1.86,1.89,
ISRG,2004-01-09,1.86,1.9,1.86,1.88,
ISRG,2004-01-12,1.87,1.89,1.86,1.89,
ISRG,2004-01-13,1.89,1.89,1.87,1.89,
ISRG,2004-01-14,1.89,1.94,1.84,1.9,
ISRG,2004-01-15,1.9,1.92,1.88,1.91,
ISRG,2004-01-16,1.89,1.96,1.89,1.94,
ISRG,2004-01-20,1.93,2.09,1.91,2.08,
ISRG,2004-01-21,2.07,2.11,2.02,2.05,
ISRG,2004-01-22,2.07,2.07,2.01,2.04,
ISRG,2004-01-23,2.02,2.05,1.97,2.03,
ISRG,2004-01-26,2.0,2.04,1.96,2.02,
ISRG,2004-01-27,2.02,2.06,1.97,2.01,
ISRG,2004-01-28,2.02,2.02,1.95,1.97,
ISRG,2004-01-29,1.99,1.99,1.91,1.94,
ISRG,2004-01-30,1.92,2.0,1.91,1.98,
ISRG,2004-02-02,1.95,2.0,1.95,1.97,
ISRG,2004-02-03,1.97,2.0,1.96,1.99,
ISRG,2004-02-04,1.97,1.97,1.91,1.91,
ISRG,2004-02-05,1.9,1.97,1.9,1.93,
ISRG,2004-02-06,1.91,2.0,1.91,2.0,
ISRG,2004-02-09,2.0,2.05,1.95,2.03,
ISRG,2004-02-10,2.0,2.09,2.0,2.09,
ISRG,2004-02-11,2.09,2.09,2.02,2.07,
ISRG,2004-02-12,2.06,2.11,2.03,2.06,
ISRG,2004-02-13,2.11,2.16,1.94,2.03,
ISRG,2004-02-17,2.02,2.07,1.99,2.0,
ISRG,2004-02-18,2.02,2.02,1.94,1.98,
ISRG,2004-02-19,2.0,2.0,1.93,1.98,
ISRG,2004-02-20,1.99,2.0,1.9,1.97,
ISRG,2004-02-23,1.96,1.98,1.91,1.91,
ISRG,2004-02-24,1.91,1.94,1.87,1.88,
ISRG,2004-02-25,1.87,1.93,1.87,1.91,
ISRG,2004-02-26,1.95,2.02,1.95,2.0,
ISRG,2004-02-27,2.0,2.04,1.97,1.99,
ISRG,2004-03-01,2.0,2.02,1.96,2.0,
ISRG,2004-03-02,1.99,2.01,1.96,1.99,
ISRG,2004-03-03,2.0,2.01,1.96,1.99,
ISRG,2004-03-04,1.99,2.01,1.96,2.0,
ISRG,2004-03-05,2.0,2.05,1.99,2.03,
ISRG,2004-03-08,2.11,2.11,2.06,2.1,
ISRG,2004-03-09,2.12,2.13,2.05,2.1,
ISRG,2004-03-10,2.1,2.1,2.02,2.02,
ISRG,2004-03-11,2.01,2.04,1.97,1.99,
ISRG,2004-03-12,1.99,2.02,1.97,2.02,
ISRG,2004-03-15,2.01,2.01,1.95,1.96,
ISRG,2004-03-16,1.96,1.99,1.93,1.94,
ISRG,2004-03-17,1.96,1.98,1.93,1.98,
ISRG,2004-03-18,1.98,1.98,1.9,1.9,
ISRG,2004-03-19,1.96,1.96,1.92,1.92,
ISRG,2004-03-22,1.92,1.95,1.84,1.88,
ISRG,2004-03-23,1.9,1.9,1.83,1.85,
ISRG,2004-03-24,1.83,1.89,1.82,1.86,
ISRG,2004-03-25,1.91,1.91,1.81,1.85,
ISRG,2004-03-26,1.85,1.86,1.82,1.83,
ISRG,2004-03-29,1.84,1.88,1.82,1.85,
ISRG,2004-03-30,1.82,1.9,1.82,1.89,
ISRG,2004-03-31,1.86,1.91,1.86,1.89,
ISRG,2004-04-01,1.89,1.94,1.87,1.9,
ISRG,2004-04-02,1.94,1.94,1.89,1.93,
ISRG,2004-04-05,1.88,1.93,1.84,1.88,
ISRG,2004-04-06,1.88,1.91,1.83,1.84,
ISRG,2004-04-07,1.83,1.85,1.79,1.8,
ISRG,2004-04-08,1.79,1.87,1.79,1.84,
ISRG,2004-04-12,1.87,1.9,1.84,1.9,
ISRG,2004-04-13,1.93,1.94,1.74,1.79,
ISRG,2004-04-14,1.79,1.81,1.76,1.78,
ISRG,2004-04-15,1.77,1.8,1.75,1.75,
ISRG,2004-04-16,1.78,1.78,1.75,1.76,
ISRG,2004-04-19,1.76,1.77,1.74,1.75,
ISRG,2004-04-20,1.74,1.79,1.69,1.7,
ISRG,2004-04-21,1.69,1.76,1.69,1.72,
ISRG,2004-04-22,1.72,1.78,1.72,1.74,
ISRG,2004-04-23,1.78,1.78,1.7,1.73,
ISRG,2004-04-26,1.73,1.77,1.7,1.75,
ISRG,2004-04-27,1.76,1.76,1.72,1.75,
ISRG,2004-04-28,1.69,1.74,1.68,1.68,
ISRG,2004-04-29,1.76,1.77,1.68,1.68,
ISRG,2004-04-30,1.76,1.89,1.74,1.8,
ISRG,2004-05-03,1.81,1.87,1.78,1.83,
ISRG,2004-05-04,1.83,1.85,1.82,1.84,
ISRG,2004-05-05,1.89,1.89,1.81,1.81,
ISRG,2004-05-06,1.81,1.86,1.77,1.85,
ISRG,2004-05-07,1.89,1.9,1.84,1.84,
ISRG,2004-05-10,1.83,1.85,1.8,1.83,
ISRG,2004-05-11,1.83,1.88,1.81,1.86,
ISRG,2004-05-12,1.86,1.88,1.81,1.85,
ISRG,2004-05-13,1.88,1.89,1.82,1.87,
ISRG,2004-05-14,1.88,1.89,1.83,1.84,
ISRG,2004-05-17,1.83,1.84,1.75,1.76,
ISRG,2004-05-18,1.75,1.81,1.75,1.79,
ISRG,2004-05-19,1.8,1.83,1.75,1.82,
ISRG,2004-05-20,1.81,1.84,1.8,1.83,
ISRG,2004-05-21,1.86,1.86,1.78,1.79,
ISRG,2004-05-24,1.81,1.81,1.78,1.79,
ISRG,2004-05-25,1.8,1.83,1.78,1.83,
ISRG,2004-05-26,1.83,1.86,1.8,1.85,
ISRG,2004-05-27,1.85,1.86,1.8,1.85,
ISRG,2004-05-28,1.83,1.84,1.78,1.84,
ISRG,2004-06-01,1.81,1.85,1.8,1.85,
ISRG,2004-06-02,1.86,1.94,1.82,1.93,
ISRG,2004-06-03,1.9,1.94,1.89,1.9,
ISRG,2004-06-04,1.92,1.98,1.89,1.98,
ISRG,2004-06-07,2.0,2.06,1.92,1.99,
ISRG,2004-06-08,1.95,1.98,1.95,1.97,
ISRG,2004-06-09,1.94,2.01,1.94,1.98,
ISRG,2004-06-10,1.96,2.0,1.95,1.97,
ISRG,2004-06-14,1.98,1.99,1.94,1.96,
ISRG,2004-06-15,1.99,1.99,1.95,1.98,
ISRG,2004-06-16,1.96,2.0,1.94,1.99,
ISRG,2004-06-17,1.96,2.01,1.96,2.0,
ISRG,2004-06-18,1.97,2.01,1.95,1.98,
ISRG,2004-06-21,1.96,2.03,1.96,2.02,
ISRG,2004-06-22,2.03,2.06,1.96,2.03,
ISRG,2004-06-23,2.01,2.06,2.01,2.05,
ISRG,2004-06-24,2.04,2.08,2.02,2.08,
ISRG,2004-06-25,2.1,2.1,2.03,2.08,
ISRG,2004-06-28,2.1,2.11,2.06,2.08,
ISRG,2004-06-29,2.12,2.12,2.07,2.11,
ISRG,2004-06-30,2.12,2.12,2.07,2.11,
ISRG,2004-07-01,2.07,2.11,2.07,2.1,
ISRG,2004-07-02,2.09,2.09,2.04,2.07,
ISRG,2004-07-06,2.05,2.08,1.98,1.99,
ISRG,2004-07-07,1.98,2.02,1.96,2.01,
ISRG,2004-07-08,2.11,2.15,2.04,2.09,
ISRG,2004-07-09,2.13,2.19,2.11,2.16,
ISRG,2004-07-12,2.2,2.24,2.19,2.22,
ISRG,2004-07-13,2.27,2.31,2.22,2.24,
ISRG,2004-07-14,2.25,2.26,2.21,2.24,
ISRG,2004-07-15,2.23,2.28,2.23,2.26,
ISRG,2004-07-16,2.27,2.28,2.22,2.22,
ISRG,2004-07-19,2.22,2.22,2.12,2.18,
ISRG,2004-07-20,2.2,2.25,2.12,2.24,
ISRG,2004-07-21,2.23,2.25,2.12,2.13,
ISRG,2004-07-22,2.12,2.18,2.11,2.11,
ISRG,2004-07-23,2.1,2.12,2.0,2.09,
ISRG,2004-07-26,2.07,2.11,2.0,2.03,
ISRG,2004-07-27,2.04,2.65,2.01,2.56,
ISRG,2004-07-28,2.41,2.58,2.3,2.38,
ISRG,2004-07-29,2.41,2.53,2.4,2.5,
ISRG,2004-07-30,2.53,2.55,2.46,2.54,
ISRG,2004-08-02,2.45,2.53,2.43,2.5,
ISRG,2004-08-03,2.51,2.54,2.42,2.49,
ISRG,2004-08-04,2.44,2.49,2.39,2.44,
ISRG,2004-08-05,2.5,2.55,2.42,2.42,
ISRG,2004-08-06,2.42,2.43,2.33,2.36,
ISRG,2004-08-09,2.33,2.39,2.3,2.33,
ISRG,2004-08-10,2.35,2.41,2.32,2.4,
ISRG,2004-08-11,2.4,2.46,2.31,2.44,
ISRG,2004-08-12,2.41,2.44,2.33,2.39,
ISRG,2004-08-13,2.42,2.47,2.35,2.44,
ISRG,2004-08-16,2.47,2.56,2.44,2.55,
ISRG,2004-08-17,2.61,2.62,2.52,2.55,
ISRG,2004-08-18,2.51,2.77,2.5,2.77,
ISRG,2004-08-19,2.79,2.79,2.68,2.72,
ISRG,2004-08-20,2.72,2.82,2.7,2.76,
ISRG,2004-08-23,2.8,2.81,2.73,2.73,
ISRG,2004-08-24,2.78,2.82,2.71,2.72,
ISRG,2004-08-25,2.77,2.79,2.71,2.75,
ISRG,2004-08-26,2.76,2.77,2.73,2.77,
ISRG,2004-08-27,2.77,2.81,2.69,2.73,
ISRG,2004-08-30,2.75,2.75,2.58,2.63,
ISRG,2004-08-31,2.64,2.71,2.6,2.69,
ISRG,2004-09-01,2.71,2.78,2.7,2.77,
ISRG,2004-09-02,2.8,2.94,2.79,2.93,
ISRG,2004-09-03,2.93,2.99,2.87,2.99,
ISRG,2004-09-07,3.02,3.02,2.89,2.92,
ISRG,2004-09-08,2.83,2.88,2.8,2.82,
ISRG,2004-09-09,2.81,2.89,2.74,2.88,
ISRG,2004-09-10,2.92,2.98,2.88,2.98,
ISRG,2004-09-13,3.03,3.03,2.93,2.95,
ISRG,2004-09-14,3.01,3.04,2.96,3.0,
ISRG,2004-09-15,3.01,3.02,2.92,2.98,
ISRG,2004-09-16,2.98,2.98,2.92,2.95,
ISRG,2004-09-17,2.95,3.03,2.89,2.95,
ISRG,2004-09-20,2.96,2.97,2.89,2.95,
ISRG,2004-09-21,2.94,3.02,2.94,3.01,
ISRG,2004-09-22,3.11,3.14,2.98,3.04,
ISRG,2004-09-23,3.04,3.07,2.95,3.05,
ISRG,2004-09-24,3.03,3.06,2.84,2.9,
ISRG,2004-09-27,2.87,2.9,2.71,2.77,
ISRG,2004-09-28,2.73,2.79,2.71,2.78,
ISRG,2004-09-29,2.78,2.83,2.77,2.79,
ISRG,2004-09-30,2.83,2.84,2.75,2.75,
ISRG,2004-10-01,2.72,2.82,2.72,2.79,
ISRG,2004-10-04,2.86,2.95,2.81,2.94,
ISRG,2004-10-05,2.93,3.0,2.87,2.96,
ISRG,2004-10-06,2.94,3.02,2.93,2.99,
ISRG,2004-10-07,3.04,3.04,2.87,2.95,
ISRG,2004-10-08,2.91,2.97,2.81,2.92,
ISRG,2004-10-11,2.92,2.95,2.86,2.91,
ISRG,2004-10-12,2.91,2.91,2.81,2.91,
ISRG,2004-10-13,2.91,2.93,2.86,2.88,
ISRG,2004-10-14,2.92,2.92,2.74,2.8,
ISRG,2004-10-15,2.81,2.81,2.71,2.74,
ISRG,2004-10-18,2.76,2.81,2.67,2.8,
ISRG,2004-10-19,2.83,2.83,2.7,2.74,
ISRG,2004-10-20,2.75,2.75,2.51,2.62,
ISRG,2004-10-21,2.58,2.62,2.51,2.59,
ISRG,2004-10-22,2.43,2.57,2.42,2.45,
ISRG,2004-10-25,2.42,2.67,2.35,2.66,
ISRG,2004-10-26,2.64,2.76,2.64,2.76,
ISRG,2004-10-27,2.97,3.29,2.93,3.25,
ISRG,2004-10-28,3.21,3.28,3.19,3.25,
ISRG,2004-10-29,3.22,3.29,3.18,3.24,
ISRG,2004-11-01,3.25,3.32,3.18,3.31,
ISRG,2004-11-02,3.33,3.36,3.29,3.32,
ISRG,2004-11-03,3.32,3.45,3.32,3.44,
ISRG,2004-11-04,3.44,3.44,3.33,3.41,
ISRG,2004-11-05,3.42,3.46,3.35,3.43,
ISRG,2004-11-08,3.46,3.46,3.37,3.42,
ISRG,2004-11-09,3.39,3.44,3.38,3.43,
ISRG,2004-11-10,3.36,3.59,3.36,3.54,
ISRG,2004-11-11,3.56,3.58,3.48,3.56,
ISRG,2004-11-12,3.51,3.56,3.48,3.55,
ISRG,2004-11-15,3.55,3.56,3.5,3.53,
ISRG,2004-11-16,3.55,3.63,3.47,3.5,
ISRG,2004-11-17,3.59,3.68,3.56,3.67,
ISRG,2004-11-18,3.67,3.75,3.63,3.73,
ISRG,2004-11-19,3.68,3.75,3.56,3.6,
ISRG,2004-11-22,3.61,3.71,3.54,3.7,
ISRG,2004-11-23,3.71,3.8,3.65,3.8,
ISRG,2004-11-24,3.8,3.9,3.73,3.88,
ISRG,2004-11-26,3.92,3.99,3.81,3.94,
ISRG,2004-11-29,3.99,3.99,3.79,3.87,
ISRG,2004-11-30,3.86,4.14,3.86,3.99,
ISRG,2004-12-01,4.07,4.11,4.03,4.06,
ISRG,2004-12-02,4.11,4.11,4.01,4.07,
ISRG,2004-12-03,4.08,4.12,4.04,4.09,
ISRG,2004-12-06,4.11,4.11,3.96,3.97,
ISRG,2004-12-07,4.01,4.04,3.6,3.61,
ISRG,2004-12-08,3.67,3.82,3.64,3.8,
ISRG,2004-12-09,3.79,3.79,3.64,3.73,
ISRG,2004-12-10,3.8,3.8,3.72,3.77,
ISRG,2004-12-13,3.82,3.92,3.8,3.92,
ISRG,2004-12-14,3.95,4.0,3.93,3.95,
ISRG,2004-12-15,3.97,4.02,3.94,4.01,
ISRG,2004-12-16,4.02,4.04,4.0,4.0,
ISRG,2004-12-17,3.99,4.05,3.93,4.01,
ISRG,2004-12-20,4.05,4.08,4.0,4.0,"Five big medical, health-care advances for 2004 SAN FRANCISCO (CBS.MW) - It was a mixed year for health care as the United States questioned its system of assuring drug safety, while accumulating a number of pharmaceutical success stories at the same time."
ISRG,2004-12-21,4.05,4.24,4.02,4.22,
ISRG,2004-12-22,4.24,4.35,4.23,4.29,
ISRG,2004-12-23,4.25,4.41,4.24,4.4,
ISRG,2004-12-27,4.41,4.44,4.38,4.43,
ISRG,2004-12-28,4.38,4.44,4.38,4.43,
ISRG,2004-12-29,4.4,4.45,4.35,4.44,
ISRG,2004-12-30,4.45,4.45,4.4,4.42,
ISRG,2004-12-31,4.44,4.51,4.42,4.45,
ISRG,2005-01-03,4.45,4.52,4.17,4.19,
ISRG,2005-01-04,4.19,4.26,4.01,4.05,
ISRG,2005-01-05,4.01,4.11,3.97,4.01,
ISRG,2005-01-06,4.02,4.18,4.02,4.09,
ISRG,2005-01-07,4.14,4.17,4.11,4.13,
ISRG,2005-01-10,4.21,4.61,4.18,4.51,
ISRG,2005-01-11,4.51,4.55,4.41,4.41,
ISRG,2005-01-12,4.42,4.48,4.39,4.46,
ISRG,2005-01-13,4.47,4.69,4.43,4.61,
ISRG,2005-01-14,4.68,4.68,4.44,4.55,
ISRG,2005-01-18,4.61,4.64,4.54,4.62,
ISRG,2005-01-19,4.65,4.66,4.52,4.56,
ISRG,2005-01-20,4.53,4.55,4.37,4.47,
ISRG,2005-01-21,4.48,4.55,4.47,4.51,
ISRG,2005-01-24,4.5,4.55,4.3,4.32,
ISRG,2005-01-25,4.33,4.44,4.27,4.32,
ISRG,2005-01-26,4.35,4.36,4.29,4.33,
ISRG,2005-01-27,4.35,4.42,4.29,4.33,
ISRG,2005-01-28,4.33,4.35,4.24,4.28,
ISRG,2005-01-31,4.31,4.44,4.29,4.43,
ISRG,2005-02-01,4.47,4.52,4.42,4.44,
ISRG,2005-02-02,4.5,4.5,4.42,4.47,
ISRG,2005-02-03,4.48,4.63,4.47,4.58,
ISRG,2005-02-04,4.62,4.68,4.59,4.64,
ISRG,2005-02-07,4.64,4.64,4.45,4.49,
ISRG,2005-02-08,4.39,4.58,4.36,4.57,
ISRG,2005-02-09,5.23,5.49,5.18,5.27,AAPL SGTL ISRG climb to 52-wk highs on the Nasdaq
ISRG,2005-02-10,5.26,5.42,5.2,5.32,
ISRG,2005-02-11,5.34,5.48,5.27,5.42,
ISRG,2005-02-14,5.33,5.42,5.24,5.28,
ISRG,2005-02-15,5.28,5.37,5.21,5.3,
ISRG,2005-02-16,5.25,5.44,5.18,5.41,
ISRG,2005-02-17,5.45,5.49,5.29,5.3,
ISRG,2005-02-18,5.32,5.39,5.26,5.27,
ISRG,2005-02-22,5.27,5.28,5.02,5.03,
ISRG,2005-02-23,5.03,5.18,5.03,5.1,
ISRG,2005-02-24,5.09,5.25,5.09,5.25,
ISRG,2005-02-25,5.281,5.3443,5.2223,5.3333,
ISRG,2005-02-28,5.34,5.361,5.2223,5.239,
ISRG,2005-03-01,5.2777,5.339,5.2557,5.3177,
ISRG,2005-03-02,5.3077,5.3433,5.2557,5.2557,
ISRG,2005-03-03,5.3233,5.3233,5.1967,5.21,
ISRG,2005-03-04,5.2223,5.2557,5.1977,5.2177,
ISRG,2005-03-07,5.201,5.319,5.1633,5.1777,
ISRG,2005-03-08,5.1667,5.2167,4.9667,5.0067,
ISRG,2005-03-09,4.9567,4.9777,4.8157,4.8877,
ISRG,2005-03-10,4.8733,4.9077,4.7077,4.779,
ISRG,2005-03-11,4.7777,5.0977,4.751,5.011,
ISRG,2005-03-14,5.0577,5.089,4.9423,5.0067,
ISRG,2005-03-15,5.0033,5.1,4.9277,4.9443,
ISRG,2005-03-16,4.9243,5.0133,4.8933,4.9077,
ISRG,2005-03-17,4.9633,5.0,4.8067,4.9723,
ISRG,2005-03-18,4.9967,5.03,4.8823,4.939,
ISRG,2005-03-21,4.9133,4.9523,4.809,4.9323,
ISRG,2005-03-22,4.91,5.0,4.91,4.961,
ISRG,2005-03-23,4.9477,5.0823,4.919,5.0277,
ISRG,2005-03-24,5.0277,5.211,5.0223,5.1033,
ISRG,2005-03-28,5.1467,5.1843,5.0277,5.119,
ISRG,2005-03-29,5.13,5.2223,4.99,5.0767,
ISRG,2005-03-30,5.051,5.1133,4.9923,5.099,Health Care Pro Sees Value in Eye Stocks Turner Investment's Frank Sustersic searches far and wide for fast-growing health-care companies. But he's particularly bullish on eye-care companies such as Bausch & Lomb and Cooper Cos.
ISRG,2005-03-31,5.1267,5.1543,5.0033,5.0523,
ISRG,2005-04-01,5.1057,5.3,5.0557,5.199,
ISRG,2005-04-04,5.1823,5.2257,5.069,5.0977,
ISRG,2005-04-05,5.1267,5.35,5.089,5.35,
ISRG,2005-04-06,5.399,5.9,5.3923,5.781,
ISRG,2005-04-07,5.7557,5.8067,5.7167,5.7833,
ISRG,2005-04-08,5.799,5.8067,5.5343,5.5977,
ISRG,2005-04-11,5.5933,5.6833,5.5277,5.6277,
ISRG,2005-04-12,5.6133,5.6533,5.449,5.6033,
ISRG,2005-04-13,5.61,5.7223,5.4667,5.4967,
ISRG,2005-04-14,5.4857,5.5543,5.449,5.46,
ISRG,2005-04-15,5.4557,5.56,5.2957,5.3243,
ISRG,2005-04-18,5.2943,5.3177,5.24,5.2657,
ISRG,2005-04-19,5.319,5.6067,5.3167,5.6067,
ISRG,2005-04-20,5.6643,5.6777,5.471,5.4877,
ISRG,2005-04-21,5.5423,5.7667,5.5423,5.7667,
ISRG,2005-04-22,5.4167,5.4367,4.461,4.58,
ISRG,2005-04-25,4.63,5.0023,4.5877,4.8333,
ISRG,2005-04-26,4.85,4.9477,4.6343,4.6723,
ISRG,2005-04-27,4.6743,4.8077,4.5867,4.73,
ISRG,2005-04-28,4.75,4.7657,4.48,4.5577,
ISRG,2005-04-29,4.6033,4.771,4.5167,4.771,
ISRG,2005-05-02,4.7733,4.83,4.6677,4.7133,
ISRG,2005-05-03,4.7257,4.801,4.669,4.7443,
ISRG,2005-05-04,4.7333,4.8443,4.721,4.801,
ISRG,2005-05-05,4.8133,4.879,4.7467,4.7957,
ISRG,2005-05-06,4.849,4.8733,4.8133,4.8457,
ISRG,2005-05-09,4.86,4.8633,4.6833,4.7977,
ISRG,2005-05-10,4.7767,4.7767,4.6067,4.6557,
ISRG,2005-05-11,4.651,4.7667,4.5967,4.7557,
ISRG,2005-05-12,4.749,4.7933,4.6667,4.691,
ISRG,2005-05-13,4.6977,4.7457,4.639,4.6443,
ISRG,2005-05-16,4.661,4.9377,4.6177,4.9377,
ISRG,2005-05-17,4.8833,4.9133,4.751,4.8433,
ISRG,2005-05-18,4.861,5.0057,4.8143,5.0033,
ISRG,2005-05-19,5.0243,5.2423,4.9967,5.2323,
ISRG,2005-05-20,5.2557,5.261,5.089,5.201,
ISRG,2005-05-23,5.1977,5.4323,5.1557,5.331,
ISRG,2005-05-24,5.331,5.441,5.2243,5.401,
ISRG,2005-05-25,5.389,5.389,5.17,5.271,
ISRG,2005-05-26,5.2777,5.4077,5.2167,5.3943,
ISRG,2005-05-27,5.4043,5.58,5.3643,5.5157,
ISRG,2005-05-31,5.5277,5.569,5.47,5.5,
ISRG,2005-06-01,5.5233,5.5377,5.3357,5.3833,
ISRG,2005-06-02,5.341,5.5277,5.3343,5.4567,
ISRG,2005-06-03,5.4557,5.5167,5.379,5.4643,
ISRG,2005-06-06,5.4533,5.5067,5.4167,5.4467,
ISRG,2005-06-07,5.4467,5.4933,5.389,5.4067,
ISRG,2005-06-08,5.429,5.431,5.169,5.2443,
ISRG,2005-06-09,5.271,5.389,5.199,5.3857,
ISRG,2005-06-10,5.38,5.38,5.3057,5.3523,
ISRG,2005-06-13,5.3333,5.409,5.3177,5.4043,
ISRG,2005-06-14,5.391,5.409,5.34,5.3877,
ISRG,2005-06-15,5.401,5.4077,5.241,5.349,
ISRG,2005-06-16,5.3577,5.5457,5.3233,5.5357,
ISRG,2005-06-17,5.5557,5.661,5.511,5.6,
ISRG,2005-06-20,5.599,5.651,5.5,5.5767,
ISRG,2005-06-21,5.5723,5.6157,5.4223,5.4577,
ISRG,2005-06-22,5.4443,5.499,5.281,5.3723,
ISRG,2005-06-23,5.3467,5.389,5.2467,5.2777,
ISRG,2005-06-24,5.28,5.399,5.251,5.2633,
ISRG,2005-06-27,5.3067,5.3067,5.0933,5.1123,
ISRG,2005-06-28,5.111,5.309,5.0977,5.261,
ISRG,2005-06-29,5.3033,5.3033,5.1823,5.2257,
ISRG,2005-06-30,5.24,5.349,5.1633,5.1823,
ISRG,2005-07-01,5.1933,5.2177,5.1557,5.1923,
ISRG,2005-07-05,5.1667,5.3967,5.1667,5.3967,
ISRG,2005-07-06,5.4,5.4833,5.3423,5.4333,
ISRG,2005-07-07,5.3523,5.5423,5.3333,5.5257,
ISRG,2005-07-08,5.5557,5.8643,5.55,5.7523,
ISRG,2005-07-11,5.8077,5.9667,5.7967,5.8777,
ISRG,2005-07-12,5.9343,6.0223,5.8357,5.9377,
ISRG,2005-07-13,5.9767,5.9767,5.561,5.659,
ISRG,2005-07-14,5.7567,5.759,5.5557,5.6043,
ISRG,2005-07-15,5.579,5.65,5.5443,5.609,
ISRG,2005-07-18,5.5943,5.7877,5.5943,5.7167,
ISRG,2005-07-19,5.7533,5.7767,5.601,5.6557,
ISRG,2005-07-20,5.6667,5.6723,5.5877,5.611,
ISRG,2005-07-21,5.611,5.66,5.361,5.4923,
ISRG,2005-07-22,5.52,5.5843,5.4933,5.5743,
ISRG,2005-07-25,5.609,5.6667,5.5223,5.5233,
ISRG,2005-07-26,5.7433,5.8557,5.6357,5.7,
ISRG,2005-07-27,7.0177,7.249,6.8333,7.2023,"[""Infospace shares dive in late-day trades SAN FRANCISCO (MarketWatch) -- Shares of Infospace Inc. sank 31% after the Internet services firm slashed its fiscal year outlook, while shares of Amazon.com rose nearly 11% after the online retailer posted revenue and earnings that were stronger than forecast."", ""Highlights of rising and falling U.S. stocks A roundup of Wednesday's biggest advancers and decliners""]"
ISRG,2005-07-28,7.2223,8.071,7.2023,8.049,
ISRG,2005-07-29,7.69,7.7233,7.2777,7.711,"Navigating the med-tech minefield Jim Cramer's been a big fan of Intuitive Surgical, and it's easy to understand why: The stock is his kind of stock. It's been going straight up, largely because the company, which makes a robotic surgical system, has been performing better than expectations. But as I noted on the TV show, there's the stock, and then there's the company -- and right now, it appears the stock's moved well ahead of the company. The fact that a stock is soaring doesn't mean a company will be a big winner."
ISRG,2005-08-01,7.6223,7.7543,7.4123,7.481,
ISRG,2005-08-02,7.469,7.69,7.3877,7.6467,
ISRG,2005-08-03,7.559,8.039,7.479,7.91,
ISRG,2005-08-04,7.85,7.9533,7.649,7.7857,
ISRG,2005-08-05,7.7767,7.8833,7.64,7.7067,
ISRG,2005-08-08,7.741,7.8843,7.679,7.75,
ISRG,2005-08-09,7.7943,8.3567,7.75,8.3157,
ISRG,2005-08-10,8.3333,8.5177,8.0457,8.1567,
ISRG,2005-08-11,8.1133,8.4033,8.0733,8.311,
ISRG,2005-08-12,8.2443,8.3277,8.211,8.3277,
ISRG,2005-08-15,8.3333,8.5443,8.2443,8.4623,
ISRG,2005-08-16,8.4523,8.4977,8.1557,8.2367,
ISRG,2005-08-17,8.1943,8.4223,8.15,8.389,
ISRG,2005-08-18,8.2333,8.3277,8.0167,8.2123,
ISRG,2005-08-19,8.18,8.32,8.18,8.29,
ISRG,2005-08-22,8.3333,8.5177,8.25,8.4923,
ISRG,2005-08-23,8.51,8.8243,8.4723,8.6523,
ISRG,2005-08-24,8.5667,8.771,8.561,8.621,
ISRG,2005-08-25,8.6057,8.6643,8.4177,8.4867,
ISRG,2005-08-26,8.1757,8.189,7.9,8.0943,
ISRG,2005-08-29,7.9233,8.111,7.8067,8.0723,
ISRG,2005-08-30,8.0577,8.0577,7.8643,7.9767,
ISRG,2005-08-31,7.9723,8.2943,7.929,8.2667,
ISRG,2005-09-01,8.111,8.2167,7.891,7.9577,
ISRG,2005-09-02,7.9723,8.0743,7.8557,7.9,
ISRG,2005-09-06,7.8743,7.8957,7.5657,7.741,
ISRG,2005-09-07,7.709,8.1323,7.64,7.9857,
ISRG,2005-09-08,8.0133,8.0723,7.821,7.871,
ISRG,2005-09-09,7.889,7.9543,7.7777,7.811,
ISRG,2005-09-12,7.8623,8.111,7.7567,8.05,
ISRG,2005-09-13,8.08,8.34,7.861,8.12,
ISRG,2005-09-14,8.131,8.211,7.7523,7.7957,
ISRG,2005-09-15,7.8623,7.889,7.6733,7.72,
ISRG,2005-09-16,7.7777,7.8243,7.6323,7.6657,
ISRG,2005-09-19,7.6557,7.799,7.65,7.75,
ISRG,2005-09-20,7.7767,7.7777,7.419,7.5657,
ISRG,2005-09-21,7.49,7.779,7.3723,7.7423,
ISRG,2005-09-22,7.7477,7.8323,7.5677,7.769,
ISRG,2005-09-23,7.7443,8.0323,7.639,7.9167,
ISRG,2005-09-26,7.9277,8.0477,7.6833,7.7623,
ISRG,2005-09-27,7.7823,8.3057,7.7733,8.2533,
ISRG,2005-09-28,8.2843,8.4157,8.129,8.2723,
ISRG,2005-09-29,8.2777,8.531,8.139,8.38,
ISRG,2005-09-30,8.3877,8.4323,8.1077,8.1433,
ISRG,2005-10-03,8.1667,8.3057,8.0977,8.211,
ISRG,2005-10-04,8.1133,8.661,8.1123,8.35,
ISRG,2005-10-05,8.3357,8.4033,8.0577,8.091,
ISRG,2005-10-06,8.1023,8.1567,7.6733,7.8177,
ISRG,2005-10-07,7.861,7.94,7.6833,7.8233,
ISRG,2005-10-10,7.8667,8.049,7.711,7.7367,
ISRG,2005-10-11,7.8333,7.8823,7.4757,7.6,
ISRG,2005-10-12,7.5757,7.6,7.1733,7.3277,
ISRG,2005-10-13,7.3057,7.4,7.0857,7.3157,
ISRG,2005-10-14,7.39,7.4777,7.2767,7.4333,
ISRG,2005-10-17,7.4267,7.59,7.4267,7.499,
ISRG,2005-10-18,7.5,7.5,7.3077,7.4023,
ISRG,2005-10-19,7.399,7.6333,7.2777,7.6243,
ISRG,2005-10-20,7.5967,7.6757,7.4,7.5057,
ISRG,2005-10-21,7.52,7.8667,7.52,7.7457,
ISRG,2005-10-24,7.8223,7.919,7.7257,7.9123,
ISRG,2005-10-25,7.9723,8.031,7.7223,7.999,
ISRG,2005-10-26,9.972,10.293,9.803,10.022,
ISRG,2005-10-27,9.913,10.067,9.75,9.768,
ISRG,2005-10-28,9.823,9.931,9.722,9.79,
ISRG,2005-10-31,9.84,9.98,9.644,9.859,
ISRG,2005-11-01,9.781,9.828,9.531,9.698,
ISRG,2005-11-02,9.663,10.438,9.638,10.311,
ISRG,2005-11-03,10.444,10.652,10.313,10.352,
ISRG,2005-11-04,10.352,10.419,10.167,10.258,
ISRG,2005-11-07,10.272,10.393,10.111,10.26,
ISRG,2005-11-08,10.282,10.503,10.056,10.238,
ISRG,2005-11-09,10.228,10.32,10.13,10.229,
ISRG,2005-11-10,10.633,11.078,10.507,10.954,
ISRG,2005-11-11,11.02,11.104,10.75,11.038,
ISRG,2005-11-14,11.111,11.937,11.067,11.65,"The New Nifty Fifty? A Q&A WITH JOSEPH McNAY -- A noted investor sees a golden age for growth stocks, including Google, aQuantive, Vertex and satellite-radio shares."
ISRG,2005-11-15,11.722,12.081,11.71,11.806,
ISRG,2005-11-16,11.833,11.853,11.341,11.471,
ISRG,2005-11-17,11.556,11.941,11.494,11.886,
ISRG,2005-11-18,11.874,12.219,11.811,12.0,
ISRG,2005-11-21,12.056,12.214,11.897,12.162,
ISRG,2005-11-22,12.218,13.164,12.116,12.833,
ISRG,2005-11-23,12.916,12.932,12.504,12.741,
ISRG,2005-11-25,12.744,12.95,12.67,12.85,
ISRG,2005-11-28,12.896,12.968,12.151,12.379,
ISRG,2005-11-29,12.39,12.788,12.294,12.386,
ISRG,2005-11-30,12.312,12.693,12.29,12.414,
ISRG,2005-12-01,12.533,12.859,12.489,12.818,
ISRG,2005-12-02,12.883,13.304,12.723,12.876,
ISRG,2005-12-05,12.867,13.166,12.668,12.951,
ISRG,2005-12-06,12.984,13.077,12.694,12.728,
ISRG,2005-12-07,12.816,12.889,12.456,12.546,
ISRG,2005-12-08,12.633,12.661,12.358,12.433,
ISRG,2005-12-09,12.447,12.988,12.444,12.943,
ISRG,2005-12-12,12.97,13.591,12.954,13.577,
ISRG,2005-12-13,13.531,13.667,13.089,13.139,
ISRG,2005-12-14,13.21,13.271,12.927,13.078,
ISRG,2005-12-15,13.171,13.183,12.711,12.791,
ISRG,2005-12-16,12.833,13.233,12.819,12.872,
ISRG,2005-12-19,12.874,12.956,12.706,12.792,
ISRG,2005-12-20,12.8,13.071,12.676,12.939,
ISRG,2005-12-21,12.999,13.418,12.944,13.274,
ISRG,2005-12-22,13.381,13.821,13.211,13.688,
ISRG,2005-12-23,13.789,13.866,13.464,13.586,
ISRG,2005-12-27,13.522,13.789,13.244,13.346,
ISRG,2005-12-28,13.444,13.484,13.007,13.301,
ISRG,2005-12-29,13.268,13.321,13.144,13.189,
ISRG,2005-12-30,13.111,13.177,12.926,13.03,
ISRG,2006-01-03,13.21,13.21,12.543,12.867,
ISRG,2006-01-04,12.914,13.564,12.889,13.562,
ISRG,2006-01-05,13.776,13.778,13.306,13.364,
ISRG,2006-01-06,13.081,13.576,13.029,13.341,
ISRG,2006-01-09,13.364,13.889,13.364,13.744,
ISRG,2006-01-10,13.667,14.328,13.642,14.249,
ISRG,2006-01-11,14.326,14.469,13.914,14.147,
ISRG,2006-01-12,14.68,14.798,14.42,14.518,
ISRG,2006-01-13,14.61,14.611,14.081,14.217,
ISRG,2006-01-17,14.178,14.601,14.009,14.566,
ISRG,2006-01-18,14.427,14.678,14.196,14.296,
ISRG,2006-01-19,14.428,14.853,14.34,14.748,
ISRG,2006-01-20,14.779,14.852,14.158,14.231,
ISRG,2006-01-23,14.349,14.59,13.962,14.398,
ISRG,2006-01-24,14.482,15.056,14.447,14.902,
ISRG,2006-01-25,15.364,15.391,14.544,14.699,
ISRG,2006-01-26,14.878,15.019,14.657,14.892,
ISRG,2006-01-27,14.862,15.267,14.824,15.103,
ISRG,2006-01-30,15.173,15.5,14.933,15.109,
ISRG,2006-01-31,15.21,15.301,14.956,15.252,
ISRG,2006-02-01,15.284,15.327,14.296,14.407,
ISRG,2006-02-02,14.333,14.617,14.046,14.14,
ISRG,2006-02-03,13.06,13.839,12.374,12.743,"[""Amazon, EA, Weyerhaeuser A look at companies whose shares are expected to see active trade in Friday's session."", ""Highlights of rising and falling U.S. stocks A roundup of Friday's top advancers and decliners""]"
ISRG,2006-02-06,12.722,12.983,10.93,11.854,
ISRG,2006-02-07,11.551,12.066,10.98,11.168,
ISRG,2006-02-08,11.176,11.176,10.458,10.882,
ISRG,2006-02-09,10.852,11.527,10.781,11.278,
ISRG,2006-02-10,11.286,11.607,11.177,11.464,
ISRG,2006-02-13,11.491,11.606,11.094,11.224,
ISRG,2006-02-14,11.26,11.474,11.163,11.356,
ISRG,2006-02-15,11.281,11.5,11.158,11.352,
ISRG,2006-02-16,11.353,11.424,11.016,11.209,
ISRG,2006-02-17,11.141,11.222,10.752,10.769,
ISRG,2006-02-21,10.722,10.756,9.891,10.148,
ISRG,2006-02-22,10.04,10.511,9.95,10.36,
ISRG,2006-02-23,10.398,10.398,10.028,10.099,
ISRG,2006-02-24,9.883,10.661,9.876,10.534,
ISRG,2006-02-27,10.598,10.688,10.353,10.48,
ISRG,2006-02-28,10.516,10.54,9.944,10.022,
ISRG,2006-03-01,9.958,10.331,9.899,10.267,
ISRG,2006-03-02,10.214,10.422,10.059,10.177,
ISRG,2006-03-03,10.167,10.194,10.03,10.041,
ISRG,2006-03-06,10.088,10.314,9.753,9.977,
ISRG,2006-03-07,9.932,9.997,9.681,9.781,
ISRG,2006-03-08,9.689,9.827,9.514,9.778,
ISRG,2006-03-09,9.842,10.0,9.76,9.889,
ISRG,2006-03-10,9.867,10.41,9.818,10.331,
ISRG,2006-03-13,10.334,10.64,10.32,10.452,
ISRG,2006-03-14,10.447,10.667,10.366,10.487,
ISRG,2006-03-15,10.526,10.573,10.418,10.524,
ISRG,2006-03-16,10.571,11.066,10.478,10.93,
ISRG,2006-03-17,10.982,11.649,10.946,11.572,
ISRG,2006-03-20,11.591,11.961,11.389,11.657,
ISRG,2006-03-21,11.667,11.818,11.417,11.483,
ISRG,2006-03-22,11.397,11.952,11.338,11.892,
ISRG,2006-03-23,11.939,12.14,11.789,12.116,
ISRG,2006-03-24,12.169,12.494,12.037,12.451,
ISRG,2006-03-27,12.489,13.311,12.398,13.233,
ISRG,2006-03-28,13.279,13.572,13.006,13.217,
ISRG,2006-03-29,13.278,13.407,12.817,12.968,
ISRG,2006-03-30,12.861,13.337,12.822,13.184,
ISRG,2006-03-31,13.169,13.488,13.0,13.111,
ISRG,2006-04-03,13.316,13.319,12.611,12.667,
ISRG,2006-04-04,12.606,12.929,12.389,12.45,
ISRG,2006-04-05,12.487,12.611,12.282,12.431,
ISRG,2006-04-06,12.387,12.646,12.333,12.403,
ISRG,2006-04-07,12.5,12.609,12.016,12.082,
ISRG,2006-04-10,12.04,12.389,12.04,12.302,
ISRG,2006-04-11,12.3,12.406,11.679,11.779,
ISRG,2006-04-12,11.728,12.077,11.686,11.779,
ISRG,2006-04-13,11.637,11.939,11.236,11.787,
ISRG,2006-04-17,11.752,11.882,11.422,11.596,
ISRG,2006-04-18,11.551,11.994,11.551,11.897,
ISRG,2006-04-19,11.987,12.159,11.698,11.826,
ISRG,2006-04-20,11.808,12.129,11.742,11.998,
ISRG,2006-04-21,12.096,12.096,11.831,11.869,
ISRG,2006-04-24,11.909,12.308,11.866,12.109,
ISRG,2006-04-25,12.064,12.219,11.778,11.961,
ISRG,2006-04-26,11.999,12.076,11.672,11.991,
ISRG,2006-04-27,11.887,11.982,11.354,11.463,
ISRG,2006-04-28,13.311,14.234,13.231,14.111,"[""Microsoft, Chevron, Conexant Systems A look at companies whose shares are expected to see active trade in Friday's session."", ""Highlights of rising and falling U.S. stocks A roundup of Friday's top advancers and decliners""]"
ISRG,2006-05-01,14.24,14.431,13.9,13.994,
ISRG,2006-05-02,14.069,14.378,13.759,13.851,
ISRG,2006-05-03,14.036,14.036,13.504,13.704,
ISRG,2006-05-04,13.651,14.304,13.642,14.217,
ISRG,2006-05-05,14.306,14.503,14.14,14.203,
ISRG,2006-05-08,14.281,14.281,14.006,14.061,
ISRG,2006-05-09,13.973,14.31,13.973,14.253,
ISRG,2006-05-10,14.182,14.667,14.127,14.313,
ISRG,2006-05-11,14.279,14.411,13.817,13.89,
ISRG,2006-05-12,13.811,13.888,12.973,13.113,
ISRG,2006-05-15,12.923,13.53,12.919,13.4,
ISRG,2006-05-16,13.461,13.636,13.143,13.421,
ISRG,2006-05-17,13.25,13.366,12.796,12.826,
ISRG,2006-05-18,12.917,13.161,12.5,12.562,
ISRG,2006-05-19,12.666,13.122,12.444,12.879,
ISRG,2006-05-22,12.803,12.818,12.353,12.623,
ISRG,2006-05-23,12.753,12.867,12.13,12.172,
ISRG,2006-05-24,12.15,12.431,11.496,12.112,
ISRG,2006-05-25,12.206,12.578,11.898,12.299,
ISRG,2006-05-26,12.333,12.648,12.173,12.529,
ISRG,2006-05-30,12.5,12.508,11.974,11.993,
ISRG,2006-05-31,12.07,12.423,11.957,12.366,
ISRG,2006-06-01,12.441,12.654,12.204,12.654,
ISRG,2006-06-02,12.778,13.189,12.722,13.009,
ISRG,2006-06-05,12.914,12.993,12.167,12.208,
ISRG,2006-06-06,12.241,12.352,11.777,12.007,
ISRG,2006-06-07,12.183,13.004,12.178,12.557,
ISRG,2006-06-08,12.486,12.744,12.222,12.706,
ISRG,2006-06-09,12.889,12.932,12.283,12.363,
ISRG,2006-06-12,12.31,12.564,12.263,12.278,
ISRG,2006-06-13,12.231,12.368,11.717,11.826,
ISRG,2006-06-14,11.803,12.033,11.569,11.8,
ISRG,2006-06-15,11.962,12.056,11.814,11.982,
ISRG,2006-06-16,11.949,11.972,11.522,11.64,
ISRG,2006-06-19,11.656,11.656,10.947,11.089,
ISRG,2006-06-20,11.024,11.211,10.787,10.999,
ISRG,2006-06-21,11.067,11.582,10.922,11.34,
ISRG,2006-06-22,11.32,11.687,11.154,11.624,
ISRG,2006-06-23,11.601,12.107,11.554,11.946,
ISRG,2006-06-26,12.018,12.077,11.621,11.861,
ISRG,2006-06-27,11.889,12.081,11.737,11.862,
ISRG,2006-06-28,11.94,12.056,11.673,11.88,
ISRG,2006-06-29,11.979,12.809,11.933,12.786,
ISRG,2006-06-30,12.886,13.108,12.45,12.778,
ISRG,2006-07-03,12.966,13.26,12.807,13.039,
ISRG,2006-07-05,12.943,13.176,12.674,13.13,
ISRG,2006-07-06,13.19,13.362,12.917,13.1,
ISRG,2006-07-07,13.044,13.063,12.712,12.787,
ISRG,2006-07-10,12.778,13.043,12.26,12.32,
ISRG,2006-07-11,12.277,12.822,12.193,12.753,
ISRG,2006-07-12,12.699,12.902,12.429,12.466,
ISRG,2006-07-13,12.581,13.111,12.581,12.736,
ISRG,2006-07-14,12.771,13.167,12.771,12.956,
ISRG,2006-07-17,12.896,13.048,12.639,12.762,
ISRG,2006-07-18,12.847,13.062,12.619,12.908,
ISRG,2006-07-19,12.95,13.57,12.896,13.474,
ISRG,2006-07-20,13.556,13.716,13.224,13.253,
ISRG,2006-07-21,13.209,13.292,12.94,13.022,
ISRG,2006-07-24,13.098,13.764,13.086,13.543,
ISRG,2006-07-25,13.652,13.73,13.296,13.546,
ISRG,2006-07-26,13.56,13.56,12.099,12.382,
ISRG,2006-07-27,11.189,11.829,10.792,11.033,
ISRG,2006-07-28,10.89,11.282,10.778,11.282,
ISRG,2006-07-31,11.282,11.282,10.5,10.578,
ISRG,2006-08-01,10.523,10.794,10.139,10.712,
ISRG,2006-08-02,10.736,10.984,10.711,10.881,
ISRG,2006-08-03,10.833,10.942,10.587,10.912,
ISRG,2006-08-04,10.922,11.267,10.922,11.06,
ISRG,2006-08-07,11.003,11.06,10.592,10.794,
ISRG,2006-08-08,10.833,11.076,10.702,10.792,
ISRG,2006-08-09,10.802,11.011,10.619,10.65,
ISRG,2006-08-10,10.568,10.648,10.252,10.602,
ISRG,2006-08-11,10.6,10.6,10.374,10.489,
ISRG,2006-08-14,10.608,10.608,10.21,10.224,
ISRG,2006-08-15,10.308,10.716,10.212,10.618,
ISRG,2006-08-16,10.686,10.772,10.494,10.772,
ISRG,2006-08-17,10.744,10.877,10.633,10.778,
ISRG,2006-08-18,10.778,10.807,10.637,10.751,
ISRG,2006-08-21,10.708,10.809,10.679,10.714,
ISRG,2006-08-22,10.67,10.768,10.438,10.516,
ISRG,2006-08-23,10.522,10.583,10.19,10.217,
ISRG,2006-08-24,10.206,10.514,10.044,10.444,
ISRG,2006-08-25,10.389,10.489,10.172,10.233,
ISRG,2006-08-28,10.206,10.437,10.206,10.357,
ISRG,2006-08-29,10.408,10.433,10.132,10.259,
ISRG,2006-08-30,10.301,10.344,10.124,10.268,
ISRG,2006-08-31,10.302,10.556,10.182,10.489,
ISRG,2006-09-01,10.563,10.591,10.417,10.561,
ISRG,2006-09-05,10.556,10.704,10.423,10.673,
ISRG,2006-09-06,10.648,10.682,10.51,10.559,
ISRG,2006-09-07,10.511,10.648,10.444,10.52,
ISRG,2006-09-08,10.583,10.632,10.358,10.371,
ISRG,2006-09-11,10.357,10.482,10.258,10.44,
ISRG,2006-09-12,10.482,10.614,10.384,10.572,
ISRG,2006-09-13,10.504,11.112,10.504,11.082,
ISRG,2006-09-14,11.114,11.33,10.783,10.819,
ISRG,2006-09-15,10.784,11.111,10.728,11.042,
ISRG,2006-09-18,11.29,11.606,11.29,11.388,
ISRG,2006-09-19,11.407,11.444,11.041,11.389,
ISRG,2006-09-20,11.444,11.498,11.233,11.293,
ISRG,2006-09-21,11.382,11.646,11.294,11.488,
ISRG,2006-09-22,11.448,11.448,11.26,11.373,
ISRG,2006-09-25,11.448,11.698,11.321,11.587,
ISRG,2006-09-26,11.639,11.709,11.472,11.616,
ISRG,2006-09-27,11.543,12.188,11.536,12.121,
ISRG,2006-09-28,12.122,12.123,11.838,11.983,
ISRG,2006-09-29,12.061,12.216,11.696,11.717,
ISRG,2006-10-02,11.69,11.781,11.369,11.39,
ISRG,2006-10-03,11.363,11.498,11.252,11.4,
ISRG,2006-10-04,11.371,11.631,11.279,11.582,
ISRG,2006-10-05,11.546,11.921,11.546,11.842,
ISRG,2006-10-06,12.011,12.044,11.75,11.802,
ISRG,2006-10-09,11.803,12.379,11.722,12.027,
ISRG,2006-10-10,12.066,12.234,11.889,12.107,
ISRG,2006-10-11,12.059,12.217,11.986,12.213,
ISRG,2006-10-12,12.37,12.679,12.26,12.442,
ISRG,2006-10-13,12.457,12.641,12.387,12.453,
ISRG,2006-10-16,12.497,12.566,12.362,12.407,
ISRG,2006-10-17,12.378,12.394,11.982,12.017,
ISRG,2006-10-18,12.034,12.136,11.84,11.924,
ISRG,2006-10-19,11.879,12.094,11.862,12.022,
ISRG,2006-10-20,11.999,12.07,11.896,11.97,
ISRG,2006-10-23,11.91,12.283,11.783,12.264,
ISRG,2006-10-24,12.227,12.264,12.0,12.118,
ISRG,2006-10-25,12.168,12.168,11.9,11.919,
ISRG,2006-10-26,12.046,13.191,11.92,12.462,
ISRG,2006-10-27,11.471,11.827,11.038,11.187,"Microsoft shares slip; McAfee surges after results SAN FRANCISCO (MarketWatch) - Shares of Microsoft Corp. edged higher Thursday evening after the world's largest software company posted quarterly results above Wall Street's expectations, while stock in McAfee Inc. surged after the security software maker's results forecast topped analyst estimates."
ISRG,2006-10-30,11.066,11.282,10.822,11.189,
ISRG,2006-10-31,11.182,11.209,10.971,11.02,
ISRG,2006-11-01,11.0,11.133,10.763,10.794,
ISRG,2006-11-02,10.759,10.967,10.747,10.796,
ISRG,2006-11-03,10.782,10.829,10.627,10.733,
ISRG,2006-11-06,10.747,11.222,10.747,11.094,
ISRG,2006-11-07,11.116,11.31,10.899,10.976,
ISRG,2006-11-08,10.889,11.056,10.818,10.878,
ISRG,2006-11-09,10.833,10.883,10.702,10.719,
ISRG,2006-11-10,10.719,10.878,10.667,10.817,
ISRG,2006-11-13,10.704,10.787,10.533,10.58,
ISRG,2006-11-14,10.593,10.656,10.506,10.583,
ISRG,2006-11-15,10.554,10.678,10.472,10.578,
ISRG,2006-11-16,10.641,10.651,10.46,10.533,
ISRG,2006-11-17,10.474,10.678,10.436,10.643,
ISRG,2006-11-20,10.686,11.326,10.686,11.05,
ISRG,2006-11-21,11.078,11.104,10.898,10.989,
ISRG,2006-11-22,11.039,11.039,10.788,10.91,
ISRG,2006-11-24,10.861,11.024,10.779,11.007,
ISRG,2006-11-27,11.179,11.333,10.967,11.026,
ISRG,2006-11-28,11.016,11.5,10.963,11.422,
ISRG,2006-11-29,11.433,11.62,11.139,11.359,
ISRG,2006-11-30,11.36,11.392,11.158,11.291,
ISRG,2006-12-01,11.322,11.348,11.092,11.283,
ISRG,2006-12-04,11.284,11.5,11.246,11.366,
ISRG,2006-12-05,11.431,11.431,11.262,11.306,
ISRG,2006-12-06,11.311,11.563,11.28,11.541,
ISRG,2006-12-07,11.604,11.832,11.474,11.712,
ISRG,2006-12-08,11.704,11.887,11.639,11.663,
ISRG,2006-12-11,11.73,11.944,11.706,11.831,
ISRG,2006-12-12,11.8,11.911,11.652,11.74,
ISRG,2006-12-13,11.754,11.781,11.486,11.544,
ISRG,2006-12-14,11.529,11.743,11.481,11.521,
ISRG,2006-12-15,11.58,11.722,11.452,11.541,
ISRG,2006-12-18,11.609,11.667,11.327,11.339,
ISRG,2006-12-19,11.299,11.333,11.129,11.278,
ISRG,2006-12-20,11.28,11.347,11.143,11.16,
ISRG,2006-12-21,11.153,11.2,10.974,10.996,
ISRG,2006-12-22,11.0,11.082,10.759,10.78,
ISRG,2006-12-26,10.78,10.801,10.696,10.718,
ISRG,2006-12-27,10.781,10.944,10.727,10.777,
ISRG,2006-12-28,10.722,10.794,10.677,10.748,
ISRG,2006-12-29,10.733,10.83,10.627,10.656,
ISRG,2007-01-03,10.782,10.877,10.337,10.498,
ISRG,2007-01-04,10.463,10.654,10.461,10.578,
ISRG,2007-01-05,10.564,10.659,10.391,10.453,
ISRG,2007-01-08,10.408,10.434,10.09,10.133,
ISRG,2007-01-09,10.116,10.227,9.866,9.93,
ISRG,2007-01-10,9.889,9.923,9.631,9.679,
ISRG,2007-01-11,9.644,10.168,9.578,10.138,
ISRG,2007-01-12,10.213,10.532,10.213,10.448,
ISRG,2007-01-16,10.524,10.524,10.312,10.346,
ISRG,2007-01-17,10.329,10.556,10.291,10.528,
ISRG,2007-01-18,10.531,10.584,10.371,10.396,
ISRG,2007-01-19,10.367,10.443,10.307,10.379,
ISRG,2007-01-22,10.522,10.83,10.459,10.787,
ISRG,2007-01-23,10.788,10.979,10.711,10.844,
ISRG,2007-01-24,10.867,10.889,10.719,10.762,
ISRG,2007-01-25,10.762,10.763,10.489,10.573,
ISRG,2007-01-26,10.592,10.647,10.414,10.553,
ISRG,2007-01-29,10.592,10.853,10.51,10.836,
ISRG,2007-01-30,10.784,10.939,10.604,10.911,
ISRG,2007-01-31,10.916,11.021,10.739,10.934,
ISRG,2007-02-01,11.016,11.096,10.931,11.036,
ISRG,2007-02-02,12.778,13.108,12.616,12.974,"Amazon.com moves lower on margin concerns; EA rises SAN FRANCISCO (MarketWatch) -- Amazon.com Inc. shares eased Thursday evening following concerns that the online retailer's margins will come under pressure, while Electronic Arts Inc. shares were lifted after the video game publisher's results came in higher than expected."
ISRG,2007-02-05,12.896,13.0,12.698,12.761,
ISRG,2007-02-06,12.727,12.922,12.639,12.833,
ISRG,2007-02-07,12.793,12.968,12.597,12.726,
ISRG,2007-02-08,12.708,12.801,12.56,12.724,
ISRG,2007-02-09,12.684,12.833,12.317,12.451,
ISRG,2007-02-12,12.449,12.633,12.247,12.611,
ISRG,2007-02-13,12.572,12.717,12.444,12.578,
ISRG,2007-02-14,12.539,12.778,12.538,12.649,
ISRG,2007-02-15,12.643,12.699,12.464,12.518,
ISRG,2007-02-16,12.468,12.722,12.463,12.712,
ISRG,2007-02-20,12.719,12.85,12.639,12.778,
ISRG,2007-02-21,12.759,12.937,12.722,12.764,
ISRG,2007-02-22,12.778,12.791,12.522,12.632,
ISRG,2007-02-23,12.63,12.65,12.488,12.564,
ISRG,2007-02-26,12.657,12.711,12.389,12.583,
ISRG,2007-02-27,12.398,12.44,12.133,12.168,
ISRG,2007-02-28,12.176,12.403,11.911,12.344,
ISRG,2007-03-01,12.12,12.222,11.839,12.111,
ISRG,2007-03-02,12.11,12.166,11.922,11.947,
ISRG,2007-03-05,11.779,11.944,11.563,11.581,
ISRG,2007-03-06,11.773,12.203,11.702,12.058,
ISRG,2007-03-07,12.062,12.141,11.944,12.027,
ISRG,2007-03-08,12.144,12.368,12.14,12.213,
ISRG,2007-03-09,12.379,12.556,12.267,12.306,
ISRG,2007-03-12,12.251,12.328,12.124,12.249,
ISRG,2007-03-13,12.111,12.271,11.983,11.989,
ISRG,2007-03-14,11.978,12.122,11.819,12.102,
ISRG,2007-03-15,12.113,12.5,12.11,12.399,
ISRG,2007-03-16,12.376,12.583,12.317,12.408,
ISRG,2007-03-19,12.507,12.917,12.408,12.692,
ISRG,2007-03-20,12.74,12.909,12.693,12.848,
ISRG,2007-03-21,12.88,12.926,12.789,12.911,
ISRG,2007-03-22,12.929,13.634,12.929,13.407,
ISRG,2007-03-23,13.312,13.603,13.293,13.519,
ISRG,2007-03-26,13.529,13.711,13.354,13.709,
ISRG,2007-03-27,13.709,13.889,13.612,13.701,
ISRG,2007-03-28,13.611,13.832,13.529,13.597,
ISRG,2007-03-29,13.816,13.827,13.47,13.668,
ISRG,2007-03-30,13.706,13.721,13.4,13.508,"Metals and mining shares shine in first quarter; housing dulls NEW YORK (MarketWatch) -- Shares of metals and mining companies were the big winners in the first quarter of 2007, propped up by strong prices for gold, copper, nickel and platinum among others, while shares of companies with any link to the housing sector got pummeled as subprime loan woes and the housing market's slowdown delivered a double whammy."
ISRG,2007-04-02,13.498,13.64,13.458,13.549,
ISRG,2007-04-03,13.579,13.823,13.563,13.697,
ISRG,2007-04-04,13.737,13.963,13.667,13.902,
ISRG,2007-04-05,13.932,13.946,13.703,13.836,
ISRG,2007-04-09,13.811,13.939,13.722,13.752,
ISRG,2007-04-10,13.729,13.778,13.596,13.647,
ISRG,2007-04-11,13.667,13.783,13.496,13.668,
ISRG,2007-04-12,13.613,13.758,13.519,13.688,
ISRG,2007-04-13,13.716,13.93,13.677,13.86,
ISRG,2007-04-16,13.974,14.197,13.911,13.943,
ISRG,2007-04-17,14.001,14.048,13.874,13.917,
ISRG,2007-04-18,13.983,14.072,13.512,13.612,
ISRG,2007-04-19,13.588,13.632,13.393,13.466,
ISRG,2007-04-20,14.221,14.956,14.221,14.639,Stocks in focus for Friday Stocks in focus for Friday
ISRG,2007-04-23,14.641,15.062,14.581,14.917,
ISRG,2007-04-24,14.759,14.888,14.552,14.823,
ISRG,2007-04-25,14.811,15.078,14.667,14.859,
ISRG,2007-04-26,14.819,14.924,14.717,14.882,
ISRG,2007-04-27,14.791,14.829,14.644,14.812,
ISRG,2007-04-30,14.733,14.811,14.361,14.407,
ISRG,2007-05-01,14.531,14.573,14.193,14.563,
ISRG,2007-05-02,14.567,14.907,14.509,14.898,
ISRG,2007-05-03,14.961,15.134,14.778,15.05,
ISRG,2007-05-04,15.021,15.056,14.742,14.882,
ISRG,2007-05-07,14.847,15.034,14.778,14.939,
ISRG,2007-05-08,14.827,14.972,14.713,14.941,
ISRG,2007-05-09,14.844,15.1,14.811,15.001,
ISRG,2007-05-10,14.996,15.0,14.452,14.534,
ISRG,2007-05-11,14.594,14.74,14.337,14.544,
ISRG,2007-05-14,14.556,14.693,14.396,14.469,
ISRG,2007-05-15,14.472,14.608,14.436,14.464,
ISRG,2007-05-16,14.586,14.642,14.184,14.372,
ISRG,2007-05-17,14.384,14.457,14.228,14.363,
ISRG,2007-05-18,14.556,14.776,14.408,14.738,
ISRG,2007-05-21,14.709,14.844,14.633,14.769,
ISRG,2007-05-22,14.743,14.954,14.628,14.843,
ISRG,2007-05-23,14.887,15.534,14.816,15.232,
ISRG,2007-05-24,15.167,15.631,15.0,15.173,
ISRG,2007-05-25,15.202,15.356,15.112,15.221,
ISRG,2007-05-29,15.222,15.29,15.139,15.189,
ISRG,2007-05-30,15.151,15.3,14.96,15.299,
ISRG,2007-05-31,15.308,15.756,15.199,15.292,
ISRG,2007-06-01,15.378,15.522,15.289,15.448,
ISRG,2007-06-04,15.647,15.998,15.544,15.932,
ISRG,2007-06-05,15.909,16.244,15.821,15.854,
ISRG,2007-06-06,15.842,15.93,15.633,15.634,
ISRG,2007-06-07,15.623,15.726,15.223,15.259,
ISRG,2007-06-08,15.189,15.583,15.123,15.444,
ISRG,2007-06-11,15.524,15.734,15.45,15.59,
ISRG,2007-06-12,15.591,15.611,15.233,15.327,
ISRG,2007-06-13,15.447,15.613,15.316,15.564,
ISRG,2007-06-14,15.55,15.79,15.533,15.696,Thursday's biggest stock gainers and decliners Thursday's biggest stock gainers and decliners
ISRG,2007-06-15,15.854,15.861,15.549,15.618,
ISRG,2007-06-18,15.619,15.747,15.56,15.649,
ISRG,2007-06-19,15.533,15.861,15.522,15.649,
ISRG,2007-06-20,15.786,15.831,15.379,15.418,
ISRG,2007-06-21,15.397,15.578,15.272,15.442,
ISRG,2007-06-22,15.389,15.526,15.223,15.283,
ISRG,2007-06-25,15.391,15.491,15.106,15.167,
ISRG,2007-06-26,15.168,15.334,15.004,15.081,
ISRG,2007-06-27,15.006,15.456,15.004,15.447,
ISRG,2007-06-28,15.447,15.579,15.338,15.389,
ISRG,2007-06-29,15.383,15.578,15.319,15.419,
ISRG,2007-07-02,15.444,15.826,15.368,15.772,
ISRG,2007-07-03,15.767,15.903,15.726,15.768,
ISRG,2007-07-05,15.723,15.904,15.627,15.86,
ISRG,2007-07-06,15.912,16.181,15.851,16.1,
ISRG,2007-07-09,16.111,16.498,16.073,16.378,
ISRG,2007-07-10,16.326,16.589,16.0,16.279,
ISRG,2007-07-11,16.281,16.463,16.146,16.378,
ISRG,2007-07-12,16.416,16.556,16.261,16.544,
ISRG,2007-07-13,16.546,16.664,16.353,16.486,
ISRG,2007-07-16,16.5,16.506,16.228,16.314,
ISRG,2007-07-17,16.487,16.75,16.222,16.549,
ISRG,2007-07-18,16.463,16.597,16.388,16.491,
ISRG,2007-07-19,16.623,16.774,16.458,16.676,"[""Stocks in focus for Friday SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trading in Friday's session are Boston Scientific Corp., Caterpillar Inc., and Citigroup Inc."", ""Google shares fall 7%; Microsoft lower; SanDisk climbs Google Inc. shares dropped more than 7% in late-trading Thursday after the Internet search giant\u2019s quarterly earnings fell short of Wall Street\u2019s outlook, and shares of Microsoft Corp. moved lower after the software giant\u2019s quarterly earnings met expectations.""]"
ISRG,2007-07-20,19.509,22.204,19.509,22.066,Friday's biggest stock gainers and decliners Friday's biggest stock gainers and decliners
ISRG,2007-07-23,22.652,23.862,22.518,23.114,
ISRG,2007-07-24,22.444,22.771,22.247,22.572,
ISRG,2007-07-25,22.781,22.812,21.683,22.241,
ISRG,2007-07-26,21.8,22.753,21.683,22.367,
ISRG,2007-07-27,22.333,23.139,22.09,22.506,
ISRG,2007-07-30,22.531,24.109,22.229,23.909,
ISRG,2007-07-31,23.987,25.002,23.592,23.623,
ISRG,2007-08-01,23.598,23.808,22.92,23.507,
ISRG,2007-08-02,23.664,23.667,23.086,23.55,
ISRG,2007-08-03,23.661,23.866,22.709,22.709,
ISRG,2007-08-06,22.883,23.322,22.137,23.17,
ISRG,2007-08-07,23.249,23.478,22.763,23.361,
ISRG,2007-08-08,23.529,23.932,23.056,23.472,
ISRG,2007-08-09,23.0,23.722,22.263,22.367,
ISRG,2007-08-10,22.056,22.647,21.784,21.9,
ISRG,2007-08-13,22.491,22.653,21.934,22.356,
ISRG,2007-08-14,22.146,22.433,21.841,21.867,
ISRG,2007-08-15,21.833,22.423,21.482,21.623,
ISRG,2007-08-16,21.378,22.041,20.567,21.07,
ISRG,2007-08-17,21.484,22.132,20.94,22.126,
ISRG,2007-08-20,22.252,22.353,21.958,22.056,
ISRG,2007-08-21,21.967,23.033,21.967,22.843,
ISRG,2007-08-22,23.108,23.578,22.949,23.437,
ISRG,2007-08-23,23.556,23.568,22.784,22.833,
ISRG,2007-08-24,22.867,23.573,22.68,23.496,
ISRG,2007-08-27,23.444,23.707,22.956,23.267,
ISRG,2007-08-28,23.056,23.417,22.679,22.887,
ISRG,2007-08-29,23.067,24.026,22.924,23.953,
ISRG,2007-08-30,23.831,24.491,23.622,24.118,
ISRG,2007-08-31,24.444,24.919,24.003,24.587,
ISRG,2007-09-04,24.841,25.347,24.556,25.187,
ISRG,2007-09-05,25.106,25.414,24.533,24.894,
ISRG,2007-09-06,25.094,25.554,24.744,25.552,
ISRG,2007-09-07,25.114,25.26,24.472,24.663,
ISRG,2007-09-10,24.883,25.089,24.292,24.794,
ISRG,2007-09-11,25.038,25.056,24.129,24.369,
ISRG,2007-09-12,24.444,25.088,24.406,24.696,
ISRG,2007-09-13,24.846,25.049,24.571,24.571,
ISRG,2007-09-14,24.444,24.649,23.66,23.778,
ISRG,2007-09-17,23.756,24.11,23.3,23.611,
ISRG,2007-09-18,23.999,25.053,23.683,25.006,
ISRG,2007-09-19,25.473,25.956,24.728,25.213,
ISRG,2007-09-20,25.491,25.538,24.911,24.982,
ISRG,2007-09-21,25.032,25.217,24.448,24.657,
ISRG,2007-09-24,25.0,25.308,24.45,24.876,
ISRG,2007-09-25,24.57,25.329,24.57,25.294,
ISRG,2007-09-26,25.512,26.156,25.408,25.701,
ISRG,2007-09-27,25.994,26.0,25.401,25.667,
ISRG,2007-09-28,25.724,25.953,25.476,25.556,
ISRG,2007-10-01,25.932,25.944,25.522,25.711,
ISRG,2007-10-02,25.849,26.443,25.722,25.902,
ISRG,2007-10-03,26.333,27.264,25.863,26.624,
ISRG,2007-10-04,26.667,26.997,26.117,26.614,
ISRG,2007-10-05,27.062,27.484,26.806,27.448,
ISRG,2007-10-08,27.544,28.554,27.476,28.529,
ISRG,2007-10-09,28.707,29.11,28.172,28.72,
ISRG,2007-10-10,28.771,29.39,28.487,28.763,
ISRG,2007-10-11,29.001,29.277,26.892,27.517,
ISRG,2007-10-12,27.717,28.143,27.283,27.71,
ISRG,2007-10-15,27.844,28.25,27.346,27.859,
ISRG,2007-10-16,27.393,27.97,26.731,27.178,"First American midcap manager is Stockpicker of the Quarter SAN FRANCISCO (MarketWatch) -- Cash may be king, but to many price-conscious investors, companies awash in cash are the true heirs to the throne."
ISRG,2007-10-17,27.578,27.6,26.009,26.302,
ISRG,2007-10-18,26.596,28.719,26.424,28.493,"Stocks in focus for Friday SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are likely to see active trading during Friday's session are Wachovia, 3M, Caterpillar, and Harley-Davidson."
ISRG,2007-10-19,29.86,31.058,29.544,29.927,
ISRG,2007-10-22,29.758,31.9,29.444,31.762,
ISRG,2007-10-23,32.944,33.817,32.278,33.81,
ISRG,2007-10-24,33.643,35.287,33.139,35.263,
ISRG,2007-10-25,35.99,37.21,35.403,36.607,
ISRG,2007-10-26,37.037,37.737,36.443,36.567,
ISRG,2007-10-29,36.943,36.96,35.13,35.7,
ISRG,2007-10-30,35.27,36.697,35.11,35.953,
ISRG,2007-10-31,36.057,36.61,35.677,36.32,
ISRG,2007-11-01,35.803,36.6,35.443,35.78,
ISRG,2007-11-02,35.947,36.21,33.763,34.643,
ISRG,2007-11-05,33.8,34.863,33.34,34.38,
ISRG,2007-11-06,34.863,35.487,34.14,35.23,
ISRG,2007-11-07,34.503,35.61,34.06,34.383,
ISRG,2007-11-08,34.507,34.873,31.556,32.653,
ISRG,2007-11-09,31.556,32.444,31.111,31.363,
ISRG,2007-11-12,30.673,31.656,29.333,29.607,
ISRG,2007-11-13,29.84,30.813,29.333,30.617,
ISRG,2007-11-14,31.383,32.436,30.841,31.249,
ISRG,2007-11-15,31.039,32.081,31.02,31.436,
ISRG,2007-11-16,31.69,31.873,30.489,31.183,
ISRG,2007-11-19,30.99,31.963,30.782,31.581,
ISRG,2007-11-20,31.781,33.103,31.111,31.989,
ISRG,2007-11-21,31.667,32.1,30.894,31.097,
ISRG,2007-11-23,31.314,31.833,31.056,31.523,
ISRG,2007-11-26,31.874,32.778,31.389,31.49,
ISRG,2007-11-27,32.08,33.043,31.556,32.942,
ISRG,2007-11-28,33.5,36.22,33.443,36.057,
ISRG,2007-11-29,36.11,36.887,35.41,35.777,
ISRG,2007-11-30,36.747,36.773,35.04,36.41,
ISRG,2007-12-03,36.63,37.193,35.89,36.467,
ISRG,2007-12-04,36.097,36.987,35.557,36.183,
ISRG,2007-12-05,36.667,37.09,36.19,36.993,
ISRG,2007-12-06,36.99,38.62,36.723,38.31,
ISRG,2007-12-07,38.557,39.417,38.333,39.223,
ISRG,2007-12-10,39.81,39.953,38.483,38.62,
ISRG,2007-12-11,38.91,39.387,37.017,37.343,
ISRG,2007-12-12,38.337,38.5,36.203,37.25,
ISRG,2007-12-13,36.717,37.25,35.667,36.51,
ISRG,2007-12-14,36.017,37.157,35.7,36.1,
ISRG,2007-12-17,36.063,36.557,33.753,33.95,
ISRG,2007-12-18,34.447,34.667,32.17,34.177,
ISRG,2007-12-19,34.06,35.43,33.9,34.773,
ISRG,2007-12-20,35.023,35.813,35.023,35.737,
ISRG,2007-12-21,36.443,36.5,35.51,36.16,
ISRG,2007-12-24,36.027,37.11,35.92,37.09,
ISRG,2007-12-26,37.14,37.543,36.573,37.25,
ISRG,2007-12-27,37.113,37.647,36.38,36.617,
ISRG,2007-12-28,36.807,37.033,35.78,36.127,
ISRG,2007-12-31,35.86,36.583,35.847,35.89,
ISRG,2008-01-02,35.96,36.72,35.0,35.993,
ISRG,2008-01-03,35.98,36.22,35.64,35.75,
ISRG,2008-01-04,35.06,35.37,33.587,33.89,
ISRG,2008-01-07,34.037,34.74,32.939,33.33,
ISRG,2008-01-08,31.778,32.514,30.072,30.192,
ISRG,2008-01-09,29.517,30.506,28.134,29.293,
ISRG,2008-01-10,28.608,30.087,28.258,29.737,
ISRG,2008-01-11,29.356,30.08,28.777,29.132,
ISRG,2008-01-14,29.621,29.86,29.147,29.521,
ISRG,2008-01-15,28.784,29.378,27.833,28.469,
ISRG,2008-01-16,27.839,29.999,27.691,29.45,
ISRG,2008-01-17,29.666,30.101,28.324,29.038,
ISRG,2008-01-18,29.001,29.566,28.446,29.119,
ISRG,2008-01-22,26.68,30.0,25.903,29.093,
ISRG,2008-01-23,28.331,30.127,27.231,30.096,
ISRG,2008-01-24,30.333,31.064,29.457,30.0,
ISRG,2008-01-25,30.552,30.947,29.802,29.889,
ISRG,2008-01-28,30.0,30.873,29.121,30.841,
ISRG,2008-01-29,30.439,30.439,27.11,27.144,
ISRG,2008-01-30,27.178,27.629,25.951,26.111,
ISRG,2008-01-31,25.45,28.333,25.251,28.222,
ISRG,2008-02-01,32.526,34.937,32.333,33.957,"Google shares fall; Motorola shares charge up 11% Shares of Google fall 8%, with the sell-off prompted after a shortfall in the search giant's quarterly revenue."
ISRG,2008-02-04,34.103,35.09,33.723,34.167,
ISRG,2008-02-05,34.103,35.0,33.91,34.21,
ISRG,2008-02-06,34.423,34.667,32.556,32.642,
ISRG,2008-02-07,32.222,33.85,31.998,33.183,
ISRG,2008-02-08,33.333,33.707,32.8,33.41,
ISRG,2008-02-11,33.28,33.763,33.0,33.537,
ISRG,2008-02-12,33.777,33.777,32.588,32.964,
ISRG,2008-02-13,33.223,34.33,33.058,34.283,
ISRG,2008-02-14,34.443,34.767,33.343,33.343,
ISRG,2008-02-15,33.193,34.163,32.89,33.697,
ISRG,2008-02-19,34.257,34.383,31.902,32.278,
ISRG,2008-02-20,32.058,32.679,31.316,32.381,
ISRG,2008-02-21,32.611,32.777,31.67,31.807,
ISRG,2008-02-22,31.904,32.449,31.493,32.397,
ISRG,2008-02-25,32.336,32.721,31.73,32.62,
ISRG,2008-02-26,32.538,33.333,31.899,32.914,
ISRG,2008-02-27,32.75,33.044,32.227,32.769,
ISRG,2008-02-28,31.944,32.72,31.908,32.212,
ISRG,2008-02-29,31.778,32.057,31.157,31.324,
ISRG,2008-03-03,31.222,31.664,30.583,31.523,
ISRG,2008-03-04,31.32,31.876,30.373,31.12,
ISRG,2008-03-05,31.352,32.101,31.132,31.813,
ISRG,2008-03-06,31.481,32.072,29.98,30.084,
ISRG,2008-03-07,29.476,30.504,28.889,29.417,
ISRG,2008-03-10,29.201,29.898,28.263,28.398,
ISRG,2008-03-11,29.559,29.947,28.984,29.686,
ISRG,2008-03-12,29.666,31.11,29.446,30.487,
ISRG,2008-03-13,29.989,31.809,29.472,31.664,
ISRG,2008-03-14,32.222,32.344,30.641,31.452,
ISRG,2008-03-17,30.168,31.869,30.167,31.097,
ISRG,2008-03-18,31.922,33.02,31.507,32.75,
ISRG,2008-03-19,32.568,33.543,32.222,32.407,
ISRG,2008-03-20,32.383,33.49,32.05,33.41,
ISRG,2008-03-24,33.637,37.223,33.533,36.36,
ISRG,2008-03-25,36.657,36.763,35.753,36.213,
ISRG,2008-03-26,36.197,36.25,35.223,35.997,
ISRG,2008-03-27,36.113,36.437,35.67,35.763,
ISRG,2008-03-28,36.047,36.89,35.797,35.857,
ISRG,2008-03-31,36.217,36.777,35.587,36.04,
ISRG,2008-04-01,36.557,38.66,36.223,38.55,
ISRG,2008-04-02,38.483,38.877,37.557,37.78,
ISRG,2008-04-03,37.837,37.947,37.117,37.443,
ISRG,2008-04-04,37.84,38.0,36.913,37.603,
ISRG,2008-04-07,38.11,39.767,37.91,38.35,
ISRG,2008-04-08,38.327,39.047,37.917,38.567,
ISRG,2008-04-09,38.767,38.8,36.877,37.34,
ISRG,2008-04-10,38.093,39.777,37.75,39.32,
ISRG,2008-04-11,38.473,38.58,36.693,37.063,
ISRG,2008-04-14,36.917,37.0,35.087,36.093,
ISRG,2008-04-15,36.443,37.757,36.15,37.757,
ISRG,2008-04-16,38.157,38.507,37.68,38.443,
ISRG,2008-04-17,38.457,39.553,38.13,38.723,"[""Google leads tech-sector surge after quarterly results Google shares leap in late trading after the search giant posts a 31% increase in quarterly profit, despite concerns about growth in the company\u2019s core search-advertising business."", ""Stocks to watch for Friday SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trade in Friday's session are Citigroup, Caterpillar, Honeywell and Xerox.""]"
ISRG,2008-04-18,34.503,34.66,31.689,32.056,"Friday's biggest gaining and declining stocks Among the companies whose shares are expected to see active trade in Friday’s session are Citigroup, Google, Caterpillar and Honeywell."
ISRG,2008-04-21,32.12,32.556,30.624,32.387,
ISRG,2008-04-22,31.669,31.887,30.556,30.613,
ISRG,2008-04-23,30.773,31.608,30.207,31.439,"[""Stocks may be cheaper, but still not worth buying The stock market's recent rough ride means \""there are a lot of good companies at low prices,\"" but Charles Mizrahi, editor of the Hidden Values Alert newsletter says that few are actually cheap enough to be \""raging bargains.\"" In a radio interview, Mizrahi said that many high-quality names remain overpriced and are, thus, unattractive, putting Google and Apple into that camp. He also said he would sell Bank of America and SunTrust Banks because they are \""too hard to value\"" while the sub-prime banking crisis is shaking out."", ""These stocks may be touted, but they remain overpriced The stock market\u2019s recent rough ride means \u201cthere are a lot of good companies at low prices,\u201d but Charles Mizrahi, editor of the Hidden Values Alert newsletter, says that few are actually cheap enough to be \u201craging bargains.\u201d""]"
ISRG,2008-04-24,31.223,31.944,30.452,30.956,
ISRG,2008-04-25,31.099,31.312,30.56,31.087,
ISRG,2008-04-28,31.439,32.188,31.352,31.722,
ISRG,2008-04-29,31.667,32.579,31.444,32.334,"Hard Times for Medical-Equipment Stocks As hospitals cut back on pricey purchases, makers of CAT scans and other devices will feel the heat."
ISRG,2008-04-30,32.122,32.872,31.809,32.14,
ISRG,2008-05-01,32.433,32.872,31.933,32.717,
ISRG,2008-05-02,33.003,33.167,32.073,32.226,
ISRG,2008-05-05,32.222,33.078,32.0,32.75,
ISRG,2008-05-06,32.619,32.769,31.846,32.593,
ISRG,2008-05-07,32.513,32.777,31.969,32.088,
ISRG,2008-05-08,32.198,32.302,31.417,31.952,
ISRG,2008-05-09,31.604,32.203,31.364,32.122,
ISRG,2008-05-12,32.056,32.4,31.729,32.36,
ISRG,2008-05-13,32.401,32.401,31.806,32.266,
ISRG,2008-05-14,32.261,32.654,31.742,31.761,
ISRG,2008-05-15,31.743,32.644,31.736,32.553,
ISRG,2008-05-16,32.553,33.81,32.478,33.307,
ISRG,2008-05-19,33.49,34.303,33.068,33.167,
ISRG,2008-05-20,33.112,33.297,32.657,33.149,
ISRG,2008-05-21,33.017,33.437,32.029,32.072,
ISRG,2008-05-22,31.457,31.643,30.312,30.528,"CA, Verigy leap after outlooks; Gap, Yahoo tick up Stronger-than-anticipated forecasts from CA Inc. and Verigy Ltd. send the companies' shares higher in late trading."
ISRG,2008-05-23,31.418,31.94,31.041,31.641,"[""Stocks in focus for Friday Stocks expected to be in focus in Friday's U.S. trading sesion include CA, Pacific Sunwear, Gap and Yahoo."", ""Friday's biggest gaining and declining stocks Among the companies whose shares are expected to see active trading in Friday\u2019s session are CA Inc., Gap Inc. and Intuitive Surgical Inc.""]"
ISRG,2008-05-27,31.778,31.827,31.251,31.787,
ISRG,2008-05-28,32.056,32.094,31.576,32.094,
ISRG,2008-05-29,31.806,32.778,31.806,32.386,
ISRG,2008-05-30,32.552,33.0,32.233,32.621,
ISRG,2008-06-02,32.594,32.95,31.778,32.064,
ISRG,2008-06-03,32.194,32.199,31.021,31.528,
ISRG,2008-06-04,31.599,32.171,31.351,31.786,
ISRG,2008-06-05,31.891,32.382,31.488,32.379,
ISRG,2008-06-06,32.111,32.193,30.963,31.212,
ISRG,2008-06-09,31.399,31.399,30.18,30.566,
ISRG,2008-06-10,30.141,30.164,29.252,30.029,
ISRG,2008-06-11,30.442,30.444,29.477,29.547,
ISRG,2008-06-12,29.667,30.506,29.279,29.962,
ISRG,2008-06-13,30.279,31.222,30.0,31.222,
ISRG,2008-06-16,30.782,31.239,30.507,31.167,
ISRG,2008-06-17,31.287,31.54,31.031,31.337,
ISRG,2008-06-18,31.057,31.641,31.007,31.458,
ISRG,2008-06-19,31.649,31.976,31.211,31.904,
ISRG,2008-06-20,31.442,31.63,31.191,31.39,
ISRG,2008-06-23,31.887,31.887,30.668,31.103,
ISRG,2008-06-24,30.683,30.967,30.012,30.592,
ISRG,2008-06-25,31.096,31.214,30.389,30.983,
ISRG,2008-06-26,30.339,30.72,30.006,30.087,
ISRG,2008-06-27,30.003,30.327,29.67,29.954,
ISRG,2008-06-30,29.834,30.537,29.778,29.933,
ISRG,2008-07-01,29.399,29.402,28.109,28.887,
ISRG,2008-07-02,29.029,29.553,27.76,27.796,
ISRG,2008-07-03,27.889,28.422,27.668,27.816,
ISRG,2008-07-07,28.556,28.974,27.529,28.133,
ISRG,2008-07-08,27.848,29.403,27.848,29.35,
ISRG,2008-07-09,29.35,30.556,29.123,29.168,
ISRG,2008-07-10,29.228,29.766,28.889,29.508,
ISRG,2008-07-11,29.272,30.37,29.144,29.998,
ISRG,2008-07-14,30.369,30.556,29.879,30.199,
ISRG,2008-07-15,29.933,30.477,29.394,30.054,
ISRG,2008-07-16,30.147,31.446,30.147,31.199,
ISRG,2008-07-17,31.626,31.626,30.842,31.361,
ISRG,2008-07-18,31.227,32.187,31.111,32.054,
ISRG,2008-07-21,32.003,32.191,31.422,31.634,"Stocks in focus for Tuesday Tuesday will be another busy day in the stock market with a number of high-profile companies -- including Yahoo, Wachovia, WaMu and UPS -- scheduled to report earnings."
ISRG,2008-07-22,30.947,31.729,30.778,31.137,
ISRG,2008-07-23,34.833,37.027,34.777,36.793,"[""Stocks in focus for Wednesday SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trade in Wednesday's session are Boeing, McDonald's, Amazon.com, and Anheuser-Busch."", ""Wednesday's biggest gaining and declining stocks Stocks seeing active trading on Wednesday include AT&T, Boeing, Broadcom, E-Trade, General Dynamics, Hershey, McDonald's, Nabors, Norfolk Southern, PepsiCo, VMWare, Yahoo and WaMu.""]"
ISRG,2008-07-24,36.677,36.977,35.56,35.963,
ISRG,2008-07-25,35.507,36.203,35.413,35.787,
ISRG,2008-07-28,34.927,35.533,34.17,34.247,"A Cheapskate's Market In Monday's tough market, stocks pinpointed as richly priced fell while some cheap issues gained value."
ISRG,2008-07-29,34.443,34.983,34.27,34.66,
ISRG,2008-07-30,34.263,35.11,34.147,34.763,
ISRG,2008-07-31,34.39,35.11,34.28,34.587,
ISRG,2008-08-01,34.483,34.74,33.253,33.38,
ISRG,2008-08-04,33.317,33.977,32.778,33.32,
ISRG,2008-08-05,33.71,34.26,33.417,34.23,
ISRG,2008-08-06,33.937,34.96,33.617,34.533,
ISRG,2008-08-07,34.37,34.37,33.51,33.667,
ISRG,2008-08-08,33.69,34.417,33.54,34.25,
ISRG,2008-08-11,33.58,34.437,33.55,34.25,
ISRG,2008-08-12,34.34,34.357,33.84,34.0,
ISRG,2008-08-13,34.103,34.217,33.36,33.82,
ISRG,2008-08-14,33.62,34.19,33.483,33.807,
ISRG,2008-08-15,33.757,33.803,32.926,33.24,
ISRG,2008-08-18,33.437,33.443,32.059,32.557,
ISRG,2008-08-19,32.54,33.91,32.5,33.48,
ISRG,2008-08-20,33.5,33.603,33.016,33.453,
ISRG,2008-08-21,33.317,34.043,33.167,33.413,
ISRG,2008-08-22,33.617,34.11,33.47,33.703,
ISRG,2008-08-25,33.377,33.663,32.991,33.157,
ISRG,2008-08-26,33.111,33.483,32.741,33.083,
ISRG,2008-08-27,32.978,33.54,32.837,33.18,
ISRG,2008-08-28,33.062,33.613,33.05,33.27,
ISRG,2008-08-29,32.966,33.36,32.757,32.808,
ISRG,2008-09-02,33.26,33.777,32.592,32.62,
ISRG,2008-09-03,32.431,32.744,31.816,32.271,
ISRG,2008-09-04,32.03,32.221,30.36,30.388,
ISRG,2008-09-05,29.829,30.143,28.833,29.873,
ISRG,2008-09-08,30.997,31.163,29.773,30.164,
ISRG,2008-09-09,30.164,31.077,29.79,29.79,
ISRG,2008-09-10,30.332,30.867,29.757,30.438,
ISRG,2008-09-11,29.889,30.889,29.37,30.852,
ISRG,2008-09-12,30.559,31.033,30.526,30.91,
ISRG,2008-09-15,30.094,30.887,29.789,29.963,
ISRG,2008-09-16,29.459,30.966,29.459,30.863,
ISRG,2008-09-17,30.297,31.396,29.981,30.336,
ISRG,2008-09-18,30.872,31.308,29.524,30.614,
ISRG,2008-09-19,31.666,32.557,30.951,32.301,
ISRG,2008-09-22,31.931,32.244,31.117,31.167,
ISRG,2008-09-23,31.229,31.698,30.81,30.953,
ISRG,2008-09-24,31.108,31.551,30.722,31.384,
ISRG,2008-09-25,31.556,31.889,30.758,31.281,
ISRG,2008-09-26,30.5,30.886,29.889,30.557,
ISRG,2008-09-29,30.01,30.211,27.778,27.933,
ISRG,2008-09-30,28.456,28.83,25.13,26.776,
ISRG,2008-10-01,26.44,27.361,25.97,26.283,
ISRG,2008-10-02,26.029,26.5,25.313,25.406,
ISRG,2008-10-03,25.882,26.971,24.726,25.078,
ISRG,2008-10-06,24.106,24.106,20.728,21.902,
ISRG,2008-10-07,22.279,22.363,20.403,20.473,
ISRG,2008-10-08,19.889,21.743,18.957,21.181,
ISRG,2008-10-09,21.776,21.889,18.896,19.206,
ISRG,2008-10-10,17.553,20.696,17.033,19.446,
ISRG,2008-10-13,21.556,23.696,21.132,23.593,
ISRG,2008-10-14,25.363,25.74,24.282,24.924,
ISRG,2008-10-15,23.679,24.857,21.111,21.124,"Stocks in focus for Thursday Among the companies whose shares are expected to see active trade in Thursday's session are Citigroup, Merrill Lynch, Google, IBM and Nokia."
ISRG,2008-10-16,21.698,23.894,20.708,23.867,"Stocks in focus for Friday Among the companies whose shares are expected to see active trade in Friday's session are Honeywell, Comerica, Schlumberger and GM."
ISRG,2008-10-17,21.544,22.221,19.238,21.014,"Friday's biggest gaining and declining stocks Shares making notable moves in the U.S. stock market Friday include Advanced Micro Devices, Google, Honeywell and Schlumberger."
ISRG,2008-10-20,21.5,21.712,20.756,21.569,
ISRG,2008-10-21,21.044,21.332,20.0,20.024,
ISRG,2008-10-22,19.446,19.889,18.732,19.232,
ISRG,2008-10-23,19.341,19.68,18.347,19.299,
ISRG,2008-10-24,17.247,18.881,17.161,17.631,
ISRG,2008-10-27,17.226,18.272,17.122,17.223,
ISRG,2008-10-28,17.796,18.489,17.167,18.393,
ISRG,2008-10-29,18.493,19.541,17.861,18.817,
ISRG,2008-10-30,19.222,19.444,18.374,18.906,
ISRG,2008-10-31,18.529,19.556,18.366,19.199,
ISRG,2008-11-03,19.609,20.928,18.917,20.376,
ISRG,2008-11-04,20.997,22.76,20.624,22.547,
ISRG,2008-11-05,22.211,22.319,20.689,20.747,
ISRG,2008-11-06,20.336,20.986,19.112,19.373,
ISRG,2008-11-07,19.782,20.659,19.477,20.274,
ISRG,2008-11-10,20.9,20.998,19.291,19.558,
ISRG,2008-11-11,18.798,19.222,18.407,18.819,
ISRG,2008-11-12,18.656,18.8,17.914,17.993,
ISRG,2008-11-13,18.052,18.483,16.034,17.738,
ISRG,2008-11-14,17.521,18.277,16.46,16.49,
ISRG,2008-11-17,16.097,16.493,13.669,13.704,
ISRG,2008-11-18,13.8,14.438,13.18,13.723,
ISRG,2008-11-19,13.821,14.433,13.434,13.454,
ISRG,2008-11-20,12.951,13.757,12.301,12.416,
ISRG,2008-11-21,12.943,13.161,12.261,13.14,
ISRG,2008-11-24,13.453,14.04,13.14,13.882,
ISRG,2008-11-25,14.221,14.222,13.206,13.821,
ISRG,2008-11-26,13.361,14.988,13.361,14.963,
ISRG,2008-11-28,14.771,14.961,14.501,14.726,
ISRG,2008-12-01,14.384,14.466,13.213,13.248,
ISRG,2008-12-02,13.451,13.589,12.694,13.106,
ISRG,2008-12-03,13.337,14.858,13.121,14.786,
ISRG,2008-12-04,14.337,15.053,13.693,14.008,
ISRG,2008-12-05,13.667,15.273,13.667,15.273,
ISRG,2008-12-08,15.804,16.06,15.401,15.598,
ISRG,2008-12-09,15.556,15.592,14.447,14.783,
ISRG,2008-12-10,14.999,15.661,14.999,15.458,
ISRG,2008-12-11,15.327,15.917,15.092,15.222,
ISRG,2008-12-12,14.539,15.328,14.453,14.931,
ISRG,2008-12-15,15.584,15.584,14.087,14.237,
ISRG,2008-12-16,14.453,15.208,14.223,15.206,
ISRG,2008-12-17,14.718,15.092,14.563,14.676,
ISRG,2008-12-18,14.808,15.166,14.448,14.591,
ISRG,2008-12-19,14.333,14.777,13.738,13.946,
ISRG,2008-12-22,13.96,14.2,13.196,13.537,
ISRG,2008-12-23,13.356,13.793,13.237,13.359,
ISRG,2008-12-24,13.36,13.577,13.209,13.524,
ISRG,2008-12-26,13.57,13.59,13.259,13.533,
ISRG,2008-12-29,13.416,13.619,13.134,13.334,
ISRG,2008-12-30,13.611,14.062,13.358,13.816,
ISRG,2008-12-31,13.901,14.194,13.866,14.11,
ISRG,2009-01-02,14.042,14.744,14.042,14.712,
ISRG,2009-01-05,14.288,14.606,13.892,13.949,
ISRG,2009-01-06,14.031,14.133,13.362,13.577,
ISRG,2009-01-07,13.389,13.72,12.944,13.098,
ISRG,2009-01-08,11.168,12.578,11.083,12.282,
ISRG,2009-01-09,12.219,12.222,11.228,11.311,
ISRG,2009-01-12,11.537,11.767,11.133,11.194,
ISRG,2009-01-13,11.084,11.586,10.936,11.406,
ISRG,2009-01-14,11.128,11.277,10.961,11.038,
ISRG,2009-01-15,11.093,11.389,10.686,11.187,
ISRG,2009-01-16,11.41,11.549,10.85,11.108,
ISRG,2009-01-20,11.164,11.321,10.469,10.517,
ISRG,2009-01-21,10.71,10.95,10.548,10.778,"Stocks in focus for Thursday Among the companies whose shares are expected to see active trade in Thursday's session are Google, Microsoft, Nokia and Advanced Micro Devices."
ISRG,2009-01-22,10.888,10.888,10.174,10.668,
ISRG,2009-01-23,9.787,10.692,9.682,10.366,
ISRG,2009-01-26,10.532,11.278,10.368,11.006,
ISRG,2009-01-27,11.109,11.332,10.983,11.278,
ISRG,2009-01-28,11.409,11.88,11.144,11.662,
ISRG,2009-01-29,11.648,11.648,11.264,11.334,
ISRG,2009-01-30,11.34,11.867,11.231,11.47,
ISRG,2009-02-02,11.33,11.63,11.158,11.434,
ISRG,2009-02-03,11.55,12.731,11.261,12.503,
ISRG,2009-02-04,12.552,12.68,11.908,12.001,
ISRG,2009-02-05,11.931,12.444,11.723,12.298,
ISRG,2009-02-06,12.412,12.889,12.21,12.736,
ISRG,2009-02-09,12.723,12.833,12.266,12.688,
ISRG,2009-02-10,12.537,12.889,11.9,11.983,
ISRG,2009-02-11,12.026,12.172,11.527,12.018,
ISRG,2009-02-12,11.821,12.472,11.728,12.47,
ISRG,2009-02-13,12.443,12.604,12.284,12.454,
ISRG,2009-02-17,11.8,12.11,11.748,11.919,
ISRG,2009-02-18,12.056,12.107,11.517,11.868,
ISRG,2009-02-19,12.22,12.22,11.888,11.889,
ISRG,2009-02-20,11.797,12.011,11.454,11.779,
ISRG,2009-02-23,11.907,12.084,11.098,11.163,
ISRG,2009-02-24,11.03,11.582,10.85,11.519,
ISRG,2009-02-25,11.461,11.552,11.051,11.247,
ISRG,2009-02-26,11.42,11.533,10.63,10.693,
ISRG,2009-02-27,10.556,10.667,10.107,10.107,
ISRG,2009-03-02,9.936,10.067,9.429,9.481,
ISRG,2009-03-03,9.571,9.872,9.4543,9.708,
ISRG,2009-03-04,10.0,10.411,9.886,10.188,
ISRG,2009-03-05,10.301,10.367,9.977,10.022,
ISRG,2009-03-06,10.167,10.66,10.112,10.654,
ISRG,2009-03-09,10.557,11.16,10.557,10.763,
ISRG,2009-03-10,10.894,11.278,10.729,11.236,
ISRG,2009-03-11,11.264,11.289,10.701,10.839,
ISRG,2009-03-12,10.77,11.532,10.563,11.471,
ISRG,2009-03-13,11.489,11.524,11.212,11.448,
ISRG,2009-03-16,11.472,11.663,11.181,11.201,
ISRG,2009-03-17,11.527,11.679,11.123,11.679,
ISRG,2009-03-18,11.306,11.578,11.012,11.312,
ISRG,2009-03-19,11.431,11.433,10.667,10.798,
ISRG,2009-03-20,10.899,10.923,10.297,10.409,
ISRG,2009-03-23,10.696,10.814,10.389,10.802,
ISRG,2009-03-24,10.579,10.749,10.477,10.563,
ISRG,2009-03-25,10.639,10.967,10.393,10.69,
ISRG,2009-03-26,10.888,10.888,10.502,10.813,
ISRG,2009-03-27,10.743,10.769,10.511,10.713,
ISRG,2009-03-30,10.504,10.592,10.318,10.433,
ISRG,2009-03-31,10.556,10.836,10.39,10.596,
ISRG,2009-04-01,10.346,10.547,10.169,10.481,
ISRG,2009-04-02,10.639,11.021,10.528,10.923,
ISRG,2009-04-03,10.944,11.074,10.667,10.748,
ISRG,2009-04-06,10.722,11.01,10.646,10.987,
ISRG,2009-04-07,10.444,10.877,10.444,10.753,
ISRG,2009-04-08,10.718,11.287,10.61,11.274,
ISRG,2009-04-09,11.55,12.544,11.528,12.471,
ISRG,2009-04-13,12.209,13.05,12.209,12.747,
ISRG,2009-04-14,13.0,13.432,12.7,13.119,
ISRG,2009-04-15,13.067,13.276,12.8,13.046,"Stocks in focus for Thursday Among the companies whose shares are expected to see active trade in Thursday's session are Google Inc., J.P. Morgan Chase & Co. and Gannett Co."
ISRG,2009-04-16,13.646,14.147,12.578,13.111,
ISRG,2009-04-17,12.986,14.717,12.678,14.483,
ISRG,2009-04-20,14.13,14.772,13.944,13.998,
ISRG,2009-04-21,13.798,14.384,13.776,14.329,
ISRG,2009-04-22,14.027,15.444,14.0,15.043,
ISRG,2009-04-23,15.136,15.372,14.607,15.168,
ISRG,2009-04-24,15.168,17.19,15.114,16.693,
ISRG,2009-04-27,16.222,16.699,15.891,16.102,
ISRG,2009-04-28,15.618,15.998,15.444,15.454,
ISRG,2009-04-29,15.667,16.393,15.634,16.262,
ISRG,2009-04-30,16.773,16.773,15.751,15.97,
ISRG,2009-05-01,15.916,16.1,15.564,15.867,
ISRG,2009-05-04,16.111,16.598,15.899,16.528,
ISRG,2009-05-05,16.54,17.132,16.54,16.96,
ISRG,2009-05-06,17.178,17.659,17.063,17.528,
ISRG,2009-05-07,17.802,18.278,17.446,17.676,
ISRG,2009-05-08,17.801,18.21,17.274,17.641,
ISRG,2009-05-11,17.383,17.944,17.062,17.648,
ISRG,2009-05-12,17.691,17.697,17.043,17.442,
ISRG,2009-05-13,17.27,17.27,16.778,16.858,
ISRG,2009-05-14,16.844,17.201,16.59,17.059,
ISRG,2009-05-15,17.057,17.077,16.619,16.658,
ISRG,2009-05-18,16.884,17.068,16.672,17.066,
ISRG,2009-05-19,16.952,17.439,16.933,17.214,
ISRG,2009-05-20,17.334,17.334,16.667,16.74,
ISRG,2009-05-21,16.599,16.768,15.654,15.826,
ISRG,2009-05-22,15.948,16.181,15.656,15.8,
ISRG,2009-05-26,15.59,16.486,15.557,16.367,
ISRG,2009-05-27,16.286,16.471,15.774,15.853,
ISRG,2009-05-28,16.05,16.096,15.372,15.616,
ISRG,2009-05-29,15.859,16.636,15.859,16.631,
ISRG,2009-06-01,16.888,17.384,16.488,16.587,
ISRG,2009-06-02,16.97,17.843,16.673,17.672,
ISRG,2009-06-03,17.444,17.444,16.947,17.401,
ISRG,2009-06-04,17.367,17.629,16.943,17.278,
ISRG,2009-06-05,17.111,17.403,16.734,17.334,
ISRG,2009-06-08,17.321,17.321,16.783,16.943,
ISRG,2009-06-09,16.904,17.667,16.904,17.418,
ISRG,2009-06-10,17.777,17.976,17.333,17.747,
ISRG,2009-06-11,17.767,18.962,17.767,18.502,
ISRG,2009-06-12,18.52,18.85,18.226,18.501,
ISRG,2009-06-15,18.223,18.223,17.623,17.698,
ISRG,2009-06-16,18.0,18.072,17.482,17.58,
ISRG,2009-06-17,17.554,17.933,17.422,17.554,
ISRG,2009-06-18,17.518,17.659,17.211,17.398,
ISRG,2009-06-19,17.562,18.168,17.488,17.906,
ISRG,2009-06-22,17.777,17.944,17.074,17.139,
ISRG,2009-06-23,17.0,17.319,17.0,17.072,
ISRG,2009-06-24,17.1,17.461,16.889,17.194,
ISRG,2009-06-25,17.116,17.793,16.936,17.606,
ISRG,2009-06-26,17.589,17.808,17.384,17.747,
ISRG,2009-06-29,17.746,18.388,17.74,18.147,
ISRG,2009-06-30,18.478,18.478,18.001,18.184,
ISRG,2009-07-01,18.333,18.539,18.08,18.122,
ISRG,2009-07-02,17.778,18.122,17.463,17.634,
ISRG,2009-07-06,17.416,17.592,17.078,17.343,Markdown Monday for Priciest Shares Expensive stocks Barron's calls ripe for pruning get cut down.
ISRG,2009-07-07,17.0,17.044,16.407,16.444,
ISRG,2009-07-08,16.363,16.543,15.89,16.131,
ISRG,2009-07-09,16.26,16.301,15.894,15.944,
ISRG,2009-07-10,15.81,16.039,15.694,15.844,
ISRG,2009-07-13,15.888,16.733,15.888,16.628,
ISRG,2009-07-14,16.528,16.91,16.361,16.807,
ISRG,2009-07-15,17.169,17.407,17.002,17.063,
ISRG,2009-07-16,17.104,17.588,16.917,17.424,
ISRG,2009-07-17,17.497,17.587,17.194,17.282,
ISRG,2009-07-20,17.748,18.354,17.747,18.269,
ISRG,2009-07-21,18.551,18.877,18.291,18.601,
ISRG,2009-07-22,19.0,19.047,18.364,18.866,"EBay shares gain after results; Qualcomm drops Shares of eBay rise following the online marketplace's report of better-than-anticipated financial results, while a light quarterly sales forecast from mobile-technology leader Qualcomm sends its shares down nearly 5%."
ISRG,2009-07-23,22.098,23.994,21.917,23.93,
ISRG,2009-07-24,23.531,24.824,23.5,24.726,
ISRG,2009-07-27,24.048,24.726,23.763,24.3,
ISRG,2009-07-28,23.778,24.95,23.679,24.847,
ISRG,2009-07-29,24.569,25.267,24.461,24.963,
ISRG,2009-07-30,25.343,25.838,25.061,25.217,
ISRG,2009-07-31,25.167,25.531,24.984,25.258,
ISRG,2009-08-03,25.766,26.078,25.61,26.077,
ISRG,2009-08-04,25.76,26.539,25.722,26.532,
ISRG,2009-08-05,26.514,26.61,25.753,26.158,
ISRG,2009-08-06,26.222,26.37,25.173,25.226,
ISRG,2009-08-07,25.902,25.997,25.4,25.567,
ISRG,2009-08-10,25.396,25.82,25.267,25.574,
ISRG,2009-08-11,25.349,25.822,24.878,25.108,
ISRG,2009-08-12,25.056,25.764,24.933,25.52,
ISRG,2009-08-13,25.7,25.817,25.127,25.35,
ISRG,2009-08-14,25.168,25.449,24.559,24.867,
ISRG,2009-08-17,24.097,24.353,23.946,24.152,
ISRG,2009-08-18,24.356,24.566,23.834,24.463,Seeing the Opportunity in Health-Care Reform A leading health-care stock investor talks about the winners and losers in Washington's most heated legislative battle.
ISRG,2009-08-19,24.0,24.811,24.0,24.723,
ISRG,2009-08-20,24.781,25.063,24.582,25.024,
ISRG,2009-08-21,25.406,25.723,25.13,25.638,
ISRG,2009-08-24,26.022,26.244,25.534,25.652,
ISRG,2009-08-25,25.693,26.032,25.391,25.491,
ISRG,2009-08-26,25.722,25.898,25.308,25.417,
ISRG,2009-08-27,25.417,25.556,24.713,25.09,
ISRG,2009-08-28,25.312,25.439,24.662,24.989,
ISRG,2009-08-31,24.396,24.86,24.39,24.746,
ISRG,2009-09-01,24.572,25.099,23.867,23.932,
ISRG,2009-09-02,23.68,24.018,23.444,23.988,
ISRG,2009-09-03,24.201,24.696,23.868,24.647,
ISRG,2009-09-04,24.599,25.506,24.456,25.268,
ISRG,2009-09-08,25.508,25.717,25.419,25.604,
ISRG,2009-09-09,25.611,27.193,25.521,26.94,
ISRG,2009-09-10,27.128,27.481,26.681,27.292,
ISRG,2009-09-11,27.374,27.626,26.553,26.711,
ISRG,2009-09-14,26.538,26.962,26.423,26.962,
ISRG,2009-09-15,26.896,27.317,26.778,27.052,
ISRG,2009-09-16,27.056,27.509,26.739,27.458,
ISRG,2009-09-17,27.512,28.216,27.091,27.188,
ISRG,2009-09-18,27.322,27.711,26.962,27.547,
ISRG,2009-09-21,27.382,27.828,27.227,27.392,
ISRG,2009-09-22,27.578,27.793,27.027,27.39,
ISRG,2009-09-23,27.5,27.778,27.201,27.203,
ISRG,2009-09-24,27.278,27.501,26.318,26.889,
ISRG,2009-09-25,26.803,28.776,26.492,28.611,
ISRG,2009-09-28,28.469,29.277,28.441,28.778,
ISRG,2009-09-29,28.826,28.89,28.324,28.51,
ISRG,2009-09-30,28.514,29.499,28.136,29.139,
ISRG,2009-10-01,28.896,29.222,28.04,28.047,
ISRG,2009-10-02,27.667,28.197,27.633,28.016,
ISRG,2009-10-05,28.111,28.432,27.794,28.341,
ISRG,2009-10-06,28.497,28.553,28.0,28.296,
ISRG,2009-10-07,28.308,28.367,28.023,28.361,
ISRG,2009-10-08,28.676,28.822,27.652,27.82,
ISRG,2009-10-09,27.849,28.423,27.688,28.221,
ISRG,2009-10-12,28.556,28.556,27.89,28.222,
ISRG,2009-10-13,28.206,28.686,26.844,27.738,
ISRG,2009-10-14,27.78,28.678,27.239,28.61,
ISRG,2009-10-15,28.394,28.918,28.056,28.814,
ISRG,2009-10-16,28.627,28.639,28.14,28.381,
ISRG,2009-10-19,28.6,29.49,28.313,29.378,
ISRG,2009-10-20,29.806,29.919,29.333,29.717,"[""SanDisk, Yahoo shares surge after results SanDisk Corp. shares surge 10% after the chip maker's profit surpasses Wall Street's expectations, and Yahoo Inc. shares pop 5% following the Internet search firm's report of a rise in quarterly earnings."", ""Stocks in focus for Wednesday Among the shares expected to see active trade in Wednesday\u2019s session are those of Boeing, Morgan Stanley and Wells Fargo.""]"
ISRG,2009-10-21,27.289,28.526,26.808,28.034,
ISRG,2009-10-22,27.737,28.933,27.611,28.791,
ISRG,2009-10-23,28.679,29.444,28.222,29.218,
ISRG,2009-10-26,28.734,29.261,28.646,28.941,
ISRG,2009-10-27,28.862,28.962,28.396,28.667,
ISRG,2009-10-28,28.472,28.667,27.456,27.501,
ISRG,2009-10-29,27.584,28.507,27.583,28.172,
ISRG,2009-10-30,28.442,28.442,27.337,27.372,
ISRG,2009-11-02,27.592,27.717,27.011,27.376,
ISRG,2009-11-03,27.318,27.667,27.091,27.554,
ISRG,2009-11-04,27.724,28.262,27.43,27.924,
ISRG,2009-11-05,28.131,28.917,28.043,28.879,
ISRG,2009-11-06,28.692,28.99,28.318,28.444,
ISRG,2009-11-09,28.474,29.382,28.469,29.346,
ISRG,2009-11-10,29.222,29.698,29.146,29.622,
ISRG,2009-11-11,29.823,30.411,29.609,30.272,
ISRG,2009-11-12,30.272,30.447,29.841,29.966,
ISRG,2009-11-13,30.1,30.556,29.984,30.502,
ISRG,2009-11-16,30.556,31.272,30.474,31.119,
ISRG,2009-11-17,30.891,31.299,30.674,31.287,
ISRG,2009-11-18,31.089,31.444,30.708,31.07,
ISRG,2009-11-19,30.779,31.101,30.632,30.964,
ISRG,2009-11-20,30.783,31.298,30.35,30.716,
ISRG,2009-11-23,30.898,31.451,30.803,31.2,
ISRG,2009-11-24,31.267,31.267,30.862,30.983,
ISRG,2009-11-25,31.117,31.454,30.916,31.406,
ISRG,2009-11-27,30.482,31.318,30.444,31.123,
ISRG,2009-11-30,31.041,31.238,30.758,31.171,
ISRG,2009-12-01,31.333,31.69,31.279,31.656,
ISRG,2009-12-02,31.519,32.169,31.507,31.96,
ISRG,2009-12-03,31.938,32.689,31.778,32.073,
ISRG,2009-12-04,32.556,32.748,31.874,32.444,
ISRG,2009-12-07,32.111,32.594,31.843,32.061,"Medical devices rise: stock market leveling off The rising shares of medical-equipment makers could be a signal that the U.S. stock market's climb is leveling off, while the more recent shift by investors into business services is an expression of optimism on the labor front."
ISRG,2009-12-08,31.691,32.002,31.543,31.892,
ISRG,2009-12-09,31.944,32.038,31.363,31.907,
ISRG,2009-12-10,32.006,32.543,31.889,32.432,
ISRG,2009-12-11,32.66,32.719,32.246,32.477,
ISRG,2009-12-14,32.423,32.864,32.423,32.546,
ISRG,2009-12-15,32.247,32.808,32.23,32.458,
ISRG,2009-12-16,32.641,32.873,32.624,32.691,
ISRG,2009-12-17,32.599,32.858,32.276,32.473,
ISRG,2009-12-18,32.627,32.76,31.958,32.13,
ISRG,2009-12-21,32.18,32.376,31.607,32.286,
ISRG,2009-12-22,32.412,33.111,32.256,33.058,
ISRG,2009-12-23,33.167,33.693,32.833,33.577,
ISRG,2009-12-24,33.577,33.99,33.373,33.987,
ISRG,2009-12-28,33.987,34.343,33.943,34.057,
ISRG,2009-12-29,34.253,34.277,34.017,34.063,
ISRG,2009-12-30,34.04,34.223,33.943,33.993,
ISRG,2009-12-31,34.183,34.203,33.703,33.713,
ISRG,2010-01-04,34.13,34.343,33.977,34.307,
ISRG,2010-01-05,34.223,34.437,33.777,34.153,
ISRG,2010-01-06,33.94,34.753,33.94,34.65,
ISRG,2010-01-07,34.523,34.89,34.38,34.52,
ISRG,2010-01-08,34.52,34.743,34.277,34.33,
ISRG,2010-01-11,34.33,34.723,34.157,34.587,
ISRG,2010-01-12,34.373,34.407,33.643,33.82,
ISRG,2010-01-13,33.957,34.24,33.477,34.003,
ISRG,2010-01-14,33.973,34.417,33.94,34.223,
ISRG,2010-01-15,34.323,34.443,33.92,34.287,
ISRG,2010-01-19,34.11,35.243,34.11,34.533,
ISRG,2010-01-20,34.677,34.727,33.653,34.333,
ISRG,2010-01-21,34.31,34.667,33.517,33.833,
ISRG,2010-01-22,36.527,38.477,36.5,37.817,
ISRG,2010-01-25,37.857,38.07,37.443,37.613,
ISRG,2010-01-26,37.183,37.777,37.013,37.273,
ISRG,2010-01-27,37.07,37.77,37.057,37.69,
ISRG,2010-01-28,37.49,37.883,37.037,37.223,
ISRG,2010-01-29,37.267,37.443,36.32,36.45,
ISRG,2010-02-01,36.483,36.8,35.97,36.517,
ISRG,2010-02-02,36.497,37.543,36.293,37.287,
ISRG,2010-02-03,37.11,37.453,36.79,36.917,
ISRG,2010-02-04,36.917,37.08,35.69,35.69,
ISRG,2010-02-05,35.75,36.273,35.057,36.157,
ISRG,2010-02-08,36.167,36.52,35.773,35.993,
ISRG,2010-02-09,36.443,36.637,36.017,36.317,
ISRG,2010-02-10,36.317,36.38,35.347,35.773,
ISRG,2010-02-11,35.643,36.667,35.63,36.64,
ISRG,2010-02-12,36.223,36.993,36.057,36.87,
ISRG,2010-02-16,37.053,37.253,36.71,37.143,
ISRG,2010-02-17,37.42,37.91,37.28,37.907,
ISRG,2010-02-18,37.883,38.323,37.683,38.307,
ISRG,2010-02-19,38.02,38.833,38.02,38.503,
ISRG,2010-02-22,38.777,38.803,38.223,38.553,
ISRG,2010-02-23,38.61,38.777,37.963,38.077,
ISRG,2010-02-24,38.143,38.363,37.89,38.247,
ISRG,2010-02-25,37.743,38.237,37.273,38.2,
ISRG,2010-02-26,38.353,38.777,37.963,38.57,
ISRG,2010-03-01,38.887,39.907,38.787,39.847,
ISRG,2010-03-02,39.757,40.723,39.53,40.143,
ISRG,2010-03-03,40.373,40.777,40.113,40.31,
ISRG,2010-03-04,39.817,39.943,38.943,39.387,
ISRG,2010-03-05,39.233,39.96,39.167,39.823,
ISRG,2010-03-08,39.623,39.917,39.513,39.553,
ISRG,2010-03-09,39.297,39.877,39.14,39.517,
ISRG,2010-03-10,39.557,40.0,39.397,39.717,
ISRG,2010-03-11,39.667,39.853,39.333,39.757,
ISRG,2010-03-12,39.77,40.257,39.53,39.877,"Now is a good time to buy stocks Historically, on average there have been two particularly auspicious times to buy stock each year. Right now is one of those times, writes Kevin Marder."
ISRG,2010-03-15,39.723,40.22,39.303,39.557,
ISRG,2010-03-16,39.743,39.84,39.35,39.5,
ISRG,2010-03-17,39.61,39.89,39.36,39.577,
ISRG,2010-03-18,39.63,39.72,39.187,39.287,
ISRG,2010-03-19,39.633,40.0,38.577,38.797,
ISRG,2010-03-22,38.443,38.887,37.853,38.643,
ISRG,2010-03-23,38.727,38.863,38.247,38.773,
ISRG,2010-03-24,38.79,38.813,38.16,38.457,
ISRG,2010-03-25,38.597,38.633,37.943,38.007,
ISRG,2010-03-26,38.007,38.357,37.613,38.0,
ISRG,2010-03-29,38.01,38.723,37.8,38.643,
ISRG,2010-03-30,38.827,39.0,37.99,38.767,
ISRG,2010-03-31,38.757,38.89,38.34,38.68,
ISRG,2010-04-01,39.087,39.15,38.44,38.843,
ISRG,2010-04-05,39.167,39.333,38.277,38.423,
ISRG,2010-04-06,38.317,38.443,38.1,38.143,
ISRG,2010-04-07,38.223,38.277,36.867,37.04,
ISRG,2010-04-08,36.807,37.85,36.673,37.79,
ISRG,2010-04-09,38.0,39.017,37.807,38.957,
ISRG,2010-04-12,39.193,39.39,38.953,39.357,
ISRG,2010-04-13,39.377,41.09,39.333,40.827,
ISRG,2010-04-14,41.11,42.727,41.003,42.66,
ISRG,2010-04-15,42.787,43.77,42.09,43.113,"Stocks in focus for Friday Shares expected to see active trade in Friday's session include those of Bank of America, General Electric and Mattel."
ISRG,2010-04-16,42.11,43.667,39.987,40.043,"Google tumbles; AMD falls after reports Google Inc.'s quarterly earnings and revenue come in higher than Wall Street's projections, but investors push shares of the Internet search giant lower."
ISRG,2010-04-19,40.067,41.077,39.467,40.22,
ISRG,2010-04-20,40.443,40.97,40.3,40.743,
ISRG,2010-04-21,40.53,41.19,40.223,40.663,
ISRG,2010-04-22,40.443,41.517,40.057,40.97,
ISRG,2010-04-23,41.037,41.21,40.417,40.553,
ISRG,2010-04-26,40.543,40.77,39.83,40.24,
ISRG,2010-04-27,40.0,40.807,39.577,39.757,
ISRG,2010-04-28,40.003,40.3,39.89,40.01,
ISRG,2010-04-29,40.167,41.297,40.11,40.93,
ISRG,2010-04-30,40.89,41.28,40.063,40.063,
ISRG,2010-05-03,40.333,41.45,40.257,41.357,
ISRG,2010-05-04,40.99,41.057,39.89,40.19,
ISRG,2010-05-05,39.077,39.33,37.9,38.55,
ISRG,2010-05-06,38.44,38.85,34.907,37.477,
ISRG,2010-05-07,37.333,37.553,34.6,36.037,
ISRG,2010-05-10,37.89,38.44,37.563,38.27,
ISRG,2010-05-11,37.91,38.61,37.557,38.31,
ISRG,2010-05-12,38.667,39.59,38.557,39.39,
ISRG,2010-05-13,39.543,39.877,38.89,38.98,
ISRG,2010-05-14,38.723,38.857,37.35,37.79,
ISRG,2010-05-17,38.11,38.21,37.153,37.9,
ISRG,2010-05-18,38.287,38.423,36.867,36.943,
ISRG,2010-05-19,36.707,37.31,35.82,36.53,
ISRG,2010-05-20,35.687,35.873,34.517,34.657,
ISRG,2010-05-21,33.89,35.757,33.45,35.677,
ISRG,2010-05-24,35.95,36.117,35.03,35.15,
ISRG,2010-05-25,34.543,35.583,33.847,35.463,
ISRG,2010-05-26,35.783,37.093,34.067,35.273,
ISRG,2010-05-27,36.07,36.75,35.667,36.717,
ISRG,2010-05-28,36.733,36.79,35.623,35.863,
ISRG,2010-06-01,36.723,36.723,35.287,36.02,
ISRG,2010-06-02,36.163,37.123,35.917,37.123,
ISRG,2010-06-03,37.15,37.777,37.127,37.487,
ISRG,2010-06-04,36.86,37.05,36.01,36.073,
ISRG,2010-06-07,36.257,36.407,35.587,35.67,
ISRG,2010-06-08,35.707,36.05,35.167,35.847,
ISRG,2010-06-09,36.157,36.493,35.607,35.69,
ISRG,2010-06-10,36.35,36.82,35.793,36.773,
ISRG,2010-06-11,36.287,37.527,36.287,37.457,
ISRG,2010-06-14,36.89,37.063,36.2,36.377,
ISRG,2010-06-15,36.41,37.09,36.103,37.047,
ISRG,2010-06-16,36.843,37.393,36.733,37.16,
ISRG,2010-06-17,37.533,37.897,37.11,37.813,
ISRG,2010-06-18,37.827,38.98,37.557,38.877,
ISRG,2010-06-21,39.57,39.877,38.793,39.033,
ISRG,2010-06-22,39.22,39.653,38.197,38.343,
ISRG,2010-06-23,38.3,38.327,37.333,37.603,
ISRG,2010-06-24,37.313,37.71,36.747,36.88,
ISRG,2010-06-25,36.937,37.537,36.667,37.49,
ISRG,2010-06-28,37.607,37.773,36.783,37.29,
ISRG,2010-06-29,36.667,36.687,35.313,36.093,
ISRG,2010-06-30,36.17,36.537,35.007,35.07,
ISRG,2010-07-01,35.083,35.33,33.517,34.673,
ISRG,2010-07-02,34.727,34.927,34.05,34.433,
ISRG,2010-07-06,34.817,35.683,34.7,34.993,
ISRG,2010-07-07,35.107,35.887,34.967,35.803,
ISRG,2010-07-08,36.26,36.493,35.333,35.693,
ISRG,2010-07-09,35.777,35.907,35.193,35.433,
ISRG,2010-07-12,35.303,35.527,35.083,35.273,
ISRG,2010-07-13,35.56,36.86,35.447,36.623,
ISRG,2010-07-14,36.67,37.893,36.67,37.53,
ISRG,2010-07-15,37.633,37.79,36.913,37.297,
ISRG,2010-07-16,37.273,37.397,35.997,36.067,
ISRG,2010-07-19,36.223,36.387,35.627,35.897,
ISRG,2010-07-20,35.417,36.33,35.333,36.233,
ISRG,2010-07-21,36.367,36.66,34.89,35.123,
ISRG,2010-07-22,34.25,36.023,34.09,35.22,
ISRG,2010-07-23,35.107,37.207,35.103,37.153,
ISRG,2010-07-26,37.037,38.287,37.023,37.833,
ISRG,2010-07-27,38.11,38.303,36.9,37.273,
ISRG,2010-07-28,37.347,37.547,36.483,36.673,
ISRG,2010-07-29,37.0,37.113,35.81,36.36,
ISRG,2010-07-30,35.907,37.05,35.857,36.487,
ISRG,2010-08-02,37.033,37.57,36.89,37.423,
ISRG,2010-08-03,37.337,37.527,36.993,37.183,
ISRG,2010-08-04,37.223,37.507,37.103,37.26,
ISRG,2010-08-05,37.147,37.293,36.713,37.213,
ISRG,2010-08-06,36.987,37.157,36.237,36.907,
ISRG,2010-08-09,37.003,37.19,36.577,36.823,
ISRG,2010-08-10,36.36,36.63,35.87,36.403,
ISRG,2010-08-11,35.693,36.143,34.947,35.223,
ISRG,2010-08-12,34.677,35.57,34.557,35.223,
ISRG,2010-08-13,35.187,35.4,34.9,35.077,
ISRG,2010-08-16,34.587,35.19,34.3,34.373,
ISRG,2010-08-17,34.807,35.3,34.41,35.213,
ISRG,2010-08-18,35.053,35.28,34.67,34.893,
ISRG,2010-08-19,34.67,34.78,33.77,34.057,
ISRG,2010-08-20,33.87,34.1,32.444,32.611,
ISRG,2010-08-23,32.694,33.193,31.338,31.438,
ISRG,2010-08-24,30.719,30.864,29.507,29.902,
ISRG,2010-08-25,30.179,30.984,29.95,30.711,
ISRG,2010-08-26,30.917,31.111,29.773,29.773,
ISRG,2010-08-27,29.889,30.37,29.112,30.341,
ISRG,2010-08-30,30.139,30.407,29.627,29.817,
ISRG,2010-08-31,29.502,29.961,29.18,29.448,
ISRG,2010-09-01,30.134,30.666,29.528,30.451,How the burgeoning app revolution will change your life
ISRG,2010-09-02,30.443,30.85,30.139,30.813,
ISRG,2010-09-03,31.111,31.659,30.889,31.242,
ISRG,2010-09-07,31.004,31.38,30.793,30.891,
ISRG,2010-09-08,30.982,31.517,30.967,31.136,
ISRG,2010-09-09,31.556,31.776,31.136,31.429,
ISRG,2010-09-10,31.534,31.534,30.944,31.114,
ISRG,2010-09-13,31.374,31.512,30.893,31.04,
ISRG,2010-09-14,30.866,31.961,30.678,31.768,
ISRG,2010-09-15,31.268,32.813,31.268,32.638,
ISRG,2010-09-16,32.607,32.688,32.14,32.472,
ISRG,2010-09-17,32.726,33.49,32.559,32.863,
ISRG,2010-09-20,33.044,34.16,33.0,34.037,
ISRG,2010-09-21,34.337,34.533,33.763,33.903,
ISRG,2010-09-22,33.853,34.493,33.407,33.467,
ISRG,2010-09-23,33.13,33.757,33.014,33.227,
ISRG,2010-09-24,33.743,34.023,33.397,33.953,
ISRG,2010-09-27,33.15,33.18,32.024,32.251,
ISRG,2010-09-28,32.256,32.518,31.601,32.226,
ISRG,2010-09-29,32.079,32.652,31.727,31.887,
ISRG,2010-09-30,32.444,32.444,31.333,31.527,
ISRG,2010-10-01,31.834,32.341,31.586,32.179,
ISRG,2010-10-04,32.067,32.172,31.15,31.472,
ISRG,2010-10-05,31.802,32.64,31.452,32.543,
ISRG,2010-10-06,32.432,32.777,32.082,32.542,
ISRG,2010-10-07,32.611,32.617,31.743,31.907,
ISRG,2010-10-08,32.011,32.349,31.697,32.202,"Must own apps for iPhone, Android, and iPad"
ISRG,2010-10-11,32.002,32.606,32.002,32.278,
ISRG,2010-10-12,32.254,32.444,31.778,31.848,
ISRG,2010-10-13,32.001,32.157,30.629,30.633,
ISRG,2010-10-14,30.67,30.711,30.053,30.463,
ISRG,2010-10-15,30.781,31.288,30.139,31.09,
ISRG,2010-10-18,31.111,31.879,30.939,31.732,
ISRG,2010-10-19,31.46,31.46,30.573,31.004,"Stocks in focus: Morgan Stanley, eBay, Boeing A look at some of the shares likely to move during Wednesday’s trading session."
ISRG,2010-10-20,29.257,29.257,28.344,28.828,
ISRG,2010-10-21,29.164,29.164,28.357,28.538,
ISRG,2010-10-22,28.538,29.82,28.417,29.538,
ISRG,2010-10-25,29.923,29.944,29.307,29.533,
ISRG,2010-10-26,29.127,29.643,28.952,29.326,
ISRG,2010-10-27,29.0,29.111,28.467,28.988,
ISRG,2010-10-28,29.042,29.373,28.916,29.197,
ISRG,2010-10-29,29.098,29.411,29.01,29.217,
ISRG,2010-11-01,29.36,29.638,28.937,29.112,
ISRG,2010-11-02,29.16,29.694,29.12,29.584,
ISRG,2010-11-03,29.639,30.023,29.397,29.998,
ISRG,2010-11-04,30.53,30.75,30.444,30.644,
ISRG,2010-11-05,30.767,31.0,30.641,30.919,
ISRG,2010-11-08,30.751,30.972,30.661,30.789,
ISRG,2010-11-09,30.898,31.193,30.67,30.884,
ISRG,2010-11-10,30.919,31.096,30.278,30.786,
ISRG,2010-11-11,30.513,30.641,30.001,30.357,
ISRG,2010-11-12,30.236,30.259,29.461,29.742,
ISRG,2010-11-15,29.951,30.039,29.444,29.8,
ISRG,2010-11-16,29.522,29.938,28.902,29.173,
ISRG,2010-11-17,29.243,29.556,29.044,29.158,
ISRG,2010-11-18,29.43,29.639,28.834,28.904,Best apps and games for every Android
ISRG,2010-11-19,28.832,28.902,27.339,27.5,
ISRG,2010-11-22,27.501,28.497,27.458,28.332,
ISRG,2010-11-23,27.971,28.228,27.81,27.92,
ISRG,2010-11-24,28.111,28.833,28.014,28.564,
ISRG,2010-11-26,28.333,28.679,28.084,28.316,
ISRG,2010-11-29,28.137,28.462,27.822,28.272,
ISRG,2010-11-30,27.957,29.154,27.843,28.921,
ISRG,2010-12-01,29.049,29.751,29.026,29.59,
ISRG,2010-12-02,29.73,29.971,29.671,29.826,
ISRG,2010-12-03,29.689,30.222,29.689,30.147,
ISRG,2010-12-06,30.111,30.219,29.754,30.021,
ISRG,2010-12-07,30.333,30.441,28.922,28.961,
ISRG,2010-12-08,29.006,29.297,28.65,28.894,
ISRG,2010-12-09,28.956,29.149,28.819,28.944,
ISRG,2010-12-10,28.988,29.11,28.686,28.897,
ISRG,2010-12-13,28.889,29.044,28.139,28.3,
ISRG,2010-12-14,28.332,29.037,28.309,28.889,
ISRG,2010-12-15,28.428,28.943,28.222,28.473,
ISRG,2010-12-16,28.5,29.282,28.342,29.25,
ISRG,2010-12-17,29.393,29.894,29.301,29.529,
ISRG,2010-12-20,29.71,30.098,29.54,30.061,
ISRG,2010-12-21,30.146,30.221,29.361,29.651,"[""U.S. markets extend the uptrend Coal, KOL, JRCC, LLEN, ANR, CNX, AMZN, UTX, IGT, ISRG, YRCW The U.S. markets have started Tuesday on a positive note, with each major benchmark edging to two-year highs."", ""A closer look at the December breakout Coal, KOL, JRCC, LLEN, ANR, CNX, AMZN, UTX, IGT, ISRG, YRCW After breaking out to start December, the U.S. markets have since plodded steadily higher.""]"
ISRG,2010-12-22,29.744,29.943,29.472,29.557,
ISRG,2010-12-23,29.474,29.638,29.147,29.247,
ISRG,2010-12-27,29.222,29.333,28.96,29.149,
ISRG,2010-12-28,29.127,29.219,28.908,28.956,
ISRG,2010-12-29,28.944,29.167,28.7,28.821,
ISRG,2010-12-30,28.76,28.776,28.51,28.551,
ISRG,2010-12-31,28.446,28.794,28.336,28.639,
ISRG,2011-01-03,29.111,30.158,29.089,29.889,
ISRG,2011-01-04,30.158,30.323,30.013,30.189,
ISRG,2011-01-05,30.013,30.556,29.78,30.403,
ISRG,2011-01-06,30.54,30.54,29.722,29.853,
ISRG,2011-01-07,29.814,29.997,29.459,29.711,
ISRG,2011-01-10,29.619,30.247,29.506,30.176,
ISRG,2011-01-11,30.287,31.598,30.226,31.221,
ISRG,2011-01-12,31.548,31.644,30.943,31.357,"S&P, Nasdaq edge to multi-year highs Focus: Coal, KOL, DIS, MSI, JOYG, ISRG, GPRO, SPMD The U.S. markets have started Wednesday on the upswing following Portugal’s successful debt auction."
ISRG,2011-01-13,31.332,31.332,30.833,31.012,
ISRG,2011-01-14,31.06,32.106,31.011,32.031,
ISRG,2011-01-18,32.111,33.001,32.051,32.924,
ISRG,2011-01-19,32.954,32.954,32.101,32.272,
ISRG,2011-01-20,32.007,32.324,31.369,32.203,"Stocks to watch for Friday: GE, Google Among the companies whose shares are expected to see active trade in Friday’s session are General Electric Co., Bank of America Corp. and Schlumberger Ltd."
ISRG,2011-01-21,35.91,37.153,35.743,36.287,"[""Google climbs in late trade after results H-P adds ex-eBay CEO Whitman as part of board shake-up Shares of Google and Intuitive Surgical rise late as each company issues better-than-anticipated quarterly results.."", ""Intuitive Surgical shares jump 12%, S&P 500 best""]"
ISRG,2011-01-24,36.277,37.11,36.013,36.443,
ISRG,2011-01-25,36.053,36.873,35.807,36.77,
ISRG,2011-01-26,36.393,37.65,36.373,37.563,
ISRG,2011-01-27,37.527,37.54,37.083,37.13,
ISRG,2011-01-28,37.267,37.323,36.217,36.437,
ISRG,2011-01-31,36.377,36.597,35.78,35.88,
ISRG,2011-02-01,36.11,37.543,36.037,36.953,
ISRG,2011-02-02,36.813,36.95,36.287,36.42,
ISRG,2011-02-03,36.29,36.81,36.11,36.72,
ISRG,2011-02-04,36.617,36.967,36.337,36.807,
ISRG,2011-02-07,36.657,37.207,36.557,37.047,
ISRG,2011-02-08,37.123,37.553,36.947,37.103,
ISRG,2011-02-09,37.3,37.49,36.913,37.06,
ISRG,2011-02-10,36.73,37.557,36.563,37.467,
ISRG,2011-02-11,37.283,38.533,37.13,38.363,
ISRG,2011-02-14,38.317,38.33,37.847,38.257,
ISRG,2011-02-15,37.96,38.25,37.753,37.91,
ISRG,2011-02-16,37.91,38.32,37.603,37.777,
ISRG,2011-02-17,37.78,37.99,37.22,37.89,
ISRG,2011-02-18,37.737,38.157,37.673,37.88,
ISRG,2011-02-22,37.54,37.843,36.527,36.79,
ISRG,2011-02-23,36.677,36.88,35.773,36.35,
ISRG,2011-02-24,36.197,36.5,36.063,36.447,
ISRG,2011-02-25,36.477,37.557,36.467,37.213,
ISRG,2011-02-28,37.383,37.527,36.22,36.44,
ISRG,2011-03-01,36.733,36.753,35.4,35.533,
ISRG,2011-03-02,35.433,35.973,35.18,35.867,
ISRG,2011-03-03,36.397,36.943,36.16,36.857,
ISRG,2011-03-04,36.627,36.95,36.183,36.893,
ISRG,2011-03-07,36.897,37.057,36.187,36.62,
ISRG,2011-03-08,36.517,37.043,36.207,36.86,
ISRG,2011-03-09,36.83,37.03,36.267,36.69,
ISRG,2011-03-10,36.363,36.897,35.95,36.1,
ISRG,2011-03-11,35.957,36.38,35.667,36.16,
ISRG,2011-03-14,35.827,36.553,35.75,36.42,
ISRG,2011-03-15,35.387,36.39,35.283,36.243,
ISRG,2011-03-16,36.017,36.247,35.0,35.47,
ISRG,2011-03-17,35.937,36.223,35.507,35.67,
ISRG,2011-03-18,35.883,36.103,35.097,35.21,
ISRG,2011-03-21,35.57,36.223,35.533,36.123,
ISRG,2011-03-22,36.127,36.507,35.813,35.99,
ISRG,2011-03-23,35.873,36.11,35.223,35.66,
ISRG,2011-03-24,35.91,36.727,35.727,36.723,
ISRG,2011-03-25,36.71,37.173,36.49,36.647,
ISRG,2011-03-28,36.823,37.08,36.693,36.71,
ISRG,2011-03-29,36.667,37.35,36.373,37.253,
ISRG,2011-03-30,37.533,37.643,37.21,37.58,
ISRG,2011-03-31,37.587,37.73,37.05,37.05,
ISRG,2011-04-01,37.423,38.997,37.337,38.317,
ISRG,2011-04-04,38.55,39.053,38.337,38.527,
ISRG,2011-04-05,38.387,39.883,38.387,39.083,
ISRG,2011-04-06,39.597,41.11,39.523,40.58,
ISRG,2011-04-07,40.803,41.777,40.487,41.343,
ISRG,2011-04-08,41.643,41.983,40.45,40.853,
ISRG,2011-04-11,40.837,41.4,40.74,41.24,
ISRG,2011-04-12,41.277,41.337,40.463,40.71,
ISRG,2011-04-13,40.977,41.193,39.667,40.27,
ISRG,2011-04-14,40.027,40.547,39.693,40.37,
ISRG,2011-04-15,40.443,40.633,40.037,40.04,
ISRG,2011-04-18,39.42,39.777,38.893,39.62,
ISRG,2011-04-19,39.707,40.733,39.45,40.52,
ISRG,2011-04-20,39.583,40.443,39.48,40.327,"[""Stocks to watch Wednesday: Apple, Intel, IBM VMWare, Juniper, Intuitive Surgical among those putting out results A large number of widely held companies are scheduled to report financial results Wednesday, on top of those that issued results late Tuesday including Yahoo, IBM and Intel."", ""Stocks to watch Wednesday: Apple, E-Trade, Yum Companies with shares seeing active trading include Apple, IBM, Intel and Yahoo.""]"
ISRG,2011-04-21,40.38,40.38,39.61,39.687,
ISRG,2011-04-25,39.29,39.62,38.613,39.117,
ISRG,2011-04-26,39.2,39.61,38.903,39.203,
ISRG,2011-04-27,39.167,39.597,39.0,39.5,
ISRG,2011-04-28,39.333,39.697,39.103,39.553,
ISRG,2011-04-29,39.307,39.587,38.857,38.857,
ISRG,2011-05-02,39.167,39.6,39.02,39.353,
ISRG,2011-05-03,39.243,39.6,38.967,39.113,
ISRG,2011-05-04,38.93,39.15,38.237,38.377,
ISRG,2011-05-05,38.113,39.04,37.937,38.55,"9 stocks up over 900% since Sept. 11, 2001 Commentary: Death of bin Laden prompts reflection on changes Many things have changed since Sept. 11, 2001, a fact brought to mind by Osama bin Laden’s death this week. The stock market, though, is mostly flat. But nine stocks stand out for their performance since that fateful day."
ISRG,2011-05-06,38.85,39.477,38.667,38.71,
ISRG,2011-05-09,38.763,39.607,38.447,39.543,
ISRG,2011-05-10,39.557,40.367,39.48,40.077,
ISRG,2011-05-11,40.05,40.333,39.133,39.41,
ISRG,2011-05-12,39.263,40.223,38.997,40.117,
ISRG,2011-05-13,40.223,40.33,39.443,39.557,
ISRG,2011-05-16,39.393,39.757,38.743,38.79,
ISRG,2011-05-17,38.69,38.88,38.05,38.88,
ISRG,2011-05-18,38.787,39.32,38.443,39.197,
ISRG,2011-05-19,39.327,39.433,38.693,39.207,
ISRG,2011-05-20,39.017,39.11,38.693,38.697,
ISRG,2011-05-23,37.867,38.287,37.527,38.127,
ISRG,2011-05-24,38.13,38.333,37.91,37.983,
ISRG,2011-05-25,38.063,38.563,37.973,38.333,"Health care’s 2011 secret? Fewer patients Sector leads S&P 500 this year thanks to lower medical-loss ratios Insurers have led the health-care sector to first place among S&P components for 2011, and the reason seems to be fewer patients"
ISRG,2011-05-26,38.133,38.493,37.783,38.357,
ISRG,2011-05-27,38.173,38.563,38.103,38.25,
ISRG,2011-05-31,38.6,38.777,38.01,38.777,
ISRG,2011-06-01,38.72,39.01,38.283,38.343,
ISRG,2011-06-02,38.267,38.647,38.02,38.297,
ISRG,2011-06-03,37.89,38.417,37.853,38.027,
ISRG,2011-06-06,37.85,38.147,37.653,37.737,
ISRG,2011-06-07,37.853,38.443,37.613,38.203,
ISRG,2011-06-08,38.057,38.39,37.71,38.197,
ISRG,2011-06-09,38.07,38.407,37.89,37.997,
ISRG,2011-06-10,37.933,38.097,37.34,37.58,
ISRG,2011-06-13,37.533,38.237,37.473,37.887,
ISRG,2011-06-14,38.11,38.643,38.047,38.507,
ISRG,2011-06-15,38.067,38.427,37.777,37.847,
ISRG,2011-06-16,37.727,38.227,37.603,37.84,
ISRG,2011-06-17,38.5,38.92,38.183,38.273,
ISRG,2011-06-20,38.61,39.273,38.407,39.08,
ISRG,2011-06-21,39.087,39.333,38.9,39.1,
ISRG,2011-06-22,39.043,40.0,39.027,39.17,
ISRG,2011-06-23,38.643,39.377,38.337,39.273,
ISRG,2011-06-24,39.113,39.167,38.477,38.6,
ISRG,2011-06-27,38.563,39.83,38.29,39.627,
ISRG,2011-06-28,39.667,40.77,39.597,40.64,
ISRG,2011-06-29,40.75,41.19,40.75,40.933,
ISRG,2011-06-30,41.013,41.797,40.97,41.347,
ISRG,2011-07-01,41.35,42.157,41.27,42.073,
ISRG,2011-07-05,42.11,42.55,41.777,42.373,"[""Stock waters get warmer Commentary: Leading stocks break out to new highs A number of quality stocks are breaking out of their ranges and hitting new highs, writes Kevin Marder."", ""Stocks to watch Wednesday: Netflix, J&J Among the companies whose shares are expected to see active trade in Wednesday\u2019s session are Netflix Inc., Kraft Foods Inc. and Johnson & Johnson Inc.""]"
ISRG,2011-07-06,42.337,42.72,42.213,42.32,
ISRG,2011-07-07,41.777,42.013,40.847,40.917,
ISRG,2011-07-08,40.72,40.997,40.257,40.967,
ISRG,2011-07-11,40.6,40.903,40.117,40.203,
ISRG,2011-07-12,40.383,40.71,39.617,39.677,
ISRG,2011-07-13,40.003,40.597,39.783,39.933,
ISRG,2011-07-14,40.017,40.217,39.36,39.55,
ISRG,2011-07-15,39.693,40.103,39.577,39.867,
ISRG,2011-07-18,39.693,40.333,39.267,40.253,
ISRG,2011-07-19,40.657,41.777,40.56,41.657,"It's not just Apple. Intuitive Surgical, Yahoo! among those reporting late Tuesday"
ISRG,2011-07-20,43.57,45.223,43.57,44.163,"[""Stocks to watch Wednesday: Apple, Riverbed High-profile earnings reports dominate the early headlines Wednesday, beginning and ending with Apple."", ""Wednesday\u2019s biggest gaining and declining stocks BigBand Networks, Hanesbrands, Manhattan Associates, Piper Jaffray MarketWatch\u2019s daily rundown of shares making notables moves in the U.S. stock market.""]"
ISRG,2011-07-21,44.21,46.133,44.21,45.97,
ISRG,2011-07-22,45.233,45.493,44.593,45.01,
ISRG,2011-07-25,44.557,44.833,44.187,44.553,
ISRG,2011-07-26,44.553,44.72,43.893,44.34,
ISRG,2011-07-27,43.993,44.947,43.62,43.73,
ISRG,2011-07-28,43.593,44.2,43.173,43.317,
ISRG,2011-07-29,43.033,44.89,42.75,44.507,
ISRG,2011-08-01,44.84,45.333,43.333,43.79,
ISRG,2011-08-02,43.53,44.157,42.47,42.53,
ISRG,2011-08-03,42.887,42.89,40.803,42.153,
ISRG,2011-08-04,41.813,41.877,39.81,39.87,
ISRG,2011-08-05,40.193,40.5,38.767,39.84,
ISRG,2011-08-08,38.68,39.32,36.783,36.863,
ISRG,2011-08-09,37.633,38.107,35.82,38.063,
ISRG,2011-08-10,37.12,37.777,36.257,36.443,
ISRG,2011-08-11,36.85,38.41,36.667,38.0,
ISRG,2011-08-12,38.303,38.94,38.057,38.537,
ISRG,2011-08-15,38.663,39.043,38.0,38.977,
ISRG,2011-08-16,38.667,39.36,38.187,38.777,
ISRG,2011-08-17,38.777,39.717,38.1,38.613,
ISRG,2011-08-18,37.513,37.94,36.793,37.15,
ISRG,2011-08-19,36.62,37.737,36.563,36.61,
ISRG,2011-08-22,37.277,37.44,35.557,35.717,
ISRG,2011-08-23,35.983,37.777,35.84,37.773,
ISRG,2011-08-24,37.383,38.89,37.333,38.857,
ISRG,2011-08-25,39.27,39.27,38.027,38.54,
ISRG,2011-08-26,38.49,39.73,37.74,39.66,
ISRG,2011-08-29,40.113,42.637,39.88,41.763,
ISRG,2011-08-30,41.563,42.32,41.303,42.06,
ISRG,2011-08-31,42.42,43.177,41.887,42.373,
ISRG,2011-09-01,42.707,43.223,41.893,42.16,
ISRG,2011-09-02,41.267,41.967,40.943,41.18,
ISRG,2011-09-06,39.747,41.97,39.443,41.867,
ISRG,2011-09-07,42.293,43.223,42.193,43.223,
ISRG,2011-09-08,42.783,43.223,42.203,42.317,"The vaudeville market Commentary: If you don’t like what you see, wait 20 minutes for the next act. A market with a lot of reasons to go lower doesn’t, which says something, writes Kevin Marder."
ISRG,2011-09-09,41.85,42.617,40.683,41.023,
ISRG,2011-09-12,40.61,41.41,40.333,41.313,
ISRG,2011-09-13,41.53,42.31,41.333,42.153,
ISRG,2011-09-14,42.467,43.333,41.837,42.89,
ISRG,2011-09-15,43.117,43.983,42.617,43.897,
ISRG,2011-09-16,44.15,44.217,43.24,43.393,
ISRG,2011-09-19,42.93,44.017,42.667,43.727,
ISRG,2011-09-20,44.107,44.707,43.113,43.187,
ISRG,2011-09-21,43.263,43.857,42.22,42.253,
ISRG,2011-09-22,40.703,41.777,40.037,40.95,
ISRG,2011-09-23,40.857,42.187,40.393,41.667,
ISRG,2011-09-26,41.717,42.153,40.323,41.863,
ISRG,2011-09-27,42.72,43.777,42.39,43.12,
ISRG,2011-09-28,43.19,43.43,41.833,41.97,
ISRG,2011-09-29,42.67,43.023,40.683,41.47,
ISRG,2011-09-30,40.917,41.11,40.367,40.477,
ISRG,2011-10-03,40.0,40.613,38.727,38.75,
ISRG,2011-10-04,38.007,40.47,37.913,40.447,
ISRG,2011-10-05,40.573,40.813,39.47,40.777,
ISRG,2011-10-06,41.037,41.687,40.527,41.433,
ISRG,2011-10-07,41.67,41.68,40.367,40.493,
ISRG,2011-10-10,41.067,42.247,41.03,42.153,
ISRG,2011-10-11,41.887,43.187,41.777,42.817,
ISRG,2011-10-12,43.057,43.333,42.31,42.463,
ISRG,2011-10-13,42.42,43.167,42.403,43.027,
ISRG,2011-10-14,43.48,43.937,43.25,43.71,
ISRG,2011-10-17,43.57,43.8,42.89,43.113,
ISRG,2011-10-18,43.31,43.55,42.223,42.53,"Stocks to watch Tuesday: Ingram Micro, AGL, Crocs A handful of downward revisions help set a bearish tone for the first Tuesday of earnings season."
ISRG,2011-10-19,45.837,47.277,45.557,46.403,"Wednesday’s biggest gaining and declining stocks Apollo, Agnico-Eagle, ON Semiconductor Shares of the following companies were among those making notable moves in Wednesday’s U.S. stock market."
ISRG,2011-10-20,46.9,46.943,45.89,46.49,
ISRG,2011-10-21,45.873,46.667,45.35,46.18,
ISRG,2011-10-24,46.1,47.717,45.833,46.933,
ISRG,2011-10-25,46.723,47.577,46.397,46.597,
ISRG,2011-10-26,47.44,47.54,46.38,46.727,
ISRG,2011-10-27,47.577,48.963,47.363,48.367,
ISRG,2011-10-28,48.22,49.223,48.0,48.503,
ISRG,2011-10-31,48.223,49.053,48.207,48.207,
ISRG,2011-11-01,47.273,47.94,46.713,47.353,
ISRG,2011-11-02,47.663,47.97,46.987,47.457,
ISRG,2011-11-03,47.937,48.69,47.4,48.593,
ISRG,2011-11-04,48.497,48.583,47.58,48.027,
ISRG,2011-11-07,47.56,48.333,47.557,48.04,
ISRG,2011-11-08,48.107,49.11,48.04,49.02,Hunting for scattered opportunities Shares hold their own following the heavy gains of October. It would be quite normal and healthy for the averages to retrace one-half or more of their rise off the Oct. 4 intraday lows.
ISRG,2011-11-09,48.333,48.587,47.4,47.697,
ISRG,2011-11-10,48.057,48.337,47.223,47.727,
ISRG,2011-11-11,48.11,49.1,48.007,48.887,
ISRG,2011-11-14,48.84,49.723,48.693,48.943,
ISRG,2011-11-15,48.793,49.89,48.793,49.863,
ISRG,2011-11-16,49.203,49.667,48.667,48.717,
ISRG,2011-11-17,49.09,49.09,47.047,47.653,
ISRG,2011-11-18,47.39,47.817,46.133,47.007,
ISRG,2011-11-21,46.48,47.033,46.01,46.757,
ISRG,2011-11-22,46.583,47.023,46.11,46.52,
ISRG,2011-11-23,46.133,46.933,45.597,46.327,
ISRG,2011-11-25,45.927,46.663,45.777,45.917,
ISRG,2011-11-28,47.0,47.5,46.673,47.217,
ISRG,2011-11-29,46.92,47.313,46.773,46.957,Market’s trend is not your friend A market in dire need of a catalyst to halt seven days of red ink got what it asked for Monday in the form of muscular holiday sales tallies and positive rumblings out of Europe.
ISRG,2011-11-30,48.3,48.663,47.64,48.247,
ISRG,2011-12-01,47.187,48.723,47.173,48.4,
ISRG,2011-12-02,48.89,49.523,47.673,48.207,
ISRG,2011-12-05,48.793,49.423,48.21,48.493,
ISRG,2011-12-06,48.667,48.937,48.16,48.883,
ISRG,2011-12-07,48.39,49.06,48.047,48.877,
ISRG,2011-12-08,48.723,48.953,47.743,47.777,
ISRG,2011-12-09,48.15,49.01,47.993,48.933,
ISRG,2011-12-12,48.727,48.727,47.973,48.19,
ISRG,2011-12-13,48.593,49.333,47.947,48.267,
ISRG,2011-12-14,47.97,48.213,46.86,47.057,
ISRG,2011-12-15,47.383,47.733,46.76,47.593,"A damp market grows damper Weakness is seen as a positive, as it will force the hand of weaker holders, hastening the cleanout of a market that still contains some excesses."
ISRG,2011-12-16,47.88,48.237,47.397,48.013,
ISRG,2011-12-19,48.257,48.55,47.897,48.02,
ISRG,2011-12-20,48.74,49.487,48.407,49.287,Outlook for 2012 We think things will get worse before they get better. The breakdown in gold for the first time since 2008 is likely signaling another liquidity crunch like we had in late 2008.
ISRG,2011-12-21,49.473,49.473,48.753,48.97,
ISRG,2011-12-22,49.293,50.0,49.2,49.763,"Markets sailing east by southeast Shares resumed their downward trajectory Wednesday, with Nasdaq volume increasing enough to qualify for a distribution day, or a day of institutional selling."
ISRG,2011-12-23,50.0,50.97,49.89,50.85,
ISRG,2011-12-27,50.943,51.74,50.62,51.497,"Dow Industrials on target for May 2 high For months the Nasdaq Composite has been the de facto leading index. Lately, however, the behavior of the industrials have merited more attention."
ISRG,2011-12-28,51.667,51.667,50.727,50.857,
ISRG,2011-12-29,50.847,51.783,50.637,51.78,
ISRG,2011-12-30,51.813,52.14,51.447,51.447,"Nasdaq 100 set to close 2011 with gain WASHINGTON (MarketWatch) -- Unlike the broader Nasdaq Composite, the Nasdaq 100 index , probably best known for the futures contract and exchange-traded fund that track it, is set to close 2011 with a gain, as it's up 3% this year through Friday morning. The best Nasdaq 100 gainers have been Intuitive Surgical , up 81.4%, and Alexion Pharmaceuticals and Hansen Natural , which have both sported gains of close to 77%. Apple , which is the largest Nasdaq 100 component and represents about 15% of the index, has gained 25.7% in 2011."
ISRG,2012-01-03,52.333,52.66,51.907,52.413,Small-Cap Stocks for 2012 Fund pro Craig Hodges likes companies that have nothing to do with Europe.
ISRG,2012-01-04,52.447,52.723,51.777,51.883,
ISRG,2012-01-05,51.893,52.513,51.563,52.483,"Revolution Investing analysis: GOOG, GRPN, APOL and more Below is a transcript of this week's chat."
ISRG,2012-01-06,52.333,52.553,50.987,51.163,
ISRG,2012-01-09,50.98,51.083,50.027,50.167,
ISRG,2012-01-10,50.663,50.717,49.617,50.02,Big money biding time This is the week when trading desks are back to full strength and should be a good test of the market’s mettle.
ISRG,2012-01-11,49.82,50.863,49.567,50.773,
ISRG,2012-01-12,50.973,51.207,50.56,50.903,What the best value investor I know is buying right now You don't often get both the best value investor and best tech trader you know buying the same stock at the same time. Here's hoping I don't jinx 'em.
ISRG,2012-01-13,50.827,51.22,50.443,51.05,
ISRG,2012-01-17,51.567,51.89,51.35,51.707,
ISRG,2012-01-18,51.73,52.357,51.713,52.317,
ISRG,2012-01-19,52.637,52.943,51.943,52.74,"Stocks to watch Thursday: BankUnited, IFF, Oneok Earnings predominate, but dividend increases also come in for attention in Thursday’s corporate headlines."
ISRG,2012-01-20,49.443,49.977,47.697,49.52,"Friday’s biggest gaining and declining stocks AsiaInfo-Linkage, Capital One Financial, Google, Sears Holdings MarketWatch’s daily rundown of shares making sizable moves in the U.S. stock market."
ISRG,2012-01-23,49.777,50.873,49.0,49.377,"Intuitive Surgical dip worth a long-term look Intuitive Surgical shares have been an stellar performer, making the stock’s sell-off after a recent earnings report a potential opportunity for longer-term investors."
ISRG,2012-01-24,49.057,49.567,48.61,48.89,
ISRG,2012-01-25,48.877,50.63,48.517,50.63,
ISRG,2012-01-26,50.773,50.97,50.223,50.71,
ISRG,2012-01-27,50.507,51.287,50.4,51.0,
ISRG,2012-01-30,50.557,50.89,50.15,50.723,
ISRG,2012-01-31,50.93,51.167,50.433,51.1,
ISRG,2012-02-01,51.333,51.66,50.99,51.437,
ISRG,2012-02-02,51.557,54.317,51.5,53.667,
ISRG,2012-02-03,54.04,55.06,53.723,54.667,
ISRG,2012-02-06,54.407,54.917,53.68,54.6,
ISRG,2012-02-07,54.353,54.953,54.267,54.89,
ISRG,2012-02-08,54.677,54.81,53.89,54.657,"Ready to bet on small-company growth stocks? Commentary: Economic improvement could boost small caps As the economy starts to show signs of expansion, it’s time to look closely at stocks likely to benefit, specifically small company growth stocks."
ISRG,2012-02-09,54.83,54.837,54.197,54.713,
ISRG,2012-02-10,54.393,54.833,54.043,54.537,
ISRG,2012-02-13,54.73,56.223,54.677,55.897,
ISRG,2012-02-14,55.857,57.173,55.623,56.71,
ISRG,2012-02-15,57.24,57.29,56.08,56.137,
ISRG,2012-02-16,56.163,57.027,55.943,56.393,
ISRG,2012-02-17,56.71,56.877,56.11,56.22,
ISRG,2012-02-21,56.31,56.553,55.557,56.1,
ISRG,2012-02-22,55.96,56.453,55.67,56.01,
ISRG,2012-02-23,56.317,56.633,55.89,56.263,
ISRG,2012-02-24,56.553,57.07,56.203,56.973,
ISRG,2012-02-27,56.433,57.607,56.387,57.137,
ISRG,2012-02-28,57.32,57.5,56.86,57.3,
ISRG,2012-02-29,57.163,57.347,56.783,56.847,
ISRG,2012-03-01,56.68,57.943,56.61,57.927,"Ben speaks and the risk trade goes weak If the job of a Fed head is to temper expectations when they need a dash of ice water, Wednesday’s action in gold and silver showed Mr. B to be a master of the craft."
ISRG,2012-03-02,57.777,58.123,57.257,57.433,
ISRG,2012-03-05,57.157,57.733,56.81,57.047,
ISRG,2012-03-06,56.74,56.833,55.92,56.293,
ISRG,2012-03-07,56.393,56.8,56.357,56.473,
ISRG,2012-03-08,56.79,57.743,56.693,57.43,
ISRG,2012-03-09,57.763,58.5,57.567,58.203,
ISRG,2012-03-12,58.29,58.857,58.047,58.497,
ISRG,2012-03-13,58.89,59.11,58.557,59.037,
ISRG,2012-03-14,59.1,59.223,58.427,58.69,
ISRG,2012-03-15,58.563,58.743,58.21,58.69,
ISRG,2012-03-16,58.437,59.013,58.437,58.86,
ISRG,2012-03-19,58.667,58.893,58.35,58.837,
ISRG,2012-03-20,58.47,59.103,58.333,59.07,
ISRG,2012-03-21,59.07,59.54,58.93,59.213,
ISRG,2012-03-22,58.973,59.78,58.777,59.423,"Want what the market wants If the market wants to go higher, the trend follower will seek to participate in the trend, as long as the risk/reward ratio is reasonably favorable."
ISRG,2012-03-23,59.633,59.633,58.957,59.267,
ISRG,2012-03-26,59.71,60.263,59.323,60.217,
ISRG,2012-03-27,60.333,61.163,59.947,60.7,
ISRG,2012-03-28,60.953,61.067,59.85,60.513,
ISRG,2012-03-29,60.49,61.023,59.577,60.41,
ISRG,2012-03-30,60.62,60.823,59.793,60.193,
ISRG,2012-04-02,59.647,60.777,59.647,60.647,
ISRG,2012-04-03,60.493,61.01,60.393,60.933,
ISRG,2012-04-04,60.593,60.833,60.0,60.44,
ISRG,2012-04-05,60.22,60.627,60.11,60.503,
ISRG,2012-04-09,60.0,60.267,59.28,59.897,
ISRG,2012-04-10,59.687,59.887,58.7,59.47,"Reading the signs of a correction There are a variety of signal the market will give off in front of a downturn, the key is being able to see them and understand what they mean. The most important of these is price and volume."
ISRG,2012-04-11,59.853,60.193,59.653,60.0,
ISRG,2012-04-12,60.423,61.57,60.253,61.287,
ISRG,2012-04-13,61.327,61.41,60.447,60.73,
ISRG,2012-04-16,61.283,61.333,59.37,60.12,
ISRG,2012-04-17,60.72,61.093,59.72,60.613,"[""Time to sell Apple and other \u2018must-owns\u2019 The liquidation is now engulfing the liquid glamours, the sacred cows prized by institutions for their dependable earnings growth and deep liquidity."", ""Picking Health-Care Stocks in a Shifting Landscape A leading investor in the sector sees opportunities in companies that help control rising costs."", ""Stocks to watch Tuesday: Lowe\u2019s, Ventas A big day beckons for corporate earnings, with four blue chips on the schedule."", ""Yahoo shares rise, Intel lower after hours IBM shares fall in late trading; Intuitive Surgical earnings, sales climb The Silicon Valley companies each post quarterly results that top Wall Street\u2019s projections, but investors push up shares of the Web portal while the chip maker\u2019s stock wades in the red late.""]"
ISRG,2012-04-18,63.787,66.1,63.29,64.947,"Stocks to watch Wednesday: Berkshire, Jakks Much for investors to sort through among the corporate headlines hitting early Wednesday."
ISRG,2012-04-19,65.167,65.54,63.923,64.357,New names for aggressive speculators Institutional participants continue to leave a raft of clues as to which titles will be the contenders on the next market advance and which will be the pretenders.
ISRG,2012-04-20,64.17,64.677,63.247,64.063,
ISRG,2012-04-23,62.97,63.4,62.257,63.05,
ISRG,2012-04-24,63.0,63.4,61.747,62.233,More market pain ahead The view remains that the market needs to put in a correction as a means of ridding the excesses that built up during the December-March advance.
ISRG,2012-04-25,62.917,64.263,62.917,63.943,
ISRG,2012-04-26,63.507,64.307,63.08,64.07,
ISRG,2012-04-27,64.443,65.15,63.787,65.09,
ISRG,2012-04-30,65.11,65.553,64.177,64.243,
ISRG,2012-05-01,64.233,65.567,64.023,65.363,
ISRG,2012-05-02,64.843,65.737,64.73,65.13,
ISRG,2012-05-03,65.493,65.643,64.07,64.263,
ISRG,2012-05-04,63.89,64.2,62.243,62.797,
ISRG,2012-05-07,62.437,63.163,62.0,62.667,
ISRG,2012-05-08,62.223,62.223,60.973,61.89,
ISRG,2012-05-09,61.183,61.827,60.623,61.067,
ISRG,2012-05-10,61.463,61.993,61.17,61.86,
ISRG,2012-05-11,61.687,62.697,61.11,62.107,
ISRG,2012-05-14,61.523,61.97,60.883,61.173,
ISRG,2012-05-15,61.757,62.1,60.517,60.76,
ISRG,2012-05-16,60.647,60.943,59.343,59.687,
ISRG,2012-05-17,59.333,59.497,57.557,57.677,
ISRG,2012-05-18,57.687,57.89,56.563,56.803,
ISRG,2012-05-21,56.793,58.667,56.383,58.563,
ISRG,2012-05-22,58.593,59.623,58.017,58.343,
ISRG,2012-05-23,58.07,59.17,57.557,58.987,
ISRG,2012-05-24,59.17,59.403,58.107,59.057,
ISRG,2012-05-25,58.853,59.007,58.333,58.507,
ISRG,2012-05-29,58.767,59.257,58.187,58.657,
ISRG,2012-05-30,58.493,59.237,57.747,59.06,
ISRG,2012-05-31,58.907,59.193,58.0,58.123,
ISRG,2012-06-01,56.863,57.453,55.357,55.89,
ISRG,2012-06-04,55.89,57.417,55.333,57.357,
ISRG,2012-06-05,57.013,58.333,56.85,58.043,
ISRG,2012-06-06,58.11,59.667,58.11,59.27,
ISRG,2012-06-07,59.943,60.307,58.753,58.833,
ISRG,2012-06-08,58.393,59.81,58.347,59.633,
ISRG,2012-06-11,60.133,60.4,57.673,57.877,
ISRG,2012-06-12,58.503,59.16,57.69,58.987,"Leaders turn shaky, signal more declines The big risk is that problems in the euro zone spark a global contagion. A high cash position remains warranted for all but the most-aggressive speculators until institutions make more of a commitment to this market."
ISRG,2012-06-13,58.523,59.64,58.333,58.44,
ISRG,2012-06-14,58.39,59.633,58.39,58.663,
ISRG,2012-06-15,58.693,59.4,58.287,59.073,
ISRG,2012-06-18,58.99,60.82,58.657,60.583,
ISRG,2012-06-19,61.01,61.52,60.513,60.953,
ISRG,2012-06-20,61.14,61.34,60.337,60.913,
ISRG,2012-06-21,61.147,61.863,59.647,59.67,"Big Ben speaks and glamour stocks yawn The speculative growth glamours, thrust into the spotlight in recent sessions as some vaulted their basing patterns, cooled their heels Wednesday. The Federal Reserve meeting, on the face of it, said . . ."
ISRG,2012-06-22,59.95,61.207,59.95,61.123,
ISRG,2012-06-25,60.41,60.767,59.697,59.98,
ISRG,2012-06-26,60.177,60.577,59.563,60.48,
ISRG,2012-06-27,60.803,61.18,60.387,60.47,
ISRG,2012-06-28,60.077,60.173,59.013,59.587,"[""Stocks remain in an uptrend The three-week uptrend continues. That it continues, despite participants' concern over Europe, healthcare, and longer-term fiscal concerns, says something."", ""How to profit from the health-care ruling The sweeping changes about to be made to America\u2019s health-care system are going to effect a huge number of companies, with many seeing greater profits, but some seeing a reduction in need.""]"
ISRG,2012-06-29,60.557,61.55,60.33,61.533,
ISRG,2012-07-02,61.83,63.017,61.737,62.887,"10 best stocks under Obama? Hint: Apple's not #1 Perhaps surprisingly, Apple is not the best performing stock in the S&P 500 during the Obama presidency."
ISRG,2012-07-03,62.64,63.327,62.49,62.957,
ISRG,2012-07-05,62.91,63.0,62.247,62.6,
ISRG,2012-07-06,62.36,62.493,61.11,61.273,
ISRG,2012-07-09,61.373,61.667,60.85,61.267,
ISRG,2012-07-10,60.623,60.873,58.603,59.087,
ISRG,2012-07-11,59.18,59.827,58.857,59.447,
ISRG,2012-07-12,59.027,59.703,57.917,59.4,
ISRG,2012-07-13,59.443,60.273,59.25,60.003,
ISRG,2012-07-16,60.06,60.227,59.333,59.613,
ISRG,2012-07-17,60.273,60.77,59.453,60.457,
ISRG,2012-07-18,60.84,61.64,60.5,61.04,
ISRG,2012-07-19,61.443,61.51,60.0,60.467,"Stocks to watch Thursday: Libbey, J.M. Smucker MarketWatch’s rundown of corporate headlines of interest to investors early Thursday."
ISRG,2012-07-20,57.333,57.557,54.95,55.39,"Hot stocks to watch Among the companies with shares expected to actively trade in Friday's session are Chipotle Mexican Grill Inc. CMG, SanDisk Corp. SNDK and Xerox Corp. XRX. Chipotle Mexican Grill Inc. CMG said its customer traffic growth has slowed recently, raising the possibility that some people are trading down to less pricey fast-food restaurants as a result of the uncertain economy."
ISRG,2012-07-23,53.667,53.96,51.917,53.053,
ISRG,2012-07-24,53.483,53.543,52.223,52.497,Stocks get socked and cash is king A reliable sign that the jig is up is when a number of glamour stocks all decide to give it up at once. This reflects a tangible change in speculative sentiment.
ISRG,2012-07-25,53.177,53.993,52.78,53.733,
ISRG,2012-07-26,54.443,54.823,54.017,54.357,
ISRG,2012-07-27,54.887,55.743,54.467,55.437,
ISRG,2012-07-30,54.427,55.23,53.787,54.623,
ISRG,2012-07-31,54.15,54.64,53.39,53.5,
ISRG,2012-08-01,53.89,54.307,52.977,52.977,
ISRG,2012-08-02,52.547,53.177,52.337,53.087,"Institutional investors exit growth stocks Shares eased for a third-straight session Wednesday, but more important is what transpired beneath the surface of the averages: …"
ISRG,2012-08-03,53.89,55.11,53.583,54.76,
ISRG,2012-08-06,54.827,55.127,54.42,54.533,
ISRG,2012-08-07,54.57,55.53,54.57,55.197,
ISRG,2012-08-08,54.9,55.797,54.893,55.69,
ISRG,2012-08-09,55.9,55.9,54.937,55.283,
ISRG,2012-08-10,55.16,55.443,54.667,55.397,
ISRG,2012-08-13,55.35,56.96,55.35,56.48,
ISRG,2012-08-14,56.94,56.94,56.027,56.65,
ISRG,2012-08-15,56.39,57.5,56.323,57.48,
ISRG,2012-08-16,57.543,57.597,56.89,57.217,
ISRG,2012-08-17,57.443,57.443,56.563,56.86,
ISRG,2012-08-20,56.687,57.077,56.383,56.703,
ISRG,2012-08-21,56.777,57.33,56.113,56.39,
ISRG,2012-08-22,56.27,56.6,55.89,56.417,
ISRG,2012-08-23,56.21,56.43,55.68,55.913,
ISRG,2012-08-24,55.977,56.437,55.557,56.17,
ISRG,2012-08-27,55.893,56.26,55.443,55.633,
ISRG,2012-08-28,55.5,55.617,55.143,55.333,
ISRG,2012-08-29,55.333,55.57,55.117,55.17,
ISRG,2012-08-30,54.813,55.107,54.067,54.63,
ISRG,2012-08-31,54.71,55.33,54.277,54.643,
ISRG,2012-09-04,54.473,55.13,54.247,54.567,
ISRG,2012-09-05,54.44,54.743,54.0,54.19,
ISRG,2012-09-06,54.447,55.173,54.35,55.103,
ISRG,2012-09-07,55.29,55.76,54.76,55.637,
ISRG,2012-09-10,55.263,55.77,54.923,55.02,
ISRG,2012-09-11,54.937,54.967,54.057,54.157,
ISRG,2012-09-12,54.41,54.783,53.89,54.01,
ISRG,2012-09-13,54.0,54.78,53.473,54.413,
ISRG,2012-09-14,54.51,55.823,54.143,55.74,
ISRG,2012-09-17,55.62,57.103,55.53,56.7,"Health-care stocks that are still bargains The health-care sector is flashing mixed signals, but the prognosis is good for investors who can navigate the risks."
ISRG,2012-09-18,57.02,57.537,56.617,56.93,"Everything you need to know about 3D Systems Commentary: Razor-and-blade business model for printing actual products The exact same dynamics of collapsing costs and widening audience leading to mass adoption in computer printers are happening right now with three-dimensional printing in general, and 3D Systems in particular, writes Cody Willard."
ISRG,2012-09-19,56.95,57.11,56.383,56.6,
ISRG,2012-09-20,56.5,56.5,55.703,56.26,
ISRG,2012-09-21,56.443,57.617,56.443,57.53,
ISRG,2012-09-24,57.223,57.717,56.733,57.5,
ISRG,2012-09-25,57.507,57.96,56.79,56.84,
ISRG,2012-09-26,56.77,56.973,54.917,55.07,
ISRG,2012-09-27,55.38,55.667,54.89,55.517,
ISRG,2012-09-28,55.357,55.39,54.613,55.07,
ISRG,2012-10-01,55.643,56.267,55.167,55.533,
ISRG,2012-10-02,55.443,55.793,54.933,55.64,
ISRG,2012-10-03,55.903,56.813,55.563,56.78,
ISRG,2012-10-04,56.973,57.777,56.523,57.387,
ISRG,2012-10-05,57.743,57.777,56.61,56.813,
ISRG,2012-10-08,56.513,56.753,56.337,56.59,
ISRG,2012-10-09,55.863,56.223,54.337,55.017,
ISRG,2012-10-10,55.17,55.387,54.4,54.96,
ISRG,2012-10-11,55.497,55.63,54.773,54.96,
ISRG,2012-10-12,54.96,55.627,54.803,54.953,
ISRG,2012-10-15,56.343,57.043,56.11,56.947,
ISRG,2012-10-16,57.247,59.42,57.22,59.237,"Intel, IBM shares turn red after hours Fortinet, Apollo Group shares pushed lower after outlooks Intel shares fall Tuesday evening, with a quarterly forecast from the world’s largest chip maker disappointing Wall Street, and shares of International Business Machines decline as the tech company’s quarterly sales misses expectations."
ISRG,2012-10-17,56.673,60.467,56.667,59.157,
ISRG,2012-10-18,59.07,59.603,58.49,59.537,
ISRG,2012-10-19,59.803,60.673,59.557,59.817,
ISRG,2012-10-22,60.0,61.327,60.0,61.243,
ISRG,2012-10-23,60.577,61.29,59.903,60.733,
ISRG,2012-10-24,61.03,61.09,60.173,60.333,
ISRG,2012-10-25,60.57,60.92,60.057,60.627,
ISRG,2012-10-26,59.857,60.533,59.443,59.537,
ISRG,2012-10-31,59.557,60.567,59.173,60.247,
ISRG,2012-11-01,60.557,61.053,59.313,60.107,
ISRG,2012-11-02,59.89,61.24,59.69,60.163,
ISRG,2012-11-05,60.057,60.36,59.71,60.09,
ISRG,2012-11-06,60.273,61.11,60.13,60.433,
ISRG,2012-11-07,59.673,60.11,59.0,59.743,
ISRG,2012-11-08,59.57,59.803,58.97,59.057,
ISRG,2012-11-09,58.553,59.537,58.553,58.843,
ISRG,2012-11-12,58.88,59.723,58.777,59.293,
ISRG,2012-11-13,59.177,59.973,58.89,59.573,
ISRG,2012-11-14,59.63,59.883,58.303,58.497,
ISRG,2012-11-15,58.26,58.777,57.81,58.253,
ISRG,2012-11-16,58.207,59.643,58.17,59.323,
ISRG,2012-11-19,60.0,61.11,59.797,60.277,
ISRG,2012-11-20,60.147,60.443,59.32,59.61,
ISRG,2012-11-21,59.523,59.917,59.133,59.383,
ISRG,2012-11-23,59.79,59.847,59.417,59.723,
ISRG,2012-11-26,59.57,60.0,59.037,59.36,
ISRG,2012-11-27,59.3,59.403,58.273,58.333,
ISRG,2012-11-28,58.223,59.033,58.0,58.943,
ISRG,2012-11-29,59.157,59.9,59.027,59.44,
ISRG,2012-11-30,59.267,59.343,58.557,58.777,
ISRG,2012-12-03,58.75,59.21,58.23,58.38,
ISRG,2012-12-04,58.417,58.75,57.843,58.573,
ISRG,2012-12-05,58.64,58.64,57.287,57.42,
ISRG,2012-12-06,57.213,57.867,56.667,57.753,
ISRG,2012-12-07,57.837,57.927,57.027,57.587,
ISRG,2012-12-10,57.46,58.543,57.46,58.54,
ISRG,2012-12-11,58.53,60.087,58.507,59.59,
ISRG,2012-12-12,59.683,60.57,59.637,59.953,
ISRG,2012-12-13,59.527,60.0,59.223,59.773,
ISRG,2012-12-14,59.587,59.823,59.103,59.233,
ISRG,2012-12-17,59.487,61.443,59.453,61.223,
ISRG,2012-12-18,61.443,61.55,60.557,60.723,
ISRG,2012-12-19,60.79,60.827,56.453,57.273,"Wednesday’s movers; Herbalife dips on Ackman short Smith & Wesson, Facebook among tickers trending Shares of General Motors, Herbalife and Intuitive Surgical make big moves during U.S. trading, while Smith & Wesson and Facebook are among Wednesday’s top trending tickers."
ISRG,2012-12-20,56.547,56.8,54.21,54.257,"Thursday’s movers: Apple ends in red on price cut Herbalife retreats as Bill Ackman makes his case Shares of Jabil Circuit, NYSE Euronext and Bed Bath & Beyond make big moves during U.S. trading Thursday, while Herbalife was among top trending tickers."
ISRG,2012-12-21,53.453,56.11,52.917,55.197,
ISRG,2012-12-24,55.023,55.097,54.197,54.413,
ISRG,2012-12-26,54.637,54.79,53.287,53.35,
ISRG,2012-12-27,53.443,54.297,53.423,54.13,
ISRG,2012-12-28,53.857,54.027,53.277,53.277,
ISRG,2012-12-31,53.36,54.52,53.29,54.487,
ISRG,2013-01-02,56.277,56.433,54.447,55.28,
ISRG,2013-01-03,55.097,56.273,55.003,55.963,
ISRG,2013-01-04,56.19,56.19,55.423,55.587,
ISRG,2013-01-07,55.287,56.043,55.287,55.777,
ISRG,2013-01-08,55.83,56.337,55.613,56.047,
ISRG,2013-01-09,56.26,56.707,56.037,56.303,
ISRG,2013-01-10,56.757,56.757,56.11,56.54,
ISRG,2013-01-11,56.307,56.417,55.843,56.223,
ISRG,2013-01-14,56.933,57.0,56.143,56.97,
ISRG,2013-01-15,56.1,56.617,55.557,55.953,
ISRG,2013-01-16,55.777,56.007,55.26,55.39,
ISRG,2013-01-17,55.733,57.497,53.977,57.133,
ISRG,2013-01-18,56.887,57.307,56.34,56.48,
ISRG,2013-01-22,56.127,57.91,56.113,57.61,"[""Big earnings on Tuesday: Verizon, J&J, DuPont Google, IBM and Texas Instruments to be featured after Street close Among the companies whose shares are expected to see active trade in Tuesday\u2019s session are Google, International Business Machines, Texas Instruments, and Verizon."", ""Google, IBM climb after hours following results Cree, Intuitive Surgical shares vault higher; KB Home shares fall Google and International Business Machines each report an increase in quarterly earnings.""]"
ISRG,2013-01-23,62.847,64.14,62.333,63.007,"Wednesday’s movers; Apple sags on tepid Q2 outlook Netflix soars on better-than-expected earnings Shares of Google, Netflix, nd Coach made big moves during U.S. trading, while Apple and Microsoft were among top trending tickers."
ISRG,2013-01-24,63.133,64.827,63.113,64.557,
ISRG,2013-01-25,64.063,64.533,63.587,64.203,
ISRG,2013-01-28,63.89,64.523,63.62,64.213,
ISRG,2013-01-29,64.213,64.213,63.417,63.827,
ISRG,2013-01-30,63.68,64.007,63.333,63.667,
ISRG,2013-01-31,63.61,63.97,63.48,63.82,
ISRG,2013-02-01,64.127,65.073,64.0,64.853,
ISRG,2013-02-04,64.263,64.543,63.57,63.733,
ISRG,2013-02-05,63.943,64.203,63.403,63.733,
ISRG,2013-02-06,63.68,64.157,63.14,63.543,
ISRG,2013-02-07,63.527,63.88,62.603,63.37,
ISRG,2013-02-08,63.557,64.407,63.393,64.307,
ISRG,2013-02-11,64.04,64.217,63.157,63.503,
ISRG,2013-02-12,63.713,63.747,63.17,63.487,
ISRG,2013-02-13,63.407,64.14,63.373,63.743,
ISRG,2013-02-14,63.247,63.733,63.007,63.473,
ISRG,2013-02-15,63.333,63.543,63.103,63.247,
ISRG,2013-02-19,63.017,64.777,62.947,64.697,
ISRG,2013-02-20,64.0,64.187,61.39,61.87,
ISRG,2013-02-21,61.26,62.633,60.75,62.36,
ISRG,2013-02-22,63.767,64.38,63.333,63.783,
ISRG,2013-02-25,64.053,64.33,62.927,62.927,
ISRG,2013-02-26,63.03,63.687,62.627,63.197,
ISRG,2013-02-27,63.087,64.31,63.087,63.723,
ISRG,2013-02-28,63.717,64.097,54.707,56.653,
ISRG,2013-03-01,61.45,62.0,60.73,61.49,"6 gut checks before the stock market's opening bell Keep those pre-written headlines on ice. That high on the Dow, which so many on Wall Street (even the grumps) seem to see as a foregone conclusion, might have to wait until next week. Stocks just aren't showing us much this morning. Still, for a Friday, there plenty to distract you."
ISRG,2013-03-04,61.223,61.43,58.917,60.147,
ISRG,2013-03-05,59.253,59.5,57.11,58.413,
ISRG,2013-03-06,58.5,59.49,57.453,57.753,
ISRG,2013-03-07,57.757,58.107,56.183,57.02,
ISRG,2013-03-08,57.137,57.66,56.373,57.18,
ISRG,2013-03-11,56.863,58.193,56.863,57.417,
ISRG,2013-03-12,57.367,57.593,56.35,56.99,
ISRG,2013-03-13,56.917,57.157,56.333,56.593,
ISRG,2013-03-14,57.187,57.493,53.71,54.433,
ISRG,2013-03-15,53.997,54.307,50.577,51.05,Friday movers: Apple posts weekly gain of 2.8% Groupon climbs on endorsement from fund manager Apple posts a weekly gain of 2.8% on Friday even as rival Samsung Electronics unveiled its new smartphone Galaxy S4. The stock also shrugged off a price target cut at Sterne Agee.
ISRG,2013-03-18,51.707,54.11,51.69,53.947,Monday movers: Apple rallies on more dividend talk Morgan Stanley slides on Cyprus jitters Apple has its best percentage gain since early February as expectations for a dividend increase mounted following a report that the iPhone company may hike its dividend by a large margin.
ISRG,2013-03-19,53.887,54.007,52.363,53.63,
ISRG,2013-03-20,53.763,55.21,53.667,55.097,
ISRG,2013-03-21,56.667,56.89,54.037,54.087,
ISRG,2013-03-22,54.287,54.77,53.56,54.377,
ISRG,2013-03-25,54.447,54.847,53.79,54.267,
ISRG,2013-03-26,54.21,55.287,53.577,55.25,
ISRG,2013-03-27,55.033,55.513,54.353,54.503,
ISRG,2013-03-28,54.443,54.993,54.26,54.577,
ISRG,2013-04-01,54.873,54.89,53.713,53.843,
ISRG,2013-04-02,53.98,55.08,53.98,54.533,
ISRG,2013-04-03,54.89,55.957,54.55,55.387,
ISRG,2013-04-04,55.443,56.0,54.447,55.183,
ISRG,2013-04-05,54.43,54.777,54.003,54.44,
ISRG,2013-04-08,54.76,55.733,54.623,54.89,
ISRG,2013-04-09,55.167,55.477,54.533,55.17,
ISRG,2013-04-10,55.227,55.833,54.99,55.427,
ISRG,2013-04-11,55.557,57.1,55.557,56.953,
ISRG,2013-04-12,56.893,57.22,56.237,56.893,
ISRG,2013-04-15,56.793,57.303,56.443,56.667,
ISRG,2013-04-16,56.873,57.223,56.16,56.71,
ISRG,2013-04-17,56.11,56.96,55.73,56.403,
ISRG,2013-04-18,56.333,56.703,54.287,54.82,
ISRG,2013-04-19,52.217,53.913,51.747,53.86,"Stocks to watch: GE, McDonald’s, IBM Vertex Pharmaceuticals, Chipotle, Cepheid also in focus Earnings from Dow industrials components will figure heavily in the market as GE and McDonald’s report, and investors chime in on IBM’s disappointing results."
ISRG,2013-04-22,54.363,54.363,52.223,52.763,
ISRG,2013-04-23,52.777,53.553,51.967,52.34,
ISRG,2013-04-24,52.237,53.287,52.14,52.987,
ISRG,2013-04-25,53.177,54.25,52.913,53.757,
ISRG,2013-04-26,53.613,54.25,53.223,54.083,
ISRG,2013-04-29,54.243,54.583,53.383,54.35,
ISRG,2013-04-30,54.263,54.83,54.177,54.7,
ISRG,2013-05-01,54.62,55.21,54.337,54.463,
ISRG,2013-05-02,54.43,54.977,54.333,54.65,
ISRG,2013-05-03,55.27,56.06,55.04,55.98,
ISRG,2013-05-06,55.89,56.057,55.68,55.73,
ISRG,2013-05-07,55.727,55.867,54.38,54.453,
ISRG,2013-05-08,54.367,54.53,53.407,54.367,
ISRG,2013-05-09,54.47,56.867,54.443,56.2,
ISRG,2013-05-10,54.777,55.627,54.323,55.507,
ISRG,2013-05-13,55.25,55.637,53.89,53.967,
ISRG,2013-05-14,53.977,54.567,53.943,54.193,
ISRG,2013-05-15,54.343,54.37,53.733,53.823,
ISRG,2013-05-16,53.567,53.913,52.687,52.913,
ISRG,2013-05-17,53.287,53.87,53.223,53.777,
ISRG,2013-05-20,53.597,54.143,53.157,53.27,
ISRG,2013-05-21,53.19,54.36,53.19,53.987,
ISRG,2013-05-22,54.017,54.383,52.067,52.257,
ISRG,2013-05-23,51.813,53.55,51.68,53.163,
ISRG,2013-05-24,54.667,56.443,54.523,55.727,"[""Stocks Down; Dean Foods Up, Abercrombie Plunges"", ""Sears, GameStop are Friday\u2019s biggest movers Shares of Dean Foods rose on Friday while Sears and GameStop shares fell""]"
ISRG,2013-05-28,56.137,56.443,55.45,55.737,
ISRG,2013-05-29,55.333,55.867,54.84,55.39,
ISRG,2013-05-30,55.447,56.377,55.113,56.077,
ISRG,2013-05-31,55.907,55.973,55.28,55.28,
ISRG,2013-06-03,55.483,55.62,55.0,55.58,
ISRG,2013-06-04,55.467,55.657,55.14,55.4,
ISRG,2013-06-05,55.393,56.15,55.317,55.617,
ISRG,2013-06-06,55.763,56.433,55.483,56.38,
ISRG,2013-06-07,56.493,57.053,56.38,57.053,
ISRG,2013-06-10,56.76,57.14,56.6,56.69,
ISRG,2013-06-11,56.28,56.383,55.46,55.507,
ISRG,2013-06-12,55.687,55.947,54.897,55.05,
ISRG,2013-06-13,54.743,56.15,54.653,56.057,
ISRG,2013-06-14,56.057,56.19,55.33,55.367,
ISRG,2013-06-17,55.913,56.103,55.337,55.48,
ISRG,2013-06-18,55.89,56.763,55.603,56.623,
ISRG,2013-06-19,56.723,57.34,56.5,56.667,
ISRG,2013-06-20,56.313,56.577,55.16,55.28,
ISRG,2013-06-21,55.583,56.12,55.333,55.877,
ISRG,2013-06-24,55.39,56.517,55.037,56.02,
ISRG,2013-06-25,56.313,56.49,55.407,55.743,
ISRG,2013-06-26,55.327,56.727,55.277,55.99,
ISRG,2013-06-27,56.27,56.4,55.667,55.8,
ISRG,2013-06-28,55.557,56.55,55.407,56.237,
ISRG,2013-07-01,56.577,56.577,55.63,55.727,
ISRG,2013-07-02,55.533,56.36,55.447,55.687,
ISRG,2013-07-03,55.59,55.977,55.48,55.523,
ISRG,2013-07-05,56.05,56.29,55.657,56.0,
ISRG,2013-07-08,55.99,56.183,55.377,55.563,
ISRG,2013-07-09,47.557,47.763,45.187,46.59,"[""5 gut checks before the stock market's opening bell Alcoa may have lost its bellwether status, but you wouldn't necessarily know it from the way the global markets are pushing higher. The buying mood bodes well for what's to come this earnings season."", ""Tuesday\u2019s movers: Home builders lead S&P higher D.R. Horton and Lennar rally on Tuesday, helping the S&P 500 to gain for a fourth session, amid signs of a continued recovery in the U.S. housing market.""]"
ISRG,2013-07-10,46.393,47.6,46.333,46.963,
ISRG,2013-07-11,47.14,47.833,46.903,47.777,
ISRG,2013-07-12,47.737,48.057,47.017,47.67,
ISRG,2013-07-15,47.507,47.6,46.423,47.42,
ISRG,2013-07-16,47.39,47.533,46.483,46.903,
ISRG,2013-07-17,47.0,47.223,45.897,46.17,
ISRG,2013-07-18,46.177,47.267,46.11,46.83,"[""Stocks to watch: Morgan Stanley, Verizon Microsoft, Google due to report results after the closing bell Among the companies whose shares are expected to see active trade in Thursday\u2019s session are Morgan Stanley, Google, Microsoft and Verizon."", ""Google, Microsoft, AMD drop after hours Tech earnings disappoint after the bell and shares of Google Inc., Microsoft Corp., and Advanced Micro Devices Inc. take it on the chin. Boeing shares come under pressure on more 787 Dreamliner problems.""]"
ISRG,2013-07-19,40.667,43.687,39.67,43.63,"[""6 gut checks before the stock market's opening bell Wall Street won't be going the way of Robinwood St. anytime soon, but if results from Google and Microsoft are indicative of what's to come for the rest of earnings season, this bull market's best days may be behind it."", ""Friday movers: Microsoft has worst day since 2009 Microsoft falls by double digits on Friday, marking its worst percentage drop since January 2009, after its fourth-quarter results came in significantly below expectations.""]"
ISRG,2013-07-22,43.703,44.43,43.577,43.99,
ISRG,2013-07-23,44.023,44.33,43.49,43.847,
ISRG,2013-07-24,43.733,43.973,42.457,42.663,
ISRG,2013-07-25,42.307,42.66,41.177,41.703,
ISRG,2013-07-26,41.557,42.653,41.033,42.477,
ISRG,2013-07-29,44.143,44.557,42.91,43.443,
ISRG,2013-07-30,43.497,43.75,42.667,42.87,
ISRG,2013-07-31,42.98,43.6,42.677,43.11,
ISRG,2013-08-01,43.233,43.977,43.167,43.607,
ISRG,2013-08-02,43.377,43.797,43.223,43.74,
ISRG,2013-08-05,43.533,43.777,43.243,43.737,
ISRG,2013-08-06,43.72,43.863,43.587,43.66,
ISRG,2013-08-07,43.68,43.747,42.91,43.327,
ISRG,2013-08-08,43.417,43.883,43.283,43.847,
ISRG,2013-08-09,43.863,43.97,43.11,43.54,
ISRG,2013-08-12,43.523,43.773,43.087,43.177,
ISRG,2013-08-13,43.277,43.39,42.067,42.843,
ISRG,2013-08-14,42.933,43.103,42.603,42.883,
ISRG,2013-08-15,42.623,42.783,42.327,42.637,"Google, Priceline, MasterCard race to $1,000 Fewer stock splits happen as ETFs attract more retail buyers With stock splits becoming less commonplace and share prices reaching record levels, several stocks including Google, Priceline and Mastercard are getting closer to that rarified level of $1,000 a share. Here’s a look at 10 stocks that hit the $1,000 mark, have been in contention, or could be close soon."
ISRG,2013-08-16,42.523,42.71,41.923,42.037,
ISRG,2013-08-19,42.147,42.997,41.727,42.773,Monday movers: Apple to ship new iPhones in Sept. Apple extends its rally following a report that its latest iPhones are likely to ship in early September.
ISRG,2013-08-20,42.73,43.53,42.72,42.827,
ISRG,2013-08-21,42.79,43.19,42.61,42.99,
ISRG,2013-08-22,42.943,43.423,42.673,43.35,
ISRG,2013-08-23,43.55,43.55,43.12,43.343,
ISRG,2013-08-26,43.533,43.777,43.253,43.52,
ISRG,2013-08-27,43.337,43.337,42.747,42.913,
ISRG,2013-08-28,43.017,43.41,42.823,43.05,
ISRG,2013-08-29,42.847,43.297,42.593,42.733,
ISRG,2013-08-30,42.667,43.347,42.437,42.947,
ISRG,2013-09-03,43.133,43.387,42.727,42.797,
ISRG,2013-09-04,42.593,43.163,42.593,43.037,
ISRG,2013-09-05,43.13,43.197,42.637,42.717,
ISRG,2013-09-06,42.69,42.957,42.333,42.743,
ISRG,2013-09-09,42.713,43.07,42.647,42.767,
ISRG,2013-09-10,42.777,43.017,41.877,41.887,
ISRG,2013-09-11,41.973,42.053,41.593,41.833,
ISRG,2013-09-12,41.777,42.073,41.15,41.41,
ISRG,2013-09-13,41.497,41.863,41.187,41.667,
ISRG,2013-09-16,41.89,42.19,41.637,41.673,
ISRG,2013-09-17,41.557,41.643,41.447,41.55,
ISRG,2013-09-18,41.647,41.667,41.147,41.39,
ISRG,2013-09-19,41.403,41.723,41.013,41.11,
ISRG,2013-09-20,41.27,41.75,40.94,41.633,
ISRG,2013-09-23,41.48,41.707,41.113,41.203,
ISRG,2013-09-24,41.18,41.203,40.383,40.433,
ISRG,2013-09-25,42.02,42.22,40.617,40.813,
ISRG,2013-09-26,40.853,41.257,40.557,40.933,
ISRG,2013-09-27,40.703,41.267,40.663,40.83,
ISRG,2013-09-30,40.707,42.0,40.477,41.807,
ISRG,2013-10-01,41.717,41.89,41.173,41.377,
ISRG,2013-10-02,41.287,41.717,40.957,41.067,
ISRG,2013-10-03,41.147,41.16,39.78,40.103,
ISRG,2013-10-04,40.103,40.653,40.03,40.477,
ISRG,2013-10-07,40.307,42.48,40.253,42.333,"[""How to avoid bubbles In today\u2019s linfkest, we have links to columns discussing the value of thinking for yourself vs. groupthink when it comes to investing, and another takes a look at how many U.S. investors are now looking toward Europe."", ""Apple gains on upgrade; BlackBerry rallies Apple extends gains to a fourth session in the wake of an analyst upgrade while BlackBerry is getting a lift from a report that it may have several high-profile suitors, including Cisco.""]"
ISRG,2013-10-08,42.367,44.59,42.33,42.36,
ISRG,2013-10-09,42.607,43.513,42.543,43.24,
ISRG,2013-10-10,43.597,43.603,42.713,43.023,
ISRG,2013-10-11,42.8,43.577,42.64,43.353,
ISRG,2013-10-14,43.127,45.05,42.8,44.63,
ISRG,2013-10-15,44.573,44.863,43.297,43.357,
ISRG,2013-10-16,43.673,44.83,43.65,44.593,"Picks to Play Johnson & Johnson Trends Wedbush cites St. Jude Medical, DexCom and Medtronic."
ISRG,2013-10-17,44.557,45.433,43.917,44.347,"[""Goldman Sachs, Google, Verizon are stocks to watch Shares of Google Inc. and Dow industrials components Goldman Sachs Group Inc. and Verizon Communications Inc. are active in premarket trade Thursday."", ""Google, Chipotle shares jump after earnings Google rallies in the extended session after the company beats Wall Street sales and earnings estimates for the third quarter. Chipotle shares surge after revenue tops estimates.""]"
ISRG,2013-10-18,41.137,42.833,41.11,41.837,"Google hits $1,000; Chipotle tops S&P 500 Google rallies by double digits to successfully test the $1,000-mark on Friday while Chipotle Mexican Grill jumps on the back of robust quarterly earnings."
ISRG,2013-10-21,41.84,41.84,40.667,41.337,
ISRG,2013-10-22,41.267,41.543,40.83,40.923,
ISRG,2013-10-23,40.753,41.877,40.62,41.663,
ISRG,2013-10-24,41.917,42.087,40.667,41.143,
ISRG,2013-10-25,41.1,41.247,40.563,41.013,
ISRG,2013-10-28,41.007,41.96,40.857,41.733,
ISRG,2013-10-29,41.653,42.357,41.4,41.963,
ISRG,2013-10-30,41.967,42.11,41.51,41.633,
ISRG,2013-10-31,41.667,42.043,41.137,41.277,
ISRG,2013-11-01,41.567,41.567,40.973,41.337,
ISRG,2013-11-04,41.427,42.743,41.36,42.47,
ISRG,2013-11-05,42.27,42.433,41.637,41.653,
ISRG,2013-11-06,41.78,42.03,41.57,41.907,
ISRG,2013-11-07,42.207,42.24,41.76,42.177,
ISRG,2013-11-08,42.07,43.407,41.9,43.313,
ISRG,2013-11-11,43.427,44.223,43.067,43.93,
ISRG,2013-11-12,43.563,44.283,43.5,44.003,
ISRG,2013-11-13,44.0,44.193,43.523,44.027,
ISRG,2013-11-14,44.113,44.223,43.903,44.14,
ISRG,2013-11-15,43.723,44.09,43.073,43.827,
ISRG,2013-11-18,43.833,44.31,43.32,43.663,
ISRG,2013-11-19,43.707,44.26,43.473,43.843,
ISRG,2013-11-20,43.963,44.22,43.673,43.833,
ISRG,2013-11-21,43.807,43.9,43.137,43.39,
ISRG,2013-11-22,43.233,43.537,43.003,43.3,
ISRG,2013-11-25,43.213,43.37,42.567,42.723,
ISRG,2013-11-26,42.393,42.643,41.483,41.613,"Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap Read a minute-by-minute of rundown of what's happening in the stock market."
ISRG,2013-11-27,41.827,42.067,41.567,42.0,
ISRG,2013-11-29,42.047,42.11,41.587,41.877,
ISRG,2013-12-02,42.023,42.057,41.597,41.72,
ISRG,2013-12-03,41.553,41.723,41.347,41.423,
ISRG,2013-12-04,40.833,41.387,40.247,41.187,"Dow, S&P 500 Fall For Fourth Straight Session"
ISRG,2013-12-05,41.21,41.327,40.593,40.87,
ISRG,2013-12-06,42.303,42.4,41.52,41.93,
ISRG,2013-12-09,41.887,41.953,41.39,41.843,
ISRG,2013-12-10,41.677,42.39,41.677,42.17,
ISRG,2013-12-11,42.07,42.07,40.523,40.737,
ISRG,2013-12-12,40.603,41.207,40.56,40.923,
ISRG,2013-12-13,40.753,41.227,40.283,40.327,
ISRG,2013-12-16,40.44,41.073,40.223,40.253,
ISRG,2013-12-17,40.097,40.443,39.017,39.547,
ISRG,2013-12-18,39.603,40.313,39.39,40.137,
ISRG,2013-12-19,39.933,40.17,39.473,39.9,
ISRG,2013-12-20,39.907,40.553,39.667,40.483,
ISRG,2013-12-23,40.557,41.453,40.403,41.247,
ISRG,2013-12-24,41.247,41.61,41.017,41.217,
ISRG,2013-12-26,41.373,41.75,41.11,41.643,
ISRG,2013-12-27,41.583,42.617,41.497,42.22,
ISRG,2013-12-30,42.217,42.617,41.993,42.563,
ISRG,2013-12-31,42.467,42.71,42.01,42.677,
ISRG,2014-01-02,42.627,42.627,42.03,42.223,
ISRG,2014-01-03,42.26,42.52,41.417,41.497,
ISRG,2014-01-06,41.44,41.917,41.113,41.217,
ISRG,2014-01-07,41.267,41.877,41.193,41.53,
ISRG,2014-01-08,41.6,42.293,41.563,42.273,
ISRG,2014-01-09,42.32,43.317,42.19,42.977,
ISRG,2014-01-10,42.94,47.177,42.807,46.683,"Alcoa tops S&P losers, Twitter extends losing streak Alcoa retreats on Friday in the wake of sharp quarterly losses while Twitter extends losing streak to fifth session in a row."
ISRG,2014-01-13,45.787,46.083,43.557,43.673,
ISRG,2014-01-14,48.947,49.333,46.217,46.653,"[""Morning Movers: Intuitive Surgical Jumps on Guidance; JPMorgan Chase Beats Forecasts"", ""Intuitive Surgical rallies 9%, best on S&P 500"", ""Dow jumps 116 points, best day this year: Stock market live blog recap MarketWatch live blogs the U.S. stock market Tuesday"", ""GameStop tumbles 20%; Tesla surges on strong sales GameStop skids after it lowers its earnings estimate for the critical holiday quarter while Tesla accelerates on stronger-than-expected car sales.""]"
ISRG,2014-01-15,46.73,46.787,44.687,45.867,
ISRG,2014-01-16,46.053,46.48,45.387,46.043,
ISRG,2014-01-17,46.197,47.917,46.0,47.793,
ISRG,2014-01-21,49.433,49.723,48.11,48.82,
ISRG,2014-01-22,48.683,48.833,48.11,48.79,
ISRG,2014-01-23,48.777,49.267,48.283,48.777,"[""McDonald\u2019s, Microsoft, Starbucks are stocks to watch Among the companies whose shares are expected to see active trade in Thursday\u2019s session are McDonald\u2019s, Microsoft, and Starbucks."", ""Dow skids on China worries; VIX, gold jump: Stock market live blog recap We're covering the stock market live on Thursday.""]"
ISRG,2014-01-24,45.817,47.39,45.14,45.64,"[""Beam, Honeywell, Procter & Gamble are stocks to watch Among the companies whose shares are expected to see active trade in Friday\u2019s session are Beam Inc., Honeywell International Inc., and Procter & Gamble Co."", ""Emerging Markets Wallop Stocks, Dow Drops 100 Points"", ""Juniper buoyed by Jana stake; Herbalife loss grows Juniper Networks stock surges on news of its fourth-quarter earnings and a second stake by an activist investor.""]"
ISRG,2014-01-27,45.69,46.267,45.36,45.403,
ISRG,2014-01-28,45.187,46.097,45.16,45.503,
ISRG,2014-01-29,45.003,46.617,45.003,46.133,
ISRG,2014-01-30,46.277,46.893,46.153,46.26,
ISRG,2014-01-31,45.547,45.937,45.117,45.287,
ISRG,2014-02-03,45.04,45.443,44.073,44.573,
ISRG,2014-02-04,44.813,45.997,44.72,45.457,
ISRG,2014-02-05,45.443,46.397,45.193,46.123,
ISRG,2014-02-06,46.33,46.667,45.947,46.087,
ISRG,2014-02-07,46.0,46.443,45.443,46.41,
ISRG,2014-02-10,46.23,48.093,46.12,47.74,
ISRG,2014-02-11,47.123,47.94,46.803,47.383,
ISRG,2014-02-12,47.637,48.743,47.467,48.707,
ISRG,2014-02-13,48.647,49.213,48.167,49.17,
ISRG,2014-02-14,48.01,49.107,47.917,48.76,
ISRG,2014-02-18,48.82,49.443,48.25,49.343,
ISRG,2014-02-19,48.91,49.75,48.76,48.883,
ISRG,2014-02-20,48.997,49.113,48.147,48.67,
ISRG,2014-02-21,48.977,49.057,48.307,48.353,
ISRG,2014-02-24,48.353,49.077,48.243,48.727,
ISRG,2014-02-25,48.57,48.777,48.11,48.32,
ISRG,2014-02-26,48.713,49.14,48.307,48.707,
ISRG,2014-02-27,48.687,49.523,48.443,49.35,
ISRG,2014-02-28,49.357,50.553,48.867,49.427,
ISRG,2014-03-03,49.143,51.387,48.893,50.427,
ISRG,2014-03-04,50.657,50.657,49.277,49.947,
ISRG,2014-03-05,49.837,50.223,49.283,49.657,
ISRG,2014-03-06,49.677,49.973,49.123,49.373,"‘Reset day’ keeps stock compass pointing northeast The fact that the market bounced back so quickly from Monday’s drubbing means that the day essentially doesn’t exist from a technical standpoint, thereby allowing traders to continue playing the game."
ISRG,2014-03-07,49.58,50.053,49.087,49.33,
ISRG,2014-03-10,49.23,49.387,48.45,48.733,
ISRG,2014-03-11,48.85,49.117,48.213,48.353,
ISRG,2014-03-12,48.093,49.1,47.673,48.127,
ISRG,2014-03-13,48.223,48.777,47.62,47.74,
ISRG,2014-03-14,47.423,47.97,46.91,47.007,
ISRG,2014-03-17,47.113,47.813,47.007,47.4,
ISRG,2014-03-18,47.307,47.75,47.24,47.67,Veteran Investor's Top Biotech and Drug Stocks Sam Isaly of the index-beating Eaton Vance Worldwide Health Sciences Fund shares his health-care insights.
ISRG,2014-03-19,47.613,48.343,47.613,48.283,
ISRG,2014-03-20,47.923,48.597,47.24,48.557,
ISRG,2014-03-21,49.283,49.283,47.603,47.653,
ISRG,2014-03-24,47.907,48.35,46.583,46.897,
ISRG,2014-03-25,46.983,47.503,46.663,46.99,
ISRG,2014-03-26,47.323,47.777,47.037,47.183,
ISRG,2014-03-27,46.943,47.947,46.477,47.623,How to Find 5-Bagger Stocks for the Next Decade Caffeine (Monster and Keurig) led the stock market in the past 10 years. What to buy now? Think boring.
ISRG,2014-03-28,47.733,48.767,47.627,48.333,
ISRG,2014-03-31,48.33,49.11,48.11,48.667,
ISRG,2014-04-01,54.007,55.923,52.247,54.843,"[""Intuitive Surgical surges; auto sales in focus CEO Mary Barra testifies on GM\u2019s handling of massive recall Intuitive Surgical rises for a sixth session Tuesday on government approval for a new surgical device, while car makers attract attention as they announce March sales results."", ""U.S. stocks rally; S&P 500 closes at record Ford shares rise after sales top forecasts The U.S. stock market ends Tuesday sharply higher, with the S&P 500 closing at a record. Investors bid up prices after mildly positive manufacturing data and better-than-expected car sales boost confidence."", ""No Joke: An April Fool's Day High for the S&P 500""]"
ISRG,2014-04-02,56.04,58.057,55.4,57.61,"[""S&P 500 rises to fresh record close; Dow just shy of one: stock market live blog recap We live blogged the stock market on Wednesday."", ""Stock market live blog: S&P 500 closes at new high, indexes see 3rd day of gains Follow MarketWatch's live blog of the U.S. stock market Tuesday."", ""Third Consecutive New High for S&P 500; Dow Industrials Not Quite Positive in 2014""]"
ISRG,2014-04-03,57.717,60.137,57.717,60.07,"[""U.S. stocks up; S&P 500 hits record Private sector adds 191,000 jobs in March The U.S. stock market ends a choppy session moderately higher on Wednesday, with the S&P 500 closing at a record."", ""Anadarko up on settlement; Amazon falls as Fire fizzles Anadarko Petroleum soars on Thursday after the company said it settled a lawsuit on behalf of its subsidiary while Amazon.com is among the weakest stocks in the S&P 500 after unveiling a new multimedia set-top box.""]"
ISRG,2014-04-04,59.443,59.63,56.13,56.17,"Facebook, Tesla slide into bear market territory GrubHub jumps 34% on debut High-flying momentum stocks Facebook Inc. and Tesla Motors Inc. fall into bear market territory on Friday after slumping in line with the broader market’s decline."
ISRG,2014-04-07,56.11,57.09,55.15,55.227,"Tesla, Facebook, Netflix are Monday’s stocks to watch Among the companies whose shares are expected to see active trade in Monday’s session are Tesla, Facebook, and Netflix in the wake of the sell-off in so-called momentum stocks recently."
ISRG,2014-04-08,55.557,55.593,53.82,54.427,
ISRG,2014-04-09,49.103,51.323,48.78,50.737,"[""Fed minutes, a Netflix short (still?) and China's negative correlation The ceremonial parsing of the Fed minutes is today's main event today, but that says more about hump day malaise than what the chairwoman has to offer with regards to the next phase of tapering.\""There's usually a bit of trepidation in the session before the FOMC minutes are released but considering the amount of flip-flopping from Janet Yellen after the meeting, anything of influence will probably be shrugged off,\"" said London Capital's Jonathan Sudaria."", ""Stock futures higher ahead of Fed minutes Strategist: Worries about lofty tech valuations haven\u2019t gone away Alcoa is inching up in premarket after the aluminum maker kicked off earnings season, while stock futures pointed to more gains for Wall Street ahead of the release of Fed minutes from its latest meeting."", ""Intuitive Surgical slumps; Facebook extends rally La Quinta recovers after initial slide on market debut Intuitive Surgical slumps Wednesday, the worst performer on the S&P 500 on a weak outlook, while Facebook extends gains for a third session following positive analyst comments."", ""U.S. stocks rally on dovish signals in Fed minutes Facebook jumps on analyst recommendations U.S. stocks rally Wednesday to end with the best gains in more than a month after the minutes of the latest Federal Open Market Committee meeting reveal a more dovish stance than investors expected.""]"
ISRG,2014-04-10,51.087,51.667,50.277,50.4,
ISRG,2014-04-11,50.017,50.18,48.19,48.847,"Blame it on Rio: Stocks Hit the Skids, Nasdaq Drops Most Since 2012"
ISRG,2014-04-14,49.127,49.193,46.933,47.223,
ISRG,2014-04-15,47.26,47.473,45.623,46.343,
ISRG,2014-04-16,47.317,47.347,45.917,46.127,
ISRG,2014-04-17,46.11,46.393,45.557,45.777,
ISRG,2014-04-21,45.557,46.303,45.38,45.68,
ISRG,2014-04-22,47.757,47.96,46.183,46.927,"[""Cash In on Earnings With This Trading Menu These 50 stocks have taken a beating recently and are primed for big moves on earnings reports."", ""McDonald\u2019s, Gilead, Yum, AT&T are stocks to watch Netflix likely to gain after earnings report; Allergan up on Pershing stake Among the companies whose shares are expected to see active trade in Tuesday\u2019s session are McDonald\u2019s, Yum Brands, Gilead and AT&T."", ""S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap We're live blogging all the action in stocks on Tuesday right here."", ""Gilead shares climb; AT&T, Amgen shares fall IBB biotechnology ETF up after hours, underscores big day for biotech, health-care Gilead shares Inc., AT&T Inc. and Amgen Inc. were among the stocks actively trading Tuesday evening, with shares of Gilead climbing after handily beating Wall Street\u2019s quarterly earnings and revenue expectations.""]"
ISRG,2014-04-23,43.013,44.157,41.37,41.547,"[""Apple, Facebook, Boeing are stocks to watch Tuesday after-hours movers include Gilead, Yum Brands, Intuitive Surgical Among the companies whose shares are expected to see active trade in Wednesday\u2019s session are Boeing, Apple, and Facebook."", ""Game day for Facebook and Apple, volume 'signalling the nasty' Seven-straight winning sessions. The Nasdaq and S&P 500 can almost taste it, but that may prove a tough order for Wednesday. While M&A breathed some life into markets yesterday, it's hard to say what kind of enthusiasm will be mustered on Wall Street ahead of a mega earnings double-header coming after the close."", ""Morning Movers: Skechers Jumps on Earnings Beat; Intuitive Surgical Tumbles"", ""Apple, Facebook stuck in red ahead of earnings Intuitive Surgical slumps as earnings shrink Apple and Facebook are both weak as they prepare to release quarterly results later Wednesday while Intuitive Surgical slumps as its earnings disappoint.""]"
ISRG,2014-04-24,41.817,41.837,40.89,41.257,
ISRG,2014-04-25,40.947,41.11,40.27,40.707,Love and Other Disasters: Stocks End Week Lower; Cheap is the New Growth
ISRG,2014-04-28,40.99,41.32,40.487,40.867,
ISRG,2014-04-29,41.377,41.89,39.263,40.177,
ISRG,2014-04-30,39.913,40.407,39.78,40.19,
ISRG,2014-05-01,40.583,41.22,39.82,39.903,
ISRG,2014-05-02,41.177,41.18,40.35,40.4,
ISRG,2014-05-05,40.207,40.643,39.92,40.44,
ISRG,2014-05-06,40.157,40.7,40.0,40.033,
ISRG,2014-05-07,40.027,40.25,39.17,39.217,
ISRG,2014-05-08,39.1,39.98,39.033,39.15,
ISRG,2014-05-09,39.063,39.257,38.497,39.23,
ISRG,2014-05-12,39.347,40.793,38.897,40.63,
ISRG,2014-05-13,40.61,40.93,40.223,40.607,
ISRG,2014-05-14,40.433,41.733,40.223,41.297,
ISRG,2014-05-15,41.393,41.44,40.063,40.493,
ISRG,2014-05-16,40.573,41.633,40.27,41.567,
ISRG,2014-05-19,41.337,41.91,41.117,41.213,
ISRG,2014-05-20,41.073,41.22,40.353,40.4,
ISRG,2014-05-21,40.61,40.937,40.347,40.703,
ISRG,2014-05-22,40.587,41.207,40.36,40.517,
ISRG,2014-05-23,40.52,40.667,40.293,40.43,
ISRG,2014-05-27,40.507,41.423,40.28,41.263,
ISRG,2014-05-28,41.247,41.32,40.517,40.52,
ISRG,2014-05-29,40.733,41.8,40.533,41.65,
ISRG,2014-05-30,41.67,41.673,40.81,41.083,
ISRG,2014-06-02,40.967,41.363,40.687,41.21,
ISRG,2014-06-03,40.997,41.547,40.997,41.217,
ISRG,2014-06-04,41.033,41.377,40.967,41.127,
ISRG,2014-06-05,41.24,41.623,40.937,40.983,
ISRG,2014-06-06,41.133,41.287,40.89,41.25,
ISRG,2014-06-09,41.213,41.757,41.097,41.65,
ISRG,2014-06-10,41.483,42.177,41.433,41.957,
ISRG,2014-06-11,41.913,42.743,41.867,42.487,
ISRG,2014-06-12,42.343,43.657,42.333,43.597,
ISRG,2014-06-13,43.54,44.317,43.403,44.09,
ISRG,2014-06-16,44.167,45.663,44.097,45.537,
ISRG,2014-06-17,45.643,45.77,44.787,44.803,
ISRG,2014-06-18,44.707,44.947,44.417,44.907,
ISRG,2014-06-19,45.117,45.117,44.227,44.69,
ISRG,2014-06-20,44.913,45.0,44.317,44.907,
ISRG,2014-06-23,45.167,45.48,44.533,44.773,
ISRG,2014-06-24,44.823,45.237,44.64,44.693,"How I learned to stop worrying and love robot stocks Opinion: Humans are being replaced by machines, and you can invest in that trend Humans are being replaced by machines, and you can invest in that trend, writes Jeff Reeves."
ISRG,2014-06-25,44.917,45.11,44.41,45.01,
ISRG,2014-06-26,44.91,45.7,44.683,45.643,
ISRG,2014-06-27,45.753,47.38,45.51,47.043,
ISRG,2014-06-30,46.823,46.907,45.557,45.757,
ISRG,2014-07-01,45.76,46.04,45.08,45.167,
ISRG,2014-07-02,45.337,45.467,44.673,44.817,
ISRG,2014-07-03,44.777,44.99,44.54,44.893,
ISRG,2014-07-07,44.843,44.887,43.473,43.807,
ISRG,2014-07-08,43.933,43.933,42.457,42.88,
ISRG,2014-07-09,43.04,43.193,42.417,42.917,
ISRG,2014-07-10,42.417,43.023,42.223,42.547,
ISRG,2014-07-11,42.697,43.387,42.667,43.25,
ISRG,2014-07-14,43.36,43.58,42.567,42.733,
ISRG,2014-07-15,42.66,43.147,42.487,42.62,
ISRG,2014-07-16,42.607,43.017,42.223,42.25,
ISRG,2014-07-17,42.25,42.82,41.777,42.47,
ISRG,2014-07-18,42.407,43.21,42.217,43.0,
ISRG,2014-07-21,42.837,43.203,42.227,43.19,
ISRG,2014-07-22,43.66,44.173,43.333,43.573,
ISRG,2014-07-23,48.903,51.487,48.727,51.293,"[""Biogen rallies on earnings; Juniper slumps 10% Latest results put Apple, Intuitive Surgical, Microsoft in focus Biogen Idec jumps following quarterly results while Juniper Networks slumps more than 10%."", ""Apple, Intuitive power S&P 500 to record: stock market live blog recap We live blogged all the action in the stock market on Wednesday.""]"
ISRG,2014-07-24,50.78,53.667,50.557,52.593,
ISRG,2014-07-25,51.543,52.417,51.173,52.19,
ISRG,2014-07-28,52.76,52.76,51.29,51.7,
ISRG,2014-07-29,51.817,52.11,51.203,51.693,
ISRG,2014-07-30,51.97,52.22,51.66,51.887,
ISRG,2014-07-31,51.763,51.777,50.77,50.84,
ISRG,2014-08-01,51.0,51.107,50.11,50.353,
ISRG,2014-08-04,50.257,50.727,50.037,50.557,
ISRG,2014-08-05,50.183,50.557,49.557,49.82,
ISRG,2014-08-06,49.603,50.06,49.303,49.827,
ISRG,2014-08-07,49.87,49.95,48.96,49.09,
ISRG,2014-08-08,49.303,49.55,48.99,49.337,
ISRG,2014-08-11,49.207,50.107,48.723,49.293,
ISRG,2014-08-12,49.503,50.213,49.47,50.17,
ISRG,2014-08-13,50.067,50.61,49.873,50.593,
ISRG,2014-08-14,50.523,51.193,50.273,51.153,
ISRG,2014-08-15,51.64,51.897,50.837,51.017,
ISRG,2014-08-18,51.177,52.033,51.1,51.59,
ISRG,2014-08-19,51.75,52.71,51.613,52.573,
ISRG,2014-08-20,52.357,52.647,51.693,51.943,
ISRG,2014-08-21,52.1,52.493,51.777,52.433,
ISRG,2014-08-22,52.49,52.497,51.987,52.417,
ISRG,2014-08-25,52.603,52.833,52.027,52.283,
ISRG,2014-08-26,52.11,53.383,51.977,53.187,
ISRG,2014-08-27,53.09,53.107,52.227,52.347,
ISRG,2014-08-28,52.037,52.39,51.533,51.73,
ISRG,2014-08-29,52.247,52.403,51.577,52.223,
ISRG,2014-09-02,52.507,52.773,52.093,52.673,
ISRG,2014-09-03,52.733,52.85,52.403,52.633,
ISRG,2014-09-04,52.683,52.823,51.507,51.633,
ISRG,2014-09-05,51.81,51.81,50.67,51.71,
ISRG,2014-09-08,51.903,51.943,51.13,51.863,
ISRG,2014-09-09,52.75,52.957,51.783,51.867,
ISRG,2014-09-10,51.653,52.8,51.353,52.617,
ISRG,2014-09-11,52.09,52.58,52.033,52.223,
ISRG,2014-09-12,52.137,53.513,52.137,53.413,
ISRG,2014-09-15,53.13,53.173,51.67,52.087,
ISRG,2014-09-16,52.033,52.997,51.453,52.743,
ISRG,2014-09-17,52.793,53.153,52.333,52.613,
ISRG,2014-09-18,52.817,53.0,52.407,52.837,
ISRG,2014-09-19,53.207,53.223,52.133,52.17,
ISRG,2014-09-22,51.783,51.867,50.167,50.787,
ISRG,2014-09-23,50.39,50.873,50.277,50.68,
ISRG,2014-09-24,50.91,51.923,50.737,51.75,
ISRG,2014-09-25,51.64,51.9,50.623,50.837,
ISRG,2014-09-26,50.77,51.533,50.537,51.143,
ISRG,2014-09-29,50.95,51.927,50.61,51.637,
ISRG,2014-09-30,51.643,52.107,50.89,51.313,
ISRG,2014-10-01,51.48,51.613,50.633,51.423,
ISRG,2014-10-02,51.507,52.39,50.71,52.183,
ISRG,2014-10-03,52.627,53.443,52.337,52.8,
ISRG,2014-10-06,54.397,56.193,53.907,54.06,
ISRG,2014-10-07,53.74,54.317,53.213,53.583,
ISRG,2014-10-08,53.75,54.62,53.317,54.427,
ISRG,2014-10-09,54.237,54.237,52.333,52.927,
ISRG,2014-10-10,52.96,53.573,52.153,52.227,
ISRG,2014-10-13,52.09,52.9,51.62,51.673,
ISRG,2014-10-14,52.467,52.743,50.833,51.257,
ISRG,2014-10-15,50.69,51.507,49.927,51.127,
ISRG,2014-10-16,50.35,51.94,50.207,50.723,
ISRG,2014-10-17,51.63,52.597,51.63,52.25,
ISRG,2014-10-20,53.323,54.077,52.403,53.917,"[""Goldman Sachs plays \u2018Moneyball\u2019 with this 22-stock roster Goldman is applying the number-crunching techniques of baseball general manager Billy Beane One could argue Goldman Sachs has always played some sort of \u201cMoneyball,\u201d but as the World Series approaches, the firm is finding parallels between the metrics intended to identify undervalued baseball players and those for picking stocks."", ""Apple shares rise past $100 after Street beat Texas Instruments shares rise, Chipotle\u2019s decline Apple shares advance in the extended session Monday after the company topped the Wall Street consensus for the quarter.""]"
ISRG,2014-10-21,53.81,55.407,52.777,55.087,"Boeing, AT&T reports due Wednesday; Yahoo up late Six Flags, iRobot shares rally Boeing, and AT&T report Wednesday, whilc Yahoo’s latest numbers will keep the share in focus"
ISRG,2014-10-22,55.57,55.743,52.997,53.533,"AT&T, Yelp shares decline after earnings Citrix, Cheesecake Factory shares also decline Shares of AT&T and Yelp fell in the extended session Wednesday following quarterly earnings reports from the companies."
ISRG,2014-10-23,53.8,54.95,53.62,53.947,
ISRG,2014-10-24,53.923,54.197,53.033,53.113,
ISRG,2014-10-27,52.833,53.33,52.193,53.08,
ISRG,2014-10-28,53.31,54.683,53.173,54.633,
ISRG,2014-10-29,53.593,54.443,53.43,54.157,
ISRG,2014-10-30,53.95,54.897,53.583,54.443,
ISRG,2014-10-31,55.217,55.613,54.723,55.09,
ISRG,2014-11-03,54.117,55.647,54.033,55.093,
ISRG,2014-11-04,55.093,55.42,54.507,55.11,
ISRG,2014-11-05,55.317,56.247,54.89,56.153,
ISRG,2014-11-06,55.56,56.913,55.447,56.517,
ISRG,2014-11-07,56.707,56.823,55.223,55.557,
ISRG,2014-11-10,55.457,56.607,55.457,56.553,
ISRG,2014-11-11,56.65,57.21,55.89,57.15,
ISRG,2014-11-12,57.15,57.423,56.61,57.027,
ISRG,2014-11-13,57.15,58.157,57.127,57.343,
ISRG,2014-11-14,57.49,57.537,56.75,56.913,
ISRG,2014-11-17,56.7,57.593,56.66,56.82,3 growth industries revolutionizing the world Here are the three biggest growth industries about to revolutionize our world next.
ISRG,2014-11-18,56.707,57.54,56.667,57.353,
ISRG,2014-11-19,57.17,57.303,56.827,57.003,
ISRG,2014-11-20,56.87,57.257,56.817,57.057,
ISRG,2014-11-21,57.777,57.777,56.57,57.27,
ISRG,2014-11-24,57.223,58.03,57.09,57.927,
ISRG,2014-11-25,57.88,58.183,57.24,57.387,
ISRG,2014-11-26,56.027,57.35,56.027,57.223,
ISRG,2014-11-28,57.31,57.743,57.15,57.53,
ISRG,2014-12-01,57.32,57.697,56.853,57.08,
ISRG,2014-12-02,56.673,57.34,56.617,56.93,
ISRG,2014-12-03,56.857,57.757,56.767,57.623,
ISRG,2014-12-04,56.943,57.773,56.557,56.743,
ISRG,2014-12-05,56.557,57.193,56.447,56.54,
ISRG,2014-12-08,55.71,57.31,55.71,57.237,
ISRG,2014-12-09,56.523,57.27,56.18,57.213,
ISRG,2014-12-10,56.993,56.993,55.453,55.643,
ISRG,2014-12-11,56.067,56.803,56.0,56.237,
ISRG,2014-12-12,55.667,56.83,55.667,55.863,
ISRG,2014-12-15,56.013,56.59,55.273,55.447,
ISRG,2014-12-16,55.93,56.31,55.183,55.24,
ISRG,2014-12-17,55.447,56.95,55.28,56.69,
ISRG,2014-12-18,57.2,58.167,56.777,58.167,
ISRG,2014-12-19,57.87,59.403,57.803,59.107,
ISRG,2014-12-22,59.22,59.87,58.39,59.317,
ISRG,2014-12-23,59.667,59.767,58.283,58.463,
ISRG,2014-12-24,58.733,59.363,58.2,58.993,
ISRG,2014-12-26,59.043,59.41,58.617,59.027,
ISRG,2014-12-29,59.12,59.263,58.6,58.86,
ISRG,2014-12-30,58.367,59.193,58.36,58.433,
ISRG,2014-12-31,58.687,59.557,58.38,58.77,
ISRG,2015-01-02,58.987,59.533,57.923,58.397,
ISRG,2015-01-05,58.087,58.167,57.087,57.153,
ISRG,2015-01-06,58.157,58.27,57.153,57.753,
ISRG,2015-01-07,58.197,59.21,57.91,58.07,
ISRG,2015-01-08,58.733,59.633,58.197,59.223,
ISRG,2015-01-09,58.997,59.583,57.83,57.873,
ISRG,2015-01-12,57.783,58.477,57.213,58.39,
ISRG,2015-01-13,59.07,59.333,57.417,57.963,
ISRG,2015-01-14,57.923,59.65,57.663,59.483,
ISRG,2015-01-15,59.473,59.787,58.05,58.263,
ISRG,2015-01-16,58.107,59.09,57.71,58.96,
ISRG,2015-01-20,59.353,59.44,57.62,57.98,
ISRG,2015-01-21,57.547,58.333,57.337,57.57,
ISRG,2015-01-22,58.007,58.507,57.34,58.377,
ISRG,2015-01-23,56.927,58.537,56.447,57.507,
ISRG,2015-01-26,57.637,57.913,56.863,57.89,
ISRG,2015-01-27,57.0,57.463,56.223,56.58,
ISRG,2015-01-28,56.11,57.083,55.777,55.817,
ISRG,2015-01-29,55.693,56.39,54.773,56.11,
ISRG,2015-01-30,55.347,56.1,54.85,54.943,
ISRG,2015-02-02,55.54,56.43,54.963,56.347,Anadarko shares slip as earnings miss Cliffs Natural shares rise as results top Street view Anadarko Petroleum Corp. shares decline in the extended session Monday after the oil and gas exploration and production company’s quarterly earnings fall short of the Wall Street estimate.
ISRG,2015-02-03,56.473,56.847,55.837,56.517,
ISRG,2015-02-04,56.38,56.977,56.01,56.103,
ISRG,2015-02-05,56.463,57.377,56.343,57.353,
ISRG,2015-02-06,57.073,58.157,56.64,56.92,
ISRG,2015-02-09,56.667,57.0,55.433,55.7,
ISRG,2015-02-10,55.86,56.11,55.057,55.54,
ISRG,2015-02-11,55.347,56.0,55.173,55.437,
ISRG,2015-02-12,55.573,56.477,55.097,56.413,
ISRG,2015-02-13,56.21,56.807,56.187,56.747,
ISRG,2015-02-17,56.747,57.363,56.357,57.11,
ISRG,2015-02-18,57.057,57.21,56.683,56.983,
ISRG,2015-02-19,56.613,56.983,56.157,56.83,
ISRG,2015-02-20,56.807,57.043,56.253,57.033,
ISRG,2015-02-23,56.627,57.213,56.513,57.077,
ISRG,2015-02-24,56.973,57.07,56.613,56.873,
ISRG,2015-02-25,57.02,57.02,56.11,56.407,
ISRG,2015-02-26,56.52,56.947,55.973,56.26,
ISRG,2015-02-27,56.093,56.26,55.283,55.557,
ISRG,2015-03-02,55.663,56.11,55.663,55.917,
ISRG,2015-03-03,56.473,56.777,55.783,56.563,
ISRG,2015-03-04,56.163,56.213,55.443,55.617,
ISRG,2015-03-05,55.717,56.047,55.34,55.503,
ISRG,2015-03-06,55.22,55.503,54.637,54.893,
ISRG,2015-03-09,54.523,54.89,54.073,54.733,
ISRG,2015-03-10,54.29,54.733,54.167,54.17,
ISRG,2015-03-11,54.127,55.213,54.12,54.833,
ISRG,2015-03-12,55.287,55.877,54.797,55.473,
ISRG,2015-03-13,55.277,55.643,54.557,54.827,
ISRG,2015-03-16,54.893,56.447,54.813,56.313,
ISRG,2015-03-17,56.027,56.533,55.937,56.193,
ISRG,2015-03-18,56.357,56.893,55.55,56.54,
ISRG,2015-03-19,56.367,56.793,56.267,56.53,
ISRG,2015-03-20,56.88,57.19,56.35,56.56,
ISRG,2015-03-23,56.56,56.797,56.107,56.467,
ISRG,2015-03-24,56.463,56.727,55.813,55.967,
ISRG,2015-03-25,55.94,56.477,54.903,55.027,
ISRG,2015-03-26,54.95,56.217,54.67,55.443,
ISRG,2015-03-27,54.933,56.077,54.933,55.25,
ISRG,2015-03-30,55.62,56.443,55.33,56.24,
ISRG,2015-03-31,56.12,57.22,55.973,56.113,
ISRG,2015-04-01,56.113,56.563,55.103,56.28,
ISRG,2015-04-02,56.48,56.777,55.633,56.477,
ISRG,2015-04-06,56.02,57.323,55.89,57.147,
ISRG,2015-04-07,57.403,57.503,56.9,56.94,
ISRG,2015-04-08,56.643,57.26,56.61,56.83,
ISRG,2015-04-09,56.917,57.49,56.58,57.01,
ISRG,2015-04-10,57.01,59.27,56.56,58.93,
ISRG,2015-04-13,59.077,60.93,58.777,60.257,
ISRG,2015-04-14,60.557,60.557,58.79,59.56,
ISRG,2015-04-15,59.64,59.927,59.037,59.3,"Johnson & Johnson Trends Favor Four Stocks The firm’s results and earnings call were positive for Intuitive Surgical, St. Jude Medical, Masimo and DexCom."
ISRG,2015-04-16,59.59,60.683,58.697,60.387,
ISRG,2015-04-17,59.533,60.28,59.367,60.077,
ISRG,2015-04-20,60.433,61.577,60.083,61.443,
ISRG,2015-04-21,61.643,62.117,60.417,60.747,
ISRG,2015-04-22,58.997,59.617,57.353,57.437,Facebook slips following results; AT&T gains on earnings beat Facebook retreats while AT&T gains following release of quarterly results.
ISRG,2015-04-23,57.303,57.697,56.943,56.973,
ISRG,2015-04-24,56.147,57.157,56.023,56.213,
ISRG,2015-04-27,56.213,56.867,55.527,55.613,
ISRG,2015-04-28,55.667,56.483,54.88,56.103,
ISRG,2015-04-29,56.103,56.147,55.0,55.503,
ISRG,2015-04-30,55.433,55.457,54.61,55.11,
ISRG,2015-05-01,54.947,55.49,54.76,55.33,
ISRG,2015-05-04,55.557,55.73,54.777,55.373,
ISRG,2015-05-05,55.06,55.373,54.693,54.773,
ISRG,2015-05-06,54.927,55.193,53.653,54.3,
ISRG,2015-05-07,54.347,55.04,53.947,54.347,
ISRG,2015-05-08,54.83,55.04,54.327,54.923,
ISRG,2015-05-11,54.87,55.367,54.337,55.153,
ISRG,2015-05-12,54.777,55.463,54.497,54.983,
ISRG,2015-05-13,54.9,55.603,54.793,55.383,
ISRG,2015-05-14,55.637,56.217,55.09,55.817,
ISRG,2015-05-15,56.097,56.097,55.493,55.963,
ISRG,2015-05-18,55.81,56.043,55.567,55.85,
ISRG,2015-05-19,55.923,56.0,55.517,55.873,
ISRG,2015-05-20,56.0,56.007,54.573,54.707,
ISRG,2015-05-21,54.553,55.267,54.527,54.993,
ISRG,2015-05-22,54.977,55.33,54.74,55.03,
ISRG,2015-05-26,54.89,54.913,54.05,54.13,
ISRG,2015-05-27,54.13,54.893,53.943,54.85,
ISRG,2015-05-28,54.613,54.777,53.823,53.977,
ISRG,2015-05-29,54.007,54.777,53.703,54.193,
ISRG,2015-06-01,54.597,56.62,54.37,55.797,
ISRG,2015-06-02,55.617,55.66,55.11,55.46,
ISRG,2015-06-03,55.437,55.82,55.097,55.683,
ISRG,2015-06-04,55.413,55.51,54.86,55.137,
ISRG,2015-06-05,55.26,55.37,54.567,55.01,
ISRG,2015-06-08,55.103,55.403,54.44,54.507,
ISRG,2015-06-09,54.383,55.413,54.16,55.247,
ISRG,2015-06-10,55.253,56.437,54.943,56.023,
ISRG,2015-06-11,55.82,56.53,55.267,55.36,
ISRG,2015-06-12,55.05,55.32,54.603,55.073,
ISRG,2015-06-15,54.81,55.063,54.113,54.63,
ISRG,2015-06-16,54.72,55.077,54.473,54.537,
ISRG,2015-06-17,54.663,55.293,54.11,54.313,
ISRG,2015-06-18,54.59,55.263,54.407,55.11,
ISRG,2015-06-19,55.08,55.413,54.773,54.973,
ISRG,2015-06-22,55.307,55.76,54.96,55.493,
ISRG,2015-06-23,55.397,55.927,55.11,55.18,
ISRG,2015-06-24,55.297,55.55,54.703,54.717,
ISRG,2015-06-25,54.793,56.11,54.793,54.983,
ISRG,2015-06-26,55.27,55.913,55.04,55.24,
ISRG,2015-06-29,54.657,55.023,53.697,53.753,
ISRG,2015-06-30,54.27,54.27,53.343,53.833,
ISRG,2015-07-01,54.16,54.473,53.643,53.983,
ISRG,2015-07-02,54.207,54.25,53.567,54.033,
ISRG,2015-07-06,53.07,53.623,52.31,53.123,
ISRG,2015-07-07,53.383,53.55,52.347,53.497,
ISRG,2015-07-08,53.373,53.803,52.747,53.183,
ISRG,2015-07-09,53.877,54.063,53.287,53.497,
ISRG,2015-07-10,54.057,54.353,53.777,54.207,
ISRG,2015-07-13,53.45,55.453,53.45,55.283,
ISRG,2015-07-14,55.443,55.49,54.293,54.66,
ISRG,2015-07-15,54.823,55.13,54.33,54.497,
ISRG,2015-07-16,54.757,54.93,54.307,54.447,
ISRG,2015-07-17,54.433,54.643,54.093,54.423,
ISRG,2015-07-20,54.38,55.443,54.16,55.29,
ISRG,2015-07-21,55.3,56.41,55.107,56.12,"Apple shares fall on disappointing revenue outlook GoPro shares have volatile after-hours ride Apple Inc. shares drop in the extended session on its latest quarterly report, shaving off more than $50 billion in market cap."
ISRG,2015-07-22,62.333,62.763,60.82,61.097,"[""Apple\u2019s slide pulls down S&P 500; U.S. stocks close lower U.S. stocks end lower on Wednesday, pulled down by a sizable loss in Apple shares following disappointing results."", ""Qualcomm shares slip after weak outlook Cigna shares jump on report of buyout offer from Anthem Qualcomm shares move lower after the chip maker\u2019s weak outlook trumps an earnings beat for the quarter and an announced restructuring plan.""]"
ISRG,2015-07-23,61.11,62.287,60.617,61.91,
ISRG,2015-07-24,58.787,61.4,58.17,60.677,
ISRG,2015-07-27,59.917,60.61,59.757,60.46,
ISRG,2015-07-28,60.143,60.39,59.777,60.03,
ISRG,2015-07-29,59.843,60.487,59.537,60.033,
ISRG,2015-07-30,60.013,60.19,59.573,59.957,
ISRG,2015-07-31,60.01,60.01,59.11,59.24,
ISRG,2015-08-03,59.073,59.277,57.907,58.5,
ISRG,2015-08-04,58.24,58.773,58.017,58.527,
ISRG,2015-08-05,58.817,59.383,58.817,59.007,
ISRG,2015-08-06,58.85,59.17,58.167,58.23,
ISRG,2015-08-07,58.237,59.333,57.903,59.22,
ISRG,2015-08-10,59.327,59.333,58.787,59.14,
ISRG,2015-08-11,59.11,59.333,58.437,58.87,
ISRG,2015-08-12,58.657,58.933,58.333,58.81,
ISRG,2015-08-13,58.757,59.067,58.423,58.653,
ISRG,2015-08-14,58.7,58.927,58.37,58.873,
ISRG,2015-08-17,58.657,59.3,58.113,59.227,
ISRG,2015-08-18,59.363,59.363,58.727,58.857,
ISRG,2015-08-19,58.967,58.967,58.093,58.513,
ISRG,2015-08-20,58.01,58.287,57.093,57.137,
ISRG,2015-08-21,56.627,57.117,55.87,56.317,
ISRG,2015-08-24,53.513,55.567,52.78,54.533,
ISRG,2015-08-25,55.67,56.657,54.777,54.94,
ISRG,2015-08-26,56.243,56.533,55.107,56.493,
ISRG,2015-08-27,56.967,57.3,56.633,57.287,
ISRG,2015-08-28,56.933,57.387,56.753,57.137,
ISRG,2015-08-31,56.91,57.523,56.717,56.773,
ISRG,2015-09-01,55.777,56.55,55.333,55.937,
ISRG,2015-09-02,56.51,56.793,55.98,56.793,
ISRG,2015-09-03,56.87,57.96,56.67,57.083,
ISRG,2015-09-04,56.443,56.84,56.25,56.49,
ISRG,2015-09-08,57.26,57.937,57.013,57.85,
ISRG,2015-09-09,58.127,58.187,56.507,56.663,
ISRG,2015-09-10,56.587,57.443,55.667,56.837,
ISRG,2015-09-11,56.713,57.547,56.327,57.257,
ISRG,2015-09-14,57.3,57.3,56.377,56.73,
ISRG,2015-09-15,56.527,57.457,56.333,57.087,
ISRG,2015-09-16,57.08,57.27,56.74,57.167,
ISRG,2015-09-17,57.277,58.5,57.277,57.693,
ISRG,2015-09-18,57.32,57.58,56.763,56.83,
ISRG,2015-09-21,56.893,57.17,55.723,56.103,
ISRG,2015-09-22,55.703,56.003,54.31,54.913,"Goldman’s 25 stocks to consider as global-growth fears grow And Goldman Sachs’s 10 stocks to avoid As anxiety over China’s economic health and when the Federal Reserve will start hiking interest rates weigh broadly on stocks, Goldman Sachs said investors need to be on the lookout for outlier stocks where performance is driven more by fundamentals than macroeconomic forces."
ISRG,2015-09-23,54.867,55.09,54.31,54.43,
ISRG,2015-09-24,54.177,54.757,54.0,54.573,
ISRG,2015-09-25,54.777,54.977,52.637,52.88,
ISRG,2015-09-28,52.807,52.85,51.253,51.5,
ISRG,2015-09-29,51.787,52.14,50.063,50.607,
ISRG,2015-09-30,51.057,51.777,50.763,51.063,
ISRG,2015-10-01,51.11,51.28,49.87,50.62,
ISRG,2015-10-02,50.22,51.693,50.0,51.653,
ISRG,2015-10-05,52.14,52.943,51.557,52.09,
ISRG,2015-10-06,51.853,51.903,50.613,51.067,
ISRG,2015-10-07,51.17,51.913,50.92,51.857,
ISRG,2015-10-08,51.65,52.13,51.217,52.047,"Strong consumer-based earnings, beats needed to counter global growth fears S&P 500 faces another projected profit decline for quarter Strength in the telecom, consumer discretionary, and health-care sectors will go up against projected profit declines this earnings season in the S&P 500 in a quarter battered by China-driven volatility and continued weakness at commodity-sensitive companies."
ISRG,2015-10-09,51.993,52.927,51.59,52.183,
ISRG,2015-10-12,52.05,52.063,51.007,51.203,
ISRG,2015-10-13,50.39,51.383,49.667,50.713,
ISRG,2015-10-14,50.79,51.083,50.167,50.54,
ISRG,2015-10-15,50.787,51.557,50.197,51.367,
ISRG,2015-10-16,51.753,52.017,51.227,51.927,
ISRG,2015-10-19,51.95,53.337,51.93,53.16,
ISRG,2015-10-20,53.11,53.377,52.333,52.557,
ISRG,2015-10-21,57.66,57.777,55.373,55.49,"Morning Movers: General Motors, Boeing Jump on Earnings; Coca-Cola, Chipotle Sink"
ISRG,2015-10-22,55.737,55.77,53.68,55.13,
ISRG,2015-10-23,55.253,56.173,55.1,55.56,
ISRG,2015-10-26,55.507,55.583,54.857,55.173,
ISRG,2015-10-27,55.083,55.457,54.71,55.197,
ISRG,2015-10-28,55.257,55.607,54.69,55.557,
ISRG,2015-10-29,55.493,55.823,55.007,55.587,
ISRG,2015-10-30,55.617,56.107,55.15,55.177,
ISRG,2015-11-02,55.233,56.11,55.2,56.03,
ISRG,2015-11-03,55.963,56.323,55.477,55.933,
ISRG,2015-11-04,55.833,56.163,55.567,55.717,
ISRG,2015-11-05,55.76,56.037,55.11,55.483,"These are the stocks to watch as robots take over the world Intuitive Surgical, Rockwell are pure robot plays Robots taking over the world is not only a popular theme in pop culture but it is also emerging as a compelling investment idea as robotics and artificial intelligence step off the pages of science fiction novels into assembly lines and homes."
ISRG,2015-11-06,55.04,55.827,55.007,55.663,
ISRG,2015-11-09,55.66,56.0,55.12,55.337,
ISRG,2015-11-10,55.443,55.953,55.043,55.84,
ISRG,2015-11-11,55.933,56.057,55.32,55.4,
ISRG,2015-11-12,55.673,55.943,55.427,55.557,
ISRG,2015-11-13,55.37,56.0,55.113,55.42,
ISRG,2015-11-16,55.37,55.873,55.363,55.657,
ISRG,2015-11-17,55.55,56.08,55.247,55.39,
ISRG,2015-11-18,55.393,56.483,55.3,56.373,
ISRG,2015-11-19,56.357,56.357,55.72,56.02,
ISRG,2015-11-20,56.407,57.433,56.35,57.397,
ISRG,2015-11-23,57.3,57.993,57.3,57.677,
ISRG,2015-11-24,57.47,57.887,56.977,57.417,
ISRG,2015-11-25,57.477,57.777,57.223,57.54,
ISRG,2015-11-27,57.677,57.893,57.43,57.693,
ISRG,2015-11-30,57.877,58.077,57.533,57.78,
ISRG,2015-12-01,57.893,58.307,57.397,58.027,
ISRG,2015-12-02,58.08,58.313,57.42,57.507,
ISRG,2015-12-03,57.52,57.877,56.007,56.517,
ISRG,2015-12-04,56.6,58.207,56.6,57.933,
ISRG,2015-12-07,57.777,58.653,57.66,58.057,
ISRG,2015-12-08,57.787,58.033,56.933,57.017,
ISRG,2015-12-09,56.88,57.44,56.553,57.073,
ISRG,2015-12-10,56.847,58.877,56.57,58.45,
ISRG,2015-12-11,57.803,58.837,57.733,58.163,
ISRG,2015-12-14,58.107,59.227,57.9,58.75,
ISRG,2015-12-15,58.947,60.34,58.323,59.673,
ISRG,2015-12-16,60.097,60.763,59.37,60.57,
ISRG,2015-12-17,60.453,60.883,59.657,59.897,
ISRG,2015-12-18,59.41,60.37,59.23,59.353,
ISRG,2015-12-21,59.6,60.0,59.307,59.923,
ISRG,2015-12-22,60.183,60.483,59.537,60.16,
ISRG,2015-12-23,60.553,60.997,59.963,60.86,
ISRG,2015-12-24,60.963,61.0,60.597,60.827,
ISRG,2015-12-28,60.73,61.057,60.287,60.79,
ISRG,2015-12-29,61.087,61.843,60.89,61.487,
ISRG,2015-12-30,61.663,61.737,61.257,61.39,
ISRG,2015-12-31,61.18,61.43,60.64,60.683,
ISRG,2016-01-04,60.797,61.093,59.867,60.82,
ISRG,2016-01-05,61.007,61.56,60.443,61.33,
ISRG,2016-01-06,60.81,61.86,60.34,61.47,
ISRG,2016-01-07,60.607,61.84,59.597,59.657,
ISRG,2016-01-08,59.963,60.35,59.223,59.617,"For U.S. stocks, it’s a China in a bull shop This is what China, laden with growth concerns, structural debt worries, and a fast-depreciating currency, has the potential to become to our bull market."
ISRG,2016-01-11,60.063,60.807,58.977,59.953,
ISRG,2016-01-12,60.517,60.793,59.443,60.237,
ISRG,2016-01-13,62.493,63.557,60.487,60.57,
ISRG,2016-01-14,61.033,61.94,59.793,61.753,
ISRG,2016-01-15,60.027,62.0,59.993,61.917,
ISRG,2016-01-19,62.06,62.927,61.393,61.833,
ISRG,2016-01-20,61.37,62.42,59.78,61.617,
ISRG,2016-01-21,61.833,62.21,60.18,61.733,
ISRG,2016-01-22,63.21,64.443,61.773,62.9,
ISRG,2016-01-25,62.653,63.4,61.86,62.023,
ISRG,2016-01-26,61.11,61.667,60.213,60.583,
ISRG,2016-01-27,60.693,60.84,59.107,59.337,
ISRG,2016-01-28,59.517,59.873,57.833,58.51,The 15 strongest stocks in the S&P 500 Just because the index may be falling doesn’t mean that there aren’t stocks worth a look in the index.
ISRG,2016-01-29,58.62,60.137,58.62,60.09,
ISRG,2016-02-01,59.89,60.707,59.74,60.35,
ISRG,2016-02-02,59.937,60.54,59.343,59.927,
ISRG,2016-02-03,60.387,60.59,59.12,60.567,
ISRG,2016-02-04,60.407,61.55,59.68,61.327,
ISRG,2016-02-05,61.223,61.603,59.327,59.583,
ISRG,2016-02-08,58.95,58.95,55.78,56.357,
ISRG,2016-02-09,56.35,57.833,55.78,56.537,
ISRG,2016-02-10,56.67,58.77,56.67,58.267,
ISRG,2016-02-11,57.147,58.333,57.147,57.95,
ISRG,2016-02-12,58.127,59.39,57.467,59.03,
ISRG,2016-02-16,59.557,59.557,58.403,59.463,
ISRG,2016-02-17,59.503,60.277,59.11,60.207,
ISRG,2016-02-18,60.097,60.547,59.79,60.29,
ISRG,2016-02-19,59.85,60.783,58.94,60.703,
ISRG,2016-02-22,61.0,61.333,60.377,61.28,
ISRG,2016-02-23,60.793,61.443,60.457,60.99,
ISRG,2016-02-24,60.447,61.667,60.447,61.517,
ISRG,2016-02-25,61.667,62.197,60.717,62.143,
ISRG,2016-02-26,62.223,63.347,61.89,63.053,
ISRG,2016-02-29,62.94,63.32,62.497,62.563,
ISRG,2016-03-01,62.693,63.833,62.377,63.5,
ISRG,2016-03-02,63.04,63.833,63.037,63.757,
ISRG,2016-03-03,63.333,64.0,63.147,63.783,
ISRG,2016-03-04,63.83,63.993,63.133,63.407,
ISRG,2016-03-07,63.383,64.04,62.78,63.633,
ISRG,2016-03-08,63.147,63.643,62.847,62.983,
ISRG,2016-03-09,63.337,63.73,62.783,63.657,
ISRG,2016-03-10,63.543,63.857,62.99,63.743,
ISRG,2016-03-11,63.89,64.923,63.69,64.493,
ISRG,2016-03-14,64.45,66.22,63.907,65.897,
ISRG,2016-03-15,65.237,66.08,64.817,65.267,
ISRG,2016-03-16,64.757,66.027,64.74,65.263,
ISRG,2016-03-17,65.393,65.557,62.337,62.483,
ISRG,2016-03-18,62.887,64.837,62.51,64.783,
ISRG,2016-03-21,64.667,65.467,64.167,64.777,
ISRG,2016-03-22,64.403,65.76,64.157,65.67,
ISRG,2016-03-23,65.693,66.22,65.127,65.147,
ISRG,2016-03-24,64.813,64.897,63.98,64.813,
ISRG,2016-03-28,65.077,65.197,64.497,64.907,
ISRG,2016-03-29,64.793,67.11,64.667,67.007,
ISRG,2016-03-30,67.527,67.527,66.003,66.477,
ISRG,2016-03-31,66.587,67.277,66.133,66.783,"Investors should avoid these momentum stocks ‘at any price’ ‘High momentum stocks may be at further risk in early April’: J.P. Morgan So far this year, with the exception of Facebook, momentum stocks are failing to live up to expectations, prompting a J.P. Morgan strategist on Thursday to recommend that investors avoid them at “any price.”"
ISRG,2016-04-01,66.133,67.393,65.67,67.39,"NYSE suspends trading of Amazon, Alphabet, 6 other securities The New York Stock Exchange on Friday suspended trading of eight securities, including Amazon and Google-parent Alphabet Inc., due to ""market data"" issues, a NYSE spokeswoman told MarketWatch. Trading in Amazon Inc., , Alphabet Inc. class A and C shares , Markel Corp. , Intuitive Surgical Inc. , and Autzone Inc. are among the securities that the exchange operator suspended for the day. The so-called Big Board discovered the glitch early Friday and said it has affected the exchange's ability to ""receive and disseminate market data"" on those names. Those securities will be trading on other exchange platforms, however. The NYSE is hoping to resolve the issue by Monday, the spokeswoman said, declining to provide further detail. Such halts are unusual but follows an unprecedented four-hour halt of the entire NYSE back in July 2015."
ISRG,2016-04-04,67.5,69.77,67.03,69.117,"42 S&P 500 stocks hit all-time highs on Monday Shares of Coke, McDonald’s, Home Depot trade at records Shares of consumer-based stocks Coca-Cola, McDonald’s, Home Depot and more than a quarter of utilities stocks on the S&P 500 reached all-time highs on Monday, suggesting that investors are throwing their weight behind consumer strength and looking for yield plays."
ISRG,2016-04-05,68.613,68.807,67.707,68.103,
ISRG,2016-04-06,67.99,69.837,67.99,69.57,
ISRG,2016-04-07,69.543,69.543,67.67,68.31,
ISRG,2016-04-08,68.993,69.643,68.353,68.863,
ISRG,2016-04-11,69.227,69.657,68.757,68.91,
ISRG,2016-04-12,69.6,69.93,68.827,69.5,
ISRG,2016-04-13,69.65,70.073,69.14,69.667,
ISRG,2016-04-14,69.667,69.843,69.11,69.233,
ISRG,2016-04-15,69.387,69.777,68.893,69.357,
ISRG,2016-04-18,69.397,69.91,69.04,69.663,
ISRG,2016-04-19,69.667,69.743,68.58,69.3,
ISRG,2016-04-20,71.663,72.763,71.327,71.617,"Why you shouldn’t let oil crush your stock hopes Critical information ahead of the U.S. market’s open Even if oil has been the boogeyman for this market, there are reasons for optimism as certain corners of it have been flying."
ISRG,2016-04-21,71.507,72.097,71.01,71.323,
ISRG,2016-04-22,70.167,71.11,69.767,70.907,
ISRG,2016-04-25,70.323,71.37,70.283,70.97,
ISRG,2016-04-26,71.11,71.11,70.037,70.277,
ISRG,2016-04-27,70.41,70.747,69.68,70.333,
ISRG,2016-04-28,69.76,71.657,69.76,70.167,
ISRG,2016-04-29,69.667,69.847,68.89,69.59,
ISRG,2016-05-02,69.753,70.597,69.58,70.373,
ISRG,2016-05-03,69.64,69.98,68.337,68.737,
ISRG,2016-05-04,68.403,68.833,67.993,68.35,
ISRG,2016-05-05,68.633,68.81,68.077,68.37,
ISRG,2016-05-06,68.21,68.863,67.913,68.773,
ISRG,2016-05-09,68.57,69.89,68.57,69.317,
ISRG,2016-05-10,69.573,69.893,68.997,69.617,
ISRG,2016-05-11,69.72,69.94,69.377,69.74,
ISRG,2016-05-12,69.943,70.413,69.11,70.367,
ISRG,2016-05-13,70.447,70.833,69.627,69.867,
ISRG,2016-05-16,69.9,71.0,69.777,70.567,
ISRG,2016-05-17,70.473,70.613,68.723,69.043,
ISRG,2016-05-18,69.09,70.06,68.12,69.447,
ISRG,2016-05-19,69.043,69.517,68.697,69.31,
ISRG,2016-05-20,69.43,70.587,69.077,70.287,
ISRG,2016-05-23,70.177,70.233,69.383,69.85,
ISRG,2016-05-24,70.347,71.097,69.88,70.963,
ISRG,2016-05-25,70.947,71.647,70.897,71.45,
ISRG,2016-05-26,71.153,71.573,70.667,70.8,
ISRG,2016-05-27,71.11,71.493,70.477,70.74,
ISRG,2016-05-31,71.013,71.1,70.207,70.523,
ISRG,2016-06-01,70.25,71.003,69.72,70.853,
ISRG,2016-06-02,70.107,71.11,70.0,71.05,
ISRG,2016-06-03,71.047,71.06,70.287,70.713,
ISRG,2016-06-06,70.727,70.97,70.153,70.623,
ISRG,2016-06-07,70.557,70.783,70.187,70.653,
ISRG,2016-06-08,70.8,71.777,70.677,71.43,
ISRG,2016-06-09,71.027,72.397,70.793,72.023,
ISRG,2016-06-10,71.303,71.717,70.75,71.287,
ISRG,2016-06-13,70.803,72.057,70.803,71.567,
ISRG,2016-06-14,71.277,71.843,71.187,71.667,
ISRG,2016-06-15,71.843,72.087,71.307,71.68,
ISRG,2016-06-16,71.79,71.79,70.597,71.48,
ISRG,2016-06-17,71.607,71.887,70.933,71.303,
ISRG,2016-06-20,72.047,72.38,71.767,72.01,
ISRG,2016-06-21,72.027,72.333,71.457,71.663,
ISRG,2016-06-22,71.757,72.443,71.69,72.383,
ISRG,2016-06-23,72.683,73.55,72.44,73.48,
ISRG,2016-06-24,71.45,72.493,71.363,71.647,
ISRG,2016-06-27,71.337,71.39,69.49,69.99,
ISRG,2016-06-28,70.333,71.11,70.053,70.957,
ISRG,2016-06-29,71.257,73.263,71.113,73.073,
ISRG,2016-06-30,73.08,73.723,72.78,73.49,
ISRG,2016-07-01,73.507,74.167,73.227,74.033,
ISRG,2016-07-05,73.873,74.26,73.52,73.853,
ISRG,2016-07-06,73.89,74.86,73.667,74.493,
ISRG,2016-07-07,74.333,75.12,74.243,75.033,
ISRG,2016-07-08,75.393,75.61,74.873,75.427,
ISRG,2016-07-11,75.697,75.733,74.78,74.81,
ISRG,2016-07-12,75.347,75.42,74.833,75.033,
ISRG,2016-07-13,75.407,75.407,74.723,74.74,
ISRG,2016-07-14,75.387,75.657,74.773,75.067,
ISRG,2016-07-15,75.377,75.42,74.24,74.487,
ISRG,2016-07-18,74.767,74.877,74.453,74.503,
ISRG,2016-07-19,74.2,75.09,73.903,74.657,
ISRG,2016-07-20,79.12,80.0,77.803,78.117,"Dow closes at 7th straight record high as tech rallies S&P 500 reaches 6th closing high in 8 days U.S. stocks close at record highs after trading within a narrow range Wednesday, buoyed by a surge in tech stocks after a flurry of corporate earnings beat lowered expectations."
ISRG,2016-07-21,77.333,77.867,76.53,76.773,
ISRG,2016-07-22,76.493,76.647,75.627,76.597,
ISRG,2016-07-25,76.273,76.79,76.067,76.263,
ISRG,2016-07-26,76.55,76.8,76.137,76.29,
ISRG,2016-07-27,76.257,76.843,75.677,75.897,
ISRG,2016-07-28,75.977,76.803,75.977,76.677,
ISRG,2016-07-29,76.667,77.46,76.56,77.307,
ISRG,2016-08-01,77.107,77.777,76.923,77.097,
ISRG,2016-08-02,77.207,77.207,76.147,76.72,
ISRG,2016-08-03,76.907,77.1,76.227,76.413,
ISRG,2016-08-04,76.487,77.433,76.0,77.067,
ISRG,2016-08-05,77.17,77.33,76.74,77.037,
ISRG,2016-08-08,76.927,77.113,76.643,76.983,
ISRG,2016-08-09,77.203,77.85,77.18,77.41,
ISRG,2016-08-10,77.41,77.497,76.77,77.027,
ISRG,2016-08-11,77.133,77.553,76.87,77.283,
ISRG,2016-08-12,77.007,77.007,76.5,76.77,
ISRG,2016-08-15,76.96,77.467,76.777,77.0,
ISRG,2016-08-16,76.78,76.78,76.157,76.227,
ISRG,2016-08-17,76.403,76.403,75.457,75.877,
ISRG,2016-08-18,75.6,76.377,75.6,76.18,
ISRG,2016-08-19,76.187,76.58,75.83,76.407,
ISRG,2016-08-22,76.447,76.987,76.327,76.917,
ISRG,2016-08-23,77.223,77.667,77.0,77.33,
ISRG,2016-08-24,77.207,77.497,76.0,76.177,
ISRG,2016-08-25,76.11,76.633,75.847,76.273,
ISRG,2016-08-26,76.493,76.85,75.847,76.143,
ISRG,2016-08-29,76.163,76.707,75.923,76.393,
ISRG,2016-08-30,76.433,76.58,75.71,76.393,
ISRG,2016-08-31,76.607,76.613,75.907,76.27,
ISRG,2016-09-01,76.317,76.807,75.927,76.633,
ISRG,2016-09-02,77.05,77.05,76.427,76.487,
ISRG,2016-09-06,76.667,77.027,75.727,77.013,
ISRG,2016-09-07,76.667,77.213,76.563,76.717,
ISRG,2016-09-08,76.423,76.96,76.237,76.793,
ISRG,2016-09-09,76.123,76.227,75.113,75.137,
ISRG,2016-09-12,75.04,76.02,74.863,75.933,
ISRG,2016-09-13,75.3,75.76,74.53,74.723,
ISRG,2016-09-14,74.75,75.277,74.55,74.79,
ISRG,2016-09-15,74.54,76.44,74.5,76.02,
ISRG,2016-09-16,76.34,76.423,75.797,76.263,
ISRG,2016-09-19,76.86,77.277,76.733,77.06,
ISRG,2016-09-20,77.353,77.883,77.19,77.66,
ISRG,2016-09-21,77.583,78.223,77.123,78.117,
ISRG,2016-09-22,78.69,79.897,78.427,79.803,
ISRG,2016-09-23,79.777,79.777,78.79,78.913,
ISRG,2016-09-26,78.687,78.89,78.227,78.583,
ISRG,2016-09-27,78.777,80.103,78.557,80.02,
ISRG,2016-09-28,79.98,80.37,79.38,79.753,
ISRG,2016-09-29,80.443,80.443,79.163,80.0,
ISRG,2016-09-30,79.773,80.793,79.707,80.537,
ISRG,2016-10-03,80.173,80.427,79.427,79.77,
ISRG,2016-10-04,79.777,80.127,79.22,79.623,
ISRG,2016-10-05,79.64,80.083,79.41,79.79,
ISRG,2016-10-06,79.627,79.89,79.35,79.577,
ISRG,2016-10-07,80.0,80.0,79.247,79.783,
ISRG,2016-10-10,79.863,80.807,79.863,80.513,
ISRG,2016-10-11,80.46,80.46,78.487,78.923,
ISRG,2016-10-12,79.11,79.247,78.747,78.993,
ISRG,2016-10-13,78.773,79.533,78.57,79.27,
ISRG,2016-10-14,79.843,79.843,78.967,79.433,
ISRG,2016-10-17,79.477,79.877,78.68,78.827,
ISRG,2016-10-18,79.66,80.367,78.89,80.193,
ISRG,2016-10-19,78.407,78.43,75.61,75.73,
ISRG,2016-10-20,75.777,76.607,75.337,75.757,
ISRG,2016-10-21,75.607,75.827,75.103,75.337,
ISRG,2016-10-24,76.117,76.387,75.753,76.11,
ISRG,2016-10-25,76.11,76.22,75.177,75.5,
ISRG,2016-10-26,75.187,75.187,73.897,73.97,
ISRG,2016-10-27,74.167,74.397,73.08,73.693,
ISRG,2016-10-28,73.603,75.06,73.53,74.06,
ISRG,2016-10-31,73.977,74.827,73.153,74.677,
ISRG,2016-11-01,74.827,74.883,73.917,74.413,
ISRG,2016-11-02,74.487,74.927,74.003,74.063,
ISRG,2016-11-03,74.447,74.91,74.193,74.81,
ISRG,2016-11-04,74.653,75.42,74.51,74.603,"11 improving health-care companies whose stocks are loved by analysts It’s the only sector that’s down this year, which means there’s plenty of opportunity It’s the only sector that’s down this year, which means there’s plenty of opportunity, says Phil van Doorn."
ISRG,2016-11-07,75.337,75.863,75.203,75.38,
ISRG,2016-11-08,75.43,76.463,75.23,76.127,
ISRG,2016-11-09,73.747,74.207,72.303,72.383,
ISRG,2016-11-10,72.457,72.713,70.07,70.613,
ISRG,2016-11-11,70.497,71.363,68.533,69.083,
ISRG,2016-11-14,69.0,70.223,68.743,69.4,
ISRG,2016-11-15,69.69,71.34,69.69,71.173,
ISRG,2016-11-16,71.287,71.723,70.777,71.483,
ISRG,2016-11-17,71.48,72.89,71.48,72.733,
ISRG,2016-11-18,72.683,73.11,72.523,72.767,
ISRG,2016-11-21,73.137,73.737,72.777,73.567,
ISRG,2016-11-22,73.11,73.187,70.843,71.133,
ISRG,2016-11-23,71.237,71.823,70.833,71.697,
ISRG,2016-11-25,72.047,73.477,71.75,72.947,
ISRG,2016-11-28,72.993,73.18,71.863,71.967,
ISRG,2016-11-29,72.11,72.753,72.0,72.257,
ISRG,2016-11-30,72.253,72.58,70.75,71.527,
ISRG,2016-12-01,71.383,71.557,69.79,70.26,
ISRG,2016-12-02,70.553,71.54,70.123,70.737,
ISRG,2016-12-05,70.81,70.947,70.477,70.773,
ISRG,2016-12-06,70.667,70.767,68.767,69.067,
ISRG,2016-12-07,68.947,69.13,67.857,68.78,
ISRG,2016-12-08,68.663,69.223,68.263,68.83,
ISRG,2016-12-09,68.87,69.763,68.757,69.467,
ISRG,2016-12-12,69.313,70.56,69.313,70.417,
ISRG,2016-12-13,70.667,72.467,70.637,70.663,
ISRG,2016-12-14,70.85,71.557,70.447,70.733,
ISRG,2016-12-15,70.793,71.29,70.237,71.0,
ISRG,2016-12-16,71.057,71.43,70.463,71.267,
ISRG,2016-12-19,71.063,71.273,70.583,70.88,
ISRG,2016-12-20,70.943,71.097,70.003,70.447,
ISRG,2016-12-21,70.453,70.513,70.0,70.033,
ISRG,2016-12-22,70.19,71.05,69.997,70.843,
ISRG,2016-12-23,71.01,71.63,70.923,71.193,
ISRG,2016-12-27,71.45,71.91,71.03,71.057,
ISRG,2016-12-28,71.09,71.38,70.413,70.617,
ISRG,2016-12-29,70.507,71.0,70.507,70.707,
ISRG,2016-12-30,70.923,70.933,70.25,70.463,
ISRG,2017-01-03,70.66,71.353,70.557,71.31,
ISRG,2017-01-04,70.89,70.89,69.413,69.943,
ISRG,2017-01-05,70.02,70.857,69.717,70.327,
ISRG,2017-01-06,70.443,71.207,70.443,70.68,
ISRG,2017-01-09,70.577,71.473,70.577,71.257,
ISRG,2017-01-10,71.393,73.777,71.303,73.577,
ISRG,2017-01-11,75.1,76.517,74.453,75.35,
ISRG,2017-01-12,75.287,75.287,73.45,73.877,
ISRG,2017-01-13,74.223,74.997,73.62,73.857,
ISRG,2017-01-17,73.833,74.15,72.777,73.75,
ISRG,2017-01-18,73.753,74.22,73.35,73.673,
ISRG,2017-01-19,73.603,73.663,72.677,73.117,
ISRG,2017-01-20,73.47,73.47,72.693,72.973,
ISRG,2017-01-23,73.06,73.553,72.397,72.78,
ISRG,2017-01-24,73.073,74.42,72.63,74.007,
ISRG,2017-01-25,75.0,77.823,74.67,77.777,
ISRG,2017-01-26,77.367,77.667,76.047,76.397,
ISRG,2017-01-27,76.043,77.25,75.793,76.81,
ISRG,2017-01-30,76.377,76.717,75.96,76.68,
ISRG,2017-01-31,76.47,77.503,76.063,76.98,
ISRG,2017-02-01,76.673,77.557,76.443,77.447,
ISRG,2017-02-02,77.017,77.887,76.783,77.797,
ISRG,2017-02-03,77.777,78.107,77.53,78.013,
ISRG,2017-02-06,77.783,78.45,77.413,78.33,
ISRG,2017-02-07,78.23,78.48,77.943,78.25,
ISRG,2017-02-08,77.947,78.293,77.703,78.073,
ISRG,2017-02-09,77.997,78.837,77.807,78.377,
ISRG,2017-02-10,78.437,78.74,78.16,78.39,
ISRG,2017-02-13,78.333,79.033,77.887,78.967,
ISRG,2017-02-14,79.157,79.777,78.917,79.437,
ISRG,2017-02-15,79.07,79.923,78.947,79.637,
ISRG,2017-02-16,79.38,80.193,79.177,80.163,
ISRG,2017-02-17,79.827,80.817,79.737,80.517,
ISRG,2017-02-21,80.557,81.463,80.397,81.353,
ISRG,2017-02-22,81.09,81.567,80.953,81.343,
ISRG,2017-02-23,81.257,81.847,81.173,81.707,
ISRG,2017-02-24,81.49,82.09,81.26,81.873,
ISRG,2017-02-27,81.93,82.11,81.4,81.56,
ISRG,2017-02-28,81.333,82.113,81.067,81.89,
ISRG,2017-03-01,81.867,82.733,81.453,82.343,
ISRG,2017-03-02,82.333,82.867,82.19,82.507,
ISRG,2017-03-03,82.27,82.92,82.103,82.753,
ISRG,2017-03-06,82.297,82.55,81.607,81.743,
ISRG,2017-03-07,81.41,81.817,81.017,81.127,
ISRG,2017-03-08,81.223,81.613,80.753,80.9,
ISRG,2017-03-09,80.793,81.887,80.793,81.78,
ISRG,2017-03-10,82.223,82.223,81.403,81.573,
ISRG,2017-03-13,81.593,81.813,80.82,81.543,
ISRG,2017-03-14,80.983,82.257,80.937,82.23,
ISRG,2017-03-15,81.873,83.493,81.777,82.963,
ISRG,2017-03-16,83.227,83.39,82.167,82.613,
ISRG,2017-03-17,83.127,83.577,82.853,83.313,
ISRG,2017-03-20,83.063,83.95,83.003,83.337,
ISRG,2017-03-21,83.723,84.22,82.823,82.883,
ISRG,2017-03-22,83.07,83.353,82.5,83.147,
ISRG,2017-03-23,83.043,83.497,82.727,82.91,
ISRG,2017-03-24,83.307,84.613,83.073,84.223,
ISRG,2017-03-27,83.937,85.457,83.69,85.257,
ISRG,2017-03-28,85.257,85.587,84.92,84.94,
ISRG,2017-03-29,84.78,85.28,84.39,85.077,
ISRG,2017-03-30,85.1,85.443,84.713,85.14,
ISRG,2017-03-31,85.04,85.553,84.923,85.163,
ISRG,2017-04-03,85.07,85.73,84.493,84.967,
ISRG,2017-04-04,85.11,85.25,84.37,84.703,
ISRG,2017-04-05,84.543,86.213,84.383,84.757,
ISRG,2017-04-06,84.683,85.107,84.48,84.753,
ISRG,2017-04-07,84.893,85.37,84.567,85.237,
ISRG,2017-04-10,85.0,85.49,85.0,85.227,
ISRG,2017-04-11,85.123,85.507,84.513,84.98,
ISRG,2017-04-12,84.653,85.0,84.54,84.917,
ISRG,2017-04-13,85.047,85.407,84.72,84.977,
ISRG,2017-04-17,85.437,85.917,85.037,85.363,
ISRG,2017-04-18,85.333,85.333,83.71,84.37,
ISRG,2017-04-19,88.89,90.8,87.887,89.743,"[""Intuitive Surgical stock rises 6% after first-quarter earnings beat Intuitive Surgical Inc. shares rose in heavy morning trade Wednesday, after the company posted better-than-expected first-quarter results late Tuesday. Shares were most recently up by 6.5% at $808.06. The company's 2017 guidance for surgical procedures with its da Vinci surgical system was \""higher than we anticipated,\"" said Raymond James analyst Lawrence Keusch. He also said, \""we see ISRG as a long-term structural growth story with an expanding technology platform driving global adoption.\"" Though the company said that its first quarter may have benefited from trends that won't continue, such as an uptick in procedures prompted by concerns about the Affordable Care Act being repealed, \""ISRG is clearly demonstrating momentum across multiple geographies, multiple indications, and platforms,\"" said Stifel analyst Rick Wise. Both Raymond James' Keusch and Stifel's Wise expressed optimism about the company's newly announced da Vinci X system, though \""limited details were provided,\"" Wise said. \""To us, da Vinci X represents the first visible and highly intriguing response to impending, potentially lower-cost capital-robotic competition from MDT and JNJ among others.\"" Intuitive Surgical shares have surged 23.6% over the last three months, compared with a 3.9% rise in the S&P 500 ."", ""Dow industrials finish more than 100 points lower as energy, IBM drag Big Blue accounts for large share blue-chip average decline The Dow industrials and the S&P 500 close down Wednesday as a drop in oil prices fueled a selloff in energy shares while a drop in International Business Machines Corp. is responsible for half the losses in the blue-chip average.""]"
ISRG,2017-04-20,89.61,90.6,89.207,90.493,
ISRG,2017-04-21,90.187,90.507,89.7,90.38,
ISRG,2017-04-24,90.777,91.56,90.353,91.353,
ISRG,2017-04-25,91.357,92.56,91.16,91.917,
ISRG,2017-04-26,91.77,92.887,91.723,92.687,
ISRG,2017-04-27,92.737,93.423,92.67,92.95,
ISRG,2017-04-28,92.963,93.83,92.53,92.873,
ISRG,2017-05-01,93.177,93.553,92.93,93.287,
ISRG,2017-05-02,93.023,93.94,93.023,93.863,
ISRG,2017-05-03,93.86,94.193,93.43,93.927,
ISRG,2017-05-04,94.033,94.28,93.863,94.137,
ISRG,2017-05-05,94.377,94.557,93.973,94.503,
ISRG,2017-05-08,94.443,94.627,93.223,93.42,
ISRG,2017-05-09,93.27,93.927,93.03,93.687,
ISRG,2017-05-10,93.79,93.89,93.193,93.673,
ISRG,2017-05-11,93.77,94.09,93.133,93.88,
ISRG,2017-05-12,94.03,94.257,93.703,93.747,
ISRG,2017-05-15,93.54,94.59,93.54,94.52,
ISRG,2017-05-16,95.26,96.083,94.833,95.497,
ISRG,2017-05-17,95.03,95.54,94.513,94.553,
ISRG,2017-05-18,94.757,95.71,94.547,95.553,
ISRG,2017-05-19,95.903,97.17,95.593,96.703,
ISRG,2017-05-22,97.443,99.71,97.343,99.117,
ISRG,2017-05-23,99.47,100.23,99.223,99.67,
ISRG,2017-05-24,99.69,100.22,99.18,99.99,
ISRG,2017-05-25,100.43,101.27,100.0,100.84,
ISRG,2017-05-26,101.49,101.64,100.92,101.15,
ISRG,2017-05-30,100.68,101.72,100.34,101.6,"Microsoft and Alphabet on track for record closes as big tech hold gains Shares of Microsoft Corp. and Alphabet Inc. were on track to set record closes Tuesday, finding a tailwind as traders returned from the holiday weekend. Just last week, Howard Silverblatt at S&P Dow Jones Indices said about 34% of the S&P 500's 2017 gains have come from Apple Inc. , Amazon.com Inc. , Facebook Inc. , Microsoft Corp. and Google's parent. Other stocks touching highs Tuesday include Nvidia Corp. , electric car maker Tesla Inc. and Intuitive Surgical . The latter was a surprise move, coming after Canaccord downgraded the stock earlier, saying its valuation was more stretched than at any other time in its 20-year history. The Dow Jones Industrial Average was down 0.2% and the S&P 500 was flat."
ISRG,2017-05-31,101.98,102.43,101.18,101.63,
ISRG,2017-06-01,101.68,102.14,101.31,102.12,
ISRG,2017-06-02,102.58,103.06,102.14,102.74,
ISRG,2017-06-05,102.36,102.88,101.94,102.45,
ISRG,2017-06-06,102.02,103.3,102.01,102.71,
ISRG,2017-06-07,103.21,103.64,102.69,103.55,
ISRG,2017-06-08,103.89,104.13,102.94,103.32,
ISRG,2017-06-09,103.87,103.92,100.69,101.82,
ISRG,2017-06-12,101.22,101.6,97.39,100.37,
ISRG,2017-06-13,100.58,101.7,100.04,100.91,
ISRG,2017-06-14,101.96,102.0,100.32,100.65,
ISRG,2017-06-15,100.08,100.19,99.117,99.88,
ISRG,2017-06-16,100.11,101.95,100.06,101.65,
ISRG,2017-06-19,102.1,104.15,102.05,104.04,
ISRG,2017-06-20,104.3,105.44,104.25,104.48,
ISRG,2017-06-21,104.7,106.04,104.56,105.92,
ISRG,2017-06-22,106.09,107.06,105.61,106.02,
ISRG,2017-06-23,105.65,106.04,104.88,105.44,
ISRG,2017-06-26,105.82,106.09,104.18,104.49,
ISRG,2017-06-27,104.59,104.88,103.34,104.0,
ISRG,2017-06-28,104.31,105.34,103.55,105.15,
ISRG,2017-06-29,104.97,104.97,102.62,103.39,
ISRG,2017-06-30,103.87,104.43,102.5,103.93,
ISRG,2017-07-03,104.55,104.62,102.29,102.34,
ISRG,2017-07-05,103.13,104.48,103.13,104.23,
ISRG,2017-07-06,103.61,104.44,103.22,103.87,
ISRG,2017-07-07,104.27,105.35,104.18,104.92,
ISRG,2017-07-10,104.83,105.65,104.22,105.25,
ISRG,2017-07-11,105.49,105.49,104.13,104.72,
ISRG,2017-07-12,105.56,106.17,105.24,105.37,
ISRG,2017-07-13,105.73,105.91,104.21,104.28,
ISRG,2017-07-14,104.49,106.01,104.49,105.75,
ISRG,2017-07-17,106.1,106.29,104.89,105.34,
ISRG,2017-07-18,105.36,105.62,104.49,105.18,
ISRG,2017-07-19,105.87,107.49,105.85,107.42,
ISRG,2017-07-20,107.67,108.3,106.97,107.97,
ISRG,2017-07-21,107.21,107.55,102.86,103.05,
ISRG,2017-07-24,102.98,105.93,102.98,105.53,
ISRG,2017-07-25,105.75,105.96,104.57,104.99,
ISRG,2017-07-26,105.12,105.57,104.38,104.93,
ISRG,2017-07-27,104.9,105.11,102.33,103.54,
ISRG,2017-07-28,103.39,104.78,103.01,104.58,
ISRG,2017-07-31,104.83,105.11,103.71,104.25,
ISRG,2017-08-01,104.33,105.0,103.79,104.55,
ISRG,2017-08-02,104.38,104.6,103.0,103.66,
ISRG,2017-08-03,103.26,104.37,103.12,103.8,
ISRG,2017-08-04,103.34,104.17,102.63,103.48,
ISRG,2017-08-07,103.3,104.13,103.07,104.07,
ISRG,2017-08-08,103.68,104.21,103.28,103.82,
ISRG,2017-08-09,103.82,105.08,103.44,104.83,
ISRG,2017-08-10,104.39,104.79,103.1,103.26,
ISRG,2017-08-11,103.36,104.89,103.36,104.69,
ISRG,2017-08-14,105.67,107.47,105.67,107.17,"Intuitive Surgical's 3-for-1 stock split seen as a 'positive sign' Shares of Intuitive Surgical Inc. surged 2.3% in midday trade Monday, in the wake of the announcement of a 3-for-1 stock split. The stock was now within 1% of its July 20 record close of $971.73. After Friday's closing bell, the company said if approved by shareholders at a special meeting on Sept. 22, the stock would begin trading on a split-adjusted basis on Oct. 6. Raymond James analyst Lawrence Keusch said that although the stock split does not generate any economic value, he believed it was a ""positive sign"" for the developer of robotic-assisted surgical platforms because ""it could be argued that the event signals confidence in the company's fundamental prospects."" In addition, Keusch said that since the number of stock splits have declined meaningfully over the past 20 years, Intuitive Surgical's ""may help raise the company's profile,"" especially among retail investors. The stock has run up 52% year to date, while the SPDR Health Care Select Sector ETF has rallied 15% and the S&P 500 has gained 10%."
ISRG,2017-08-15,107.47,110.05,107.22,109.49,4 Growth Stocks That Will Own the Future The Morgan Stanley Institutional Growth Portfolio has trounced its peers over both the short and long term.
ISRG,2017-08-16,109.56,110.17,109.0,109.88,
ISRG,2017-08-17,109.75,110.33,108.02,108.12,
ISRG,2017-08-18,108.17,110.26,107.62,109.37,
ISRG,2017-08-21,109.12,109.44,108.27,109.19,
ISRG,2017-08-22,109.21,110.89,109.19,110.73,
ISRG,2017-08-23,110.42,110.42,109.24,109.63,
ISRG,2017-08-24,109.66,110.18,109.24,110.06,
ISRG,2017-08-25,110.12,110.33,108.48,108.74,
ISRG,2017-08-28,109.11,109.85,108.95,109.56,
ISRG,2017-08-29,109.08,109.89,108.56,109.71,
ISRG,2017-08-30,109.12,110.72,109.0,110.67,
ISRG,2017-08-31,110.67,111.74,110.26,111.6,
ISRG,2017-09-01,111.32,112.07,110.82,111.86,
ISRG,2017-09-05,111.99,114.01,111.89,113.49,
ISRG,2017-09-06,113.75,114.33,112.34,113.6,
ISRG,2017-09-07,113.6,115.32,113.59,115.16,
ISRG,2017-09-08,114.76,117.2,113.89,115.85,
ISRG,2017-09-11,115.91,117.11,115.12,116.16,"Low-Volatility ETFs Can Help Investors Ride Out A Market Pullback Given that the fourth quarter has historically been a strong period for stock market gains, investors should try to stay in the market even if there is a pullback in September."
ISRG,2017-09-12,116.06,116.47,115.76,116.11,
ISRG,2017-09-13,115.8,115.99,115.11,115.88,
ISRG,2017-09-14,115.64,116.12,115.28,115.61,
ISRG,2017-09-15,115.5,115.89,115.14,115.34,
ISRG,2017-09-18,115.69,116.55,115.17,116.25,"Analysts have raised, or lowered, their price targets the most on these U.S. stocks They’re bullish on Vertex Pharmaceuticals, Boeing and Nvidia, and bearish on Foot Locker, Chipotle and Advance Auto Parts They’re bullish on Vertex Pharmaceuticals, Boeing and Nvidia, and bearish on Foot Locker, Chipotle and Advance Auto Parts."
ISRG,2017-09-19,115.87,117.0,115.63,116.16,
ISRG,2017-09-20,116.15,116.89,115.56,116.26,
ISRG,2017-09-21,116.46,116.53,114.42,114.44,
ISRG,2017-09-22,114.5,114.76,113.58,114.61,
ISRG,2017-09-25,114.98,114.98,112.62,113.04,
ISRG,2017-09-26,113.55,114.08,112.6,112.96,
ISRG,2017-09-27,113.19,113.98,113.17,113.79,
ISRG,2017-09-28,113.82,114.36,113.4,113.99,
ISRG,2017-09-29,114.24,116.53,114.03,116.21,
ISRG,2017-10-02,116.57,118.3,116.4,117.83,
ISRG,2017-10-03,118.29,119.56,118.07,119.32,
ISRG,2017-10-04,119.73,121.11,119.58,120.54,
ISRG,2017-10-05,121.38,121.62,119.33,121.04,
ISRG,2017-10-06,120.7,122.5,120.07,120.49,
ISRG,2017-10-09,121.18,121.18,117.96,118.2,
ISRG,2017-10-10,118.97,119.15,117.6,118.33,
ISRG,2017-10-11,119.1,120.17,118.71,120.1,
ISRG,2017-10-12,121.3,121.64,120.43,120.84,
ISRG,2017-10-13,121.0,121.92,120.57,120.76,"How to invest in health-care stocks regardless of what happens in Washington, D.C. It’s easy to make broad investments in a sector with incredible long-term potential Jeff Reeves says it’s easy to make broad investments in a sector with incredible long-term potential."
ISRG,2017-10-16,119.41,120.56,117.64,117.85,
ISRG,2017-10-17,118.67,118.86,117.75,118.33,
ISRG,2017-10-18,119.3,119.42,117.96,118.12,
ISRG,2017-10-19,118.47,119.19,116.67,119.15,
ISRG,2017-10-20,119.16,124.96,118.97,123.19,"Intuitive Surgical: Does It Make the Cut? Shares of the surgical robot company spiked after it delivered ""solid"" third quarter financial results. One analyst thinks the stock is overvalued."
ISRG,2017-10-23,124.17,126.11,124.15,124.51,
ISRG,2017-10-24,124.21,124.45,123.11,123.83,
ISRG,2017-10-25,123.88,124.57,122.83,124.14,
ISRG,2017-10-26,124.5,127.38,123.88,124.12,
ISRG,2017-10-27,124.37,124.88,123.17,124.59,
ISRG,2017-10-30,124.66,125.52,123.49,125.36,
ISRG,2017-10-31,125.35,126.63,124.9,125.12,
ISRG,2017-11-01,125.77,126.13,124.62,125.35,
ISRG,2017-11-02,125.98,128.07,125.67,126.58,
ISRG,2017-11-03,126.88,128.86,126.72,128.08,
ISRG,2017-11-06,127.71,128.65,127.67,128.28,
ISRG,2017-11-07,128.73,130.41,128.67,130.35,
ISRG,2017-11-08,130.33,131.17,129.06,130.78,
ISRG,2017-11-09,130.52,130.78,129.63,130.0,
ISRG,2017-11-10,129.94,130.38,128.72,129.63,
ISRG,2017-11-13,129.62,130.93,128.77,130.71,
ISRG,2017-11-14,130.34,131.1,129.76,130.32,
ISRG,2017-11-15,130.08,130.96,129.0,129.9,
ISRG,2017-11-16,130.21,131.63,130.17,131.27,
ISRG,2017-11-17,131.58,133.33,130.17,130.83,
ISRG,2017-11-20,130.83,131.43,130.1,131.01,
ISRG,2017-11-21,132.07,132.98,131.67,132.83,
ISRG,2017-11-22,132.67,132.83,131.56,132.2,
ISRG,2017-11-24,132.2,132.92,132.06,132.72,
ISRG,2017-11-27,133.0,135.02,133.0,134.57,
ISRG,2017-11-28,134.08,134.82,134.08,134.08,
ISRG,2017-11-29,134.12,134.86,130.34,131.43,
ISRG,2017-11-30,132.67,133.67,131.17,132.96,
ISRG,2017-12-01,132.87,134.0,129.42,132.22,
ISRG,2017-12-04,133.28,133.33,123.03,123.32,
ISRG,2017-12-05,123.23,125.85,121.87,123.17,
ISRG,2017-12-06,122.93,126.56,121.87,126.35,
ISRG,2017-12-07,127.24,128.31,126.23,127.93,
ISRG,2017-12-08,128.87,129.8,126.2,126.54,
ISRG,2017-12-11,126.11,126.57,123.86,124.52,
ISRG,2017-12-12,124.52,124.92,122.84,123.5,
ISRG,2017-12-13,123.5,124.36,122.84,123.69,
ISRG,2017-12-14,123.33,124.62,119.92,120.19,
ISRG,2017-12-15,121.38,124.44,120.41,123.29,
ISRG,2017-12-18,124.03,124.72,122.68,123.97,
ISRG,2017-12-19,123.83,125.1,122.15,122.44,
ISRG,2017-12-20,122.38,123.2,121.27,122.4,
ISRG,2017-12-21,122.7,122.83,120.36,120.44,
ISRG,2017-12-22,120.33,121.51,119.93,121.05,
ISRG,2017-12-26,120.63,122.95,120.01,121.94,
ISRG,2017-12-27,122.0,123.05,121.71,122.7,
ISRG,2017-12-28,122.72,123.24,122.23,122.96,
ISRG,2017-12-29,122.86,123.19,121.59,121.65,
ISRG,2018-01-02,122.63,125.27,121.7,125.08,
ISRG,2018-01-03,125.71,128.06,125.0,127.94,
ISRG,2018-01-04,128.58,129.83,125.03,125.64,
ISRG,2018-01-05,126.96,126.96,125.27,126.34,
ISRG,2018-01-08,126.24,130.88,125.74,130.62,
ISRG,2018-01-09,131.24,134.71,131.0,132.58,
ISRG,2018-01-10,141.17,142.33,136.15,141.25,"[""Exxon Mobil: Two Stocks It\u2019s Buying Now The energy giant\u2019s investment arm bought more shares of EQT and Intuitive Surgical in the fourth quarter."", ""Intuitive Surgical's stock jumps to record high after upbeat sales update Shares of Intuitive Surgical Inc. surged 6.5% toward a record high in midday trade Wednesday, enough to pace the S&P 500's gainers, after the robotic-assisted surgery technologies company provided upbeat sales guidance. The company, which has a market capitalization of $47.5 billion, said it expects to report fourth-quarter revenue $892 million, which is up 18% from a year ago, and well above the FactSet consensus of about $849 million, as preliminary instrument and accessory revenue rose 18% to $457 million to beat expectations of $441 million. The stock has soared 92% over the past 12 months, while the S&P 500 has rallied 21%.""]"
ISRG,2018-01-11,140.67,141.32,138.74,140.46,
ISRG,2018-01-12,139.71,140.64,138.58,139.68,
ISRG,2018-01-16,140.67,142.23,139.0,140.02,
ISRG,2018-01-17,141.2,144.08,140.84,143.7,
ISRG,2018-01-18,143.79,144.97,142.14,144.02,
ISRG,2018-01-19,144.65,145.52,142.83,144.41,
ISRG,2018-01-22,145.0,145.0,142.5,144.65,
ISRG,2018-01-23,144.58,147.17,143.94,146.52,
ISRG,2018-01-24,147.25,147.4,144.09,145.83,
ISRG,2018-01-25,147.27,150.67,146.67,149.94,
ISRG,2018-01-26,145.96,146.75,139.0,146.75,
ISRG,2018-01-29,147.26,148.63,144.34,145.45,
ISRG,2018-01-30,144.4,144.65,141.2,142.61,
ISRG,2018-01-31,143.33,145.44,142.44,143.89,
ISRG,2018-02-01,144.2,144.38,141.12,141.97,
ISRG,2018-02-02,141.0,142.07,138.76,138.99,
ISRG,2018-02-05,138.56,138.97,133.0,133.0,
ISRG,2018-02-06,130.23,137.52,128.5,136.11,
ISRG,2018-02-07,135.71,136.96,133.07,133.18,
ISRG,2018-02-08,133.49,133.55,127.2,127.29,
ISRG,2018-02-09,128.98,132.28,126.67,130.97,
ISRG,2018-02-12,131.83,133.96,130.59,132.84,
ISRG,2018-02-13,132.22,134.3,131.33,134.0,
ISRG,2018-02-14,132.5,137.07,132.5,136.63,
ISRG,2018-02-15,137.67,139.6,136.67,139.52,
ISRG,2018-02-16,139.52,140.38,138.15,138.66,
ISRG,2018-02-20,138.5,142.46,138.49,140.59,
ISRG,2018-02-21,140.43,142.27,138.77,138.85,
ISRG,2018-02-22,139.91,141.98,139.46,139.93,
ISRG,2018-02-23,140.44,142.58,139.66,142.5,
ISRG,2018-02-26,143.33,144.31,142.02,144.0,
ISRG,2018-02-27,144.33,145.13,143.14,143.66,
ISRG,2018-02-28,143.82,145.4,142.07,142.15,
ISRG,2018-03-01,142.81,142.95,136.63,137.38,
ISRG,2018-03-02,136.52,139.45,135.39,139.13,
ISRG,2018-03-05,137.74,142.04,137.45,141.42,
ISRG,2018-03-06,142.0,144.04,141.15,142.17,
ISRG,2018-03-07,140.9,144.05,140.46,143.49,
ISRG,2018-03-08,143.63,144.44,142.99,144.12,
ISRG,2018-03-09,144.67,148.32,144.67,146.82,
ISRG,2018-03-12,146.84,148.37,146.01,146.32,
ISRG,2018-03-13,147.21,148.23,145.99,146.74,
ISRG,2018-03-14,147.46,148.3,146.37,146.92,
ISRG,2018-03-15,146.67,148.05,145.68,147.32,
ISRG,2018-03-16,147.79,148.17,144.6,145.29,
ISRG,2018-03-19,144.43,145.37,140.53,142.29,
ISRG,2018-03-20,142.91,144.38,142.35,143.4,
ISRG,2018-03-21,143.47,143.9,140.84,141.66,
ISRG,2018-03-22,140.32,141.38,137.87,137.97,
ISRG,2018-03-23,138.17,139.4,132.94,133.05,
ISRG,2018-03-26,135.93,138.49,134.58,138.37,
ISRG,2018-03-27,138.77,139.61,134.03,135.07,
ISRG,2018-03-28,135.46,136.21,132.4,134.13,
ISRG,2018-03-29,134.56,140.64,133.78,137.61,
ISRG,2018-04-02,137.42,138.29,131.46,133.63,
ISRG,2018-04-03,134.25,135.25,132.2,134.49,
ISRG,2018-04-04,132.67,134.74,131.19,133.97,
ISRG,2018-04-05,135.46,136.7,134.49,135.37,
ISRG,2018-04-06,134.51,135.6,131.33,132.18,
ISRG,2018-04-09,133.63,137.82,133.35,135.22,
ISRG,2018-04-10,137.2,140.44,136.67,139.57,
ISRG,2018-04-11,137.37,138.98,136.92,137.37,
ISRG,2018-04-12,138.02,139.47,137.62,138.35,
ISRG,2018-04-13,139.33,140.22,137.27,138.21,
ISRG,2018-04-16,139.9,140.97,139.23,139.46,
ISRG,2018-04-17,141.14,145.57,140.0,145.15,
ISRG,2018-04-18,151.25,157.93,149.64,157.01,
ISRG,2018-04-19,155.67,156.0,152.73,154.24,
ISRG,2018-04-20,153.29,153.4,151.2,152.09,
ISRG,2018-04-23,152.33,153.0,148.67,149.28,
ISRG,2018-04-24,149.61,150.49,143.33,145.49,
ISRG,2018-04-25,145.33,146.6,143.01,145.99,
ISRG,2018-04-26,146.55,149.51,145.7,148.73,
ISRG,2018-04-27,149.95,150.47,147.65,149.01,
ISRG,2018-04-30,149.54,150.22,146.9,146.93,
ISRG,2018-05-01,146.67,149.35,146.67,149.18,
ISRG,2018-05-02,149.08,151.14,148.42,149.67,
ISRG,2018-05-03,148.67,150.28,146.02,149.41,"These 5 stocks offer a great balance between the growth of tech and the stability of health care Align Technology, Intuitive Surgical, Mazor Robotics, Varian Medical Systems and Veeva Systems This small group of companies either are either technology companies that focus on the health-care system or they are medical companies that are unlocking growth and innovation through the use of cutting-edge technologies, writes Jeff Reeves"
ISRG,2018-05-04,149.02,153.77,147.67,153.47,
ISRG,2018-05-07,153.67,156.13,153.53,155.13,
ISRG,2018-05-08,154.33,154.68,153.17,154.2,
ISRG,2018-05-09,154.6,155.29,153.08,154.09,
ISRG,2018-05-10,154.67,156.21,154.24,156.13,
ISRG,2018-05-11,156.03,157.59,154.75,156.12,
ISRG,2018-05-14,156.52,157.25,154.66,155.4,
ISRG,2018-05-15,153.87,154.64,151.04,152.28,
ISRG,2018-05-16,152.66,155.14,151.56,153.68,"For stock market investors, there really is a great future in plastic It’s about how, not where, people spend money, says fund manager Tom Plumb, who’s loaded up on Visa, Mastercard and Discover Financial Services It’s about how, not where, people spend money, says fund manager Tom Plumb, who’s loaded up on Visa, Mastercard and Discover Financial Services."
ISRG,2018-05-17,153.68,154.26,151.92,152.64,
ISRG,2018-05-18,152.93,153.19,151.26,152.93,
ISRG,2018-05-21,154.03,155.8,153.22,154.46,
ISRG,2018-05-22,154.67,154.95,151.26,151.54,
ISRG,2018-05-23,150.0,153.07,150.0,152.9,
ISRG,2018-05-24,153.07,153.75,151.42,152.6,
ISRG,2018-05-25,153.12,153.69,150.92,152.19,
ISRG,2018-05-29,151.1,151.7,149.88,151.54,
ISRG,2018-05-30,152.07,155.19,151.73,153.22,
ISRG,2018-05-31,153.33,155.48,152.85,153.22,
ISRG,2018-06-01,153.94,160.0,153.14,159.75,
ISRG,2018-06-04,160.0,161.37,157.53,159.31,
ISRG,2018-06-05,159.33,164.47,158.73,164.12,
ISRG,2018-06-06,164.33,164.69,161.46,164.46,
ISRG,2018-06-07,164.33,164.33,158.74,161.78,
ISRG,2018-06-08,161.67,162.8,160.14,161.53,
ISRG,2018-06-11,161.53,164.78,161.3,163.57,
ISRG,2018-06-12,163.9,165.41,162.88,164.97,
ISRG,2018-06-13,165.0,165.64,162.5,163.49,
ISRG,2018-06-14,164.12,165.54,164.12,165.17,
ISRG,2018-06-15,164.83,165.33,163.21,163.5,
ISRG,2018-06-18,162.91,164.0,161.78,163.56,
ISRG,2018-06-19,162.29,162.94,161.05,162.87,
ISRG,2018-06-20,163.67,164.67,162.16,162.48,
ISRG,2018-06-21,162.92,163.84,161.0,162.36,
ISRG,2018-06-22,162.91,163.2,160.72,161.07,
ISRG,2018-06-25,160.12,160.89,155.99,157.83,
ISRG,2018-06-26,157.86,161.96,157.86,160.93,
ISRG,2018-06-27,162.67,163.66,158.7,158.8,
ISRG,2018-06-28,158.8,161.78,157.39,161.24,Five outperforming health-care funds and the top 10 stocks they hold The group of mutual funds is highly rated for outperforming the S&P 500 health-care sector The group of mutual funds is highly rated for outperforming the S&P 500 health-care sector.
ISRG,2018-06-29,161.34,161.84,159.42,159.49,
ISRG,2018-07-02,158.83,162.85,157.27,162.7,"Stocks close higher as technology shares rally Trade-war fears linger; Energy proves worst performer in S&P 500, down 1.6% U.S. stocks kick off the third quarter on an upbeat note Monday with the main indexes finishing higher on the back of the a rally in technology shares."
ISRG,2018-07-03,163.45,163.45,160.66,161.86,
ISRG,2018-07-05,163.07,163.91,161.31,162.46,
ISRG,2018-07-06,162.99,166.02,162.12,165.15,
ISRG,2018-07-09,166.24,167.22,164.15,166.47,
ISRG,2018-07-10,166.67,167.62,165.12,167.37,
ISRG,2018-07-11,167.16,168.97,166.76,168.07,
ISRG,2018-07-12,168.93,175.04,168.93,175.0,
ISRG,2018-07-13,174.51,177.43,174.13,174.78,
ISRG,2018-07-16,174.78,174.78,170.81,172.69,
ISRG,2018-07-17,172.16,174.95,171.67,174.59,
ISRG,2018-07-18,175.0,176.15,172.95,175.97,
ISRG,2018-07-19,174.99,175.96,173.43,173.76,"[""Intuitive Surgical stock rises after earnings beat Intuitive Surgical Inc. shares rose 3.1% in the extended session Thursday after the company beat earnings and revenue expectations. If the stock maintains the after-hours gains in Friday trading it will rise to a potential record. The company reported second-quarter net income of $255.3 million, or $2.15 a share, compared with $223 million, or $1.94 a share, in the year-ago period. Earnings adjusted for items such as stock-based compensation were $2.76 a share. Revenue rose to $909.3 million from $758.8 million in the year-ago period. Analysts surveyed by FactSet had estimated adjusted earnings of $2.50 a share on revenue of $876 million. For the third quarter, analysts model adjusted earnings of $2.56 a share on sales of $893 million. Intuitive Surgical stock closed up 1.3% to $521.29 and has gained 43% this year, with the S&P 500 index rising 5.3%."", ""Dow snaps 5-day win streak as financials sell off Travelers falls after results, but IBM rallies U.S. stocks close lower on Thursday, as major indexes consolidated their gains after a five-day rally that was driven largely by optimism over the strength of corporate earnings.""]"
ISRG,2018-07-20,178.72,179.66,172.12,172.26,"[""The world\u2019s \u2018inward thinking\u2019 is a threat to stocks, says Blackstone\u2019s Byron Wien Critical information for the U.S. trading day As the stock market works on nabbing a weekly win, one veteran Wall Street strategist is calling out the changes to the market\u2019s backdrop as a worrying \u201cinward shift.\u201d"", ""Stocks end day and week mostly flat as Trump stokes fresh worry on trade, monetary policy U.S. equity benchmarks on track for third straight weekly advance U.S. stocks finish Friday\u2019s trade pretty much where they started the session and the week as losses in consumer-discretionary and energy sectors offset a rise in staples and financials.""]"
ISRG,2018-07-23,172.26,173.51,171.1,173.29,
ISRG,2018-07-24,173.88,175.88,172.57,174.41,
ISRG,2018-07-25,174.93,179.77,174.93,179.32,
ISRG,2018-07-26,179.0,179.02,172.67,175.65,
ISRG,2018-07-27,176.67,176.68,170.49,173.07,
ISRG,2018-07-30,172.9,172.9,166.22,167.67,
ISRG,2018-07-31,168.23,170.67,167.2,169.4,"These Big Tech stocks have taken the most brutal beatings Outperformers including Netflix, Tesla and Take-Two get their comeuppance Outperformers including Netflix, Tesla and Take-Two get their comeuppance."
ISRG,2018-08-01,170.14,172.76,169.97,172.1,
ISRG,2018-08-02,170.37,175.0,170.0,173.97,
ISRG,2018-08-03,174.62,174.72,171.9,174.2,
ISRG,2018-08-06,174.13,174.61,172.58,173.6,
ISRG,2018-08-07,173.33,174.33,171.73,172.63,
ISRG,2018-08-08,172.93,173.9,172.21,173.09,
ISRG,2018-08-09,173.52,176.25,173.52,174.23,
ISRG,2018-08-10,173.72,175.95,172.99,173.67,
ISRG,2018-08-13,174.2,176.58,173.41,173.45,
ISRG,2018-08-14,174.08,176.77,174.08,176.33,
ISRG,2018-08-15,175.0,176.56,172.72,174.26,
ISRG,2018-08-16,175.41,176.02,173.59,174.63,
ISRG,2018-08-17,174.33,175.78,172.06,174.97,
ISRG,2018-08-20,175.68,176.17,172.94,175.12,
ISRG,2018-08-21,175.33,178.28,175.33,176.35,
ISRG,2018-08-22,176.33,178.49,175.86,178.33,
ISRG,2018-08-23,178.5,180.63,178.15,179.07,These 7 little-known health-care ETFs are up 20%-plus in 2018 The exchange traded funds have more than tripled the returns of the S&P 500 this year The exchange traded funds have more than tripled the returns of the S&P 500 this year.
ISRG,2018-08-24,179.67,180.71,179.38,180.51,
ISRG,2018-08-27,181.22,181.87,180.33,181.74,
ISRG,2018-08-28,182.08,183.4,180.25,181.64,
ISRG,2018-08-29,182.2,185.1,182.0,184.67,"Guidewire, Tesla Pay Off for a Fund That Bets on Change Mike Lippert, manager of Baron Opportunity fund, homes in on companies instigating or benefiting from sustainable changes in the way people live and work."
ISRG,2018-08-30,183.97,186.15,183.0,185.06,
ISRG,2018-08-31,184.95,186.8,184.5,186.67,
ISRG,2018-09-04,186.33,186.83,184.12,185.34,
ISRG,2018-09-05,185.59,185.7,177.99,178.91,
ISRG,2018-09-06,179.55,182.75,178.1,180.62,
ISRG,2018-09-07,180.47,181.77,178.97,179.32,
ISRG,2018-09-10,180.11,181.75,179.67,180.63,
ISRG,2018-09-11,180.65,183.56,180.46,182.13,
ISRG,2018-09-12,183.14,183.59,180.3,183.19,
ISRG,2018-09-13,184.45,186.32,182.91,186.27,
ISRG,2018-09-14,186.67,190.99,186.57,189.45,
ISRG,2018-09-17,188.98,188.98,185.11,186.22,
ISRG,2018-09-18,186.2,189.17,186.17,188.27,
ISRG,2018-09-19,187.22,187.52,184.21,185.49,"7 ways to invest in the automation megatrend Zebra Technologies, Flir Systems, Cognex, Intuitive Surgical, Rockwell Automation, AeroVironment and automation ETFs These automation stocks trump any trade war."
ISRG,2018-09-20,186.55,187.32,185.61,187.06,
ISRG,2018-09-21,187.42,188.29,185.49,185.59,
ISRG,2018-09-24,185.45,189.9,184.36,189.76,Johnson & Johnson Might Be Tempted to Buy These 2 Device Makers Either Boston Scientific or Edwards Lifesciences could be tempting acquisition targets for Johnson & Johnson.
ISRG,2018-09-25,189.76,191.8,188.76,191.4,
ISRG,2018-09-26,191.33,191.76,188.49,189.85,
ISRG,2018-09-27,190.0,190.74,189.33,189.9,
ISRG,2018-09-28,190.0,191.48,189.73,191.33,
ISRG,2018-10-01,191.72,193.71,190.66,191.58,
ISRG,2018-10-02,191.47,191.88,188.42,190.49,
ISRG,2018-10-03,190.96,191.38,187.02,187.16,
ISRG,2018-10-04,187.16,187.4,183.67,184.81,
ISRG,2018-10-05,184.68,186.56,180.11,182.9,
ISRG,2018-10-08,182.14,182.67,171.05,175.49,
ISRG,2018-10-09,175.89,179.33,174.57,177.07,
ISRG,2018-10-10,178.33,179.17,170.43,170.74,
ISRG,2018-10-11,169.83,173.42,166.67,169.41,
ISRG,2018-10-12,174.0,179.15,173.73,177.34,
ISRG,2018-10-15,176.36,176.36,172.48,173.1,
ISRG,2018-10-16,175.17,181.46,175.17,180.97,
ISRG,2018-10-17,181.34,182.7,179.47,180.97,
ISRG,2018-10-18,181.58,181.96,173.34,174.1,
ISRG,2018-10-19,179.62,179.99,167.46,168.09,
ISRG,2018-10-22,168.22,171.19,167.4,170.47,
ISRG,2018-10-23,166.31,169.68,161.82,168.98,
ISRG,2018-10-24,168.58,169.9,160.72,161.04,
ISRG,2018-10-25,163.1,166.1,160.92,164.31,
ISRG,2018-10-26,160.67,164.68,158.48,162.3,
ISRG,2018-10-29,165.13,166.0,155.69,159.29,
ISRG,2018-10-30,159.01,163.9,157.49,163.61,
ISRG,2018-10-31,171.29,175.44,169.33,173.73,
ISRG,2018-11-01,174.28,174.5,168.22,172.87,
ISRG,2018-11-02,173.33,176.33,170.2,172.07,
ISRG,2018-11-05,172.27,173.33,167.63,169.13,
ISRG,2018-11-06,168.88,173.5,168.67,173.23,
ISRG,2018-11-07,174.46,182.02,174.43,181.89,
ISRG,2018-11-08,180.78,181.66,178.77,180.01,"Here are the post-election stock-market winners in the Dow, S&P 500 and Nasdaq The three benchmark indices were up over 2% after the midterm elections The three benchmark indices were up over 2% after the midterm elections."
ISRG,2018-11-09,178.22,178.55,175.0,177.52,
ISRG,2018-11-12,177.1,177.66,167.84,168.0,
ISRG,2018-11-13,168.83,172.33,166.68,167.81,
ISRG,2018-11-14,169.33,170.01,164.43,166.21,
ISRG,2018-11-15,165.7,171.47,161.83,171.21,
ISRG,2018-11-16,169.35,174.68,169.04,172.85,
ISRG,2018-11-19,172.49,173.15,160.01,160.89,
ISRG,2018-11-20,156.67,164.29,154.0,161.75,
ISRG,2018-11-21,164.08,166.29,161.84,163.87,
ISRG,2018-11-23,162.74,164.47,162.55,163.19,
ISRG,2018-11-26,165.31,167.95,163.0,167.76,
ISRG,2018-11-27,166.09,166.69,164.35,165.62,
ISRG,2018-11-28,166.47,174.09,166.34,173.97,
ISRG,2018-11-29,171.96,173.97,170.3,173.66,
ISRG,2018-11-30,173.66,178.0,172.46,176.96,
ISRG,2018-12-03,180.62,182.99,178.63,182.98,
ISRG,2018-12-04,180.73,182.45,172.14,172.94,
ISRG,2018-12-06,168.45,173.03,165.6,173.03,
ISRG,2018-12-07,171.22,171.94,162.71,163.9,
ISRG,2018-12-10,163.73,166.94,160.75,166.04,
ISRG,2018-12-11,168.85,170.85,166.24,169.35,
ISRG,2018-12-12,171.99,175.38,171.39,171.88,
ISRG,2018-12-13,174.12,175.13,169.35,170.75,
ISRG,2018-12-14,168.54,169.31,163.79,163.94,
ISRG,2018-12-17,163.5,164.01,158.21,160.58,
ISRG,2018-12-18,162.11,162.68,159.08,160.79,
ISRG,2018-12-19,161.11,164.46,155.28,157.31,
ISRG,2018-12-20,156.0,157.55,150.69,153.29,
ISRG,2018-12-21,153.62,155.0,148.46,148.67,
ISRG,2018-12-24,147.17,147.85,143.41,144.96,
ISRG,2018-12-26,145.28,154.16,145.0,153.99,
ISRG,2018-12-27,151.55,156.33,149.72,156.23,
ISRG,2018-12-28,157.37,159.69,155.18,157.07,
ISRG,2018-12-31,159.05,161.09,157.79,159.64,
ISRG,2019-01-02,156.5,157.74,153.92,155.34,
ISRG,2019-01-03,153.28,154.5,148.82,150.08,"The best and worst stocks of 2018 Merck leads Dow industrials gainers; AMD tops S&P 500 Merck leads Dow industrials gainers; AMD tops S&P 500, despite a horrible fourth quarter."
ISRG,2019-01-04,152.69,159.2,152.24,157.23,
ISRG,2019-01-07,157.33,161.63,157.22,159.48,
ISRG,2019-01-08,161.23,161.86,157.02,161.0,
ISRG,2019-01-09,167.0,173.16,164.66,172.37,
ISRG,2019-01-10,170.16,173.24,170.06,172.69,
ISRG,2019-01-11,171.67,172.2,167.11,168.44,
ISRG,2019-01-14,167.0,168.23,166.35,167.57,
ISRG,2019-01-15,167.71,172.15,167.71,171.82,
ISRG,2019-01-16,172.82,175.28,171.94,171.98,
ISRG,2019-01-17,170.97,178.38,170.41,178.09,
ISRG,2019-01-18,179.8,181.25,175.9,180.85,
ISRG,2019-01-22,179.02,179.88,177.08,178.93,
ISRG,2019-01-23,178.75,179.51,173.8,176.65,
ISRG,2019-01-24,178.0,178.91,176.22,178.71,
ISRG,2019-01-25,172.0,175.3,169.61,171.68,
ISRG,2019-01-28,169.7,170.37,165.01,165.58,
ISRG,2019-01-29,165.67,167.41,162.21,164.75,
ISRG,2019-01-30,165.76,169.77,163.96,169.49,
ISRG,2019-01-31,170.05,175.32,169.08,174.55,
ISRG,2019-02-01,174.28,176.0,172.67,174.88,
ISRG,2019-02-04,174.19,174.41,172.47,174.14,
ISRG,2019-02-05,173.96,175.94,172.68,174.3,
ISRG,2019-02-06,173.79,174.62,171.1,173.98,
ISRG,2019-02-07,172.24,173.33,169.14,169.79,
ISRG,2019-02-08,168.22,172.49,167.33,172.35,
ISRG,2019-02-11,173.9,176.98,173.33,176.49,
ISRG,2019-02-12,177.35,181.5,177.02,179.9,
ISRG,2019-02-13,176.66,179.9,175.45,177.82,"Intuitive Surgical's stock turns lower after J&J-Auris deal, falls 1.4% premarket after being up 1.0% earlier"
ISRG,2019-02-14,176.95,179.4,175.05,178.69,
ISRG,2019-02-15,180.31,182.87,179.55,182.83,
ISRG,2019-02-19,181.02,183.16,180.45,182.72,
ISRG,2019-02-20,182.56,183.33,181.51,183.22,
ISRG,2019-02-21,182.57,184.12,180.74,183.29,
ISRG,2019-02-22,183.87,185.92,183.37,183.95,
ISRG,2019-02-25,185.0,186.32,184.21,184.46,
ISRG,2019-02-26,183.74,183.74,181.31,182.82,
ISRG,2019-02-27,181.94,183.85,180.5,183.14,
ISRG,2019-02-28,182.45,184.94,182.15,182.54,
ISRG,2019-03-01,183.93,188.1,183.17,186.18,
ISRG,2019-03-04,186.34,187.33,180.47,183.31,
ISRG,2019-03-05,183.37,183.65,181.94,182.2,GM and Other ‘Goldilocks’ Stocks Popular With Fund Managers A new report provides insights into stock ownership trends among actively managed large-cap mutual funds. And it offers up some suggestions for stocks to buy now.
ISRG,2019-03-06,182.33,182.94,178.18,178.84,
ISRG,2019-03-07,178.79,178.79,174.56,177.72,
ISRG,2019-03-08,175.37,178.18,175.0,177.92,
ISRG,2019-03-11,178.9,181.68,178.34,180.98,
ISRG,2019-03-12,181.9,184.07,180.8,183.38,"Want to ride the health-care stock wave? Here are 19 companies growing sales rapidly The health-care sector has lagged this year, but many companies have bright futures The health-care sector has lagged this year, but many companies have bright futures."
ISRG,2019-03-13,183.72,186.9,183.67,185.72,
ISRG,2019-03-14,185.67,186.47,183.16,186.24,
ISRG,2019-03-15,186.8,187.0,185.01,186.07,
ISRG,2019-03-18,186.16,186.62,184.36,186.5,Intuitive Surgical Faces New Competition and FDA Concerns The Food and Drug Administration is now warning consumers about the use of robotic equipment for mastectomies and other cancer-related surgeries for women.
ISRG,2019-03-19,186.67,188.47,185.14,187.57,
ISRG,2019-03-20,187.67,190.57,187.0,189.79,
ISRG,2019-03-21,189.26,193.08,188.91,192.66,
ISRG,2019-03-22,191.22,191.42,186.92,187.09,
ISRG,2019-03-25,187.0,188.37,185.87,187.57,
ISRG,2019-03-26,189.49,191.08,188.41,189.21,
ISRG,2019-03-27,188.52,189.21,184.0,186.09,
ISRG,2019-03-28,186.19,188.0,184.93,187.63,
ISRG,2019-03-29,188.57,190.66,187.22,190.19,
ISRG,2019-04-01,191.67,193.28,190.94,191.85,
ISRG,2019-04-02,191.99,193.26,191.7,191.99,
ISRG,2019-04-03,192.99,193.42,191.35,192.09,
ISRG,2019-04-04,192.39,192.39,186.6,190.09,
ISRG,2019-04-05,191.51,192.65,190.9,191.91,
ISRG,2019-04-08,191.49,192.96,189.2,192.78,
ISRG,2019-04-09,192.46,193.85,192.01,193.13,
ISRG,2019-04-10,193.2,195.62,191.67,195.3,
ISRG,2019-04-11,195.3,195.52,192.48,194.88,
ISRG,2019-04-12,195.99,196.44,193.58,194.28,
ISRG,2019-04-15,195.15,195.44,191.69,192.27,
ISRG,2019-04-16,194.03,194.16,185.93,187.14,
ISRG,2019-04-17,188.33,188.58,173.89,175.0,
ISRG,2019-04-18,176.67,179.27,174.51,176.02,
ISRG,2019-04-22,166.63,168.62,162.22,163.69,"[""Tesla Stock Falls, Halliburton Gains, and 3 More Monday Movers Shares of Fastenal, Intuitive Surgical, and Lam Research were getting attention, while the Dow was poised to open lower."", ""The Dow Dropped 48 Points Because It\u2019s the Breather Before Big Earnings Roll In The Dow Jones Industrial Average ended down 0.18% to end at 26,511.05. The S&P 500 Index rose 0.10% to close at 2907.97, and the Nasdaq Composite gained 0.22% to end at 8015.27.""]"
ISRG,2019-04-23,165.33,167.77,162.47,166.81,
ISRG,2019-04-24,168.33,170.56,167.0,169.38,
ISRG,2019-04-25,171.04,173.93,169.6,172.6,
ISRG,2019-04-26,173.83,174.8,170.67,173.04,
ISRG,2019-04-29,173.33,174.0,169.97,170.11,
ISRG,2019-04-30,170.59,171.2,169.5,170.21,
ISRG,2019-05-01,170.54,170.67,165.51,165.68,
ISRG,2019-05-02,165.49,168.7,165.33,167.37,
ISRG,2019-05-03,168.82,169.77,168.11,169.31,
ISRG,2019-05-06,165.71,169.63,165.56,169.49,
ISRG,2019-05-07,167.6,168.33,163.07,163.77,
ISRG,2019-05-08,163.77,166.67,161.02,165.23,
ISRG,2019-05-09,163.51,165.71,161.67,165.35,
ISRG,2019-05-10,164.5,166.07,160.86,165.1,
ISRG,2019-05-13,160.84,161.97,158.87,159.58,
ISRG,2019-05-14,160.6,164.23,160.6,162.45,
ISRG,2019-05-15,161.8,163.93,161.22,163.05,
ISRG,2019-05-16,163.3,166.6,163.17,163.91,
ISRG,2019-05-17,163.04,165.61,161.68,163.38,
ISRG,2019-05-20,162.22,162.8,160.04,161.07,
ISRG,2019-05-21,162.54,164.33,160.96,161.19,
ISRG,2019-05-22,161.01,163.27,160.2,161.79,
ISRG,2019-05-23,160.84,160.85,155.88,157.93,
ISRG,2019-05-24,158.46,159.63,157.21,158.84,
ISRG,2019-05-28,158.45,161.23,156.99,157.07,
ISRG,2019-05-29,156.43,158.21,155.78,157.31,
ISRG,2019-05-30,157.57,160.25,157.32,159.07,
ISRG,2019-05-31,156.19,157.16,154.31,154.95,"[""How the New Tariffs Will Hit U.S. Medical-Device Manufacturers The sector relies on Mexico for 15% of its imports and 7% of its exports."", ""The Dow Fell 355 Points Because News of Mexico Tariffs Sent the Market South The Dow Jones Industrial Average slumped 1.41% to close at 24,815.04. The S&P 500 lost 1.32% to end at 2752.06, and the Nasdaq Composite dropped 1.51% to close at 7453.15.""]"
ISRG,2019-06-03,154.28,156.0,151.72,152.76,
ISRG,2019-06-04,154.6,158.26,154.16,158.14,
ISRG,2019-06-05,159.79,161.92,159.18,161.69,
ISRG,2019-06-06,161.69,162.94,160.15,161.75,
ISRG,2019-06-07,162.15,166.62,161.79,166.35,
ISRG,2019-06-10,166.87,172.02,166.87,169.91,
ISRG,2019-06-11,170.91,172.17,167.53,168.85,
ISRG,2019-06-12,168.59,169.95,166.58,167.31,
ISRG,2019-06-13,167.96,169.25,166.96,168.53,
ISRG,2019-06-14,167.49,168.33,163.67,165.51,
ISRG,2019-06-17,166.17,169.11,166.0,169.05,
ISRG,2019-06-18,170.0,172.98,169.19,172.43,
ISRG,2019-06-19,172.08,174.2,170.93,173.98,
ISRG,2019-06-20,175.0,177.94,174.67,177.68,
ISRG,2019-06-21,176.7,176.74,173.84,175.74,
ISRG,2019-06-24,176.0,176.96,175.06,175.27,
ISRG,2019-06-25,175.33,175.69,173.05,173.51,
ISRG,2019-06-26,174.51,174.51,170.26,171.24,
ISRG,2019-06-27,172.38,173.33,169.84,172.59,
ISRG,2019-06-28,172.65,175.0,171.0,174.85,
ISRG,2019-07-01,177.33,178.33,175.32,176.44,
ISRG,2019-07-02,176.34,177.17,174.4,176.51,
ISRG,2019-07-03,176.67,180.15,176.17,179.06,
ISRG,2019-07-05,177.34,179.67,175.61,179.08,"The Best Mutual Funds You’ve Never Heard Of In the world of asset management, the big have only gotten bigger. But there are plenty of small fund companies offering some great funds. Here are five."
ISRG,2019-07-08,178.21,178.21,176.41,177.72,
ISRG,2019-07-09,176.34,177.55,175.44,176.09,
ISRG,2019-07-10,176.67,179.19,176.36,177.43,
ISRG,2019-07-11,178.03,179.27,177.55,178.67,
ISRG,2019-07-12,177.07,177.07,173.5,175.42,
ISRG,2019-07-15,176.34,178.08,175.53,175.92,
ISRG,2019-07-16,175.71,176.78,171.42,171.85,
ISRG,2019-07-17,172.17,175.61,172.17,174.5,
ISRG,2019-07-18,178.88,179.07,173.8,178.88,
ISRG,2019-07-19,177.75,181.62,175.12,176.27,
ISRG,2019-07-22,178.0,179.64,176.04,178.5,
ISRG,2019-07-23,177.38,180.0,176.37,179.26,
ISRG,2019-07-24,178.58,181.27,177.64,181.01,
ISRG,2019-07-25,179.43,180.0,176.7,177.23,
ISRG,2019-07-26,177.81,178.0,174.65,175.88,
ISRG,2019-07-29,176.2,176.86,174.33,176.54,
ISRG,2019-07-30,175.4,178.36,175.18,177.21,
ISRG,2019-07-31,177.01,177.06,171.67,173.17,
ISRG,2019-08-01,173.5,177.63,172.22,174.65,
ISRG,2019-08-02,173.43,173.96,169.81,171.2,
ISRG,2019-08-05,167.08,167.66,162.29,163.82,
ISRG,2019-08-06,164.79,168.16,164.25,167.92,
ISRG,2019-08-07,166.41,169.11,164.46,168.45,
ISRG,2019-08-08,173.14,173.21,169.14,173.14,
ISRG,2019-08-09,172.03,172.88,169.35,171.83,
ISRG,2019-08-12,171.0,172.25,169.34,169.96,
ISRG,2019-08-13,169.3,173.66,167.67,172.67,
ISRG,2019-08-14,170.17,171.08,166.67,166.82,
ISRG,2019-08-15,168.77,169.17,165.03,166.62,
ISRG,2019-08-16,168.32,168.33,164.47,165.15,
ISRG,2019-08-19,167.83,167.83,162.9,165.17,
ISRG,2019-08-20,165.88,166.67,164.13,165.94,
ISRG,2019-08-21,167.17,168.27,166.67,167.09,
ISRG,2019-08-22,167.33,167.94,165.2,166.76,
ISRG,2019-08-23,166.33,167.33,160.67,161.53,
ISRG,2019-08-26,163.29,163.74,160.86,163.7,
ISRG,2019-08-27,165.0,166.63,164.08,165.01,
ISRG,2019-08-28,164.0,167.64,164.0,167.08,
ISRG,2019-08-29,168.56,170.17,167.65,169.39,
ISRG,2019-08-30,170.13,171.22,169.35,170.45,
ISRG,2019-09-03,168.41,169.94,163.36,164.65,
ISRG,2019-09-04,165.78,166.35,163.11,165.41,
ISRG,2019-09-05,167.23,171.0,166.33,169.39,
ISRG,2019-09-06,169.82,170.05,167.33,168.42,
ISRG,2019-09-09,168.33,168.67,165.31,165.56,
ISRG,2019-09-10,165.0,167.6,162.67,167.43,
ISRG,2019-09-11,168.18,175.0,167.43,174.27,
ISRG,2019-09-12,174.54,175.99,173.75,174.37,
ISRG,2019-09-13,174.55,175.66,173.11,174.41,
ISRG,2019-09-16,172.93,174.79,171.35,174.55,
ISRG,2019-09-17,175.0,177.49,173.75,176.72,
ISRG,2019-09-18,176.1,177.06,174.51,176.92,
ISRG,2019-09-19,176.45,179.33,176.08,176.48,
ISRG,2019-09-20,175.68,178.96,175.33,177.05,
ISRG,2019-09-23,176.49,178.12,175.47,175.99,
ISRG,2019-09-24,177.33,182.08,176.03,180.49,
ISRG,2019-09-25,180.01,181.81,177.57,181.67,"Pelosi’s impeachment inquiry into Trump could derail her drug-pricing bill House leader’s investigation into president could be a plus for drug stocks As the move to impeach President Donald Trump moves forward, one analyst contends that the proceedings could essentially bring Congress to even more of a screeching halt, notably on a bill that would curb some drug prices from pharmaceutical companies."
ISRG,2019-09-26,181.67,182.48,178.85,181.1,
ISRG,2019-09-27,182.36,183.0,177.12,177.91,
ISRG,2019-09-30,178.64,181.35,178.44,179.98,
ISRG,2019-10-01,179.98,180.98,176.07,176.2,
ISRG,2019-10-02,176.0,176.09,168.76,170.63,
ISRG,2019-10-03,170.76,173.08,167.34,173.02,
ISRG,2019-10-04,174.11,176.51,173.66,176.39,
ISRG,2019-10-07,176.15,176.87,175.21,175.53,
ISRG,2019-10-08,174.08,174.74,169.51,169.67,
ISRG,2019-10-09,171.59,172.26,170.37,171.37,
ISRG,2019-10-10,170.24,172.22,169.58,170.41,
ISRG,2019-10-11,172.67,175.96,172.43,172.68,
ISRG,2019-10-14,172.88,174.6,172.69,172.96,
ISRG,2019-10-15,173.96,176.78,173.83,176.07,
ISRG,2019-10-16,175.64,177.9,175.0,176.75,
ISRG,2019-10-17,178.23,179.0,176.15,176.47,
ISRG,2019-10-18,182.33,189.99,181.85,188.75,
ISRG,2019-10-21,188.07,188.61,186.34,187.57,
ISRG,2019-10-22,185.72,186.48,178.3,178.58,
ISRG,2019-10-23,178.39,181.48,178.39,179.95,
ISRG,2019-10-24,181.0,183.28,178.72,182.65,
ISRG,2019-10-25,182.33,184.5,180.2,183.09,
ISRG,2019-10-28,182.74,187.1,182.0,186.22,
ISRG,2019-10-29,184.98,188.24,184.23,185.39,
ISRG,2019-10-30,185.18,186.0,183.33,185.44,
ISRG,2019-10-31,184.57,186.33,182.56,184.32,
ISRG,2019-11-01,185.82,187.62,184.0,186.46,
ISRG,2019-11-04,187.5,187.94,186.15,186.95,
ISRG,2019-11-05,186.81,189.6,186.5,187.79,
ISRG,2019-11-06,187.7,189.33,184.59,184.72,
ISRG,2019-11-07,186.07,186.31,182.68,183.96,
ISRG,2019-11-08,183.78,185.12,182.43,182.98,
ISRG,2019-11-11,181.7,182.61,180.06,181.6,
ISRG,2019-11-12,181.67,184.55,181.67,183.12,
ISRG,2019-11-13,180.8,183.74,180.61,183.51,"Sales winners in the third quarter include Netflix, Autodesk and PayPal Plenty of companies have produced double-digit sales increases and wider profit margins during an otherwise dismal earnings season Plenty of companies have produced double-digit sales increases and wider margins during an otherwise dismal earnings season."
ISRG,2019-11-14,183.46,186.88,183.05,184.81,
ISRG,2019-11-15,186.43,189.85,185.67,189.85,
ISRG,2019-11-18,189.67,192.67,189.18,189.7,
ISRG,2019-11-19,190.0,193.39,189.17,192.6,
ISRG,2019-11-20,192.22,194.33,189.4,190.84,
ISRG,2019-11-21,189.33,190.66,187.68,190.61,
ISRG,2019-11-22,190.57,190.69,187.48,189.83,
ISRG,2019-11-25,190.73,193.86,190.24,193.83,
ISRG,2019-11-26,192.6,195.5,192.0,195.33,
ISRG,2019-11-27,195.52,197.9,195.52,197.08,
ISRG,2019-11-29,196.67,198.05,196.0,197.63,
ISRG,2019-12-02,197.33,197.63,194.5,195.79,
ISRG,2019-12-03,192.93,193.92,191.96,193.08,
ISRG,2019-12-04,193.41,194.95,192.74,194.11,
ISRG,2019-12-05,194.24,195.19,193.18,193.6,
ISRG,2019-12-06,194.88,196.22,194.15,195.19,
ISRG,2019-12-09,194.58,195.45,190.86,191.06,
ISRG,2019-12-10,191.52,192.64,190.97,191.79,
ISRG,2019-12-11,192.67,192.78,190.99,191.6,
ISRG,2019-12-12,191.83,194.87,190.96,193.66,
ISRG,2019-12-13,193.63,194.78,192.53,193.22,
ISRG,2019-12-16,195.0,197.11,194.01,196.68,
ISRG,2019-12-17,196.9,198.67,195.7,197.91,
ISRG,2019-12-18,197.42,198.68,196.95,197.42,
ISRG,2019-12-19,198.21,198.21,195.4,196.24,
ISRG,2019-12-20,197.15,197.77,195.82,197.1,
ISRG,2019-12-23,197.33,199.67,196.1,199.14,
ISRG,2019-12-24,198.67,199.77,197.77,199.6,
ISRG,2019-12-26,199.63,199.67,197.67,199.35,
ISRG,2019-12-27,199.46,200.53,198.56,199.29,
ISRG,2019-12-30,199.33,200.33,196.67,197.11,
ISRG,2019-12-31,197.1,197.99,196.08,197.05,
ISRG,2020-01-02,198.57,199.28,196.93,199.09,
ISRG,2020-01-03,196.06,198.19,194.05,197.78,
ISRG,2020-01-06,196.67,199.21,195.98,198.59,
ISRG,2020-01-07,196.65,196.65,191.25,194.27,
ISRG,2020-01-08,193.85,195.12,192.2,193.93,
ISRG,2020-01-09,195.84,196.58,194.03,195.26,
ISRG,2020-01-10,201.83,205.52,199.3,199.57,
ISRG,2020-01-13,200.16,202.31,199.62,201.04,
ISRG,2020-01-14,200.91,201.43,199.2,200.9,
ISRG,2020-01-15,200.9,201.83,198.67,199.08,
ISRG,2020-01-16,200.53,201.27,197.69,199.43,
ISRG,2020-01-17,200.18,200.28,198.0,200.01,
ISRG,2020-01-21,199.43,200.83,199.12,200.55,
ISRG,2020-01-22,201.67,204.83,200.84,203.41,
ISRG,2020-01-23,203.95,205.0,202.2,205.0,
ISRG,2020-01-24,201.6,201.67,194.61,196.4,
ISRG,2020-01-27,190.64,191.0,186.42,189.17,"These U.S. stocks are down the most as the coronavirus spreads Travel-related, energy and semiconductor shares are hit the hardest Travel-related, energy and semiconductor shares are hit the hardest."
ISRG,2020-01-28,190.11,191.15,189.17,189.91,
ISRG,2020-01-29,191.67,192.57,189.33,190.47,
ISRG,2020-01-30,189.55,191.58,186.06,190.28,
ISRG,2020-01-31,189.28,190.07,185.01,186.59,
ISRG,2020-02-03,187.43,188.75,186.2,188.54,
ISRG,2020-02-04,192.06,195.0,190.89,191.36,
ISRG,2020-02-05,193.79,193.83,190.93,192.19,
ISRG,2020-02-06,192.67,194.54,191.77,193.85,
ISRG,2020-02-07,193.78,194.34,192.78,193.14,
ISRG,2020-02-10,192.96,195.03,192.23,194.98,"Looking for another Apple or Amazon? These stocks have one important thing in common with tech’s big winners The companies, including AMD, NextEra Energy and Vertex Pharmaceuticals, improved their pricing power as sales grew rapidly The companies, including AMD, NextEra Energy and Vertex Pharmaceuticals, improved their pricing power as sales grew rapidly."
ISRG,2020-02-11,196.22,196.87,195.25,195.94,
ISRG,2020-02-12,197.19,198.32,196.13,197.61,
ISRG,2020-02-13,199.67,200.3,197.5,200.12,
ISRG,2020-02-14,200.33,201.45,198.14,201.12,
ISRG,2020-02-18,200.44,201.67,199.9,201.56,
ISRG,2020-02-19,198.71,206.19,198.71,204.96,
ISRG,2020-02-20,203.66,206.33,202.57,206.1,
ISRG,2020-02-21,204.12,204.98,202.23,204.36,
ISRG,2020-02-24,196.82,198.81,192.84,193.39,
ISRG,2020-02-25,194.65,195.08,185.29,186.17,
ISRG,2020-02-26,187.33,191.27,186.27,186.51,
ISRG,2020-02-27,183.46,186.83,181.39,181.54,
ISRG,2020-02-28,175.97,178.95,172.85,177.99,
ISRG,2020-03-02,178.43,186.53,177.41,186.36,"These companies are spending billions so robots can perform surgery without a doctor in the room Scientists are excited about the potential for AI and other technological advancements to make robotic surgery more accurate and accessible Scientists are excited about the potential for artificial intelligence, improved connectivity, and other technological advancements to make robotic surgery more accurate and accessible."
ISRG,2020-03-03,185.57,191.67,181.26,186.09,
ISRG,2020-03-04,189.33,194.57,187.66,194.3,
ISRG,2020-03-05,190.6,192.26,186.84,189.46,
ISRG,2020-03-06,183.33,186.49,179.36,185.05,
ISRG,2020-03-09,171.71,175.97,167.0,170.22,
ISRG,2020-03-10,176.89,179.65,168.52,179.13,
ISRG,2020-03-11,173.33,174.19,167.59,169.85,
ISRG,2020-03-12,162.09,166.07,152.02,152.51,
ISRG,2020-03-13,159.34,160.77,144.19,156.99,
ISRG,2020-03-16,138.77,149.17,134.08,134.76,
ISRG,2020-03-17,137.66,143.01,123.33,141.83,
ISRG,2020-03-18,133.17,136.12,122.69,135.57,
ISRG,2020-03-19,133.75,144.63,124.0,136.07,
ISRG,2020-03-20,138.95,144.8,130.43,131.4,
ISRG,2020-03-23,127.33,130.26,120.17,122.58,
ISRG,2020-03-24,132.97,144.54,132.36,143.97,
ISRG,2020-03-25,144.43,161.33,143.33,153.44,
ISRG,2020-03-26,154.21,168.2,154.21,167.16,
ISRG,2020-03-27,159.58,168.8,158.89,163.47,"Here are Thursday’s best-performing stocks as the Dow Jones Industrial Average produces a three-day gain of 21% Boeing led the Dow higher Thursday. Still, the index is down 24% from its record closing high last month Boeing led the Dow higher Thursday. Still, the index is down 24% from its record closing high last month."
ISRG,2020-03-30,163.33,168.96,161.43,168.07,
ISRG,2020-03-31,166.28,169.8,164.1,165.07,
ISRG,2020-04-01,153.42,158.33,150.09,152.75,
ISRG,2020-04-02,150.0,157.99,150.0,155.91,"These U.S. stocks fell the most April 1 after Trump turned grim on coronavirus forecast Utility, real estate and financial stocks led the declines as three major indexes drop 4.4% Utility, real estate and financial stocks led the declines as three major indexes drop 4.4%."
ISRG,2020-04-03,154.77,156.88,150.0,154.16,
ISRG,2020-04-06,163.16,167.8,159.01,166.75,
ISRG,2020-04-07,173.33,174.78,161.96,163.33,
ISRG,2020-04-08,165.0,171.56,162.01,170.17,
ISRG,2020-04-09,171.24,171.73,163.58,167.93,
ISRG,2020-04-13,165.41,166.68,162.72,164.84,
ISRG,2020-04-14,167.09,171.48,166.31,169.31,
ISRG,2020-04-15,165.2,171.1,163.69,170.33,
ISRG,2020-04-16,171.63,171.98,165.18,170.15,
ISRG,2020-04-17,173.37,176.03,165.37,175.44,
ISRG,2020-04-20,174.5,176.5,172.55,172.78,
ISRG,2020-04-21,168.73,170.42,162.67,165.54,
ISRG,2020-04-22,167.92,171.48,166.44,170.71,This battle-tested pro in the stock market explains how you can ‘come out swinging’ when the pandemic eases Kim Scott of the Ivy Mid Cap Growth Fund says to avoid ‘cyclical’ companies and focus on those with strong growth prospects Kim Scott of the Ivy Mid Cap Growth Fund says to avoid ‘cyclical’ companies and focus on those with strong growth prospects.
ISRG,2020-04-23,171.71,174.67,170.53,171.07,
ISRG,2020-04-24,173.01,173.5,169.55,171.64,
ISRG,2020-04-27,174.15,174.4,171.0,172.37,
ISRG,2020-04-28,171.96,173.0,166.67,167.82,
ISRG,2020-04-29,170.9,175.39,168.68,173.24,
ISRG,2020-04-30,172.5,172.67,169.48,170.29,
ISRG,2020-05-01,167.67,168.99,164.0,166.29,
ISRG,2020-05-04,165.8,168.12,165.18,167.33,
ISRG,2020-05-05,169.92,173.0,168.19,170.95,
ISRG,2020-05-06,171.77,174.34,169.29,170.62,
ISRG,2020-05-07,174.02,178.85,172.55,178.65,
ISRG,2020-05-08,180.97,181.48,178.25,179.26,
ISRG,2020-05-11,177.33,180.0,176.5,179.7,
ISRG,2020-05-12,178.66,180.23,174.28,174.29,
ISRG,2020-05-13,174.08,175.72,167.33,169.64,
ISRG,2020-05-14,167.26,172.82,167.04,172.42,
ISRG,2020-05-15,171.35,173.47,170.4,173.47,
ISRG,2020-05-18,177.17,182.12,176.48,179.47,
ISRG,2020-05-19,180.12,180.99,176.87,177.0,
ISRG,2020-05-20,180.0,185.15,179.16,184.1,
ISRG,2020-05-21,183.48,184.8,181.27,181.98,
ISRG,2020-05-22,182.32,187.71,181.3,187.6,
ISRG,2020-05-26,191.64,194.16,186.67,187.03,
ISRG,2020-05-27,188.83,189.07,183.12,188.24,
ISRG,2020-05-28,187.55,195.2,187.55,190.8,
ISRG,2020-05-29,191.33,193.86,189.0,193.34,
ISRG,2020-06-01,191.6,193.57,190.21,191.53,
ISRG,2020-06-02,191.89,193.52,189.65,193.27,
ISRG,2020-06-03,193.17,194.87,191.32,191.49,
ISRG,2020-06-04,191.33,191.33,186.39,188.08,
ISRG,2020-06-05,189.29,200.4,189.17,197.59,
ISRG,2020-06-08,196.87,197.91,194.8,197.57,
ISRG,2020-06-09,195.02,197.58,194.26,194.84,
ISRG,2020-06-10,191.46,196.68,190.43,195.13,
ISRG,2020-06-11,191.32,192.23,182.38,182.61,
ISRG,2020-06-12,187.68,189.78,181.84,186.14,
ISRG,2020-06-15,182.17,190.66,181.62,190.43,
ISRG,2020-06-16,195.96,196.42,190.85,191.69,
ISRG,2020-06-17,193.45,195.21,192.19,192.83,
ISRG,2020-06-18,192.73,195.25,192.33,195.18,
ISRG,2020-06-19,197.24,198.45,193.22,195.84,
ISRG,2020-06-22,196.09,196.76,194.16,196.32,
ISRG,2020-06-23,197.0,198.77,195.67,196.17,
ISRG,2020-06-24,194.21,194.34,184.14,184.99,
ISRG,2020-06-25,185.57,185.76,181.01,185.04,
ISRG,2020-06-26,185.52,185.96,181.62,183.28,
ISRG,2020-06-29,184.5,185.0,181.39,184.59,
ISRG,2020-06-30,184.88,191.13,183.99,189.94,
ISRG,2020-07-01,190.67,192.33,189.03,191.85,
ISRG,2020-07-02,194.1,194.48,192.28,193.49,
ISRG,2020-07-06,196.29,197.12,193.7,194.88,
ISRG,2020-07-07,193.23,195.64,191.71,191.78,
ISRG,2020-07-08,192.99,194.36,191.87,193.65,
ISRG,2020-07-09,193.07,194.41,189.33,191.49,
ISRG,2020-07-10,191.57,192.37,189.17,191.96,
ISRG,2020-07-13,193.05,196.26,190.0,190.43,
ISRG,2020-07-14,189.88,195.49,188.74,195.11,
ISRG,2020-07-15,197.08,203.0,196.86,202.6,
ISRG,2020-07-16,201.57,204.26,198.79,201.42,
ISRG,2020-07-17,203.33,218.27,202.12,216.91,
ISRG,2020-07-20,215.15,223.88,210.52,222.51,
ISRG,2020-07-21,222.41,225.02,217.52,219.38,
ISRG,2020-07-22,223.15,228.28,220.01,227.11,
ISRG,2020-07-23,228.26,233.24,223.91,228.85,
ISRG,2020-07-24,221.71,225.7,219.66,225.11,
ISRG,2020-07-27,224.36,229.94,222.69,228.45,
ISRG,2020-07-28,226.67,228.33,224.75,226.56,
ISRG,2020-07-29,227.57,234.67,226.67,231.93,
ISRG,2020-07-30,229.65,230.76,226.7,229.13,
ISRG,2020-07-31,229.28,230.21,225.24,228.48,
ISRG,2020-08-03,228.58,231.08,228.46,229.65,
ISRG,2020-08-04,229.08,229.8,227.17,227.83,
ISRG,2020-08-05,229.22,232.52,228.44,230.96,
ISRG,2020-08-06,230.07,230.84,225.36,230.42,
ISRG,2020-08-07,230.34,231.37,226.67,228.62,
ISRG,2020-08-10,228.25,228.45,225.33,227.67,
ISRG,2020-08-11,228.66,228.66,223.87,225.0,
ISRG,2020-08-12,225.41,228.66,224.26,227.7,
ISRG,2020-08-13,227.57,231.33,226.7,230.19,
ISRG,2020-08-14,230.85,230.85,227.12,228.17,
ISRG,2020-08-17,228.34,231.69,228.11,231.33,
ISRG,2020-08-18,230.54,232.07,230.24,230.8,
ISRG,2020-08-19,231.67,233.0,229.89,230.47,
ISRG,2020-08-20,229.75,231.74,229.0,231.02,
ISRG,2020-08-21,230.18,231.66,228.89,231.29,
ISRG,2020-08-24,233.0,233.99,229.76,231.91,
ISRG,2020-08-25,231.93,233.62,231.39,233.17,
ISRG,2020-08-26,233.33,233.83,230.93,233.33,
ISRG,2020-08-27,233.61,239.37,230.7,236.46,
ISRG,2020-08-28,237.78,243.32,236.23,242.34,
ISRG,2020-08-31,241.06,244.82,240.33,243.61,
ISRG,2020-09-01,244.15,247.48,242.44,247.19,
ISRG,2020-09-02,247.34,259.61,246.11,255.04,
ISRG,2020-09-03,250.95,252.33,241.38,247.2,"These 74 stocks in the S&P 500 hit all-time records on Wednesday It was a broad rally, one that wasn’t led by the information technology sector It was a broad rally, one that wasn’t led by the information technology sector."
ISRG,2020-09-04,247.7,249.95,239.25,245.09,
ISRG,2020-09-08,236.67,239.29,230.68,231.39,
ISRG,2020-09-09,234.45,242.24,234.05,239.83,
ISRG,2020-09-10,239.5,242.9,233.76,235.2,
ISRG,2020-09-11,237.94,238.51,232.66,234.18,
ISRG,2020-09-14,237.47,240.71,237.05,238.78,
ISRG,2020-09-15,241.42,242.05,237.04,238.52,
ISRG,2020-09-16,240.11,241.18,229.89,230.46,
ISRG,2020-09-17,228.4,230.1,224.5,226.96,
ISRG,2020-09-18,226.88,228.38,216.47,218.52,
ISRG,2020-09-21,216.03,216.03,211.1,213.98,
ISRG,2020-09-22,216.15,222.48,213.88,222.01,
ISRG,2020-09-23,225.21,225.4,218.39,219.14,
ISRG,2020-09-24,217.38,221.23,215.85,219.18,
ISRG,2020-09-25,218.22,225.97,217.67,224.58,
ISRG,2020-09-28,228.33,231.85,226.68,231.05,
ISRG,2020-09-29,232.67,238.63,230.18,230.98,
ISRG,2020-09-30,232.38,239.3,230.18,236.51,
ISRG,2020-10-01,237.7,239.48,234.67,236.84,
ISRG,2020-10-02,233.36,235.86,230.7,232.09,
ISRG,2020-10-05,233.03,236.19,232.27,235.9,
ISRG,2020-10-06,236.51,238.74,232.1,233.01,
ISRG,2020-10-07,236.15,240.66,236.15,240.09,
ISRG,2020-10-08,241.67,242.87,240.04,241.01,
ISRG,2020-10-09,243.29,247.09,242.67,246.06,
ISRG,2020-10-12,249.58,253.01,247.74,251.89,"[""Goldman Sachs, United Airlines, and Other Stocks to Watch Wednesday Goldman Sachs and other big banks will report. Plus, producer price index."", ""Delta, JPMorgan, and Other Stocks to Watch Tuesday JPMorgan Chase and other big banks will report. Plus, small business optimism and consumer price data.""]"
ISRG,2020-10-13,251.97,253.68,249.91,251.78,"Podcast: Online Shopping Could Be Up 35% This Holiday Season Third-quarter earnings season kicks off today. Apple is widely expected to release 5G-capable iPhones. And with Amazon’s delayed Prime Day under way, shopping for the holiday season has begun early."
ISRG,2020-10-14,253.1,255.39,248.72,250.36,"Morgan Stanley, Walgreens, and Other Stocks to Watch Thursday Morgan Stanley and other banks will report. Plus, jobless claims and manufacturing data."
ISRG,2020-10-15,247.36,251.8,246.67,247.0,"Bank of New York Mellon, State Street, and Other Stocks to Watch Friday Bank of New York Mellon and other banks will report. Plus, consumer sentiment and retail-sales data."
ISRG,2020-10-16,241.67,253.63,238.76,250.89,
ISRG,2020-10-19,251.75,257.21,243.12,245.37,
ISRG,2020-10-20,245.37,248.52,243.3,244.33,
ISRG,2020-10-21,243.6,244.89,240.86,242.83,
ISRG,2020-10-22,243.21,246.11,241.3,244.31,
ISRG,2020-10-23,246.11,246.66,242.5,245.16,
ISRG,2020-10-26,242.36,243.26,233.56,237.26,
ISRG,2020-10-27,237.84,242.68,237.12,240.3,
ISRG,2020-10-28,234.77,235.05,229.26,229.27,
ISRG,2020-10-29,230.0,231.49,227.79,228.76,
ISRG,2020-10-30,227.4,228.67,217.67,222.36,
ISRG,2020-11-02,226.87,227.67,223.1,225.33,
ISRG,2020-11-03,228.0,232.26,226.94,227.33,
ISRG,2020-11-04,236.23,239.32,233.57,236.55,
ISRG,2020-11-05,244.85,244.93,239.55,242.76,
ISRG,2020-11-06,243.14,245.8,240.08,244.62,
ISRG,2020-11-09,251.93,264.18,251.93,257.82,
ISRG,2020-11-10,257.01,257.24,247.33,249.83,
ISRG,2020-11-11,251.51,253.28,245.37,245.85,
ISRG,2020-11-12,248.06,250.59,245.66,246.92,
ISRG,2020-11-13,249.44,251.77,248.24,251.13,
ISRG,2020-11-16,253.33,254.68,249.37,252.73,
ISRG,2020-11-17,249.32,250.76,246.88,249.72,
ISRG,2020-11-18,249.08,249.24,244.33,244.46,
ISRG,2020-11-19,243.59,245.81,241.16,244.65,
ISRG,2020-11-20,243.67,245.08,242.21,243.58,
ISRG,2020-11-23,243.83,244.68,237.69,239.68,
ISRG,2020-11-24,242.3,242.88,240.34,241.61,
ISRG,2020-11-25,243.1,244.25,241.62,242.12,
ISRG,2020-11-27,245.12,245.19,242.0,243.27,
ISRG,2020-11-30,241.8,244.63,240.33,242.02,
ISRG,2020-12-01,244.43,245.51,240.62,244.55,
ISRG,2020-12-02,243.67,251.4,243.67,250.43,
ISRG,2020-12-03,250.66,254.75,249.62,252.91,
ISRG,2020-12-04,251.16,260.63,251.16,260.11,
ISRG,2020-12-07,259.33,260.18,254.11,254.8,
ISRG,2020-12-08,254.29,255.86,251.67,255.12,
ISRG,2020-12-09,255.87,255.87,250.03,251.17,
ISRG,2020-12-10,251.87,255.6,249.36,252.69,
ISRG,2020-12-11,251.38,253.97,248.63,253.33,
ISRG,2020-12-14,254.67,260.21,254.02,254.93,
ISRG,2020-12-15,252.34,257.19,251.67,256.16,
ISRG,2020-12-16,255.25,256.65,254.02,255.35,
ISRG,2020-12-17,257.13,260.42,255.75,259.93,
ISRG,2020-12-18,262.26,263.6,258.35,263.03,
ISRG,2020-12-21,259.34,263.33,256.06,263.09,
ISRG,2020-12-22,263.37,272.28,262.76,271.75,
ISRG,2020-12-23,272.34,275.6,269.51,269.88,
ISRG,2020-12-24,270.24,270.78,267.67,269.0,
ISRG,2020-12-28,272.74,273.33,265.74,268.39,
ISRG,2020-12-29,270.79,273.43,269.04,271.36,
ISRG,2020-12-30,273.33,274.05,270.68,271.77,
ISRG,2020-12-31,271.84,273.68,270.1,272.7,
ISRG,2021-01-04,275.28,275.28,262.96,266.67,
ISRG,2021-01-05,264.63,270.46,263.13,268.35,
ISRG,2021-01-06,265.09,266.67,262.29,264.26,
ISRG,2021-01-07,266.29,270.14,263.33,269.4,
ISRG,2021-01-08,268.07,275.13,268.02,272.92,
ISRG,2021-01-11,272.81,272.81,267.95,271.22,
ISRG,2021-01-12,270.45,271.01,262.77,262.81,
ISRG,2021-01-13,262.46,274.67,262.0,270.48,
ISRG,2021-01-14,271.43,271.92,265.02,265.71,
ISRG,2021-01-15,266.69,267.35,259.0,259.47,
ISRG,2021-01-19,261.7,264.0,258.47,259.47,
ISRG,2021-01-20,261.85,267.22,260.54,266.19,
ISRG,2021-01-21,265.44,267.33,260.87,266.22,
ISRG,2021-01-22,261.01,263.07,247.84,248.03,
ISRG,2021-01-25,249.14,251.55,245.21,250.67,
ISRG,2021-01-26,251.49,257.54,251.0,256.55,
ISRG,2021-01-27,253.47,256.46,248.99,252.91,
ISRG,2021-01-28,255.68,259.41,254.98,255.12,
ISRG,2021-01-29,251.45,253.72,247.17,249.21,
ISRG,2021-02-01,250.67,253.62,246.67,248.7,
ISRG,2021-02-02,251.22,256.16,251.22,252.61,
ISRG,2021-02-03,251.66,252.59,248.2,248.47,
ISRG,2021-02-04,250.0,254.88,248.42,252.35,
ISRG,2021-02-05,254.87,255.44,253.5,254.08,
ISRG,2021-02-08,256.09,258.35,253.95,256.66,
ISRG,2021-02-09,257.66,262.97,256.93,259.78,
ISRG,2021-02-10,262.33,264.84,259.64,262.7,
ISRG,2021-02-11,264.67,266.8,262.74,266.28,
ISRG,2021-02-12,266.42,269.47,264.6,269.27,
ISRG,2021-02-16,270.0,270.93,262.96,263.98,
ISRG,2021-02-17,260.67,262.8,258.14,260.02,
ISRG,2021-02-18,258.19,258.81,252.6,255.84,
ISRG,2021-02-19,257.75,257.75,249.89,250.05,
ISRG,2021-02-22,250.6,250.93,245.67,247.13,
ISRG,2021-02-23,247.27,249.54,244.03,248.24,
ISRG,2021-02-24,247.91,253.22,246.1,252.9,
ISRG,2021-02-25,251.62,252.96,243.97,247.26,
ISRG,2021-02-26,247.97,249.23,242.1,245.6,
ISRG,2021-03-01,249.68,253.59,248.55,253.07,
ISRG,2021-03-02,253.33,253.33,248.93,250.0,
ISRG,2021-03-03,248.69,248.69,240.49,242.38,
ISRG,2021-03-04,241.67,242.41,233.01,236.39,
ISRG,2021-03-05,237.42,239.48,229.08,237.79,
ISRG,2021-03-08,235.12,236.86,227.47,228.3,
ISRG,2021-03-09,232.51,236.75,230.0,234.27,
ISRG,2021-03-10,240.33,242.54,237.61,239.94,
ISRG,2021-03-11,243.45,246.33,241.45,244.0,
ISRG,2021-03-12,240.37,245.47,240.0,244.66,
ISRG,2021-03-15,242.44,245.85,241.68,245.02,
ISRG,2021-03-16,246.8,247.17,240.5,242.21,
ISRG,2021-03-17,241.44,242.99,237.6,241.55,
ISRG,2021-03-18,238.57,239.86,231.69,233.11,
ISRG,2021-03-19,233.83,238.24,231.8,235.83,
ISRG,2021-03-22,235.91,240.38,234.38,238.24,
ISRG,2021-03-23,238.84,240.33,235.88,236.94,
ISRG,2021-03-24,237.33,240.11,235.16,237.02,
ISRG,2021-03-25,236.88,238.14,231.21,234.83,
ISRG,2021-03-26,235.69,243.95,234.92,243.58,
ISRG,2021-03-29,243.15,244.71,239.11,241.32,
ISRG,2021-03-30,239.7,243.0,238.17,242.16,
ISRG,2021-03-31,242.85,247.98,242.42,246.31,
ISRG,2021-04-01,250.0,252.69,248.63,249.2,
ISRG,2021-04-05,250.07,256.88,250.07,255.31,
ISRG,2021-04-06,255.71,258.76,253.6,255.62,
ISRG,2021-04-07,255.8,257.0,253.19,253.67,
ISRG,2021-04-08,255.32,258.03,255.32,256.78,
ISRG,2021-04-09,257.86,262.11,256.16,261.49,
ISRG,2021-04-12,259.38,261.89,259.1,259.75,
ISRG,2021-04-13,259.65,265.61,259.65,264.82,
ISRG,2021-04-14,264.0,266.75,261.6,261.94,
ISRG,2021-04-15,264.22,269.33,263.1,268.24,
ISRG,2021-04-16,269.22,271.13,267.28,270.86,
ISRG,2021-04-19,269.59,271.89,267.51,270.4,
ISRG,2021-04-20,268.89,274.84,268.88,270.37,
ISRG,2021-04-21,280.31,297.93,273.33,297.13,
ISRG,2021-04-22,294.96,295.96,286.19,286.55,
ISRG,2021-04-23,283.73,294.3,280.91,291.84,
ISRG,2021-04-26,288.81,290.69,286.72,288.65,
ISRG,2021-04-27,289.0,289.0,286.17,287.13,
ISRG,2021-04-28,287.52,291.94,286.99,289.6,
ISRG,2021-04-29,291.23,291.23,285.94,287.74,
ISRG,2021-04-30,285.66,288.64,285.09,288.33,
ISRG,2021-05-03,291.16,291.66,286.71,289.18,
ISRG,2021-05-04,287.24,287.36,278.04,283.0,
ISRG,2021-05-05,284.71,286.99,278.84,279.47,
ISRG,2021-05-06,278.09,280.9,275.22,280.82,
ISRG,2021-05-07,281.77,287.76,281.77,285.7,
ISRG,2021-05-10,286.34,287.33,277.69,278.26,
ISRG,2021-05-11,274.39,280.27,273.66,278.92,
ISRG,2021-05-12,274.68,275.16,268.09,270.6,
ISRG,2021-05-13,271.07,275.69,271.07,273.53,
ISRG,2021-05-14,274.32,279.81,273.84,277.79,
ISRG,2021-05-17,276.26,276.26,270.53,272.34,
ISRG,2021-05-18,273.89,274.67,271.19,271.54,
ISRG,2021-05-19,267.25,272.34,265.9,272.32,
ISRG,2021-05-20,273.89,278.97,273.25,277.55,
ISRG,2021-05-21,280.0,281.0,274.69,275.0,
ISRG,2021-05-24,277.68,280.12,277.42,278.31,
ISRG,2021-05-25,280.1,282.25,279.46,282.0,
ISRG,2021-05-26,282.37,283.23,278.4,279.79,
ISRG,2021-05-27,279.57,282.18,276.4,278.12,
ISRG,2021-05-28,279.66,284.77,279.66,280.73,
ISRG,2021-06-01,284.26,284.26,276.25,278.68,
ISRG,2021-06-02,278.74,279.3,272.98,273.85,
ISRG,2021-06-03,270.96,274.95,270.37,272.22,
ISRG,2021-06-04,273.85,278.6,273.71,277.15,
ISRG,2021-06-07,278.39,281.06,276.27,277.04,
ISRG,2021-06-08,278.45,280.38,275.4,277.89,
ISRG,2021-06-09,278.76,281.32,278.25,280.08,
ISRG,2021-06-10,281.02,286.54,280.38,286.38,
ISRG,2021-06-11,286.67,288.1,285.12,288.09,
ISRG,2021-06-14,287.43,291.14,286.55,290.93,
ISRG,2021-06-15,291.67,291.78,289.89,290.79,
ISRG,2021-06-16,291.45,293.87,288.33,290.47,
ISRG,2021-06-17,289.75,297.09,288.79,295.0,
ISRG,2021-06-18,293.51,295.33,291.87,292.95,
ISRG,2021-06-21,294.95,300.32,291.86,298.0,
ISRG,2021-06-22,298.42,301.0,295.69,300.65,
ISRG,2021-06-23,300.0,303.79,299.73,301.81,
ISRG,2021-06-24,304.43,304.57,300.12,301.52,
ISRG,2021-06-25,301.67,304.06,301.22,302.78,
ISRG,2021-06-28,303.26,304.85,301.5,304.14,
ISRG,2021-06-29,305.0,308.68,303.66,306.91,
ISRG,2021-06-30,306.68,308.33,304.01,306.55,
ISRG,2021-07-01,305.84,309.33,305.5,309.15,
ISRG,2021-07-02,310.29,313.16,309.77,312.72,
ISRG,2021-07-06,314.18,316.43,309.16,316.01,
ISRG,2021-07-07,318.0,320.29,316.23,318.23,
ISRG,2021-07-08,313.75,317.94,312.11,317.29,
ISRG,2021-07-09,317.29,318.4,312.72,316.93,
ISRG,2021-07-12,317.45,320.22,315.51,319.68,
ISRG,2021-07-13,320.77,321.68,318.28,318.75,
ISRG,2021-07-14,321.52,321.65,317.39,318.36,
ISRG,2021-07-15,317.69,319.64,315.85,317.89,
ISRG,2021-07-16,318.55,319.64,316.45,316.7,
ISRG,2021-07-19,314.67,314.67,308.83,310.73,
ISRG,2021-07-20,311.65,321.99,309.64,318.35,
ISRG,2021-07-21,328.33,329.09,308.84,314.98,
ISRG,2021-07-22,317.07,325.31,315.44,324.63,
ISRG,2021-07-23,323.88,326.13,320.84,325.49,
ISRG,2021-07-26,323.28,324.67,318.08,322.03,
ISRG,2021-07-27,322.54,325.03,320.07,325.03,
ISRG,2021-07-28,325.03,326.67,322.98,324.17,
ISRG,2021-07-29,324.33,327.71,323.47,327.16,
ISRG,2021-07-30,326.37,331.7,325.71,330.49,
ISRG,2021-08-02,332.0,332.89,328.68,330.85,
ISRG,2021-08-03,331.68,333.67,329.68,333.2,
ISRG,2021-08-04,333.33,334.0,329.91,330.29,
ISRG,2021-08-05,337.33,341.33,332.89,339.7,
ISRG,2021-08-06,340.0,343.49,335.75,343.34,
ISRG,2021-08-09,344.36,345.35,341.93,344.0,
ISRG,2021-08-10,344.63,345.03,331.47,331.87,
ISRG,2021-08-11,333.17,335.67,328.89,331.88,
ISRG,2021-08-12,332.92,337.04,332.16,333.33,
ISRG,2021-08-13,333.9,335.17,332.13,334.35,
ISRG,2021-08-16,334.74,339.69,333.16,339.41,
ISRG,2021-08-17,338.64,346.67,337.2,345.0,
ISRG,2021-08-18,344.48,349.67,344.34,346.46,
ISRG,2021-08-19,345.94,352.98,344.24,351.88,
ISRG,2021-08-20,352.12,353.94,346.97,347.94,
ISRG,2021-08-23,350.57,353.27,344.78,348.67,
ISRG,2021-08-24,350.0,352.97,346.58,348.9,
ISRG,2021-08-25,348.9,350.0,346.35,347.99,
ISRG,2021-08-26,349.37,350.02,345.3,347.42,
ISRG,2021-08-27,348.51,350.05,344.67,345.51,
ISRG,2021-08-30,347.06,353.32,347.06,352.97,
ISRG,2021-08-31,353.04,353.92,347.92,351.19,
ISRG,2021-09-01,351.67,354.79,349.18,354.24,
ISRG,2021-09-02,355.6,359.03,355.16,357.18,
ISRG,2021-09-03,357.1,358.76,352.68,357.26,
ISRG,2021-09-07,357.75,359.52,354.33,359.39,
ISRG,2021-09-08,359.33,362.34,357.47,360.85,
ISRG,2021-09-09,361.05,361.95,356.55,356.67,
ISRG,2021-09-10,359.55,360.68,337.67,341.16,
ISRG,2021-09-13,343.81,344.19,337.0,342.61,
ISRG,2021-09-14,344.52,348.96,342.66,346.34,
ISRG,2021-09-15,346.67,348.99,343.71,348.51,
ISRG,2021-09-16,348.53,349.14,342.92,344.67,
ISRG,2021-09-17,345.1,346.82,342.68,345.76,
ISRG,2021-09-20,341.47,343.96,333.35,338.0,
ISRG,2021-09-21,340.29,343.21,337.67,338.01,
ISRG,2021-09-22,340.0,345.77,338.33,342.82,
ISRG,2021-09-23,343.75,350.63,343.51,348.28,
ISRG,2021-09-24,346.86,348.66,343.49,347.78,
ISRG,2021-09-27,346.63,346.66,334.33,337.92,
ISRG,2021-09-28,335.18,335.58,326.18,330.83,
ISRG,2021-09-29,331.97,334.68,329.67,330.78,
ISRG,2021-09-30,332.49,336.77,331.11,331.38,
ISRG,2021-10-01,331.33,340.52,325.33,336.5,
ISRG,2021-10-04,333.35,333.72,321.05,323.5,
ISRG,2021-10-05,325.93,335.08,323.6,330.07,
ISRG,2021-10-06,329.54,335.38,327.5,334.94,
ISRG,2021-10-07,341.36,346.84,337.85,338.34,
ISRG,2021-10-08,339.69,342.1,328.01,328.54,
ISRG,2021-10-11,326.5,329.21,323.84,324.18,
ISRG,2021-10-12,328.0,329.1,321.88,324.45,
ISRG,2021-10-13,325.67,328.72,325.14,326.0,
ISRG,2021-10-14,328.39,332.78,328.32,330.95,
ISRG,2021-10-15,332.2,333.45,330.0,331.5,
ISRG,2021-10-18,330.33,332.38,323.045,332.3,
ISRG,2021-10-19,338.11,345.16,332.17,336.3,
ISRG,2021-10-20,338.0,341.9,327.387,339.8,
ISRG,2021-10-21,342.22,343.26,337.44,339.63,
ISRG,2021-10-22,339.75,342.82,337.64,341.52,
ISRG,2021-10-25,340.19,347.09,336.76,343.59,
ISRG,2021-10-26,346.71,351.19,343.59,348.7,
ISRG,2021-10-27,348.69,350.63,340.85,348.98,
ISRG,2021-10-28,349.24,356.63,349.24,355.61,
ISRG,2021-10-29,353.85,362.67,352.92,361.13,
ISRG,2021-11-01,361.69,365.52,354.53,355.03,
ISRG,2021-11-02,356.58,361.5,354.55,360.37,
ISRG,2021-11-03,360.29,362.92,353.96,361.49,
ISRG,2021-11-04,361.49,364.4,359.01,363.32,
ISRG,2021-11-05,363.42,369.69,359.49,364.95,
ISRG,2021-11-08,366.02,368.14,361.97,365.42,
ISRG,2021-11-09,365.0,366.79,362.57,364.15,
ISRG,2021-11-10,363.0,367.48,357.89,359.49,
ISRG,2021-11-11,360.0,360.26,348.65,350.79,
ISRG,2021-11-12,353.68,356.665,350.47,354.93,
ISRG,2021-11-15,355.51,357.189,351.73,353.56,
ISRG,2021-11-16,351.86,362.82,351.86,361.12,
ISRG,2021-11-17,361.12,364.22,358.0,361.42,
ISRG,2021-11-18,361.46,362.66,356.42,359.2,
ISRG,2021-11-19,359.2,359.96,346.0,348.65,
ISRG,2021-11-22,348.0,349.0,340.43,340.72,
ISRG,2021-11-23,341.0,341.69,332.81,335.9,
ISRG,2021-11-24,335.45,340.5,331.79,339.42,
ISRG,2021-11-26,330.67,334.95,328.04,329.23,
ISRG,2021-11-29,332.814,339.67,328.2,334.74,
ISRG,2021-11-30,335.22,336.22,321.5,324.34,
ISRG,2021-12-01,328.61,330.13,319.65,319.93,
ISRG,2021-12-02,319.93,329.52,318.44,327.32,
ISRG,2021-12-03,329.2,329.99,313.69,321.63,
ISRG,2021-12-06,321.24,325.53,314.0,323.77,
ISRG,2021-12-07,329.91,342.62,329.495,340.49,
ISRG,2021-12-08,340.85,341.99,337.125,340.8,
ISRG,2021-12-09,339.73,345.98,338.774,340.34,
ISRG,2021-12-10,343.16,346.08,341.47,344.96,
ISRG,2021-12-13,344.74,345.77,339.63,340.36,
ISRG,2021-12-14,336.51,336.51,325.6,328.24,
ISRG,2021-12-15,330.35,334.9,323.79,331.66,
ISRG,2021-12-16,338.01,341.72,333.13,334.53,
ISRG,2021-12-17,332.4,343.1,332.4,337.4,
ISRG,2021-12-20,330.38,334.2,326.06,332.11,
ISRG,2021-12-21,333.45,348.77,332.64,348.09,
ISRG,2021-12-22,346.96,362.54,346.83,362.21,
ISRG,2021-12-23,360.65,365.67,357.33,363.94,
ISRG,2021-12-27,363.46,366.53,361.61,364.58,
ISRG,2021-12-28,364.58,366.72,362.026,364.54,
ISRG,2021-12-29,365.36,369.21,364.02,365.27,
ISRG,2021-12-30,366.09,367.65,362.81,363.3,
ISRG,2021-12-31,363.02,366.15,358.79,359.3,
ISRG,2022-01-03,358.65,360.51,353.13,360.0,
ISRG,2022-01-04,360.0,362.0,352.57,354.63,
ISRG,2022-01-05,352.49,355.7,341.65,341.95,
ISRG,2022-01-06,339.88,341.71,333.38,334.18,
ISRG,2022-01-07,330.94,333.07,323.23,324.29,
ISRG,2022-01-10,321.18,325.81,315.25,325.53,
ISRG,2022-01-11,325.77,328.16,318.739,328.02,
ISRG,2022-01-12,324.81,327.14,319.56,323.16,
ISRG,2022-01-13,324.98,325.01,312.39,313.21,
ISRG,2022-01-14,310.39,311.505,303.89,307.74,
ISRG,2022-01-18,301.37,301.48,294.67,295.49,
ISRG,2022-01-19,296.065,299.625,293.0,293.46,
ISRG,2022-01-20,296.0,304.43,291.82,292.73,
ISRG,2022-01-21,275.04,281.58,267.3,269.53,
ISRG,2022-01-24,264.62,272.78,254.2,271.98,
ISRG,2022-01-25,261.64,268.4,260.3,264.14,
ISRG,2022-01-26,269.0,275.01,261.195,264.46,
ISRG,2022-01-27,267.59,270.83,261.02,262.77,
ISRG,2022-01-28,264.42,272.04,258.12,271.79,
ISRG,2022-01-31,276.23,285.23,273.81,284.18,
ISRG,2022-02-01,285.18,289.7,281.61,286.51,
ISRG,2022-02-02,292.08,295.26,289.065,292.94,
ISRG,2022-02-03,286.84,291.96,284.91,285.6,
ISRG,2022-02-04,282.85,288.29,280.46,285.73,
ISRG,2022-02-07,284.41,290.9,283.56,284.89,
ISRG,2022-02-08,283.65,285.353,277.81,283.39,
ISRG,2022-02-09,287.11,292.94,287.11,292.18,
ISRG,2022-02-10,287.69,294.98,286.74,292.49,
ISRG,2022-02-11,291.53,294.48,282.2,283.16,
ISRG,2022-02-14,283.24,286.17,279.03,281.14,
ISRG,2022-02-15,285.0,290.612,284.8,289.31,
ISRG,2022-02-16,289.0,292.36,282.72,291.14,
ISRG,2022-02-17,289.47,290.0,283.5,284.08,
ISRG,2022-02-18,283.37,286.6,280.235,280.78,
ISRG,2022-02-22,278.12,287.316,277.345,284.0,
ISRG,2022-02-23,284.95,286.45,275.56,276.5,
ISRG,2022-02-24,266.22,289.29,266.02,288.38,
ISRG,2022-02-25,289.08,293.62,284.65,293.51,
ISRG,2022-02-28,290.21,293.33,286.47,290.33,
ISRG,2022-03-01,289.96,293.79,287.01,291.55,
ISRG,2022-03-02,294.15,300.72,291.81,299.01,
ISRG,2022-03-03,301.22,304.276,298.41,299.82,
ISRG,2022-03-04,296.71,303.0,294.72,302.28,
ISRG,2022-03-07,300.5,304.68,291.61,292.69,
ISRG,2022-03-08,286.66,288.98,268.92,269.32,
ISRG,2022-03-09,277.45,279.8,272.74,278.82,
ISRG,2022-03-10,272.89,276.72,271.0,275.72,
ISRG,2022-03-11,278.25,281.75,273.46,273.69,
ISRG,2022-03-14,272.34,277.81,262.53,263.8,
ISRG,2022-03-15,267.65,270.84,265.0,270.0,
ISRG,2022-03-16,273.55,279.77,268.71,277.85,
ISRG,2022-03-17,277.74,283.5,276.53,282.95,
ISRG,2022-03-18,283.31,291.2,278.56,290.11,
ISRG,2022-03-21,287.66,290.09,279.51,283.28,
ISRG,2022-03-22,283.11,287.91,281.74,286.44,
ISRG,2022-03-23,284.52,284.52,274.52,275.2,
ISRG,2022-03-24,276.82,281.19,273.65,281.08,
ISRG,2022-03-25,285.09,286.94,282.28,286.87,
ISRG,2022-03-28,286.04,295.458,285.32,294.95,
ISRG,2022-03-29,298.35,302.505,298.35,302.0,
ISRG,2022-03-30,301.68,306.59,299.52,304.44,
ISRG,2022-03-31,305.08,307.85,301.59,301.68,
ISRG,2022-04-01,303.995,306.07,301.2,305.54,
ISRG,2022-04-04,306.5,308.97,301.09,302.25,
ISRG,2022-04-05,301.99,303.8,293.34,295.92,
ISRG,2022-04-06,290.95,291.77,283.25,288.67,
ISRG,2022-04-07,286.38,293.56,286.12,291.82,
ISRG,2022-04-08,290.04,293.0,287.08,289.86,
ISRG,2022-04-11,286.28,286.68,278.47,278.96,
ISRG,2022-04-12,281.06,286.4,276.19,277.85,
ISRG,2022-04-13,279.17,286.25,278.6,285.22,
ISRG,2022-04-14,286.1,287.15,278.95,279.7,
ISRG,2022-04-18,278.99,280.28,273.41,276.35,
ISRG,2022-04-19,278.5,295.69,278.04,294.86,
ISRG,2022-04-20,297.08,307.37,294.93,302.9,
ISRG,2022-04-21,303.32,308.0,293.81,294.57,
ISRG,2022-04-22,275.0,276.32,251.52,252.34,
ISRG,2022-04-25,250.29,259.72,250.29,255.12,
ISRG,2022-04-26,253.04,255.64,244.44,244.52,
ISRG,2022-04-27,244.44,247.93,235.07,235.35,
ISRG,2022-04-28,236.29,244.59,235.95,243.26,
ISRG,2022-04-29,241.45,246.3,238.5,239.3,
ISRG,2022-05-02,239.99,242.235,234.15,240.66,
ISRG,2022-05-03,239.5,242.0,236.14,238.11,
ISRG,2022-05-04,236.99,246.99,233.82,246.31,
ISRG,2022-05-05,242.93,244.67,231.13,233.98,
ISRG,2022-05-06,232.07,232.27,221.07,224.85,
ISRG,2022-05-09,221.55,221.55,207.18,208.71,
ISRG,2022-05-10,214.7,217.31,206.6,211.39,
ISRG,2022-05-11,210.74,217.89,208.48,210.87,
ISRG,2022-05-12,208.08,214.06,207.24,211.69,
ISRG,2022-05-13,215.0,224.68,215.0,223.69,
ISRG,2022-05-16,221.12,223.3,217.57,219.53,
ISRG,2022-05-17,223.52,226.29,220.61,225.18,
ISRG,2022-05-18,221.21,223.4,214.31,215.35,
ISRG,2022-05-19,215.06,221.17,213.96,218.14,
ISRG,2022-05-20,222.31,223.27,212.905,219.07,
ISRG,2022-05-23,222.28,222.99,216.9,221.61,
ISRG,2022-05-24,219.21,219.69,214.88,218.39,
ISRG,2022-05-25,216.18,224.26,216.17,222.58,
ISRG,2022-05-26,223.41,226.06,221.135,223.3,
ISRG,2022-05-27,226.5,229.89,224.44,229.16,
ISRG,2022-05-31,228.4,230.0,224.795,227.64,
ISRG,2022-06-01,227.74,230.0,212.2,216.39,
ISRG,2022-06-02,216.4,227.34,214.07,227.21,
ISRG,2022-06-03,224.04,224.505,216.97,217.79,
ISRG,2022-06-06,221.45,222.84,215.484,216.43,
ISRG,2022-06-07,215.29,222.57,214.58,221.95,
ISRG,2022-06-08,221.04,222.82,218.15,218.6,
ISRG,2022-06-09,216.35,216.965,209.91,209.95,
ISRG,2022-06-10,206.8,208.0,203.66,205.27,
ISRG,2022-06-13,199.0,200.24,193.76,194.97,
ISRG,2022-06-14,194.63,195.33,188.81,191.1,
ISRG,2022-06-15,194.0,200.15,192.36,196.13,
ISRG,2022-06-16,191.87,193.05,186.83,190.71,
ISRG,2022-06-17,191.8,195.5,189.9,192.08,
ISRG,2022-06-21,195.635,197.65,193.93,194.32,
ISRG,2022-06-22,192.91,203.7,191.9,200.62,
ISRG,2022-06-23,202.9,206.93,201.81,204.5,
ISRG,2022-06-24,207.61,209.845,203.82,209.67,
ISRG,2022-06-27,208.8,209.88,205.88,207.94,
ISRG,2022-06-28,209.02,211.47,201.17,201.99,
ISRG,2022-06-29,201.85,203.85,197.85,202.59,
ISRG,2022-06-30,201.46,203.38,197.61,200.71,
ISRG,2022-07-01,201.07,206.33,200.0,206.1,
ISRG,2022-07-05,203.06,207.32,200.12,206.75,
ISRG,2022-07-06,207.78,209.48,204.33,205.35,
ISRG,2022-07-07,204.79,209.37,204.25,208.71,
ISRG,2022-07-08,206.05,211.22,205.73,208.81,
ISRG,2022-07-11,207.48,208.14,202.49,205.72,
ISRG,2022-07-12,206.59,209.135,201.07,202.13,
ISRG,2022-07-13,198.3,204.286,196.1,202.06,
ISRG,2022-07-14,200.41,204.51,197.3,204.31,
ISRG,2022-07-15,207.88,211.17,207.365,210.92,
ISRG,2022-07-18,211.43,213.66,205.32,206.26,
ISRG,2022-07-19,210.45,214.615,208.81,214.44,
ISRG,2022-07-20,215.0,221.085,214.17,219.22,
ISRG,2022-07-21,220.91,225.44,219.58,224.75,
ISRG,2022-07-22,207.44,217.49,203.31,211.85,
ISRG,2022-07-25,213.21,221.8,212.27,219.17,
ISRG,2022-07-26,218.11,219.92,214.08,216.79,
ISRG,2022-07-27,219.45,226.57,219.45,225.34,
ISRG,2022-07-28,224.99,231.26,221.21,230.54,
ISRG,2022-07-29,228.65,230.95,227.01,230.17,
ISRG,2022-08-01,227.31,231.495,226.57,228.54,
ISRG,2022-08-02,234.425,244.99,233.53,238.48,
ISRG,2022-08-03,239.04,243.31,236.44,242.18,
ISRG,2022-08-04,242.07,242.92,239.61,242.46,
ISRG,2022-08-05,237.68,241.68,236.55,240.32,
ISRG,2022-08-08,241.0,245.36,238.64,239.13,
ISRG,2022-08-09,238.16,238.68,232.435,232.88,
ISRG,2022-08-10,239.76,240.79,236.63,237.85,
ISRG,2022-08-11,238.38,242.56,235.23,236.02,
ISRG,2022-08-12,236.75,238.57,234.73,238.37,
ISRG,2022-08-15,237.03,239.64,235.81,238.26,
ISRG,2022-08-16,235.9,236.95,231.51,233.71,
ISRG,2022-08-17,230.71,232.47,228.35,229.71,
ISRG,2022-08-18,230.79,231.34,226.82,229.59,
ISRG,2022-08-19,227.36,227.95,223.555,224.78,
ISRG,2022-08-22,221.13,222.51,217.01,218.54,
ISRG,2022-08-23,216.99,218.515,214.86,216.81,
ISRG,2022-08-24,218.19,222.6,217.94,220.47,
ISRG,2022-08-25,222.84,225.12,220.9,225.02,
ISRG,2022-08-26,224.57,225.38,210.94,211.09,
ISRG,2022-08-29,209.27,211.68,207.84,208.9,
ISRG,2022-08-30,210.12,211.75,205.38,206.5,
ISRG,2022-08-31,208.51,210.48,205.188,205.74,
ISRG,2022-09-01,203.85,206.44,200.187,206.11,
ISRG,2022-09-02,207.72,209.37,202.04,203.67,
ISRG,2022-09-06,204.34,205.38,201.15,202.3,
ISRG,2022-09-07,203.36,211.37,202.44,210.87,
ISRG,2022-09-08,207.755,217.39,207.755,214.78,
ISRG,2022-09-09,215.86,221.89,215.45,221.32,
ISRG,2022-09-12,220.76,223.41,219.41,222.02,
ISRG,2022-09-13,214.62,216.725,210.88,211.4,
ISRG,2022-09-14,210.78,212.98,208.555,210.78,
ISRG,2022-09-15,211.0,215.49,209.17,209.62,
ISRG,2022-09-16,206.75,207.43,203.455,206.28,
ISRG,2022-09-19,203.87,204.32,199.48,202.21,
ISRG,2022-09-20,201.13,201.17,196.71,199.55,
ISRG,2022-09-21,200.39,203.52,195.0,195.04,
ISRG,2022-09-22,193.45,194.45,189.08,191.08,
ISRG,2022-09-23,190.2,191.14,186.95,190.52,
ISRG,2022-09-26,189.95,192.46,187.02,187.93,
ISRG,2022-09-27,190.56,191.5,184.935,186.38,
ISRG,2022-09-28,188.35,193.63,186.265,192.4,
ISRG,2022-09-29,189.6,191.247,187.09,189.06,
ISRG,2022-09-30,190.12,194.46,187.06,187.44,
ISRG,2022-10-03,189.4,195.17,187.97,193.36,
ISRG,2022-10-04,197.87,202.8,197.635,201.54,
ISRG,2022-10-05,198.27,202.58,196.36,201.38,
ISRG,2022-10-06,200.09,202.68,197.23,197.7,
ISRG,2022-10-07,194.65,195.6,187.62,188.68,
ISRG,2022-10-10,187.94,188.65,184.32,186.55,
ISRG,2022-10-11,186.22,189.67,183.53,185.9,
ISRG,2022-10-12,186.56,186.973,183.57,186.34,
ISRG,2022-10-13,181.11,192.44,180.07,190.38,
ISRG,2022-10-14,193.29,194.5,182.56,183.06,
ISRG,2022-10-17,186.26,190.745,185.82,190.12,
ISRG,2022-10-18,195.94,199.77,192.395,193.73,
ISRG,2022-10-19,217.94,220.98,210.36,211.14,
ISRG,2022-10-20,211.41,221.0,211.12,212.0,
ISRG,2022-10-21,210.5,219.04,206.77,218.49,
ISRG,2022-10-24,218.84,221.56,217.64,220.27,
ISRG,2022-10-25,231.03,238.07,226.11,237.87,
ISRG,2022-10-26,237.75,249.14,235.94,241.66,
ISRG,2022-10-27,242.44,244.1,238.32,241.69,
ISRG,2022-10-28,240.94,248.11,240.395,244.16,
ISRG,2022-10-31,243.0,248.41,242.79,246.47,
ISRG,2022-11-01,248.07,251.29,245.185,246.86,
ISRG,2022-11-02,245.43,247.97,236.0,236.13,
ISRG,2022-11-03,233.01,236.16,231.07,234.19,
ISRG,2022-11-04,237.92,240.77,233.7,239.53,
ISRG,2022-11-07,241.72,244.2,239.8,242.33,
ISRG,2022-11-08,242.18,245.745,237.56,240.7,
ISRG,2022-11-09,238.76,241.13,235.58,236.13,
ISRG,2022-11-10,248.66,258.73,247.03,257.86,
ISRG,2022-11-11,255.74,267.67,255.74,265.08,
ISRG,2022-11-14,262.19,263.09,257.84,259.44,
ISRG,2022-11-15,262.96,266.14,261.09,264.18,
ISRG,2022-11-16,264.84,265.38,260.99,263.04,
ISRG,2022-11-17,258.46,262.0,255.4,260.77,
ISRG,2022-11-18,264.44,266.6,260.05,262.11,
ISRG,2022-11-21,260.96,264.81,259.64,260.35,
ISRG,2022-11-22,258.99,263.75,258.48,262.9,
ISRG,2022-11-23,264.49,267.11,262.825,264.45,
ISRG,2022-11-25,263.69,265.35,261.41,265.13,
ISRG,2022-11-28,264.54,266.5,261.82,262.64,
ISRG,2022-11-29,262.04,262.99,257.2,258.8,
ISRG,2022-11-30,260.48,270.48,260.48,270.39,
ISRG,2022-12-01,270.39,275.835,269.9,274.49,
ISRG,2022-12-02,268.15,272.96,267.427,272.25,
ISRG,2022-12-05,269.14,271.25,267.22,269.72,
ISRG,2022-12-06,269.0,269.42,264.505,266.31,
ISRG,2022-12-07,266.19,268.6,265.14,267.96,
ISRG,2022-12-08,270.71,274.2,268.63,272.02,
ISRG,2022-12-09,270.49,273.79,269.94,270.6,
ISRG,2022-12-12,272.22,274.06,270.0,273.84,
ISRG,2022-12-13,284.92,285.055,276.88,281.74,
ISRG,2022-12-14,280.75,285.09,277.39,280.65,
ISRG,2022-12-15,275.08,275.28,266.34,267.3,
ISRG,2022-12-16,264.71,265.78,261.06,264.68,
ISRG,2022-12-19,264.99,264.99,260.39,261.01,
ISRG,2022-12-20,261.1,262.11,257.76,261.8,
ISRG,2022-12-21,263.69,267.27,262.535,266.16,
ISRG,2022-12-22,263.48,264.29,259.0,263.61,
ISRG,2022-12-23,261.92,263.99,260.51,262.66,
ISRG,2022-12-27,262.76,265.495,260.59,263.97,
ISRG,2022-12-28,262.94,267.51,261.54,261.65,
ISRG,2022-12-29,263.24,269.828,261.85,267.79,
ISRG,2022-12-30,265.31,265.47,261.43,265.35,
ISRG,2023-01-03,269.59,270.89,263.67,265.63,
ISRG,2023-01-04,269.36,271.01,266.84,270.0,
ISRG,2023-01-05,267.69,271.87,266.51,268.62,
ISRG,2023-01-06,271.17,273.4,264.68,270.39,
ISRG,2023-01-09,272.59,273.58,264.21,264.93,
ISRG,2023-01-10,263.33,271.41,263.33,271.36,
ISRG,2023-01-11,261.39,265.49,254.56,259.96,
ISRG,2023-01-12,258.74,260.35,254.98,256.94,
ISRG,2023-01-13,255.4,259.8,253.77,258.9,
ISRG,2023-01-17,258.48,261.97,254.86,261.73,
ISRG,2023-01-18,261.57,264.89,255.61,256.35,
ISRG,2023-01-19,254.84,255.675,250.62,252.5,
ISRG,2023-01-20,252.44,256.84,248.96,256.77,
ISRG,2023-01-23,256.77,257.87,254.01,255.98,
ISRG,2023-01-24,254.6,259.405,254.23,257.98,
ISRG,2023-01-25,241.09,247.0,238.84,243.8,
ISRG,2023-01-26,246.48,250.82,243.5,250.55,
ISRG,2023-01-27,248.58,250.21,246.89,247.26,
ISRG,2023-01-30,245.0,246.809,241.98,242.23,
ISRG,2023-01-31,243.2,245.73,241.19,245.69,
ISRG,2023-02-01,246.8,253.54,244.66,251.19,
ISRG,2023-02-02,253.85,261.95,252.88,260.9,
ISRG,2023-02-03,257.81,260.5,252.93,254.68,
ISRG,2023-02-06,251.76,252.97,248.24,248.98,
ISRG,2023-02-07,247.81,254.55,246.895,253.06,
ISRG,2023-02-08,249.15,253.23,248.2,248.85,
ISRG,2023-02-09,250.52,251.07,243.65,244.18,
ISRG,2023-02-10,242.91,246.53,242.6,245.27,
ISRG,2023-02-13,246.09,246.54,244.74,245.13,
ISRG,2023-02-14,243.42,245.66,239.67,241.09,
ISRG,2023-02-15,239.75,245.5,239.1,244.77,
ISRG,2023-02-16,240.77,244.06,238.54,240.16,
ISRG,2023-02-17,238.95,240.015,236.61,238.91,
ISRG,2023-02-21,236.55,236.98,232.87,233.58,
ISRG,2023-02-22,233.88,236.49,232.96,233.55,
ISRG,2023-02-23,234.85,235.82,231.93,234.9,
ISRG,2023-02-24,230.61,232.39,229.04,231.05,
ISRG,2023-02-27,233.96,233.96,231.0,231.74,
ISRG,2023-02-28,230.74,231.739,228.74,229.39,
ISRG,2023-03-01,228.47,229.29,226.28,227.33,
ISRG,2023-03-02,226.07,229.41,224.48,228.9,
ISRG,2023-03-03,230.48,235.2,229.29,234.87,
ISRG,2023-03-06,233.59,236.779,233.04,234.85,
ISRG,2023-03-07,235.42,236.14,229.42,230.71,
ISRG,2023-03-08,230.0,231.708,227.96,231.09,
ISRG,2023-03-09,232.73,235.26,228.18,228.57,
ISRG,2023-03-10,228.77,229.76,223.39,224.75,
ISRG,2023-03-13,224.0,232.45,222.65,227.78,
ISRG,2023-03-14,232.54,235.62,231.17,235.28,
ISRG,2023-03-15,232.01,235.81,229.72,234.18,
ISRG,2023-03-16,232.59,242.37,231.5,240.5,
ISRG,2023-03-17,240.39,242.0,236.26,237.8,
ISRG,2023-03-20,238.12,242.03,237.58,240.5,
ISRG,2023-03-21,242.45,247.37,242.115,246.68,
ISRG,2023-03-22,245.44,248.28,240.54,240.81,
ISRG,2023-03-23,244.12,247.31,242.29,244.47,
ISRG,2023-03-24,248.0,257.46,248.0,256.42,
ISRG,2023-03-27,257.51,259.025,251.888,252.57,
ISRG,2023-03-28,253.0,253.37,248.5,249.49,
ISRG,2023-03-29,250.0,251.545,246.63,250.76,
ISRG,2023-03-30,254.05,254.2,248.29,251.3,
ISRG,2023-03-31,253.22,256.74,252.07,255.47,
ISRG,2023-04-03,254.3,254.435,250.01,253.53,
ISRG,2023-04-04,253.58,256.23,253.11,254.71,
ISRG,2023-04-05,254.23,258.89,253.745,257.99,
ISRG,2023-04-06,258.33,259.33,255.24,256.9,
ISRG,2023-04-10,255.6,259.11,252.04,258.94,
ISRG,2023-04-11,259.6,263.62,259.165,262.77,
ISRG,2023-04-12,265.0,265.895,261.42,261.77,
ISRG,2023-04-13,264.0,266.7,262.87,266.56,
ISRG,2023-04-14,265.54,268.4,264.57,267.02,
ISRG,2023-04-17,266.99,268.94,265.83,268.89,
ISRG,2023-04-18,270.0,270.23,266.45,269.28,
ISRG,2023-04-19,292.0,304.84,292.0,298.57,
ISRG,2023-04-20,298.96,302.23,296.76,297.41,
ISRG,2023-04-21,297.87,300.88,296.5,300.22,
ISRG,2023-04-24,299.11,303.1,297.727,300.46,
ISRG,2023-04-25,299.83,301.57,292.91,294.97,
ISRG,2023-04-26,293.03,296.95,291.02,294.96,
ISRG,2023-04-27,295.41,296.31,290.67,295.92,
ISRG,2023-04-28,297.62,301.57,296.755,301.22,
ISRG,2023-05-01,301.0,308.46,300.26,303.02,
ISRG,2023-05-02,300.71,302.894,297.63,301.22,
ISRG,2023-05-03,302.99,307.76,302.24,305.06,
ISRG,2023-05-04,303.53,304.99,300.79,303.21,
ISRG,2023-05-05,303.33,305.48,301.26,304.88,
ISRG,2023-05-08,304.54,304.6,301.01,303.09,
ISRG,2023-05-09,303.08,303.08,300.33,301.55,
ISRG,2023-05-10,303.1,304.05,300.53,302.59,
ISRG,2023-05-11,302.0,304.19,300.41,303.47,
ISRG,2023-05-12,304.28,305.95,303.09,305.27,
ISRG,2023-05-15,305.01,308.28,304.852,308.05,
ISRG,2023-05-16,306.67,308.36,306.1,306.61,
ISRG,2023-05-17,307.51,308.78,303.96,308.22,
ISRG,2023-05-18,307.87,312.65,307.04,312.23,
ISRG,2023-05-19,313.0,315.195,311.42,313.61,
ISRG,2023-05-22,312.83,317.81,312.57,313.62,
ISRG,2023-05-23,311.23,311.918,297.83,301.44,
ISRG,2023-05-24,300.01,303.65,299.2,302.48,
ISRG,2023-05-25,299.95,305.24,297.38,303.77,
ISRG,2023-05-26,302.76,307.855,302.76,306.9,
ISRG,2023-05-30,308.88,313.13,305.97,307.07,
ISRG,2023-05-31,307.0,308.26,300.14,307.84,
ISRG,2023-06-01,308.0,311.33,305.58,310.54,
ISRG,2023-06-02,310.54,313.47,308.82,312.18,
ISRG,2023-06-05,311.851,318.62,310.87,317.49,
ISRG,2023-06-06,316.9,318.92,313.0,315.72,
ISRG,2023-06-07,314.67,314.815,306.79,307.24,
ISRG,2023-06-08,306.32,311.23,304.79,310.82,
ISRG,2023-06-09,310.82,313.5,308.61,312.76,
ISRG,2023-06-12,313.83,316.28,312.0,313.64,
ISRG,2023-06-13,313.47,316.98,312.69,315.45,
ISRG,2023-06-14,323.07,327.415,319.25,323.07,
ISRG,2023-06-15,322.24,330.53,320.45,328.27,
ISRG,2023-06-16,331.69,333.14,328.0,329.36,
ISRG,2023-06-20,328.0,329.682,324.065,327.83,
ISRG,2023-06-21,327.83,327.83,322.145,323.74,
ISRG,2023-06-22,323.69,328.28,322.28,327.615,
ISRG,2023-06-23,324.71,328.68,323.72,327.26,
ISRG,2023-06-26,326.04,328.432,323.233,325.16,
ISRG,2023-06-27,329.51,330.99,325.29,330.02,
ISRG,2023-06-28,330.0,334.51,329.48,332.98,
ISRG,2023-06-29,335.0,340.59,334.61,338.49,
ISRG,2023-06-30,341.33,344.08,340.57,341.94,
ISRG,2023-07-03,339.92,339.92,334.25,336.03,
ISRG,2023-07-05,334.16,336.275,331.44,333.89,
ISRG,2023-07-06,328.78,331.65,328.02,330.14,
ISRG,2023-07-07,329.99,332.97,327.62,331.29,
ISRG,2023-07-10,333.33,341.15,333.33,340.27,
ISRG,2023-07-11,340.92,342.76,336.64,339.11,
ISRG,2023-07-12,342.88,348.63,341.454,347.59,
ISRG,2023-07-13,348.32,349.58,345.95,346.97,
ISRG,2023-07-14,347.5,355.38,346.4,354.0,
ISRG,2023-07-17,354.0,355.54,348.6,353.84,
ISRG,2023-07-18,351.61,355.495,346.54,354.93,
ISRG,2023-07-19,357.64,358.07,348.0,349.7,
ISRG,2023-07-20,350.05,353.46,346.85,347.66,
ISRG,2023-07-21,335.91,345.4,329.53,336.66,
ISRG,2023-07-24,336.76,337.85,322.64,323.56,
ISRG,2023-07-25,322.76,331.555,322.46,330.9,
ISRG,2023-07-26,328.27,331.02,326.56,329.37,
ISRG,2023-07-27,331.71,333.68,322.66,323.56,
ISRG,2023-07-28,327.4,328.7,324.93,326.53,
ISRG,2023-07-31,325.89,326.27,321.91,324.4,
ISRG,2023-08-01,322.0,324.52,321.7,323.95,
ISRG,2023-08-02,320.59,322.615,313.34,313.87,
ISRG,2023-08-03,310.38,313.285,306.09,311.28,
ISRG,2023-08-04,311.9,313.27,308.25,309.31,
ISRG,2023-08-07,310.0,312.86,307.66,309.24,
ISRG,2023-08-08,306.24,306.27,297.17,302.87,
ISRG,2023-08-09,302.87,307.4,302.47,304.1,
ISRG,2023-08-10,305.75,308.6,303.822,304.67,
ISRG,2023-08-11,302.93,306.091,302.52,304.49,
ISRG,2023-08-14,304.86,305.89,303.23,305.08,
ISRG,2023-08-15,306.09,312.3,305.93,306.62,
ISRG,2023-08-16,305.6,306.27,299.1,299.32,
ISRG,2023-08-17,298.06,299.57,289.11,290.08,
ISRG,2023-08-18,287.46,291.06,284.88,285.95,
ISRG,2023-08-21,286.12,286.88,282.5,286.67,
ISRG,2023-08-22,287.73,289.08,285.725,287.16,
ISRG,2023-08-23,287.56,292.7,287.56,290.39,
ISRG,2023-08-24,292.88,293.49,285.47,285.64,
ISRG,2023-08-25,287.28,298.36,286.74,297.55,
ISRG,2023-08-28,301.22,304.91,300.0,301.48,
ISRG,2023-08-29,301.5,311.08,301.5,310.39,
ISRG,2023-08-30,312.05,319.525,312.05,318.58,
ISRG,2023-08-31,319.6,321.31,312.46,312.68,
ISRG,2023-09-01,317.55,318.2,309.2,310.41,
ISRG,2023-09-05,310.0,311.38,306.68,307.68,
ISRG,2023-09-06,309.48,309.65,303.802,307.84,
ISRG,2023-09-07,305.53,305.97,295.01,297.22,
ISRG,2023-09-08,297.55,300.22,296.575,298.22,
ISRG,2023-09-11,300.0,304.185,298.697,302.35,
ISRG,2023-09-12,300.92,302.88,300.0,301.55,
ISRG,2023-09-13,301.05,304.95,300.14,302.7,
ISRG,2023-09-14,305.23,305.87,299.81,303.74,
ISRG,2023-09-15,303.74,304.04,294.845,295.54,
ISRG,2023-09-18,296.13,303.795,296.0,298.17,
ISRG,2023-09-19,298.17,300.48,295.25,299.65,
ISRG,2023-09-20,303.17,303.39,291.79,291.96,
ISRG,2023-09-21,290.06,290.66,283.74,284.35,
ISRG,2023-09-22,286.49,293.92,284.42,288.2,
ISRG,2023-09-25,286.4,293.39,285.74,293.25,
ISRG,2023-09-26,291.73,292.85,288.95,290.74,
ISRG,2023-09-27,292.0,297.455,288.55,291.43,
ISRG,2023-09-28,292.13,297.4,292.13,296.15,
ISRG,2023-09-29,297.87,298.35,291.7,292.29,
ISRG,2023-10-02,291.96,296.393,290.01,294.98,
ISRG,2023-10-03,291.54,292.83,286.47,288.04,
ISRG,2023-10-04,289.62,290.82,285.466,290.28,
ISRG,2023-10-05,291.85,292.45,284.795,290.09,
ISRG,2023-10-06,286.47,296.73,284.99,295.68,
ISRG,2023-10-09,293.13,295.13,289.603,294.49,
ISRG,2023-10-10,295.13,301.07,292.52,297.83,
ISRG,2023-10-11,298.66,298.72,278.205,281.79,
ISRG,2023-10-12,281.93,283.265,265.6,266.12,
ISRG,2023-10-13,266.83,273.72,265.5,273.15,
ISRG,2023-10-16,276.0,278.61,270.6,274.16,
ISRG,2023-10-17,272.41,279.62,268.43,275.37,
ISRG,2023-10-18,275.0,278.7,273.05,275.52,
ISRG,2023-10-19,277.1,278.13,271.71,273.45,
ISRG,2023-10-20,260.05,269.49,256.72,266.91,
ISRG,2023-10-23,268.5,278.18,267.05,272.59,
ISRG,2023-10-24,271.93,280.02,271.77,277.39,
ISRG,2023-10-25,280.13,281.88,266.13,266.61,
ISRG,2023-10-26,264.24,264.24,255.95,259.51,
ISRG,2023-10-27,263.82,264.77,257.01,258.98,
ISRG,2023-10-30,260.08,261.15,254.85,258.49,
ISRG,2023-10-31,260.39,263.95,260.17,262.22,
ISRG,2023-11-01,262.17,272.18,262.0,270.46,
ISRG,2023-11-02,274.57,278.15,272.63,277.89,
ISRG,2023-11-03,280.22,281.58,277.39,278.52,
ISRG,2023-11-06,278.13,279.52,273.7,277.26,
ISRG,2023-11-07,277.22,279.62,275.275,278.69,
ISRG,2023-11-08,280.5,282.448,276.8,277.93,
ISRG,2023-11-09,277.98,278.95,271.895,272.4,
ISRG,2023-11-10,273.41,278.55,269.49,277.49,
ISRG,2023-11-13,285.328,289.99,281.12,282.48,
ISRG,2023-11-14,288.37,294.135,287.98,291.62,
ISRG,2023-11-15,291.39,297.34,291.39,293.22,
ISRG,2023-11-16,296.79,305.3,295.02,303.95,
ISRG,2023-11-17,306.34,311.235,304.615,305.28,
ISRG,2023-11-20,305.44,312.2,305.0,311.34,
ISRG,2023-11-21,311.0,312.22,308.85,311.82,
ISRG,2023-11-22,315.0,317.39,313.92,315.8,
ISRG,2023-11-24,316.95,318.26,316.0,318.01,
ISRG,2023-11-27,314.68,316.0,312.02,314.98,
ISRG,2023-11-28,311.84,312.76,309.26,310.95,
ISRG,2023-11-29,312.0,316.305,309.965,310.76,
ISRG,2023-11-30,310.76,311.99,304.7,310.84,
ISRG,2023-12-01,310.59,315.64,308.73,315.2,
ISRG,2023-12-04,311.92,315.93,308.91,311.84,
ISRG,2023-12-05,312.0,312.0,304.5,309.52,
ISRG,2023-12-06,311.39,313.6,308.61,310.26,
ISRG,2023-12-07,310.97,312.745,307.72,311.56,
ISRG,2023-12-08,310.52,312.88,308.58,310.42,
ISRG,2023-12-11,310.0,319.8,309.8,315.43,
ISRG,2023-12-12,316.965,321.36,314.38,320.71,
ISRG,2023-12-13,320.68,329.45,320.22,328.96,
ISRG,2023-12-14,330.0,332.61,324.83,326.18,
ISRG,2023-12-15,325.83,327.0,322.59,324.35,
ISRG,2023-12-18,325.73,331.99,325.01,328.42,
ISRG,2023-12-19,328.42,336.58,328.0,335.72,
ISRG,2023-12-20,334.05,334.05,325.26,325.43,
ISRG,2023-12-21,328.97,333.98,327.53,333.45,
ISRG,2023-12-22,334.52,337.06,333.46,336.26,
ISRG,2023-12-26,336.92,338.345,335.21,337.39,
ISRG,2023-12-27,337.0,337.67,335.065,337.47,
ISRG,2023-12-28,337.01,340.49,336.34,338.39,
ISRG,2023-12-29,337.83,339.26,336.62,337.36,
ISRG,2024-01-02,333.0,336.2,328.38,330.98,
ISRG,2024-01-03,328.1,328.1,320.68,322.13,
ISRG,2024-01-04,320.43,326.407,320.26,323.27,
ISRG,2024-01-05,322.55,327.518,321.31,322.5,
ISRG,2024-01-08,324.5,329.53,324.12,328.86,
ISRG,2024-01-09,326.03,332.8,325.765,330.56,
ISRG,2024-01-10,348.0,364.87,345.53,364.45,
ISRG,2024-01-11,364.45,366.8,357.63,362.31,
ISRG,2024-01-12,365.0,366.86,360.96,363.71,
ISRG,2024-01-16,363.39,364.48,359.395,362.33,
ISRG,2024-01-17,358.4,361.23,355.17,358.88,
ISRG,2024-01-18,369.88,374.18,366.791,371.93,
ISRG,2024-01-19,374.0,376.9,370.655,374.82,
ISRG,2024-01-22,377.91,379.39,375.07,375.81,
ISRG,2024-01-23,377.25,377.802,367.5,371.41,
ISRG,2024-01-24,383.93,384.0,362.14,370.07,
ISRG,2024-01-25,372.61,377.325,370.6,374.97,
ISRG,2024-01-26,371.6,375.06,368.01,374.76,
ISRG,2024-01-29,374.41,379.34,373.06,379.16,
ISRG,2024-01-30,377.37,381.79,376.42,377.29,
ISRG,2024-01-31,378.5,383.74,375.595,378.22,
ISRG,2024-02-01,378.41,384.29,375.67,383.83,
ISRG,2024-02-02,382.33,385.43,377.9,383.77,
ISRG,2024-02-05,384.47,388.62,380.57,383.94,
ISRG,2024-02-06,385.26,389.79,384.12,389.69,
ISRG,2024-02-07,390.38,392.0,385.72,391.375,
ISRG,2024-02-08,389.51,391.6,385.36,386.94,
ISRG,2024-02-09,387.46,389.92,383.05,388.22,
ISRG,2024-02-12,386.09,387.36,381.07,382.13,
ISRG,2024-02-13,375.0,383.245,371.0,378.89,
ISRG,2024-02-14,380.09,381.91,378.0,381.76,
ISRG,2024-02-15,382.03,383.0,377.54,380.17,
ISRG,2024-02-16,378.29,381.15,376.0,378.63,
ISRG,2024-02-20,379.69,382.88,374.61,377.64,
ISRG,2024-02-21,376.75,380.47,373.15,380.23,
ISRG,2024-02-22,382.43,389.68,382.21,389.08,
ISRG,2024-02-23,389.08,391.25,387.28,389.77,
ISRG,2024-02-26,389.4,391.81,386.15,388.27,
ISRG,2024-02-27,386.46,389.47,385.275,386.46,
ISRG,2024-02-28,384.6,386.746,383.56,386.59,
ISRG,2024-02-29,384.41,389.26,383.93,385.6,
ISRG,2024-03-01,383.48,399.67,382.32,397.9,
ISRG,2024-03-04,398.3,403.0,396.51,400.59,
ISRG,2024-03-05,400.0,400.41,386.3,387.32,
ISRG,2024-03-06,386.76,393.136,386.76,388.16,
ISRG,2024-03-07,393.3,396.61,390.35,392.68,
ISRG,2024-03-08,392.02,395.93,390.79,391.85,
ISRG,2024-03-11,391.0,391.0,377.44,378.9,
ISRG,2024-03-12,378.9,390.255,378.52,389.4,
ISRG,2024-03-13,389.67,390.69,380.985,382.99,
ISRG,2024-03-14,383.23,384.43,376.6,384.31,
ISRG,2024-03-15,398.16,398.16,382.63,396.28,
ISRG,2024-03-18,399.6,401.27,390.79,392.62,
ISRG,2024-03-19,391.99,392.58,381.77,390.53,
ISRG,2024-03-20,390.39,390.67,384.4,390.37,
ISRG,2024-03-21,394.0,397.0,391.93,391.96,
ISRG,2024-03-22,392.45,394.51,387.17,394.07,
ISRG,2024-03-25,393.59,396.9,390.5,391.71,
ISRG,2024-03-26,394.37,399.562,392.285,397.63,
ISRG,2024-03-27,403.02,403.759,397.5,400.1,
ISRG,2024-03-28,401.45,402.5,397.06,399.09,
ISRG,2024-04-01,399.0,399.64,392.22,394.87,
ISRG,2024-04-02,391.99,391.99,380.51,382.36,
ISRG,2024-04-03,383.77,388.29,382.22,383.42,
ISRG,2024-04-04,387.76,389.025,378.62,378.92,
ISRG,2024-04-05,381.12,393.66,379.24,388.39,
ISRG,2024-04-08,388.39,389.885,383.04,386.93,
ISRG,2024-04-09,389.95,391.18,383.81,390.96,
ISRG,2024-04-10,387.16,391.46,385.51,388.46,
ISRG,2024-04-11,387.58,392.8,387.58,392.26,
ISRG,2024-04-12,387.0,388.26,380.71,384.8,
ISRG,2024-04-15,392.25,392.29,376.33,377.36,
ISRG,2024-04-16,376.63,383.85,371.54,378.55,
ISRG,2024-04-17,378.93,379.71,371.14,374.17,
ISRG,2024-04-18,372.57,375.335,369.15,372.63,
ISRG,2024-04-19,385.27,388.65,364.17,366.34,
ISRG,2024-04-22,369.54,371.83,364.31,368.93,
ISRG,2024-04-23,370.88,379.773,368.68,377.08,
ISRG,2024-04-24,374.0,383.62,372.83,375.01,
ISRG,2024-04-25,374.12,375.46,367.66,373.12,
ISRG,2024-04-26,368.1,377.83,368.1,375.33,
ISRG,2024-04-29,375.39,377.99,372.06,374.14,
ISRG,2024-04-30,373.18,373.68,368.75,370.62,
ISRG,2024-05-01,369.57,379.5,368.6,371.7,
ISRG,2024-05-02,373.64,377.88,367.385,377.65,
ISRG,2024-05-03,380.0,384.47,378.87,381.36,
ISRG,2024-05-06,382.63,384.35,380.6,383.05,
ISRG,2024-05-07,385.005,389.78,383.05,388.65,
ISRG,2024-05-08,384.93,386.01,380.125,380.37,
ISRG,2024-05-09,381.79,387.33,380.69,385.45,
ISRG,2024-05-10,385.55,389.76,383.88,386.7,
ISRG,2024-05-13,389.16,389.16,380.65,380.88,
ISRG,2024-05-14,382.4,384.805,379.67,384.19,
ISRG,2024-05-15,387.22,399.66,386.0,399.39,
ISRG,2024-05-16,398.28,401.36,396.02,396.43,
ISRG,2024-05-17,396.19,398.96,393.978,398.82,
ISRG,2024-05-20,398.58,400.41,395.6,400.03,
ISRG,2024-05-21,400.0,403.0,397.1,402.11,
ISRG,2024-05-22,402.56,408.43,399.17,400.9,
ISRG,2024-05-23,402.47,405.38,396.38,398.39,
ISRG,2024-05-24,397.61,407.33,397.01,404.85,
ISRG,2024-05-28,403.845,405.99,398.29,401.03,
ISRG,2024-05-29,396.59,403.0,396.151,398.4,
ISRG,2024-05-30,405.0,412.29,400.49,403.39,
ISRG,2024-05-31,404.94,408.9,396.48,402.12,
ISRG,2024-06-03,402.89,405.33,398.603,403.86,
ISRG,2024-06-04,402.55,408.01,397.47,406.61,
ISRG,2024-06-05,407.72,418.14,407.33,417.24,
ISRG,2024-06-06,413.92,419.17,405.08,418.15,
ISRG,2024-06-07,418.13,420.57,415.8,417.61,
ISRG,2024-06-10,416.6,419.87,413.522,418.38,
ISRG,2024-06-11,417.04,420.22,415.51,418.78,
ISRG,2024-06-12,421.06,428.86,420.86,428.38,
ISRG,2024-06-13,424.74,428.0,422.51,422.8,
ISRG,2024-06-14,418.8,426.315,413.98,425.78,
ISRG,2024-06-17,425.36,431.6,423.58,430.17,
ISRG,2024-06-18,429.05,436.94,428.75,435.0,
ISRG,2024-06-20,435.99,437.2,428.67,432.55,
ISRG,2024-06-21,436.08,436.08,430.0,432.56,
ISRG,2024-06-24,432.45,435.7,426.97,429.04,
ISRG,2024-06-25,431.12,443.81,430.49,442.31,
ISRG,2024-06-26,441.25,443.83,437.71,442.65,
ISRG,2024-06-27,442.1,445.79,439.61,445.11,
ISRG,2024-06-28,444.74,447.11,441.49,444.98,
ISRG,2024-07-01,445.85,448.1,433.79,436.24,
ISRG,2024-07-02,436.31,439.643,432.2,438.81,
ISRG,2024-07-03,439.0,439.0,432.91,434.81,
ISRG,2024-07-05,437.94,445.05,433.44,443.75,
ISRG,2024-07-08,442.04,445.96,441.56,444.53,
ISRG,2024-07-09,447.62,447.62,441.27,442.3,
ISRG,2024-07-10,441.69,445.43,438.85,444.74,
ISRG,2024-07-11,444.74,449.0,442.7,443.5,
ISRG,2024-07-12,442.84,447.14,439.61,444.16,
ISRG,2024-07-15,444.0,444.0,433.91,437.25,
ISRG,2024-07-16,440.06,442.092,433.22,438.01,
ISRG,2024-07-17,430.01,436.325,426.01,426.19,
ISRG,2024-07-18,425.0,427.33,413.82,416.14,
ISRG,2024-07-19,449.43,456.81,439.0,455.087,
ISRG,2024-07-22,462.33,468.78,459.18,461.12,
ISRG,2024-07-23,459.1,462.61,454.36,455.06,
ISRG,2024-07-24,455.25,460.59,452.25,454.08,
ISRG,2024-07-25,453.22,457.07,436.24,436.74,
ISRG,2024-07-26,438.6,446.16,432.87,441.3,
ISRG,2024-07-29,446.6,448.27,439.41,443.66,
ISRG,2024-07-30,443.66,447.66,431.56,432.69,
ISRG,2024-07-31,438.5,447.31,432.405,444.66,
ISRG,2024-08-01,443.3,452.72,443.3,451.27,
ISRG,2024-08-02,455.73,455.73,440.06,449.45,
ISRG,2024-08-05,437.36,444.575,430.0,438.01,
ISRG,2024-08-06,439.03,456.24,438.66,447.66,
ISRG,2024-08-07,452.0,461.71,448.59,449.33,
ISRG,2024-08-08,453.6,464.135,451.06,464.0,
ISRG,2024-08-09,462.59,465.7,460.12,463.425,
ISRG,2024-08-12,464.76,466.815,458.265,465.53,
ISRG,2024-08-13,468.23,470.49,463.01,469.23,
ISRG,2024-08-14,468.78,473.75,466.34,471.21,
ISRG,2024-08-15,476.87,480.54,474.16,480.31,
ISRG,2024-08-16,478.01,482.5,477.1,478.98,
ISRG,2024-08-19,475.44,482.78,475.44,482.16,
ISRG,2024-08-20,483.0,488.48,482.326,483.21,
ISRG,2024-08-21,484.2,488.47,482.0,487.42,
ISRG,2024-08-22,490.0,491.83,486.92,490.55,
ISRG,2024-08-23,492.98,493.97,478.18,486.55,
ISRG,2024-08-26,486.88,487.275,476.88,479.19,
ISRG,2024-08-27,478.44,483.57,477.01,482.35,
ISRG,2024-08-28,482.93,485.36,479.28,482.21,
ISRG,2024-08-29,482.21,491.66,481.25,487.17,
ISRG,2024-08-30,489.065,493.44,485.28,492.3,
ISRG,2024-09-03,491.67,493.42,480.8,483.57,
ISRG,2024-09-04,480.96,483.865,478.28,481.73,
ISRG,2024-09-05,480.32,480.32,468.458,476.67,
ISRG,2024-09-06,476.92,478.08,466.0,471.89,
ISRG,2024-09-09,475.0,479.99,473.98,479.44,
ISRG,2024-09-10,477.5,484.79,477.5,484.24,
ISRG,2024-09-11,484.18,491.83,477.08,490.93,
ISRG,2024-09-12,491.0,494.15,486.05,494.1,
ISRG,2024-09-13,490.28,496.18,489.19,489.86,
ISRG,2024-09-16,493.47,494.01,488.58,491.39,
ISRG,2024-09-17,491.27,491.27,482.375,483.32,
ISRG,2024-09-18,484.21,488.747,479.58,482.05,
ISRG,2024-09-19,492.0,492.74,486.98,490.01,
ISRG,2024-09-20,485.11,486.3,480.16,486.03,
ISRG,2024-09-23,488.5,491.832,486.27,489.07,
ISRG,2024-09-24,484.4,484.4,482.35,484.4,
ISRG,2024-09-25,486.0,487.117,482.29,484.39,
ISRG,2024-09-26,488.25,490.95,484.76,486.33,
ISRG,2024-09-27,490.03,490.03,478.57,479.18,
ISRG,2024-09-30,480.0,492.25,478.69,491.32,
ISRG,2024-10-01,492.5,496.48,481.71,484.76,
ISRG,2024-10-02,482.72,489.71,479.0,486.62,
ISRG,2024-10-03,484.42,486.0,478.559,479.5,
ISRG,2024-10-04,484.45,484.45,476.597,481.95,
ISRG,2024-10-07,476.86,479.305,470.14,471.23,
ISRG,2024-10-08,473.79,482.88,473.79,480.785,
ISRG,2024-10-09,480.595,490.58,478.49,490.38,
ISRG,2024-10-10,486.23,488.263,483.2,483.84,
ISRG,2024-10-11,486.0,487.58,483.12,484.78,
ISRG,2024-10-14,487.04,488.63,483.969,487.61,
ISRG,2024-10-15,488.34,489.625,476.675,478.36,
ISRG,2024-10-16,478.11,479.3,473.505,476.59,
ISRG,2024-10-17,481.06,481.06,472.12,473.73,
ISRG,2024-10-18,496.0,523.34,495.0,521.15,
ISRG,2024-10-21,519.04,522.665,514.55,518.86,
ISRG,2024-10-22,515.0,519.18,511.81,517.5,
ISRG,2024-10-23,513.89,516.0,507.28,512.58,
ISRG,2024-10-24,510.79,515.31,509.78,511.63,
ISRG,2024-10-25,514.0,516.893,510.46,511.27,
ISRG,2024-10-28,513.66,514.325,508.28,510.88,
ISRG,2024-10-29,506.52,517.5,504.35,516.31,
ISRG,2024-10-30,516.56,516.98,508.01,513.91,
ISRG,2024-10-31,510.01,511.06,500.67,503.84,
ISRG,2024-11-01,502.02,510.809,502.01,506.34,
ISRG,2024-11-04,504.32,511.205,503.85,507.55,
ISRG,2024-11-05,506.33,518.25,506.33,515.17,
ISRG,2024-11-06,523.13,525.0,506.8,515.42,
ISRG,2024-11-07,516.0,524.825,515.58,524.28,
ISRG,2024-11-08,527.0,538.49,524.0,536.45,
ISRG,2024-11-11,539.89,542.59,534.57,535.975,
ISRG,2024-11-12,534.0,538.905,531.69,537.07,
ISRG,2024-11-13,535.43,540.02,534.04,536.75,
ISRG,2024-11-14,537.36,544.38,537.17,537.8,
ISRG,2024-11-15,533.21,536.98,526.71,527.61,
ISRG,2024-11-18,527.36,537.53,526.607,531.64,
ISRG,2024-11-19,526.78,540.08,526.01,538.82,
ISRG,2024-11-20,538.78,542.37,533.83,541.82,
ISRG,2024-11-21,544.85,551.78,540.355,550.62,
ISRG,2024-11-22,550.42,552.0,541.99,547.87,
ISRG,2024-11-25,548.82,549.31,533.56,536.55,
ISRG,2024-11-26,542.06,545.0,537.28,542.1,
ISRG,2024-11-27,543.08,543.97,538.23,538.55,
ISRG,2024-11-29,539.0,543.17,536.03,542.0,
ISRG,2024-12-02,546.3,546.45,540.77,542.85,
ISRG,2024-12-03,538.455,541.99,533.01,541.71,
ISRG,2024-12-04,542.01,552.08,539.195,549.95,
ISRG,2024-12-05,547.24,551.81,544.43,547.65,
ISRG,2024-12-06,548.21,556.23,548.21,550.41,
ISRG,2024-12-09,552.31,553.561,532.14,538.86,
ISRG,2025-01-27,574.68,579.34,563.35,573.48,
ISRG,2025-01-28,566.6,584.48,563.85,574.14,
ISRG,2025-01-29,571.11,578.41,569.49,572.71,
ISRG,2025-01-30,581.24,584.423,577.35,580.18,
ISRG,2025-01-31,576.74,586.89,570.86,571.88,
ISRG,2025-02-03,564.87,583.576,563.268,578.55,
ISRG,2025-02-04,573.21,582.85,573.08,579.65,
ISRG,2025-02-05,580.46,592.64,580.16,590.9,
ISRG,2025-02-06,592.78,592.86,585.4,588.5,
ISRG,2025-02-07,590.5,594.081,582.155,582.98,
ISRG,2025-02-10,590.0,595.96,586.775,595.7,
ISRG,2025-02-11,591.23,592.83,587.0,591.65,
ISRG,2025-02-12,586.49,591.82,581.055,589.61,
ISRG,2025-02-13,590.86,593.17,583.233,591.39,
ISRG,2025-02-14,593.16,599.26,588.52,595.55,
ISRG,2025-02-18,595.455,601.59,586.614,600.89,
ISRG,2025-02-19,601.33,609.08,596.47,608.48,
ISRG,2025-02-20,607.15,608.165,597.77,606.57,
ISRG,2025-02-21,605.09,607.35,590.365,591.79,
ISRG,2025-02-24,594.47,600.58,590.66,591.31,
ISRG,2025-02-25,583.7,584.877,557.365,573.91,
ISRG,2025-02-26,570.85,586.74,569.64,580.93,
ISRG,2025-02-27,581.83,583.25,562.4,563.94,
ISRG,2025-02-28,566.95,574.0,556.75,573.27,
ISRG,2025-03-03,573.78,584.69,563.96,566.36,
ISRG,2025-03-04,563.69,565.8,545.537,557.77,
ISRG,2025-03-05,554.17,569.0,554.17,568.02,
ISRG,2025-03-06,538.57,538.57,537.509,538.57,
ISRG,2025-03-07,533.18,534.24,502.84,517.91,
ISRG,2025-03-10,503.91,503.91,476.371,482.49,
ISRG,2025-03-11,480.67,496.185,478.45,493.45,
ISRG,2025-03-12,511.06,518.925,496.305,497.3,
ISRG,2025-03-13,498.71,499.77,474.37,476.627,
ISRG,2025-03-14,482.69,492.28,476.57,484.22,
ISRG,2025-03-17,481.16,495.82,474.9,488.8,
ISRG,2025-03-18,487.34,488.5,478.41,483.95,
ISRG,2025-03-19,486.0,496.268,482.8,492.06,Steris Stock Gets Relative Strength Rating Lift A Relative Strength Rating upgrade for Steris shows improving technical performance. Will it continue?
ISRG,2025-03-20,490.4,500.1,490.4,491.81,
ISRG,2025-03-21,484.16,492.73,477.275,492.67,
ISRG,2025-03-24,505.0,510.78,501.842,508.58,
ISRG,2025-03-25,514.0,520.39,513.135,519.81,
ISRG,2025-03-26,520.89,520.89,506.69,509.03,
ISRG,2025-03-27,507.24,513.05,502.51,507.9,
ISRG,2025-03-28,505.06,505.19,488.57,491.84,
ISRG,2025-03-31,484.46,497.77,479.48,495.178,
ISRG,2025-04-01,492.26,497.3,487.66,496.36,
ISRG,2025-04-02,488.6,508.62,486.43,507.05,
ISRG,2025-04-03,486.86,504.09,484.88,494.58,
ISRG,2025-04-04,477.45,480.56,451.02,451.37,
ISRG,2025-04-07,430.97,479.89,430.01,463.79,
ISRG,2025-04-08,477.5,488.18,450.91,457.72,
ISRG,2025-04-09,448.365,529.189,442.9,522.78,
ISRG,2025-04-10,489.52,489.52,472.02,489.52,"AI-Powered Service Robots Redefine Hospitality as Industry Innovators Lead the Charge NetworkNewsWire Editorial Coverage NEW YORK, April 10, 2025 /CNW/ -- Facing ongoing labor shortages and rising consumer demands, the hospitality and food service sectors are increasingly turning to artificial intelligence (AI)-driven service robots. These cutting-edge technologies are helping hotels, restaurants, and cafes streamline operations, lower costs, and elevate customer experiences. As the hospitality robotics market is expected to surge to $65.4 billion by 2032 (https://ibn.fm/WxsRw), robotic innovations are swiftly becoming central to addressing workforce gaps and modernizing service delivery. Nightfood Holdings Inc. (OTCQB: NGTF) (profile) is at the forefront of this evolution—not merely as a tech player, but as a hospitality veteran. With operational oversight of more than 130 hotels and the development of over 50 properties, Nightfood's leadership brings deep-rooted industry expertise, enabling the company to implement robotic solutions with greater agility and impact than many traditional technology firms. Other companies committed to transforming their sectors through robotics include Amazon.com Inc. (NASDAQ: AMZN), Intuitive Surgical Inc. (NASDAQ: ISRG), Richtech Robotics Inc. (NASDAQ: RR) and Serve Robotics Inc. (NASDAQ: SERV). AI-driven service robots are gaining momentum as a game-changing tool in a range of different industries. With a strong acquisition strategy in place, Nightfood Holdings is focused on securing assets that support scalable growth and broaden its reach in the hospitality sector. Nightfood is also leveraging high-impact partnerships to reinforce its leadership in the hospitality robotics sector. Redefining Hospitality with Robotic Innovation As the hospitality and food-service sectors face mounting challenges in 2025—most notably labor shortages and rising guest expectations—industry leaders are turning to technology for sustainable solutions. A report by the American Hotel & Lodging Association reveals that 76% of hotels are still struggling to fill staff roles, with many increasing wages and offering flexible work arrangements to stay competitive (https://ibn.fm/ZtFz5). To address these operational pressures, AI-driven service robots are gaining momentum as a game-changing tool. From hotels to cafés, these intelligent machines are streamlining workflows, cutting costs, and elevating the customer experience. With the hospitality robotics market projected to grow at a CAGR of 17.89% through 2032, automation is quickly becoming a cornerstone of modern hospitality. Accelerating Growth with Key Acquisitions Nightfood Holdings Inc. (OTCQB: NGTF), a hospitality technology and asset acquisition company, is making strategic moves to redefine hotel operations through artificial intelligence and targeted acquisitions. With a strong acquisition strategy in place, the company is focused on securing assets that support scalable growth and broaden its reach in the hospitality sector. Recently, Nightfood finalized the acquisition of Skytech Automated Solutions Inc., a company known for its AI-powered service technologies tailored for hotels (https://ibn.fm/OtSEz). Among its innovations is the Laundry Helper robot, which is already being implemented in a growing number of hotel properties. With Skytech's capabilities now integrated into Nightfood's platform, the company plans to deliver full-scale automation—from behind-the-scenes operations to direct guest interactions. ""Closing the Skytech acquisition represents a transformative leap forward for Nightfood,"" said Nightfood Holdings chair Jamie Steigerwald. ""This strengthens our ability to scale automation across the hospitality industry, addressing key operational pain points such as labor shortages and rising costs."" This move comes on the heels of Nightfood's acquisition of SWC Group Inc., operating as CarryOutSupplies.com, through an all-stock transaction (https://nnw.fm/EQSuy). CarryOut is a major supplier of custom takeout packaging to the foodservice industry. According to company leadership, the addition of CarryOut brings several advantages, including greater operational efficiency, an expanded client base, and an enhanced product portfolio. ""We are thrilled to announce the successful acquisition of CarryoutSupplies.com and excited for what we believe this acquisition will allow Nightfood to accomplish,"" said Nightfood Holdings CEO Sonny Wang. ""This deal not only strengthens our position in the foodservice industry but also can drive immense value through operational efficiencies and the integration of complementary products and services across Nightfood's subsidiaries."" In a recent shareholder update, the company emphasized that these acquisitions are central to its long-term strategic plan. ""These acquisitions highlight Nightfood's strategic vision, positioning the company as a prominent innovator at the intersection of advanced AI and hospitality automation, significantly expanding its market presence and competitive positioning. Nightfood continues actively evaluating further strategic opportunities to enhance its innovative market leadership, demonstrating a clear commitment to aggressive, value-driven expansion,"" the update stated (https://nnw.fm/yQena). With its dual focus on cutting-edge automation and market-driven acquisitions, Nightfood is carving out a distinctive role in the evolving landscape of hospitality and service innovation. Strengthening Leadership through Key Partnerships Acquisitions are only part of the Nightfood Holdings strategy. The company is also eyeing key partnerships that will help it strengthen its position as a leader in the hospitality robotic space. Late last year, Future Hospitality Ventures Holdings Inc., a subsidiary of Nightfood Holdings, announced an exclusive partnership with Bear Robotics Inc., a global leader in AI-driven automation solutions (https://ibn.fm/qL1eP). Calling the collaboration ""a major milestone,"" the company noted that its mission is to redefine the U.S. hospitality industry, beginning in Greater Los Angeles and with plans to expand nationwide. ""FHV is committed to advancing innovation within the hospitality sector,"" stated Wang. ""Our partnership with Bear Robotics will redefine operational efficiency and service delivery, setting new standards for the industry. We look forward to implementing these AI-powered solutions in a dynamic and evolving market."" Expands Hospitality Innovation Through Strategic Partnership While acquisitions remain a vital component of Nightfood Holdings Inc.'s (OTCQB: NGTF) growth strategy, the company is also leveraging high-impact partnerships to reinforce its leadership in the hospitality robotics sector. One of its most significant recent collaborations is an exclusive agreement between its subsidiary, Future Hospitality Ventures Holdings Inc. (FHV), and Bear Robotics Inc., a global leader in AI-driven automation solutions (https://nnw.fm/go8aC). Announced late last year, the partnership marks a strategic move to revolutionize hotel and restaurant operations with intelligent service automation, starting in Greater Los Angeles and with plans for a national rollout. Nightfood described the agreement as ""a major milestone"" in its mission to redefine the U.S. hospitality industry. ""FHV is committed to advancing innovation within the hospitality sector,"" said Nightfood CEO Sonny Wang. ""Our partnership with Bear Robotics will redefine operational efficiency and service delivery, setting new standards for the industry. We look forward to implementing these AI-powered solutions in a dynamic and evolving market."" As Nightfood continues to integrate advanced technologies and expand its footprint, this partnership underscores the company's forward-thinking approach to reshaping guest services through automation and artificial intelligence. Solidifying a Presence in a Transformative Field With the rapid expansion and innovation in the robotics industry, several visionary companies are making significant moves to solidify their presence in this transformative field. Through investments in advanced technologies and strategic alliances, these companies are positioning themselves as leaders in automation, impacting industries from hospitality to supply chain. Amazon.com Inc. (NASDAQ: AMZN) robotics division, Amazon Robotics, was founded more than a decade ago when Amazon acquired Massachusetts-based Kiva Systems in 2012. Since then, Amazon has developed, produced, and deployed more than 750,000 robots across its operations network (https://ibn.fm/KpG6K). The scaling of these systems has reached a new crescendo with the recent launch of Amazon's next-generation, state-of-the-art fulfillment center in Shreveport, Louisiana, equipped with the latest innovations in robotics to support employees who package and deliver customer orders. This site uses eight different robotics systems that work in harmony to support package fulfillment and delivery. Intuitive Surgical Inc. (NASDAQ: ISRG), a global leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced the publication of two peer-reviewed studies in Surgical Endoscopy, on its first-of-its-kind Force Feedback technology incorporated in the da Vinci 5 surgical system (https://ibn.fm/nVL4x). Force Feedback technology allows surgeons to feel the forces applied to tissue during surgery, such as pushing and pulling. These studies - conducted in the pre-clinical setting using tissue models - demonstrate its potential to reduce the amount of force placed on tissue during surgery and enhance surgeon performance. Richtech Robotics Inc. (NASDAQ: RR), a Nevada-based provider of AI-driven service robots, recently announced the opening of its newest One Kitchen restaurant in collaboration with Ghost Kitchens America (https://ibn.fm/zGTYz). The Peachtree City, Georgia, Walmart Supercenter One Kitchen is the third to open as part of the two companies' partnership and first to feature AI-driven service robot Scorpion. Richtech Robotics' Scorpion robot will serve patrons a variety of coffees, milk teas, and fruit tea drinks. Serve Robotics Inc. (NASDAQ: SERV), a leading autonomous sidewalk delivery company, has announced the launch of its service in the Dallas-Fort Worth metro area (https://ibn.fm/QXOFW). This strategic expansion, in continued partnership with Uber Eats, represents a major milestone in Serve's plan to deploy 2,000 AI-powered delivery robots across the U.S. by the end of 2025. Serve robots have begun operating in the Uptown neighborhoods of Pearl, State Thomas, West Village and South Routh, reaching more than 22,000 new households. Customers placing orders through the Uber Eats app in these areas may now receive their meal via Serve's autonomous delivery robots. As robotics transforms the future of work and service, the companies at the forefront are those that merge technological advancements with specialized industry knowledge. The strategic actions they take now are laying the groundwork for a more efficient, automated, and intelligent future, solidifying their positions as major influencers in the evolving robotics field. For more information about Nightfood Holdings, visit Nightfood Holdings Inc. About NetworkNewsWire NetworkNewsWire (""NNW"") is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. For more information, please visit https://www.NetworkNewsWire.com Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer NetworkNewsWire is powered by IBN DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE This release contains ""forward-looking statements"" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ""Forward-looking statements"" describe future expectations, plans, results, or strategies and are generally preceded by words such as ""may"", ""future"", ""plan"" or ""planned"", ""will"" or ""should"", ""expected,"" ""anticipates"", ""draft"", ""eventually"" or ""projected"". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements. NetworkNewsWire New York, NY www.NetworkNewsWire.com 212.418.1217 Office Editor@NetworkNewsWire.com Logo - https://mma.prnewswire.com/media/2660018/5261540/NetworkNewsWire_Logo.jpg View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-powered-service-robots-redefine-hospitality-as-industry-innovators-lead-the-charge-302425566.html SOURCE NetworkNewsWire View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/10/c3416.html"
ISRG,2025-04-11,489.212,496.605,481.35,493.6,
ISRG,2025-04-14,502.27,506.142,487.202,490.13,
ISRG,2025-04-15,488.04,494.64,483.69,488.27,
ISRG,2025-04-16,485.92,492.04,477.62,481.34,
ISRG,2025-04-17,484.85,489.164,481.39,482.74,
ISRG,2025-04-21,475.94,478.9,463.05,468.32,
ISRG,2025-04-22,475.53,482.59,465.07,478.74,
ISRG,2025-04-23,499.275,517.05,485.09,488.11,
ISRG,2025-04-24,490.21,511.755,489.443,508.13,"Closing Bell Movers: Tesla jumps on Musk plans to pare back his DOGE work In the opening hour of the evening session, U.S. equity futures are sharply higher, tacking on to broad-based gains seen during Tuesday’s regular hours. S&P 500 futures are up 1.6% above 5,400, Nasdaq 100 is up 2% above 18,700, and Dow Industrials are up 1.4% just shy of 40,000. Comments from President Trump that he has no intention of firing Fed Chairman Powell, but rather only prefers him to move faster on cutting rates, are helping restore constructive sentiment and reverse concerns that capital would flee U.S. shores due to an acrimonious environment between the White House and the Fed. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Earlier, gains on the major indices were led by Financials and Consumer Discretionary. Equifax was the best performing stock in the S&P 500 after reporting better than expected Q1 while also announcing a $3B buyback. In earnings, Tesla was the first of the MAG-7 names to post results for Q1. Earnings were well shy of estimates and Auto segment revenue was down 20% from last year, but with the stock having declined over 40% year-to-date heading into the quarter, the initial reaction to the earnings miss was muted. The stock moved notably higher however as CEO Elon Musk indicated on the earnings call that his time with DOGE would be dropping “significantly” starting next month. Check out this evening’s top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – Pegasystems (PEGA) up 24.8% SAP SE (SAP) up 9.9% Manhattan Associates (MANH) up 6.0% Tesla (TSLA) up 5.4% Capital One (COF) up 4.3% USANA Health (USNA) up 3.1% Steel Dynamics (STLD) up 1.8% DOWN AFTER EARNINGS – Enphase (ENPH) down 11.1% Intuitive Surgical (ISRG) down 2.2% Baker Hughes (BKR) down 1.6% ALSO LOWER – Oklo (OKLO) down 5.5% after confirming Sam Altman out as Chairman Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on PEGA: Disclaimer & DisclosureReport an Issue Pegasystems up 23% at $84.29 after Q1 earnings beat Pegasystems reports Q1 EPS $1.53, consensus 50c Notable companies reporting after market close Pegasystems price target lowered to $107 from $119 at Citi Pegasystems price target lowered to $84 from $97 at Barclays"
ISRG,2025-04-25,512.04,515.36,505.752,514.89,
ISRG,2025-04-28,515.91,518.4,508.17,514.01,
ISRG,2025-04-29,512.5,516.78,507.75,514.89,
ISRG,2025-04-30,509.99,517.6,501.67,515.51,
ISRG,2025-05-01,518.12,524.44,512.67,517.18,
ISRG,2025-05-02,526.74,535.4,525.02,529.42,
ISRG,2025-05-05,528.32,536.06,523.55,531.82,
ISRG,2025-05-06,526.16,533.56,523.59,530.46,"2 Stocks I Can't Wait to Buy During the Next Market Correction Intuitive Surgical's lead in the robot-assisted surgery niche appears unassailable. Sportradar Group is the leading data provider in a rapidly growing market for sports-related information. Investors never know when the next market correction -- a drop of from 10% to 20% in an index -- is coming, but we know that it will eventually happen. And because that's true, it makes sense to make a list of the stocks you'd like to buy if they dip during a correction. The next big market correction could happen next week, next month, or next year. Investors who scoop up shares of Intuitive Surgical (NASDAQ: ISRG) and Sports Radar (NASDAQ: SRAD) if they dip during the inevitable correction could come out miles ahead over the long run. Read on to see why these two belong on growth stock investors' watch lists. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Since the turn of the century, Intuitive Surgical has been leading the trend toward minimally invasive surgical procedures performed with the aid of its da Vinci robots. Medtronic and Johnson & Johnson are growing their footprint in this lucrative space, but they generally develop their devices to perform procedures that da Vinci robots haven't already dominated. In 2024, Intuitive Surgical launched an updated system called da Vinci 5, which could significantly reduce procedure times and complications. That combination makes spending over $1 million on a da Vinci system and training surgeons to use it a worthwhile investment for hospitals. During the 12 months that ended this March, the number of da Vinci systems installed worldwide grew 15% to 10,189. All of those da Vinci machines use instruments and accessories that need to be replaced between procedures. First-quarter instrument and accessory sales rose 18% year over year to $1.4 billion. Since Intuitive Surgical is the only company hospitals can buy these instruments from, investors can reasonably expect continued growth at this pace. Shares of Intuitive Surgical have been trading for more than 75 times trailing earnings, and valuations this high aren't unusual for this magnificent growth stock. During the bear market of 2022, though, its valuation sank below 50 times trailing earnings. Folks who keep this one on a watch list and jump on it during the next downturn that takes it down could reap enormous gains over the long run. Keeping box scores was my favorite part about watching ball games as a kid. So naturally I'm fascinated with Sportradar Group, a company that takes recording and sharing sports statistics to a new level. Sportradar is quickly becoming the go-to data provider to media outlets and the growing online sports betting industry. At the end of February, online sports betting was legal in 34 U.S. states, according to the American Gaming Association. Well-established relationships with sports leagues such as Major League Baseball and the Union of European Football Associations give Sportradar a level of access to stadiums that its future competitors won't have. On the data consumption side, Sportradar is already partnered with Flutter Entertainment and DraftKings, which don't have much choice when it comes to information providers. Sportradar grew sales by 26% in 2024 to $1.3 billion, which is just a tiny fraction of the revenue its clients generate with help from its data services. In the U.S. market alone, online sports betting raked in $115 billion last year. Sportsbook (betting) providers rely on accurate data to set lines that don't result in huge losses for the house. As betting during sporting events becomes increasingly normalized, people will demand more information that media outlets can only get from Sportradar. With media outlets and betting operators beating a path to its doors, at least another decade of growth at a double-digit percentage isn't an unreasonable expectation. Sportradar stock has been trading at 22 times management's adjusted EBITDA expectation for 2025. This valuation is high, but it isn't unacceptable for a rapidly growing business with a large growth runway and a lack of competitors. However, I think it would make sense to start only a small position now, then add heavily during the next market correction that brings its valuation down. Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intuitive Surgical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $623,685!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $701,781!* Now, it’s worth noting Stock Advisor’s total average return is 906% — a market-crushing outperformance compared to 164% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 5, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical and Sportradar Group Ag. The Motley Fool recommends Flutter Entertainment Plc. The Motley Fool has a disclosure policy. 2 Stocks I Can't Wait to Buy During the Next Market Correction was originally published by The Motley Fool"
ISRG,2025-05-07,531.32,539.05,528.87,536.15,"[""Q1 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks Let\u2019s dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q1 surgical equipment & consumables - specialty earnings season. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a slower Q1. As a group, revenues beat analysts\u2019 consensus estimates by 1.8% while next quarter\u2019s revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 8.8% since the latest earnings results. Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions. LeMaitre reported revenues of $59.87 million, up 12% year on year. This print exceeded analysts\u2019 expectations by 3.7%. Despite the top-line beat, it was still a mixed quarter for the company with full-year revenue guidance exceeding analysts\u2019 expectations but a miss of analysts\u2019 EPS estimates. Chairman/CEO George LeMaitre said, \u201cQ1 sales momentum allows us to increase our 2025 reported ($245mm) and organic (+13%) sales guidance, up from prior guidance of $239mm and 10%. $303mm of cash also provides strategic optionality.\u201d LeMaitre achieved the biggest analyst estimates beat and highest full-year guidance raise of the whole group. Still, the market seems discontent with the results. The stock is down 12.8% since reporting and currently trades at $80.52. Is now the time to buy LeMaitre? Access our full analysis of the earnings results here, it\u2019s free. Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Intuitive Surgical reported revenues of $2.25 billion, up 19.2% year on year, outperforming analysts\u2019 expectations by 3.1%. The business had a satisfactory quarter with a decent beat of analysts\u2019 EPS estimates but a miss of analysts\u2019 sales volume estimates. Intuitive Surgical scored the fastest revenue growth among its peers. The market seems happy with the results as the stock is up 12.8% since reporting. It currently trades at $540. Is now the time to buy Intuitive Surgical? Access our full analysis of the earnings results here, it\u2019s free. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Integra LifeSciences reported revenues of $382.7 million, up 3.7% year on year, in line with analysts\u2019 expectations. It was a slower quarter as it posted a significant miss of analysts\u2019 EPS guidance for next quarter estimates and a miss of analysts\u2019 EPS estimates. Integra LifeSciences delivered the weakest full-year guidance update in the group. As expected, the stock is down 25.4% since the results and currently trades at $12.54. Read our full analysis of Integra LifeSciences\u2019s results here. With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide. Teleflex reported revenues of $700.7 million, down 5% year on year. This number was in line with analysts\u2019 expectations. However, it was a slower quarter as it recorded a significant miss of analysts\u2019 full-year EPS guidance estimates and constant currency revenue in line with analysts\u2019 estimates. Teleflex had the weakest performance against analyst estimates and slowest revenue growth among its peers. The stock is down 12% since reporting and currently trades at $120.57. Read our full, actionable report on Teleflex here, it\u2019s free. In response to the Fed\u2019s rate hikes in 2022 and 2023, inflation has been gradually trending down from its post-pandemic peak, trending closer to the Fed\u2019s 2% target. Despite higher borrowing costs, the economy has avoided flashing recessionary signals. This is the much-desired soft landing that many investors hoped for. The recent rate cuts (0.5% in September and 0.25% in November 2024) have bolstered the stock market, making 2024 a strong year for equities. Donald Trump\u2019s presidential win in November sparked additional market gains, sending indices to record highs in the days following his victory. However, debates continue over possible tariffs and corporate tax adjustments, raising questions about economic stability in 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here."", ""Q1 Earnings Highlights: Teleflex (NYSE:TFX) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks As the Q1 earnings season wraps, let\u2019s dig into this quarter\u2019s best and worst performers in the surgical equipment & consumables - specialty industry, including Teleflex (NYSE:TFX) and its peers. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a slower Q1. As a group, revenues beat analysts\u2019 consensus estimates by 1.8% while next quarter\u2019s revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 8.8% since the latest earnings results. With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide. Teleflex reported revenues of $700.7 million, down 5% year on year. This print was in line with analysts\u2019 expectations, but overall, it was a slower quarter for the company with a significant miss of analysts\u2019 full-year EPS guidance estimates and constant currency revenue in line with analysts\u2019 estimates. Teleflex delivered the weakest performance against analyst estimates and slowest revenue growth of the whole group. Unsurprisingly, the stock is down 12% since reporting and currently trades at $120.57. Read our full report on Teleflex here, it\u2019s free. Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Intuitive Surgical reported revenues of $2.25 billion, up 19.2% year on year, outperforming analysts\u2019 expectations by 3.1%. The business had a satisfactory quarter with a decent beat of analysts\u2019 EPS estimates but a miss of analysts\u2019 sales volume estimates. Intuitive Surgical pulled off the fastest revenue growth among its peers. The market seems happy with the results as the stock is up 12.8% since reporting. It currently trades at $540. Is now the time to buy Intuitive Surgical? Access our full analysis of the earnings results here, it\u2019s free. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Integra LifeSciences reported revenues of $382.7 million, up 3.7% year on year, in line with analysts\u2019 expectations. It was a slower quarter as it posted a significant miss of analysts\u2019 EPS guidance. Integra LifeSciences delivered the weakest full-year guidance update in the group. As expected, the stock is down 25.4% since the results and currently trades at $12.54. Read our full analysis of Integra LifeSciences\u2019s results here. Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions. LeMaitre reported revenues of $59.87 million, up 12% year on year. This print beat analysts\u2019 expectations by 3.7%. Taking a step back, it was a mixed quarter as it also produced full-year revenue guidance exceeding analysts\u2019 expectations but a miss of analysts\u2019 EPS estimates. LeMaitre achieved the biggest analyst estimates beat and highest full-year guidance raise among its peers. The stock is down 10.8% since reporting and currently trades at $80.52. Read our full, actionable report on LeMaitre here, it\u2019s free. The Fed\u2019s interest rate hikes throughout 2022 and 2023 have successfully cooled post-pandemic inflation, bringing it closer to the 2% target. Inflationary pressures have eased without tipping the economy into a recession, suggesting a soft landing. This stability, paired with recent rate cuts (0.5% in September 2024 and 0.25% in November 2024), fueled a strong year for the stock market in 2024. The markets surged further after Donald Trump\u2019s presidential victory in November, with major indices reaching record highs in the days following the election. Still, questions remain about the direction of economic policy, as potential tariffs and corporate tax changes add uncertainty for 2025. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.""]"
ISRG,2025-05-08,539.36,546.559,538.01,538.16,
ISRG,2025-05-09,540.78,542.74,532.9,536.51,
ISRG,2025-05-12,552.295,561.615,552.295,561.521,
ISRG,2025-05-13,561.625,568.69,559.88,563.95,
ISRG,2025-05-14,563.0,566.8,560.29,565.94,
ISRG,2025-05-15,559.32,564.06,549.99,560.18,
ISRG,2025-05-16,563.575,563.94,555.62,563.6,
ISRG,2025-05-19,554.34,562.605,553.94,561.63,
ISRG,2025-05-20,557.29,558.0,553.0,557.16,
ISRG,2025-05-21,556.56,558.76,545.525,547.07,
ISRG,2025-05-22,544.81,546.036,540.785,542.67,
ISRG,2025-05-23,535.5,542.066,529.16,539.54,"Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report? A month has gone by since the last earnings report for Penumbra (PEN). Shares have lost about 10.6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Penumbra due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. It turns out, fresh estimates have trended downward during the past month. Currently, Penumbra has a strong Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Penumbra has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Penumbra is part of the Zacks Medical - Instruments industry. Over the past month, Intuitive Surgical, Inc. (ISRG), a stock from the same industry, has gained 6.8%. The company reported its results for the quarter ended March 2025 more than a month ago. Intuitive Surgical reported revenues of $2.25 billion in the last reported quarter, representing a year-over-year change of +19.2%. EPS of $1.81 for the same period compares with $1.50 a year ago. For the current quarter, Intuitive Surgical is expected to post earnings of $1.93 per share, indicating a change of +8.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -1% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Intuitive Surgical. Also, the stock has a VGM Score of D. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-05-27,548.66,553.16,547.086,550.19,
ISRG,2025-05-28,550.51,556.16,549.43,552.41,"[""Intuitive Surgical (NASDAQ:ISRG): Strongest Q1 Results from the Surgical Equipment & Consumables - Specialty Group The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let\u2019s take a look at how Intuitive Surgical (NASDAQ:ISRG) and the rest of the surgical equipment & consumables - specialty stocks fared in Q1. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a slower Q1. As a group, revenues beat analysts\u2019 consensus estimates by 1.8% while next quarter\u2019s revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 7.4% since the latest earnings results. Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Intuitive Surgical reported revenues of $2.25 billion, up 19.2% year on year. This print exceeded analysts\u2019 expectations by 3.1%. Overall, it was a satisfactory quarter for the company with a decent beat of analysts\u2019 EPS estimates but a miss of analysts\u2019 sales volume estimates. Intuitive Surgical pulled off the fastest revenue growth of the whole group. Unsurprisingly, the stock is up 15.1% since reporting and currently trades at $550.94. Is now the time to buy Intuitive Surgical? Access our full analysis of the earnings results here, it\u2019s free. Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions. LeMaitre reported revenues of $59.87 million, up 12% year on year, outperforming analysts\u2019 expectations by 3.7%. The business performed better than its peers, but it was unfortunately a mixed quarter with full-year revenue guidance exceeding analysts\u2019 expectations but a miss of analysts\u2019 EPS estimates. LeMaitre delivered the biggest analyst estimates beat and highest full-year guidance raise among its peers. Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 13% since reporting. It currently trades at $78.55. Is now the time to buy LeMaitre? Access our full analysis of the earnings results here, it\u2019s free. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Integra LifeSciences reported revenues of $382.7 million, up 3.7% year on year, in line with analysts\u2019 expectations. It was a slower quarter as it posted a significant miss of analysts\u2019 EPS guidance for next quarter estimates and a miss of analysts\u2019 EPS estimates. Integra LifeSciences delivered the weakest full-year guidance update in the group. As expected, the stock is down 22.1% since the results and currently trades at $13.10. Read our full analysis of Integra LifeSciences\u2019s results here. With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide. Teleflex reported revenues of $700.7 million, down 5% year on year. This result was in line with analysts\u2019 expectations. However, it was a slower quarter as it logged a significant miss of analysts\u2019 full-year EPS guidance estimates and constant currency revenue in line with analysts\u2019 estimates. Teleflex had the weakest performance against analyst estimates and slowest revenue growth among its peers. The stock is down 9.7% since reporting and currently trades at $123.60. Read our full, actionable report on Teleflex here, it\u2019s free. Thanks to the Fed\u2019s series of rate hikes in 2022 and 2023, inflation has cooled significantly from its post-pandemic highs, drawing closer to the 2% goal. This disinflation has occurred without severely impacting economic growth, suggesting the success of a soft landing. The stock market thrived in 2024, spurred by recent rate cuts (0.5% in September and 0.25% in November), and a notable surge followed Donald Trump\u2019s presidential election win in November, propelling indices to historic highs. Nonetheless, the outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. The path forward holds both optimism and caution as new policies take shape. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here."", ""Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know Intuitive Surgical, Inc. (ISRG) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this company have returned +6.9% over the past month versus the Zacks S&P 500 composite's +7.4% change. The Zacks Medical - Instruments industry, to which Intuitive Surgical belongs, has gained 2.6% over this period. Now the key question is: Where could the stock be headed in the near term? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Intuitive Surgical is expected to post earnings of $1.92 per share for the current quarter, representing a year-over-year change of +7.9%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.2%. For the current fiscal year, the consensus earnings estimate of $7.84 points to a change of +6.8% from the prior year. Over the last 30 days, this estimate has changed -0.4%. For the next fiscal year, the consensus earnings estimate of $9.03 indicates a change of +15.1% from what Intuitive Surgical is expected to report a year ago. Over the past month, the estimate has changed -0.8%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Intuitive Surgical. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. For Intuitive Surgical, the consensus sales estimate for the current quarter of $2.35 billion indicates a year-over-year change of +16.8%. For the current and next fiscal years, $9.65 billion and $11.11 billion estimates indicate +15.6% and +15.1% changes, respectively. Intuitive Surgical reported revenues of $2.25 billion in the last reported quarter, representing a year-over-year change of +19.2%. EPS of $1.81 for the same period compares with $1.50 a year ago. Compared to the Zacks Consensus Estimate of $2.18 billion, the reported revenues represent a surprise of +3.27%. The EPS surprise was +5.85%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Intuitive Surgical is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intuitive Surgical. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
ISRG,2025-05-29,556.47,559.8,551.4,555.75,"ISRG vs. MDT: Which Robotic Surgery Stock Is a Smarter Buy Now? Intuitive Surgical ISRG and Medtronic MDT are two powerhouses in the rapidly evolving field of robotic-assisted surgery. As hospitals increasingly adopt minimally invasive technologies, both companies are racing to capture market share with their flagship systems — da Vinci for Intuitive and Hugo for Medtronic. With growing demand for surgical precision and better patient outcomes, investors are closely watching which company holds the edge. In this article, we’ll compare their market positions, growth potential, and innovation pipelines to determine which stock may be the smarter buy in today’s competitive medtech landscape. ISRG & MDT: Price Performance Image Source: Zacks Investment Research The year-to-date price performances of both Intuitive Surgical and Medtronic have not been impressive, likely due to tariff concerns and rising competition from Chinese robotic device makers. Shares of ISRG have gained 5.8% year to date, while those of MDT have improved 1.7%. The S&P 500 Index has increased 0.2% in the same period. ISRG’s Da Vinci: An Established Player Intuitive Surgical started 2025 with strong momentum, underpinned by its dominant position in robotic-assisted surgery and growing global demand for minimally invasive procedures. The company’s flagship da Vinci Surgical System remains the industry gold standard, with almost 10,000 systems installed worldwide — a testament to its technological edge and deep hospital integration. ISRG continues to post robust recurring revenues from instrument and accessory sales, a high-margin stream that scales with increased surgical procedures. As procedure volumes rise, especially in general surgery and international markets, the company benefits from a growing installed base and deepening utilization. Intuitive is poised to leverage AI integration, real-time analytics, and next-generation robotics to further differentiate its platform going forward. Recent FDA approvals and expanding indications — particularly in urology and gynecology — support continued volume growth. Its strong balance sheet, zero debt, and consistent free cash flow provide ample firepower for R&D and international expansion, especially in underserved markets like Asia and Latin America. With a long runway for innovation and procedure growth, ISRG’s fundamentals remain strong. For investors seeking exposure to healthcare technology with a recurring-revenue business model and high barriers to entry, Intuitive Surgical stands out as a high-quality, long-term growth story in 2025. The Zacks Consensus Estimate for ISRG’s fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 7.1%, respectively. EPS estimates for 2025 and 2026 have moved southward over the past 60 days. ISRG Estimate Movement Image Source: Zacks Investment Research MDT’s Hugo: A New Entrant Medtronic, one of the world’s largest medical device companies, entered 2025 with a diversified product portfolio and ongoing efforts to reinvigorate growth. The company’s operations span cardiovascular, diabetes, neuroscience, and surgical innovations, providing stability across economic cycles. A key area of focus is its Hugo robotic-assisted surgery platform, which aims to challenge Intuitive Surgical’s dominance. Early adoption is promising, but Hugo still faces regulatory hurdles and limited market penetration compared to da Vinci. However, Medtronic maintains solid revenue from its legacy businesses and a respectable dividend yield, appealing to income-focused investors. The company’s cost-saving initiatives and restructuring efforts are beginning to improve margins, and its pipeline includes next-gen devices and AI-enhanced surgical tools, which could support long-term growth. However, challenges remain. MDT has experienced slower top-line growth in recent years, partially due to supply-chain constraints and delayed procedure volumes during the pandemic. Competition is intensifying across multiple segments, and innovation pacing remains a concern for some analysts. Regulatory scrutiny and pricing pressures also weigh on margins. The Zacks Consensus Estimate for Medtronics’ 2025 sales and EPS implies a year-over-year improvement of 8.6% and 10.4%, respectively. However, EPS estimates for 2025 and 2026 have declined 2 cents each over the past 60 days. MDT Estimate Movement Image Source: Zacks Investment Research ISRG or MDT: Which Is a Better Pick? Intuitive Surgical’s da Vinci dominance — nearly 80% market share, sustainable 19% revenue growth, recurring consumables and Ion lung biopsy system — underpins broad surgical robotics leadership. While Medtronics’ Hugo has been launched in select international markets and shown early adoption potential, it remains under limited commercial release. The company is actively working toward securing full FDA approval. With a 16.5% robotic-surgery market CAGR through 2029 per this Surgical Robots Market report,ISRG is most likely to continue to grow on the back of its strong da Vinci portfolio. However, MDT’s prospects in this market are yet to be seen as Hugo’s full commercial launch is expected next year. While Intuitive Surgical carries a Zacks Rank #3 (Hold) at present, Medtronic has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-05-30,554.52,555.0,545.73,551.92,"[""Intuitive Surgical, Inc. (ISRG) Laps the Stock Market: Here's Why Intuitive Surgical, Inc. (ISRG) closed the latest trading day at $555.75, indicating a +0.6% change from the previous session's end. This change outpaced the S&P 500's 0.4% gain on the day. Meanwhile, the Dow gained 0.28%, and the Nasdaq, a tech-heavy index, added 0.39%. Coming into today, shares of the company had gained 7.1% in the past month. In that same time, the Medical sector lost 3.41%, while the S&P 500 gained 6.69%. Investors will be eagerly watching for the performance of Intuitive Surgical, Inc. in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $1.92, marking a 7.87% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $2.35 billion, up 16.81% from the prior-year quarter. For the annual period, the Zacks Consensus Estimates anticipate earnings of $7.84 per share and a revenue of $9.65 billion, signifying shifts of +6.81% and +15.56%, respectively, from the last year. Investors should also take note of any recent adjustments to analyst estimates for Intuitive Surgical, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.38% downward. Intuitive Surgical, Inc. is currently a Zacks Rank #3 (Hold). Looking at its valuation, Intuitive Surgical, Inc. is holding a Forward P/E ratio of 70.45. Its industry sports an average Forward P/E of 26.28, so one might conclude that Intuitive Surgical, Inc. is trading at a premium comparatively. Also, we should mention that ISRG has a PEG ratio of 4.3. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Instruments industry had an average PEG ratio of 2.32 as trading concluded yesterday. The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""2 Profitable Stocks Worth Investigating and 1 to Think Twice About A company with profits isn\u2019t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. A business making money today isn\u2019t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here are two profitable companies that leverage their financial strength to beat the competition and one best left off your watchlist. Trailing 12-Month GAAP Operating Margin: 24% Addressing the demand for aesthetically-pleasing and unique outdoor living spaces, Trex Company (NYSE:TREX) makes wood-alternative decking, railing, and patio furniture. Why Do We Think Twice About TREX? Trex\u2019s stock price of $56.42 implies a valuation ratio of 25.5x forward P/E. If you\u2019re considering TREX for your portfolio, see our FREE research report to learn more. Trailing 12-Month GAAP Operating Margin: 18.1% With low-pressure heating systems as the first product, Trane (NYSE:TT) designs, manufactures, and sells HVAC and refrigeration systems, the former to commercial and residential building customers and the latter to commercial truck manufacturers. Why Is TT a Good Business? Trane Technologies is trading at $430.30 per share, or 33.1x forward P/E. Is now the right time to buy? Find out in our full research report, it\u2019s free. Trailing 12-Month GAAP Operating Margin: 28.2% Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Why Should ISRG Be on Your Watchlist? At $555.52 per share, Intuitive Surgical trades at 66.3x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it\u2019s free. Donald Trump\u2019s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free.""]"
ISRG,2025-06-02,549.06,554.697,542.52,553.29,"Goldman Sachs Adjusts Price Target on Intuitive Surgical to $636 From $569, Maintains Buy Rating Intuitive Surgical (ISRG) has an average rating of overweight and mean price target of $582.51, acco"
ISRG,2025-06-03,550.68,555.13,548.015,551.85,"Two biopharma stocks to consider outside of Moderna Moderna (MRNA) shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investment Management portfolio manager Jason Kritzer shares his perspective on the pharmaceutical industry amid pushback from the Trump administration's Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. Kritzer also weighs in on pet drug manufacturer Zoetis (ZTS). To watch more expert insights and analysis on the latest market action, check out more Catalysts here."
ISRG,2025-06-04,552.575,559.69,550.93,557.95,"Surgical Equipment & Consumables - Specialty Stocks Q1 In Review: Integra LifeSciences (NASDAQ:IART) Vs Peers Wrapping up Q1 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - specialty stocks, including Integra LifeSciences (NASDAQ:IART) and its peers. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a slower Q1. As a group, revenues beat analysts’ consensus estimates by 1.8% while next quarter’s revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 6.6% since the latest earnings results. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Integra LifeSciences reported revenues of $382.7 million, up 3.7% year on year. This print was in line with analysts’ expectations, but overall, it was a slower quarter for the company with a miss of analysts’ EPS estimates. “We remain laser focused on strengthening our quality systems, improving supply reliability, and driving operational excellence. There remains significant work ahead, but we are continuing to put the processes and people in place to execute on our comprehensive Compliance Master Plan and build a foundation for sustainable performance. With the launch of our Transformation and Program Management Office and the addition of key leadership, including in global operations, we are driving improved accountability and execution across the enterprise to deliver meaningful long-term value for patients, customers, and shareholders,” said Mojdeh Poul, president and chief executive officer. Integra LifeSciences delivered the weakest full-year guidance update of the whole group. The stock is down 22.5% since reporting and currently trades at $13.03. Read our full report on Integra LifeSciences here, it’s free. Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Intuitive Surgical reported revenues of $2.25 billion, up 19.2% year on year, outperforming analysts’ expectations by 3.1%. The business had a satisfactory quarter with a decent beat of analysts’ EPS estimates but a miss of analysts’ sales volume estimates. Intuitive Surgical achieved the fastest revenue growth among its peers. The market seems happy with the results as the stock is up 15.5% since reporting. It currently trades at $553. Is now the time to buy Intuitive Surgical? Access our full analysis of the earnings results here, it’s free. With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide. Teleflex reported revenues of $700.7 million, down 5% year on year, in line with analysts’ expectations. It was a slower quarter as it posted a significant miss of analysts’ full-year EPS guidance estimates and constant currency revenue in line with analysts’ estimates. Teleflex delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 11.3% since the results and currently trades at $121.44. Read our full analysis of Teleflex’s results here. Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions. LeMaitre reported revenues of $59.87 million, up 12% year on year. This result topped analysts’ expectations by 3.7%. Aside from that, it was a satisfactory quarter as it also recorded a solid beat of analysts’ organic revenue estimates but a miss of analysts’ EPS estimates. LeMaitre achieved the biggest analyst estimates beat and highest full-year guidance raise among its peers. The stock is down 8.2% since reporting and currently trades at $82.86. Read our full, actionable report on LeMaitre here, it’s free. As a result of the Fed’s rate hikes in 2022 and 2023, inflation has come down from frothy levels post-pandemic. The general rise in the price of goods and services is trending towards the Fed’s 2% goal as of late, which is good news. The higher rates that fought inflation also didn't slow economic activity enough to catalyze a recession. So far, soft landing. This, combined with recent rate cuts (half a percent in September 2024 and a quarter percent in November 2024) have led to strong stock market performance in 2024. The icing on the cake for 2024 returns was Donald Trump’s victory in the U.S. Presidential Election in early November, sending major indices to all-time highs in the week following the election. Still, debates around the health of the economy and the impact of potential tariffs and corporate tax cuts remain, leaving much uncertainty around 2025. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate."
ISRG,2025-06-05,560.7,563.944,557.21,558.06,"[""These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Broadcom Results Ahead As the stock market extends its rebound, it's important to watch the stocks most loved among equity analysts. Netflix and GE Aerospace are two of the seven best stocks where investors can find magnificent profit growth prospects. Of 54 analysts covering Netflix, 38 have buy or overweight ratings on the video streaming service."", ""Intuitive Surgical, Inc. (ISRG) Outpaces Stock Market Gains: What You Should Know Intuitive Surgical, Inc. (ISRG) closed at $557.95 in the latest trading session, marking a +1.11% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.01%. Meanwhile, the Dow experienced a drop of 0.22%, and the technology-dominated Nasdaq saw an increase of 0.32%. Shares of the company have appreciated by 4.03% over the course of the past month, outperforming the Medical sector's loss of 2.72% and lagging the S&P 500's gain of 5.2%. Investors will be eagerly watching for the performance of Intuitive Surgical, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.92, showcasing a 7.87% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $2.35 billion, showing a 16.81% escalation compared to the year-ago quarter. For the full year, the Zacks Consensus Estimates project earnings of $7.84 per share and a revenue of $9.65 billion, demonstrating changes of +6.81% and +15.56%, respectively, from the preceding year. It's also important for investors to be aware of any recent modifications to analyst estimates for Intuitive Surgical, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.38% lower. Right now, Intuitive Surgical, Inc. possesses a Zacks Rank of #3 (Hold). In the context of valuation, Intuitive Surgical, Inc. is at present trading with a Forward P/E ratio of 70.38. This signifies a premium in comparison to the average Forward P/E of 26.38 for its industry. Investors should also note that ISRG has a PEG ratio of 4.3 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 2.29 at yesterday's closing price. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Intuitive Surgical's da Vinci 5: Gaining Precision, Power and Potential Intuitive Surgical\u2019s ISRG da Vinci 5 (dV5) rollout continues to gain traction, reinforcing its position as the next-generation surgical robotics platform. In first-quarter 2025 alone, the company placed 147 dV5 systems and performed over 32,000 procedures using the system, reflecting strong customer response. The system\u2019s most notable innovation, Force Feedback technology, has started to show clinical potential. Preliminary data suggest that it enhances surgical precision and post-op recovery, including a significant improvement in bowel function recovery times and reduced suturing errors among novice surgeons. These capabilities not only improve clinical outcomes but also shorten the learning curve, expanding the addressable user base. Additional upgrades, such as real-time 3D model review, integrated simulation software and surgical video review, are expected to be launched mid-year following 510(k) clearance. These improvements aim to bolster procedural insight and surgeon performance. Meanwhile, supply-chain scaling is underway to support a broader launch. Though force feedback instruments are still in limited supply, their adoption is expected to grow steadily through 2025. By aligning innovation with surgeon training needs and operational efficiency, Intuitive Surgical is positioning da Vinci 5 as a cornerstone of its future growth. With strong early adoption and a clear roadmap for advanced features, dV5 is on track to redefine robotic-assisted surgery at scale. Competing Robotic Surgery Updates At the 2025 AAOS Annual Meeting, Stryker SYK introduced its fourth-generation Mako SmartRobotics system, Mako 4, featuring the first FDA-cleared robotic hip revision capability. With this advancement, Stryker enhances surgical planning and execution across hip, knee, spine, and shoulder procedures. Mako 4 integrates Stryker\u2019s Q Guidance System, offering improved intraoperative visibility and streamlined workflows. Simultaneously, Globus Medical GMED showcased its ExcelsiusFlex robotic navigation system for Total Knee Arthroplasty. Globus Medical\u2019s system offers both CT-based and imageless registration options, providing surgeons with ergonomic control and procedural flexibility. Globus Medical\u2019s ExcelsiusFlex is designed to enhance surgical precision and accommodate diverse patient needs and surgeon preferences. ISRG\u2019s Price Performance, Valuation and Estimates Shares of ISRG have gained 0.2% in the year-to-date period against the industry\u2019s decline of 4.3%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 36.05, above the industry average. But, it is still lower than its five-year median of 52.54. DOCS carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical\u2019s 2025 earnings implies a 2.8% rise from the year-ago period\u2019s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
ISRG,2025-06-06,562.18,564.15,555.76,557.08,"Intuitive Surgical Stock Gains 12.7% QTD: Is it Still a Buy Now? Shares of Intuitive Surgical ISRG seem to gain momentum after declining between February to April. The stock has risen 12.7% in the quarter so far after declining more than 30% from its all-time high of $616 in January. The recent rally reflects Intuitive Surgical’s strong fundamentals, even amid tariff-related concerns. A temporary U.S.-China trade agreement has eased tariffs for 90 days, likely reducing the projected 170 basis point impact on the cost of goods sold in 2025. Intuitive Surgical continues to lead the robotic-assisted surgery market, supported by robust revenue growth and rising procedure volumes. Looking ahead into the second half of 2025, the company remains focused on advancing its technology, expanding internationally and enhancing manufacturing efficiency. However, global macroeconomic headwinds remain, particularly with the resurgence of U.S. protectionism under President Trump, heightening the risk of renewed trade tensions. ISRG reported first-quarter 2025 revenues of $2.25 billion, marking a 19.2% year-over-year increase. This underscores the company’s ability to generate consistent, recurring revenues, now 85% of total earnings. ISRG recorded strong earnings per share (EPS) growth of 20% (to $1.81) and an operating margin of 34.1%. It anticipates a declining operating margin for 2025 due to increased depreciation expenses and a higher mix of lower-margin products like da Vinci 5, Ion and SP. Despite the recent fall in share price, ISRG’s shares are up 6.9%, outperforming the Zacks Medical - Instruments industry’s decline of 8.6% year to date. The broader Zacks Medical sector has declined 4.5% and the S&P 500 Index has increased 0.9% in the same period. YTD Price Performance Image Source: Zacks Investment Research In the first quarter, Intuitive Surgical’s revenue growth was primarily driven by continued strength in da Vinci procedure volumes, along with solid growth in Ion and SP procedures. The company’s strategic price increases helped offset inflationary pressures, further supporting top-line gains. The growing adoption of the da Vinci 5 system also contributed to the top line, with a broader rollout planned for the second half of the year, which is expected to boost system sales. However, softer demand in Germany, the U.K., and Japan could affect the pace of adoption. International expansion efforts are gaining momentum, with Ion platform clearance in Australia and its launch in China expected to drive system placements and procedural volumes. Additionally, U.S. clearance of the da Vinci SP SureForm 45 stapler, which enables thoracic and colorectal applications, opens new clinical use cases. Further upside is expected from the recent FDA clearance of the da Vinci SP surgical system for transanal local excision/resection. This approval supports Intuitive’s move into natural orifice surgery, particularly for minimally invasive colorectal procedures, and should drive future system demand. ISRG Stock Trades Above 200-Day Average Image Source: Zacks Investment Research To fuel further expansion, ISRG plans to market its da Vinci products directly in Italy, Spain, and Portugal, at a cost of EUR 290 million, thereby deepening its customer relationships. Manufacturing expansion continues with the addition of new facilities in California, Germany, and Bulgaria, ensuring scalable production for the Da Vinci 5 and Ion systems. Additionally, digital tools, such as the My Intuitive app and VR simulators, should improve surgeon training and optimize procedural outcomes. In 2025, Intuitive Surgical anticipates a 170 basis point gross margin headwind driven by newly implemented global tariffs. The added costs primarily stem from three sources — escalating U.S.-China trade tensions, European retaliatory tariffs and limited Mexican exports failing to meet USMCA certification standards. Notably, the company faces steep U.S. tariffs on components imported from China and on finished goods re-entering the country, including Chinese-sourced parts and subassemblies for the Ion platform. Tariff-related costs are expected to rise sequentially through the year. However, the overall impact may be moderated by recent policy shifts — U.S. tariffs on Chinese imports have been reduced from 145% to 30%, while U.S. exports to China will now face a 10% tariff, down from a prior 125%. Meanwhile, competitive pressure in the robotic-assisted surgery market continues to intensify. Larger players like Johnson & Johnson JNJ and Medtronic MDT are ramping up investments in the space. Notably, Medtronic has filed for FDA clearance for its Hugo robotic-assisted surgery system, with potential approval anticipated in the second half of 2025. In this environment, maintaining cost efficiency will be critical for Intuitive Surgical. ISRG’s P/E F12M Higher Than Industry Image Source: Zacks Investment Research The share price of ISRG is trading above the significant levels of 50-DMA and 200-DMA, reflecting strength. However, the company’s share flashed a bearish pattern — death cross — on May 1 and is currently seen to form a lower high, raising skepticism about the continuation of its recent rally. Moroever, the stock’s pricey valuation raises concerns. The company is trading significantly higher than the industry. However, it is currently trading below its five-year median, which can act as a cushion against further decline. ISRG currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Moreover, the Style Scores don’t look quite promising. The company has a Value Score of D and a Growth Score of C. The valuation chart also shows the significant premium for ISRG stock compared with the industry. Moreover, the Momentum score of ‘F’ implies that the stock may trade within the range in the upcoming few months. As such, we believe that investors may hold the stock for now. Nevertheless, we caution against taking a new position. Strong fundamentals suggest an upside to the share price, but investors should wait for an attractive entry point. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-06-09,531.5,531.588,498.167,526.15,
ISRG,2025-06-10,525.81,531.93,520.3,529.6,"[""Intuitive Surgical analyst raises eyebrows with new stock price target Intuitive Surgical analyst raises eyebrows with new stock price target originally appeared on TheStreet. Jim Cramer wants answers. The CNBC anchor and Mad Money maven wants to know why Deutsche Bank was being so rough on Intuitive Surgical (ISRG) . The investment firm downgraded the biotech to sell from hold and slashed its stock price target to $440 from $515. \ud83d\udcb5\ud83d\udcb0Don't miss the move: Subscribe to TheStreet's free daily newsletter \ud83d\udcb0 \""This is quite a controversial call,\"" Cramer said on CNBC's Squawk on The Street, \""because this is a premier fast-growing company, premier super growth, and I want to find out more about it.\"" The Sunnyvale, Calif., company, founded in 1995, specializes in robotic-assisted surgery equipment, most notably the Da Vinci surgical systems, which use a minimally invasive approach. Intuitive Surgical's shares were down 6.1% at last check but are up 25.4% from a year ago. Deutsche Bank said in a note to investors on June 9 that remanufactured instruments are going to increasingly encroach on Intuitive's instruments and accessories segment over the next few years. The investment firm expects a growing number of Intuitive's customers to explore adopting remanufactured instruments, given potentially significant profitability gains. The firm cited its discussions with multiple robotic surgery programs. Remanufactured instruments are previously used surgical instruments that have been rigorously overhauled. More Tech Stocks: Palantir gets great news from the Pentagon Analyst has blunt words on Trump's iPhone tariff plans OpenAI teams up with legendary Apple exec Deutsche Bank says 46% of Intuitive's U.S. instruments and accessories revenue could be at risk of encroachment by third-party-remanufactured devices. The firm's model assumes no material impact in 2026 but steadily increasing headwinds in 2027 and especially 2028. Cramer begged to differ. \""This is a pristine company and people who know this company have been rewarded repeatedly by owning it,\"" he said. Just a few days earlier, on June 5, Erste Group analyst Hans Engel upgraded Intuitive Surgical to buy from hold, according to The Fly. The company's operating margin should widen again in 2026 and profit growth should increase significantly, the analyst said. Engel said that he expected the share price to rise further due to Intuitive's expected acceleration in growth. On April 2 Intuitive Surgical beat Wall Street's first-quarter earnings and revenue expectations, with sales increasing 19% from a year ago to $2.25 billion. \""Our business performed well in the first quarter of the year with physicians using our products at the high end of our expectations, driven by strong procedure growth in core general surgery in the United States, and strong procedures outside the United States,\"" CEO Gary Guthart told analysts. \""New system placements in the quarter were solid with particular strength in the U.S.\"" First-quarter 2025 instruments and accessories revenue increased 18% from a year earlier to $1.37 billion, driven primarily by roughly 17% growth in da Vinci procedure volume and about 58% volume growth in the Ion procedure, which gives doctors a nonsurgical way to biopsy lung nodules. Related: Analysts reboot Intuitive Surgical stock price target ahead of earnings \""Mad Money\"" marked its 20th anniversary this year and Cramer, who co-founded TheStreet in 1996, said Intuitive Surgical was the eighth best performer of the \u201cMad Money era.\u201d \""This is another name that we found early on,\"" he said. \""I first interviewed someone from the company back in July of 2005 when the stock was trading at a split-adjusted price of $5 and change.\"" He added that the company was now a \u201c$184 billion behemoth, and this stock has given you more than 10,000% gain since the show got started.\"" \""I think this is as relevant as ever,\"" Cramer said. \""I\u2019m proud to be a huge supporter of this.\u201d The company recently said that effective July 1, Guthart would become executive chairman while Dave Rosa, currently president, would become CEO. On May 22, Citi raised its price target on Intuitive Surgical to $650 from $590 and kept a buy rating on the shares. The firm updated models in medical technology following the Q1 reports. Underlying fundamentals in the sector appear intact, including volumes, pricing, and capital spending, the investment firm said. In March, The Robot Report said that while Intuitive Surgical. remains the leading surgical robotics provider \u201cother companies with savvy strategies are generating buzz and raising money.\u201d The report listed several companies, including Medtronic (MDT) , Stryker (SYK) and CMR Surgical, which reportedly has brought in advisers to explore a potential sale. Related: Fund-management veteran skips emotion in investment strategy Intuitive Surgical analyst raises eyebrows with new stock price target first appeared on TheStreet on Jun 9, 2025 This story was originally reported by TheStreet on Jun 9, 2025, where it first appeared."", ""Tesla, Intuitive Surgical downgraded: Wall Street\u2019s top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today\u2019s research calls that investors need to know, as compiled by The Fly. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Top 5 Upgrades: Redburn Atlantic upgraded Charles Schwab (SCHW) to Neutral from Sell with a price target of $82, up from $65. Schwab is the dominant player in the two fastest growing segments of the U.S. retail wealth management market \u2013 the self-directed market and the independent registered investment advisor custody market, the firm tells investors in a research note. Seaport Research upgraded Oklo (OKLO) to Buy from Neutral with a $71 price target. The firm sees fuel availability as the key variable in Oklo\u2019s future success. Jefferies upgraded Quaker Houghton (KWR) to Buy from Hold with a price target of $146, up from $115. The firm says that solid margins and return on capital employed above 2019 levels despite soft end markets, a 64% cut in the stock\u2019s valuation over four years leading to share prices last seen when earnings per share were less than $5, and a 7% free cash flow yield mark Quaker as a \u201cgood quality-at-a-reasonable-price candidate.\u201d Redburn Atlantic upgraded LPL Financial (LPLA) to Buy from Neutral with a price target of $460, up from $420. LPL is positioned to benefit from \u201ctwo durable secular shifts\u201d in the advisor-mediated market \u2013 the continued migration of advisors from captive models to independence in pursuit of autonomy, higher revenue retention and client ownership, and the move towards outsourcing in the institutional market, the firm says. Williams Trading upgraded Steven Madden (SHOO) to Buy from Hold with a $31 price target. Trends, especially in women\u2019s dress shoes and western boots, \u201care starting to move Steve Madden\u2019s way,\u201d the firm tells investors in a research note. Top 5 Downgrades: Argus downgraded Tesla (TSLA) to Hold from Buy with no price target. The stock \u201cappears to be currently trading on non-fundamental events,\u201d says the firm, which is concerned that the \u201cwar of words\u201d between President Trump and Tesla CEO Elon Musk, along with expiration of EV credits, could further weaken demand for new Teslas. Baird also downgraded Tesla to Neutral from Outperform with an unchanged price target of $320. Deutsche Bank downgraded Intuitive Surgical (ISRG) to Sell from Hold with a price target of $440, down from $515. Encroachment to Intuitive\u2019s Instruments and Accessories segment by remanufactured instruments is inevitable and likely to be increasingly meaningful over the next few years, the firm tells investors in a research note. Morgan Stanley downgraded McDonald\u2019s (MCD) to Equal Weight from Overweight with a price target of $324, down from $329. McDonald\u2019s is a \u201ctop quality business but hasn\u2019t been, and probably will not be, insulated from some structural pressures on fast food,\u201d the firm argues. Mizuho downgraded Chewy (CHWY) to Neutral from Outperform with a price target of $47, up from $43. The firm remains constructive on the long-term trajectory of Chewy\u2019s business model, but says the current setup into and post the Q1 results is \u201cincreasingly less attractive.\u201d Redburn Atlantic downgraded Robinhood (HOOD) to Sell from Neutral with a price target of $48, up from $40. The company \u201chas executed a notable turnaround,\u201d but the Robinhood bull case requires conviction that recent improvements are sustainable, says the firm, which believes there is some uncertainty around the company\u2019s \u201cmoats,\u201d adoption rates of new products and the durability of user engagement. Top 5 Initiations: Arete initiated coverage of SanDisk (SNDK) with a Buy rating and $63 price target. The shares trade at a \u201csteep discount\u201d to their historical valuation multiples, likely reflecting SanDisk\u2019s weaker market position today, the firm argues. Morgan Stanley coverage of Molina Healthcare (MOH) with an Overweight rating and $364 price target. While \u201cvarying permutations of policy headwinds are looming\u201d across Medicaid, the overhang is disproportionately reflected in Molina at \u201ctrough valuations,\u201d the firm tells investors in a research note. Morgan Stanley also started coverage of Centene (CNC) with an Overweight rating and $70 price target. Citizens JMP initiated coverage of eToro (ETOR) with an Outperform rating and $85 price target, implying 24% upside from the last close. eToro\u2019s shift to consistent profitability reduces downside risk in the stock, the firm tells investors in a research note. Goldman Sachs, Jefferies, Needham, Canaccord, Cantor Fitzgerald and Mizuho also started coverage of the name with Buy-equivalent ratings, while Keefe Bruyette, Citi, UBS, Susquehanna, Deutsche Bank, BofA and Redburn Atlantic initiated eToro with Neutral-equivalent ratings. Barclays initiated coverage of Ryder (R) with an Overweight rating and $190 price target. Ryder appears to be executing on a revised operating strategy emphasizing transportation services, with a \u201clarge, flexible asset base that should position the company favorably in a potential upcycle,\u201d the firm tells investors in a research note. Cantor Fitzgerald initiated coverage of Docebo (DCBO) with an Overweight rating and $35 price target. The firm estimates the company is targeting an estimated total addressable market in excess of $60B towards the end of this decade, \u201coffering plenty of opportunity for revenue expansion.\u201d Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders\u2019 Hot Stocks on TipRanks >> Read More on SCHW: Disclaimer & DisclosureReport an Issue Charles Schwab upgraded to Neutral from Sell at Redburn Atlantic Charles Schwab, Arbor Realty, Iron Mountain, Phillips 66, and Joby Aviation: Major Stock Moves Unveiled! Charles Schwab\u2019s Strong Financial Performance and Strategic Positioning Earns Buy Rating Charles Schwab Elects Directors at Annual Meeting \u201cStructurally Reducing Costs\u201d: TD Bank Stock (TSE:TD) Jumps as Bank Plans 2% Layoff"", ""Intuitive Surgical Stock Is Falling. The MedTech Got Its First Sell Rating. Deutsche Bank is the first group on Wall Street to issue a Sell rating on shares of Intuitive Surgical."", ""Intuitive Surgical cut to sell at Deutsche Bank Investing.com -- In a note to clients Monday, analysts at Deutsche Bank cut their rating for Intuitive Surgical (NASDAQ:ISRG) to Sell from Neutral, lowering their price target for the stock to $440 from $515 a share. ISRG shares are down more than 5% so far in the session, trading above the $525.50 mark. The bank stated that in conjunction with its note, it is hosting an investor webinar with Jon Reuter, COO of Keck Hospitals of USC, on Monday, June 9, with the discussion expected to help inform how Intuitive\u2019s hospital customers are thinking about the adoption of remanufactured Endowrist instruments. Deutsche Bank told investors that it believes Intuitive Surgical will likely face increasing competition. While the firm is \u201chighly confident in the durability of da Vinci (EPA:SGEF) surgery\u2019s dominance in the years ahead,\u201d it noted that there are multiple competitor robotic systems on the horizon, including the FDA approval of Medtronic\u2019s Hugo, expected in late 2025. These systems could impact ISRG\u2019s competitive moat. Despite downgrading the stock, Deutsche Bank did state that Intuitive\u2019s da Vinci platform \u201chas proven to be amongst the most disruptive technologies in medtech history.\u201d They also acknowledged that shareholders have \u201caccordingly been rewarded with the stock up over +26000% since its 2000 IPO (vs S&P 500 returning ~+500%) \u2013 and ISRG remains a consensus long.\u201d Related articles Intuitive Surgical cut to sell at Deutsche Bank Safran shares inch lower after Citi downgrades rating of French jet engine maker Tesla shares gain as Trump wishes Musk \u2019well\u2019"", ""Why Intuitive Surgical Stock Plunged Today Deutsche Bank downgraded Intuitive Surgical stock to sell this morning. The banker worries third-party remanufacturers will cut into Intuitive's surgical tools business. Deutsche's new price target sees 16% downside to the stock. 10 stocks we like better than Intuitive Surgical \u203a Intuitive Surgical (NASDAQ: ISRG), the maker of surgical robots and tools for robotic surgery, is taking it on the chin in afternoon trading Monday. Through 2:22 p.m. ET, Intuitive stock has lost 5.5% of its value. You can blame Deutsche Bank for that. Deutsche Bank downgraded Intuitive Surgical stock to \""sell\"" this morning, with a $440 price target implying more than 16% downside. \""Intuitive's da Vinci platform has proven to be among the most disruptive technologies in medtech history,\"" admits the banker, with more than 10,000 systems in service globally, performing more than 3 million robotic surgeries per year. Nevertheless, Deutsche sees risks in the company's business model, primarily to its \""Instruments and Accessories\"" business, where third-party companies have begun \""remanufacturing\"" old surgical instruments, once produced and sold by Intuitive but later worn out and removed from service. In theory, such instruments would be replaced by new equipment produced (and sold) by Intuitive to its customers. Repair and restored-to-service old instruments, however, could cut into that business, potentially reducing the company's U.S. I&A revenue by as much as 46%, warns Deutsche today in a note covered on The Fly. How worried should investors be about this? Pretty worried, I think. Consider that Intuitive Surgical stock sells for a sky-high 82 times trailing earnings at present, and requires a brisk growth rate to justify that valuation. Most analysts only expect the company to grow earnings 16% annually over the next five years, however, which isn't really that fast for a growth stock. And now Deutsche is saying even the \""16%\"" could be at risk? Sounds like a good reason to sell Intuitive Surgical stock and take some profits, if you ask me. Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now\u2026 and Intuitive Surgical wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you\u2019d have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you\u2019d have $868,615!* Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 792% \u2014 a market-crushing outperformance compared to 173% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks \u00bb *Stock Advisor returns as of June 9, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool has a disclosure policy. Why Intuitive Surgical Stock Plunged Today was originally published by The Motley Fool"", ""Why Intuitive Surgical (ISRG) Shares Are Trading Lower Today Shares of medical technology company Intuitive Surgical (NASDAQ:ISRG) fell 6.2% in the afternoon session after Deutsche Bank cut the stock's rating from Hold to Sell and slashed its price target to $440 from $515, after identifying accelerating competition from lower-cost remanufactured instruments in the Instruments & Accessories segment. Conversations with multiple robotic-surgery programs suggest a growing shift toward these third-party devices, threatening both Intuitive's market share and margins, and putting up to 46 % of its U.S. I&A revenue at risk. While the bank's model shows little financial drag in 2026, it expects pressure to emerge in 2027 and intensify through 2028. The shares closed the day at $525.93, down 5.6% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Intuitive Surgical? Access our full analysis report here, it\u2019s free. Intuitive Surgical\u2019s shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today\u2019s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. Intuitive Surgical is up 0.4% since the beginning of the year, but at $526.01 per share, it is still trading 13.8% below its 52-week high of $610.45 from January 2025. Investors who bought $1,000 worth of Intuitive Surgical\u2019s shares 5 years ago would now be looking at an investment worth $2,700. Today\u2019s young investors likely haven\u2019t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next."", ""3 Monster Stocks -- including Nvidia -- to Hold for the Next 10 Years Nvidia has been growing by an average of more than 70% annually. Intuitive Surgical is the 800-pound gorilla in the robotic surgery world. Microsoft is huge and getting bigger -- while paying a dividend. 10 stocks we like better than Intuitive Surgical \u203a The S&P 500 index tracks the stock performance of America's biggest companies, and it has averaged annual gains of roughly 10% over multiple decades. That's pretty darn good performance, enough to more than quintuple an investment over 15 years for those who purchased exchange-traded funds (ETFs) mirroring the index. Some individual stocks, though, have done better than that -- much better. In the table below, you'll see that the S&P 500 has been growing at a much faster rate over the past 15 years compared to its long-term 10% average. That outsized performance is due, in part, to the eye-popping average annual gains of some of its components, including what some might label as monster stocks, that have managed monster performances. Data source: Morningstar.com as of June 6, 2025. These kinds of returns are not guaranteed to continue. Many dynamically growing companies see their growth rates slow as they become massive companies. But a select few manage to keep up that outsized growth. Here's a closer look at three companies with this potential and some reasons why you might want to buy and/or keep holding any of them. Nvidia got its start as a maker of semiconductor chips for the videogame industry, but it has expanded its scope in the past decade. A side hustle into chip design catered to aid cryptocurrency mining has led to the development of chips and software that are now fueling the artificial intelligence (AI) boom, and it is churning out gobs of chips for data centers -- enough to be the world's leading supplier of graphics processing units for the data centers used in cloud computing. Data centers have replaced gaming as Nvidia's focus, and the company raked in $39 billion in revenue in fiscal 2026's first quarter from its data center business -- fully 89% of total revenue. Better still, CEO Jensen Huang forecasts that AI infrastructure spending could top $1 trillion annually within a few years, and he sees Nvidia capturing most of that business. Despite the monster performance over the past several years, Nvidia stock doesn't appear to be wildly overvalued at recent levels. Its recent forward-looking price-to-earnings (P/E) ratio of 33, for example, is well below the five-year average of 40. Consider buying Nvidia to hold for the next 10 years or more to take advantage of this forecasted growth. Intuitive Surgical is another strong stock performer, though it's not as attractively valued as Nvidia lately. Its forward P/E was recently at a steep 72, well above the five-year average of 56 (which is steep as well). So think twice before buying at these levels and look for opportunities to buy on the dip. But if you already own the stock, you might want to hold on. Intuitive Surgical is a leader in robotic surgery equipment. It has more than 8,600 of its million-dollar-plus da Vinci robotic surgery systems installed in 71 countries. Together, they've been used to perform more than 14 million medical procedures. I'm a shareholder and I'm hanging on because I expect the company to keep selling and installing surgical systems, and to keep raking in profits from doing so. Notably, Intuitive Surgical derives 84% of its revenue not from the systems themselves, but from dependable recurring sales of servicing, supplies, and accessories for the machines. Microsoft is a tech giant with many growing operations contributing to its steady growth. It's home to the dominant Office 365 suite of applications, the Azure cloud computing platform, the Xbox gaming platform, the Windows operating system, and even the business-oriented social media giant LinkedIn, among other ventures. Microsoft is huge (its market value hovers around $3.5 trillion), but it's still growing at a fairly rapid clip, with some of its recent growth largely attributable to its AI-related ventures. In its third quarter of fiscal 2025, revenue was up by 13% year over year, and net income rose by 18%. Its intelligent cloud division grew by 21%. The company is generating more cash than it needs to spend on growth, so it's paying shareholders a dividend that recently yielded 0.71%. (That might not seem like a lot, but the yield is pushed down because of strong share price performance and the dividend is growing briskly -- up from $2.09 per share in 2020 to $3.24 per share currently.) Despite the strong share price performance, its stock remains appealingly valued, too, with a recent forward P/E of 31 only a bit above the five-year average of 30. Given the steady growth, the stock seems well worth hanging on to for the next decade -- and beyond. Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now\u2026 and Intuitive Surgical wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you\u2019d have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you\u2019d have $868,615!* Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 792% \u2014 a market-crushing outperformance compared to 173% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks \u00bb *Stock Advisor returns as of June 9, 2025 Selena Maranjian has positions in Intuitive Surgical, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Intuitive Surgical, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 3 Monster Stocks -- including Nvidia -- to Hold for the Next 10 Years was originally published by The Motley Fool"", ""Should You Invest in Intuitive Surgical (ISRG) Based on Bullish Wall Street Views? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Intuitive Surgical, Inc. (ISRG). Intuitive Surgical currently has an average brokerage recommendation (ABR) of 1.62, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 29 brokerage firms. An ABR of 1.62 approximates between Strong Buy and Buy. Of the 29 recommendations that derive the current ABR, 20 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 69% and 6.9% of all recommendations. Check price target & stock forecast for Intuitive Surgical here>>> While the ABR calls for buying Intuitive Surgical, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every \""Strong Sell\"" recommendation, brokerage firms assign five \""Strong Buy\"" recommendations. This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. Although both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether. The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks. There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices. In terms of earnings estimate revisions for Intuitive Surgical, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $7.84. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Intuitive Surgical. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Intuitive Surgical. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Analyst Report: Intuitive Surgical, Inc. Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets."", ""Is Trending Stock Intuitive Surgical, Inc. (ISRG) a Buy Now? Intuitive Surgical, Inc. (ISRG) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this company have returned -6.3%, compared to the Zacks S&P 500 composite's +6.3% change. During this period, the Zacks Medical - Instruments industry, which Intuitive Surgical falls in, has gained 1.1%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, Intuitive Surgical is expected to post earnings of $1.92 per share, indicating a change of +7.9% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. For the current fiscal year, the consensus earnings estimate of $7.84 points to a change of +6.8%. from the prior year. Over the last 30 days, this estimate has remained unchanged. For the next fiscal year, the consensus earnings estimate of $9.05 indicates a change of +15.5% from what Intuitive Surgical is expected to report a year ago. Over the past month, the estimate has remained unchanged. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Intuitive Surgical is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. In the case of Intuitive Surgical, the consensus sales estimate of $2.35 billion for the current quarter points to a year-over-year change of +16.8%. The $9.65 billion and $11.11 billion estimates for the current and next fiscal years indicate changes of +15.6% and +15.1%, respectively. Intuitive Surgical reported revenues of $2.25 billion in the last reported quarter, representing a year-over-year change of +19.2%. EPS of $1.81 for the same period compares with $1.5 a year ago. Compared to the Zacks Consensus Estimate of $2.18 billion, the reported revenues represent a surprise of +3.27%. The EPS surprise was +5.85%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Intuitive Surgical is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intuitive Surgical. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""AMD price target, Intuitive Surgical downgrade: Trending Tickers Citi analysts lifted their price target for Advanced Micro Devices (AMD) to $120 from $100, highlighting potential positive catalysts in the second half of the year. Deutsche Bank downgraded Intuitive Surgical (ISRG) to Sell from Neutral and cut its price target for the company to $440. To watch more expert insights and analysis on the latest market action, check out more Wealth here.""]"
ISRG,2025-06-11,529.14,529.34,521.5,522.41,"ISRG Margin Outlook Dips on Tariffs, Demand Signals Stay Strong Intuitive Surgical ISRG delivered strong top-line growth in the first quarter of 2025, with revenue rising 19% year over year to $2.25 billion, supported by a 17% increase in da Vinci procedures and a 58% increase in Ion procedures. However, despite these positive fundamentals, the company revised its full-year gross margin guidance downward to 65%–66.5% compared with approximately 69.1% in 2024. The adjustment reflects an estimated 170 basis point impact from higher U.S.–China tariffs, which are expected to increase costs on imported components. For a company historically known for margin consistency, the update introduces a level of near-term uncertainty. The longer-term concern is not just the immediate margin drag, but the signaling effect it has on Intuitive Surgical’s cost structure resilience. The da Vinci system, especially the newly launched da Vinci 5, relies on a global supply chain of high-spec components and precision manufacturing. This makes the company more exposed to tariff volatility than peers with more geographically diversified operations. Management has not announced any supply chain reshoring plans, suggesting the gross margin impact could persist if trade tensions remain elevated. However, Intuitive Surgical remains fundamentally well-positioned. Its recurring revenue base is stable and growing, procedure volumes continue to expand at a healthy pace, and the company maintains a strong balance sheet with approximately $9 billion in cash. This financial strength supports continued investment in innovation and infrastructure, giving Intuitive Surgical the tools to navigate near-term pressures and preserve its long-term competitive position. Per the fourth quarter fiscal 2025 earnings presentation, Medtronic MDT expects a $700–950 million gross impact from U.S.–China tariffs in fiscal 2026 but aims to offset $500–600 million, resulting in a net COGS hit of $200–$350 million. The impact will ramp through the year, with approximately 60% expected in the fiscal fourth quarter. While margin guidance remains unchanged, Medtronic’s broad global manufacturing base positions it to manage trade volatility more effectively than peers with more concentrated supply chains. Per the first-quarter earnings call, Zimmer Biomet ZBH anticipates a $60–$80 million tariff-related drag on its 2025 operating profit, with most of the impact expected in the second half of the year. Despite this headwind, the company is actively implementing mitigation strategies including country-of-origin optimization, dual sourcing, transfer pricing adjustments, and selective cuts in discretionary spending, measures expected to confine near-term cost pressure to a manageable range. Shares of ISRG have gained 1.5% in the year-to-date period against the industry’s decline of 9.4%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-sales ratio of 18.43, above the industry average. But it is still lower than its five-year median of 19.23. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 6.8% rise from the year-ago period’s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-06-12,520.255,521.39,511.76,513.0,"[""Institutional investors in Intuitive Surgical, Inc. (NASDAQ:ISRG) lost 6.4% last week but have reaped the benefits of longer-term growth Institutions' substantial holdings in Intuitive Surgical implies that they have significant influence over the company's share price The top 24 shareholders own 51% of the company Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Every investor in Intuitive Surgical, Inc. (NASDAQ:ISRG) should be aware of the most powerful shareholder groups. With 87% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Losing money on investments is something no shareholder enjoys, least of all institutional investors who saw their holdings value drop by 6.4% last week. However, the 22% one-year returns may have helped alleviate their overall losses. They should, however, be mindful of further losses in the future. In the chart below, we zoom in on the different ownership groups of Intuitive Surgical. See our latest analysis for Intuitive Surgical Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Intuitive Surgical already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Intuitive Surgical's historic earnings and revenue below, but keep in mind there's always more to the story. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. Intuitive Surgical is not owned by hedge funds. The Vanguard Group, Inc. is currently the company's largest shareholder with 9.1% of shares outstanding. In comparison, the second and third largest shareholders hold about 8.8% and 4.3% of the stock. A closer look at our ownership figures suggests that the top 24 shareholders have a combined ownership of 51% implying that no single shareholder has a majority. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our data suggests that insiders own under 1% of Intuitive Surgical, Inc. in their own names. Being so large, we would not expect insiders to own a large proportion of the stock. Collectively, they own US$945m of stock. In this sort of situation, it can be more interesting to see if those insiders have been buying or selling. The general public-- including retail investors -- own 13% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. It's always worth thinking about the different groups who own shares in a company. But to understand Intuitive Surgical better, we need to consider many other factors. Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."", ""Intuitive Surgical, Inc. (ISRG) Suffers a Larger Drop Than the General Market: Key Insights The latest trading session saw Intuitive Surgical, Inc. (ISRG) ending at $522.41, denoting a -1.36% adjustment from its last day's close. This change lagged the S&P 500's 0.27% loss on the day. The company's shares have seen a decrease of 6.09% over the last month, not keeping up with the Medical sector's gain of 4.77% and the S&P 500's gain of 6.9%. The investment community will be closely monitoring the performance of Intuitive Surgical, Inc. in its forthcoming earnings report. The company's upcoming EPS is projected at $1.92, signifying a 7.87% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $2.35 billion, indicating a 16.81% growth compared to the corresponding quarter of the prior year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $7.84 per share and a revenue of $9.65 billion, representing changes of +6.81% and +15.56%, respectively, from the prior year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Intuitive Surgical, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Intuitive Surgical, Inc. is currently sporting a Zacks Rank of #3 (Hold). Looking at its valuation, Intuitive Surgical, Inc. is holding a Forward P/E ratio of 67.55. This signifies a premium in comparison to the average Forward P/E of 26.59 for its industry. Also, we should mention that ISRG has a PEG ratio of 4.47. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.28 based on yesterday's closing prices. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 137, which puts it in the bottom 45% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
ISRG,2025-06-13,503.29,518.17,500.29,512.18,
ISRG,2025-06-16,514.0,523.53,514.0,519.04,
ISRG,2025-06-17,515.81,517.72,508.99,512.11,"[""The Top 5 Analyst Questions From Intuitive Surgical\u2019s Q1 Earnings Call Intuitive Surgical\u2019s first quarter results drew a positive market response, as the company delivered solid sales and non-GAAP profitability above Wall Street\u2019s expectations. Management attributed the strong performance to accelerating adoption of its da Vinci 5 platform, broader utilization of robotic-assisted procedures in the United States, and robust international procedural growth\u2014particularly in markets like India, Korea, and the U.K. CEO Gary Guthart highlighted that \u201cphysicians using our products [were] at the high end of our expectations,\u201d with notable expansion in both general and after-hours surgeries. The quarter also saw continued momentum for the Ion and single-port systems, reflecting the company\u2019s ongoing focus on minimally invasive care. Is now the time to buy ISRG? Find out in our full research report (it\u2019s free). Revenue: $2.25 billion vs analyst estimates of $2.19 billion (19.2% year-on-year growth, 3.1% beat) Adjusted EPS: $1.81 vs analyst estimates of $1.73 (4.4% beat) Operating Margin: 25.7%, in line with the same quarter last year Market Capitalization: $186 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Travis Steed (Bank of America Securities) asked about the breakdown and cadence of tariff impacts. CFO Jamie Samath explained that roughly half of the impact is tied to U.S.-China trade, with the effect increasing in later quarters, and that mitigation strategies would depend on how policies evolve. Larry Biegelsen (Wells Fargo) pressed for details on mitigating tariffs and the timeline for operational changes. Samath stated that the company is prioritizing stability before acting and that any supply chain adjustments will be considered carefully to avoid disruption. Robbie Marcus (JPMorgan) questioned the rationale behind raising the procedure growth forecast early in the year. Samath said day-adjusted Q1 procedure growth provided strong momentum, while CEO Gary Guthart added that customers view the platform as part of the solution to care delivery. Rick Wise (Stifel) asked about sustainability of international procedure growth and after-hours surgery expansion. President David Rosa highlighted growth in early-stage markets, increased engagement with key opinion leaders, and investments in after-hours and cardiac surgery programs. Adam Maeder (Piper Sandler) inquired about adoption and clinical validation of force feedback technology. Management outlined ongoing studies, supply constraints, and plans for broader clinical validation as manufacturing ramps up. In coming quarters, the StockStory team will be watching (1) the pace and breadth of da Vinci 5 feature rollouts and regulatory clearances, (2) the impact and management response to rising tariff-related costs and trade policy shifts, and (3) continued growth in international procedures despite capital budget constraints. Progress on manufacturing expansion and clinical validation of digital and force feedback tools will also be closely tracked. Intuitive Surgical currently trades at $516, up from $478.74 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it\u2019s free). Donald Trump\u2019s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today."", ""ISRG's Minimally Invasive Ecosystem Powers Surgical Precision Intuitive Surgical ISRG has built a comprehensive and integrated portfolio focused on advancing minimally invasive care, with its cornerstone being the da Vinci robotic surgical systems. The da Vinci platforms \u2014 ranging from the established multi-port Xi and X systems to the next-generation da Vinci 5 \u2014 enable surgeons to perform complex procedures through small incisions with enhanced precision, visualization and control. These systems are widely adopted across specialties such as urology, gynecology, general surgery, and thoracic care. Complementing the multi-port systems is the da Vinci SP (single-port) platform, designed for narrow-access procedures through a single incision, further minimizing patient trauma and recovery time. Expanding beyond surgery, Intuitive\u2019s Ion endoluminal system targets early-stage lung cancer diagnosis through minimally invasive robotic bronchoscopy. Ion is gaining strong commercial traction, diversifying ISRG\u2019s revenues and broadening its presence in the diagnostic space. The portfolio also includes advanced surgical tools like EndoWrist instruments, SureForm staplers, SynchroSeal vessel sealers, and Firefly fluorescence imaging, all aimed at enhancing procedural efficiency and surgical outcomes. Supporting this hardware ecosystem is a growing suite of digital and training tools, including the My Intuitive app, SimNow virtual simulators, and real-time analytics via Intuitive Hub. These offerings help improve surgeon proficiency and optimize workflow within hospitals. With over 12 million da Vinci procedures performed globally and more than 10,000 systems installed, Intuitive Surgical continues to solidify its position as a leader in minimally invasive care, leveraging technology to reduce open surgeries, improve outcomes and expand access worldwide. Other Players in Minimal Invasive Space Johnson & Johnson JNJ, or J&J continues to invest heavily in its minimally invasive surgery portfolio through its MedTech division, particularly Ethicon. J&J\u2019s offerings span advanced energy devices, surgical staplers, and robotic-assisted systems like the VELYS Robotic-Assisted Solution for orthopedic procedures. J&J is also developing the Ottava soft-tissue robotic system, aiming to challenge incumbents in the robotic-assisted surgery space. JNJ\u2019s strength lies in its scale, legacy in surgical innovation, and integration across devices and digital platforms to support better surgical outcomes. With Ottava in clinical trials, J&J is positioning itself to gain share in the rapidly growing minimally invasive surgery market. Edwards Lifesciences EW is a leader in structural heart therapies, transforming minimally invasive care with its transcatheter aortic valve replacement (TAVR) solutions. EW\u2019s SAPIEN valve platform is widely adopted, and the company continues to expand into mitral and tricuspid segments. With a strong pipeline and global reach, EW remains pivotal to minimally invasive surgery innovation. ISRG\u2019s Price Performance, Valuation and Estimates Shares of ISRG have lost 1.9% in the year-to-date period compared with the industry\u2019s decline of 11%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-sales ratio of 18.02, above the industry average. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical\u2019s 2025 earnings implies a 6.8% rise year over year. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Intuitive Surgical (ISRG): Buy, Sell, or Hold Post Q1 Earnings? Over the past six months, Intuitive Surgical\u2019s stock price fell to $516.25. Shareholders have lost 5.3% of their capital, disappointing when considering the S&P 500 was flat. This may have investors wondering how to approach the situation. Following the pullback, is now a good time to buy ISRG? Find out in our full research report, it\u2019s free. Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful Surgical Equipment & Consumables - Specialty company because there\u2019s a ceiling to what customers will pay. Intuitive Surgical\u2019s system placement punched in at 367 in the latest quarter, and over the last two years, averaged 11.8% year-on-year growth. This performance was impressive and shows its offerings have a unique value proposition (and perhaps some degree of customer loyalty). Forecasted revenues by Wall Street analysts signal a company\u2019s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite, though some deceleration is natural as businesses become larger. Over the next 12 months, sell-side analysts expect Intuitive Surgical\u2019s revenue to rise by 14.6%. While this projection is slightly below its 16.4% annualized growth rate for the past two years, it is admirable and indicates the market is baking in success for its products and services. We track the long-term change in earnings per share (EPS) because it highlights whether a company\u2019s growth is profitable. Intuitive Surgical\u2019s EPS grew at a spectacular 12.3% compounded annual growth rate over the last five years. This performance was better than most healthcare businesses. Intuitive Surgical possesses several positive attributes. After the recent drawdown, the stock trades at 61.9\u00d7 forward P/E (or $516.25 per share). Is now a good time to buy? See for yourself in our comprehensive research report, it\u2019s free. The market surged in 2024 and reached record highs after Donald Trump\u2019s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we\u2019re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver\u2019s seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.""]"
ISRG,2025-06-18,512.11,513.96,506.535,509.49,"[""ISRG vs BSX: Which Medical Device Stock Has More Room to Run? In a healthcare landscape increasingly shaped by technology, two names that stand out for their innovation and long-term potential are Intuitive Surgical ISRG and Boston Scientific BSX. Both companies are at the forefront of minimally invasive procedures \u2014 Intuitive as the undisputed leader in robotic-assisted surgery, and Boston Scientific as a powerhouse in interventional medical devices. With growing demand for advanced surgical solutions and aging global populations driving healthcare needs, investors are eyeing these med-tech giants as attractive long-term plays. But, which stock offers more compelling upside right now? Let\u2019s break down the fundamentals, growth trajectories, and market positions of ISRG and BSX to find out which one deserves a place in your portfolio. ISRG & BSX: Price Performance Intuitive Surgical represents a high-growth, high-premium pure play on robotic-assisted surgery. Its exceptional performance and growth provide compelling upside, but investors must accept margin compression and valuation risk in the short-to-medium term. Boston Scientific offers broader exposure to medical device innovation, with reliable growth driven by cardiovascular and interventional segments. It trades at a more moderate valuation and may appeal to investors seeking growth with less volatility. The year-to-date price performance of Intuitive Surgical has not been impressive, likely due to tariff concerns and rising competition from Chinese robotic device makers. However, BSX has outperformed ISRG likely due to its diversified business as well as strong U.S. demand. Shares of ISRG have lost 1.9% year to date, while those of BSX have gained 13.9%. Image Source: Zacks Investment Research Market Position & Core Offerings Intuitive Surgical dominates the surgical robotics niche with its flagship da???Vinci system, which continues to gain traction globally \u2014 367 new units placed in the first quarter of 2025 alone, leading to a 17% year-over-year increase in procedures. Boston Scientific, by contrast, operates across a broader landscape of interventional medical devices, from cardiovascular to neuromodulation. Its success with Farapulse pulsed field ablation and strong cardiovascular sales (+26% in first-quarter 2025) highlight its diversified growth drivers. Growth & Performance ISRG delivered robust first-quarter 2025 results: revenues grew 19% to $2.25 billion, adjusted net income rose 22% to $767.5 million, and adjusted EPS grew 21% to $1.81. Its projected procedure growth remains strong at 15-17% for the year, though margins may be pressured by tariffs. BSX also posted solid first-quarter 2025 earnings, with adjusted EPS of $0.75 and sales worth $4.66 billion, both beating expectations on the back of cardiovascular and medical-surgical divisions. For the second quarter of 2025, revenues are expected to grow by double digits, driven by PFA and other interventions. Estimates Comparison for ISRG & BSX The Zacks Consensus Estimate for ISRG\u2019s fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 6.8%, respectively. EPS estimates for 2025 and 2026 have trended southward over the past 60 days. ISRG Estimate Movement Image Source: Zacks Investment Research The Zacks Consensus Estimate for Boston Scientific\u2019s 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. Moreover, EPS estimates for 2025 and 2026 have improved over the past 60 days. BSX Estimate Movement Image Source: Zacks Investment Research Cash & Cash Flow Intuitive Surgical maintains an exceptionally strong balance sheet, with $4.51 billion in cash and no debt as of the first quarter of 2025. The company generated free cash flow of around $465 million and operating cash flow of $582 million, driven by continued growth in da Vinci system procedures and high-margin recurring revenues from instruments and accessories. Boston Scientific, operates with a more leveraged profile. The company reported $725 million in cash and $11.31 billion in total debt, with a debt-to-equity ratio of nearly 50%. Despite this, BSX maintains strong cash generation, posting $541 million in operating cash flow and $354 million in free cash flow for the first quarter of 2025 alone. Its diversified product base, especially in cardiovascular and electrophysiology, supports ongoing growth and debt service. Risks & Operational Challenges ISRG is exposed to geopolitical and trade-related tariff risks \u2014 especially a 125% tariff on Chinese exports \u2014 which have led to margin revisions for 2025. Mitigation efforts include supply-chain adjustments and pricing flexibility. BSX contends with regulatory and legal exposures (notably from past medical-device recalls and mesh product lawsuits), but its diversified supply chain and global footprint help buffer macroeconomic pressures. ISRG or BSX: Which Is a Better Bet? For investors focused on explosive, category-leading growth in surgical robotics, ISRG may still be the superior choice. But those who prefer balanced exposure across med-tech segments with a steadier valuation profile might consider BSX as a more diversified, resilient option. Intuitive Surgical stands out for its pristine balance sheet, zero debt, and strong free cash flow, making it an appealing choice for investors prioritizing financial stability and growth. Boston Scientific's leveraged balance sheet is offset by a diversified product base and solid, consistent cash generation, positioning it as a resilient and innovative med-tech player for investors comfortable with moderate financial risk. Both companies currently carry a Zacks Rank #3 (Hold). However, if we go by the Zacks Style Score, BSX seems to be a better bet compared to ISRG. While ISRG has a Zacks Style Score of \u2018D\u2019, BSX\u2019s score is \u2018C\u2019, reflecting better growth potential. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Weekly Picks: \ud83d\udc8a VLS' Solvable Headwinds, VOS' Multi-Year Growth, and ISRG's Valuation Concerns Each week our analysts hand pick their favourite Narratives from the community ( what is a Narrative? ). This week\u2019s picks cover: \ud83d\udc8a Why Vita Life Science\u2019s is a solid business with solvable headwinds. \ud83c\uddea\ud83c\uddfa How 2 massive tailwinds will drive multi-year growth for Vossloh. \u26a0\ufe0f Why Intuitive Surgical\u2019s strengths don\u2019t outweigh the valuation risks. \ud83d\udca1 Why we like it: This is a nuanced take on a steady but under-appreciated small-cap. The author doesn\u2019t ignore the headwinds (margin compression, FCF volatility) but frames them as solvable, giving this story both realism and recovery potential. \ud83d\udca1 Why we like it: This is a clear-eyed thesis that connects macro-scale infrastructure spending with company-specific catalysts like Sateba and smart digital upgrades. Their case blends revenue visibility, margin expansion, and a rising moat, making Vossloh a rare industrial that has both stability and upside. \ud83d\udca1 Why we like it: It\u2019s a well-structured growth thesis with clear timelines and layered catalysts. The blend of bullish conviction and valuation caution makes it a balanced take on a premium-priced healthcare innovator with serious staying power. This author thinks it\u2019s one for the watchlist. Disclaimer Simply Wall St analyst Michael Paige and Simply Wall St have no position in any of the companies mentioned. These narratives are general in nature and explore scenarios and estimates created by the authors. These narratives do not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company\u2019s future performance and are exploratory in the ideas they cover. The fair value estimate\u2019s are estimations only, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author\u2019s analysis may not factor in the latest price-sensitive company announcements or qualitative material. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com Simply Wall St analyst Michael Paige and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material."", ""Intuitive Surgical, Inc. (ISRG) Suffers a Larger Drop Than the General Market: Key Insights Intuitive Surgical, Inc. (ISRG) closed at $512.11 in the latest trading session, marking a -1.34% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.84%. Elsewhere, the Dow lost 0.7%, while the tech-heavy Nasdaq lost 0.91%. Coming into today, shares of the company had lost 7.91% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 1.44%. Analysts and investors alike will be keeping a close eye on the performance of Intuitive Surgical, Inc. in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.92, signifying a 7.87% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $2.35 billion, up 16.81% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of $7.84 per share and revenue of $9.65 billion, which would represent changes of +6.81% and +15.56%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for Intuitive Surgical, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.02% higher. At present, Intuitive Surgical, Inc. boasts a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that Intuitive Surgical, Inc. has a Forward P/E ratio of 83.26 right now. This represents a premium compared to its industry average Forward P/E of 26.88. Investors should also note that ISRG has a PEG ratio of 5.51 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical - Instruments industry stood at 2.26 at the close of the market yesterday. The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 151, placing it within the bottom 39% of over 250 industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Virtual Incision Appoints Jim Alecxih as Chief Executive Officer Seasoned medtech leader and former Intuitive Surgical executive to accelerate development and commercialization of the company\u2019s next-generation MIRA Surgical System platforms and technologies LINCOLN, Neb., June 18, 2025--(BUSINESS WIRE)--Virtual Incision Corporation, the developer of the MIRA Surgical System authorized by the FDA through the De Novo regulatory pathway, today announced the appointment of Jim Alecxih as chief executive officer. Alecxih, a recognized commercial leader in the medical device industry, brings more than 30 years of experience advancing transformative surgical technologies worldwide, including a distinguished tenure at Intuitive Surgical, where he played a pivotal role in the adoption and growth of the da Vinci Surgical System. Virtual Incision is now preparing for the accelerated development and commercialization of their next system, M2, with plans for a series of FDA submissions in various specialties. M2 is a miniaturized, single port surgical robotic system designed to be smart, simple and small, with the potential to minimize the cost and complexity of current mainframe cart-based surgical robotic systems. M2 will be optimized to bring robotic-assisted surgery to hospitals and surgical settings that lack access to surgical robotics technologies. Mr. Alecxih previously served as CEO of DH Medical, an AI software company, and has held executive leadership roles across multiple healthcare startups and growth-stage companies. At Intuitive Surgical, he led U.S. sales and was instrumental in driving adoption of robotic-assisted surgery among hospitals and health systems nationwide. \""The opportunity to lead Virtual Incision at this pivotal time is an extraordinary honor,\"" said Jim Alecxih, CEO of Virtual Incision. \""I believe deeply in the benefits of robotic-assisted surgery to both patients, surgeons and hospitals. M2 has the potential to dramatically expand access to robotic-assisted surgery in rural hospitals, HOPD and ASC settings, and around the world. Virtual Incision\u2019s visionary approach is to ensure that robotic-assisted surgery is more accessible, flexible and scalable for a broader range of operating environments. I\u2019m thrilled to join this talented team and help accelerate our impact on patients and providers.\"" \""We are delighted to welcome Mr. Alecxih to Virtual Incision at this significant stage in the company\u2019s growth,\"" said Tyler Stowater, partner at Bluestem Capital and Virtual Incision board member. \""Mr. Alecxih\u2019s exceptional leadership skills and deep industry knowledge make him the ideal person to lead us into our next phase of growth and innovation.\"" Mr. Alecxih joins Virtual Incision at a time of significant momentum. In 2025, the company has been honored as a finalist or winner in three prestigious innovation awards: Fast Company\u2019s World\u2019s Most Innovative Companies SXSW Innovation Award Fierce MedTech\u2019s Fierce 15 Virtual Incision\u2019s MIRA Surgical System is designed to offer a portable, scalable solution for minimally invasive procedures with a small footprint and a simple setup. With M2, the company aims to expand clinical capabilities and will continue redefining the future of robotic-assisted surgery. About the MIRA Surgical System MIRA is the world\u2019s first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room \u2013 a dedicated operating room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a legacy surgical robotic system. With MIRA, every operating room is RAS-ready. About Virtual Incision Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision\u2019s goal is to make every operating room RAS-ready. For more information, visit our website or follow us on LinkedIn. Important Safety Information The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. For important safety information, indications for use, risks, and warnings, please refer to www.virtualincision.com/safety-information. Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute \""forward-looking statements\"" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. View source version on businesswire.com: https://www.businesswire.com/news/home/20250618564562/en/ Contacts Media Contact: Ashlynn Meyer Virtual Incision ashlynn.meyer@virtualincision.com""]"
ISRG,2025-06-20,514.7,515.01,508.76,509.36,"Deutsche Bank Slashes Intuitive Surgical (ISRG) To Sell from Neutral Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best stocks to buy. On June 9, Deutsche Bank slashed its rating for ISRG from Neutral to Sell, trimming the price target from $440 to $515. Deutsche Bank announced that it will hold an investor webinar with Jon Reuter, COO of Keck Hospitals of USC, on June 9, to explore how hospitals are viewing Intuitive’s remanufactured Endowrist instruments. The bank projected rising competition for Intuitive Surgical, signaling potential headwinds ahead. Deutsche Bank, though confident in da Vinci’s lasting dominance, pointed to several upcoming rival systems, including Medtronic’s Hugo, expected FDA approval in late 2025, as potential threats to ISRG’s competitive edge. Even with a Sell rating, the firm highlighted the da Vinci system as a historic disruptor within medical technology. A medical team performing minimally invasive surgery with a da Vinci Surgical System. Deutsche Bank noted that shareholders have realized substantial gains, with shares soaring more than 26,000% since the company’s IPO in 2000, compared to a nearly 500% rise in the broader market, and ISRG remains a bullish idea. Intuitive Surgical, Inc. (NASDAQ:ISRG) develops robotic systems like da Vinci and Ion to advance minimally invasive procedures, supported by specialized tools, training, and digital services to enhance surgical outcomes and healthcare efficiency. While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None."
ISRG,2025-06-23,508.0,515.36,503.18,515.09,"Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock Intuitive Surgical, Inc. (ISRG) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this company have returned -5.6%, compared to the Zacks S&P 500 composite's +0.5% change. During this period, the Zacks Medical - Instruments industry, which Intuitive Surgical falls in, has lost 4.7%. The key question now is: What could be the stock's future direction? While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Intuitive Surgical is expected to post earnings of $1.92 per share, indicating a change of +7.9% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. The consensus earnings estimate of $7.84 for the current fiscal year indicates a year-over-year change of +6.8%. This estimate has remained unchanged over the last 30 days. For the next fiscal year, the consensus earnings estimate of $9.05 indicates a change of +15.5% from what Intuitive Surgical is expected to report a year ago. Over the past month, the estimate has remained unchanged. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Intuitive Surgical is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. In the case of Intuitive Surgical, the consensus sales estimate of $2.35 billion for the current quarter points to a year-over-year change of +16.8%. The $9.65 billion and $11.11 billion estimates for the current and next fiscal years indicate changes of +15.6% and +15.1%, respectively. Intuitive Surgical reported revenues of $2.25 billion in the last reported quarter, representing a year-over-year change of +19.2%. EPS of $1.81 for the same period compares with $1.5 a year ago. Compared to the Zacks Consensus Estimate of $2.18 billion, the reported revenues represent a surprise of +3.27%. The EPS surprise was +5.85%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Intuitive Surgical is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intuitive Surgical. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-06-24,518.805,523.97,510.78,523.08,"[""Intuitive Surgical, Inc. (ISRG) Surpasses Market Returns: Some Facts Worth Knowing In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $515.09, marking a +1.12% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.96% for the day. Elsewhere, the Dow saw an upswing of 0.89%, while the tech-heavy Nasdaq appreciated by 0.94%. Heading into today, shares of the company had lost 5.59% over the past month, lagging the Medical sector's loss of 0.85% and the S&P 500's gain of 0.5%. Market participants will be closely following the financial results of Intuitive Surgical, Inc. in its upcoming release. In that report, analysts expect Intuitive Surgical, Inc. to post earnings of $1.92 per share. This would mark year-over-year growth of 7.87%. Our most recent consensus estimate is calling for quarterly revenue of $2.35 billion, up 16.81% from the year-ago period. For the full year, the Zacks Consensus Estimates are projecting earnings of $7.84 per share and revenue of $9.65 billion, which would represent changes of +6.81% and +15.56%, respectively, from the prior year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Intuitive Surgical, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.02% rise in the Zacks Consensus EPS estimate. Intuitive Surgical, Inc. currently has a Zacks Rank of #3 (Hold). Looking at valuation, Intuitive Surgical, Inc. is presently trading at a Forward P/E ratio of 64.96. This valuation marks a premium compared to its industry average Forward P/E of 26.39. One should further note that ISRG currently holds a PEG ratio of 4.3. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.24. The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 159, this industry ranks in the bottom 36% of all industries, numbering over 250. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""cultivate(MD) Announces Portfolio Company, Virtual Incision Corporation, Appoints Jim Alecxih as Chief Executive Officer GRAND RAPIDS, Mich., June 24, 2025 /PRNewswire/ -- cultivate(MD), a leading medical device venture capital company, is pleased to announce that its portfolio company, Virtual Incision Corporation, the developer of the MIRA Surgical System authorized by the FDA through the De Novo regulatory pathway, has appointed Jim Alecxih as Chief Executive Officer. Alecxih, a recognized commercial leader in the medical device industry, brings more than 30 years of experience advancing transformative surgical technologies worldwide, including a distinguished tenure at Intuitive Surgical, where he played a pivotal role in the adoption and growth of the da Vinci Surgical System. Virtual Incision is now preparing for the accelerated development and commercialization of their next system, M2, with plans for a series of FDA submissions in various specialties. M2 is a miniaturized, single port surgical robotic system designed to be smart, simple and small, with the potential to minimize the cost and complexity of current mainframe cart-based surgical robotic systems. M2 will be optimized to bring robotic-assisted surgery to hospitals and surgical settings that lack access to surgical robotics technologies. Mr. Alecxih previously served as CEO of DH Medical, an AI software company, and has held executive leadership roles across multiple healthcare startups and growth-stage companies. At Intuitive Surgical, he led U.S. sales and was instrumental in driving adoption of robotic-assisted surgery among hospitals and health systems nationwide. \""The opportunity to lead Virtual Incision at this pivotal time is an extraordinary honor,\"" said Jim Alecxih, CEO of Virtual Incision. \""I believe deeply in the benefits of robotic-assisted surgery to both patients, surgeons and hospitals. M2 has the potential to dramatically expand access to robotic-assisted surgery in rural hospitals, Hospital Outpatient Department (HOPD) and Ambulatory Surgery Centers (ASC) settings, and around the world. Virtual Incision's visionary approach is to ensure that robotic-assisted surgery is more accessible, flexible and scalable for a broader range of operating environments. I'm thrilled to join this talented team and help accelerate our impact on patients and providers.\"" \""We are excited for this next significant phase and stage in the life of Virtual Incision's important journey to continue to bring \""MIRA\"", the miniature innovative robot, to the world,\"" said Dave Blue, Director, cultivate(MD) Capital Funds. Mr. Alecxih joins Virtual Incision at a time of significant momentum. In 2025, the company has been honored as a finalist or winner in three prestigious innovation awards: Fast Company's World's Most Innovative Companies SXSW Innovation Award Fierce MedTech's Fierce 15 Virtual Incision's MIRA Surgical System is designed to offer a portable, scalable solution for minimally invasive procedures with a small footprint and a simple setup. With M2, the company aims to expand clinical capabilities and will continue redefining the future of robotic-assisted surgery. About cultivate(MD) cultivate(MD) is a medical device venture capital firm dedicated to advancing healthcare innovation. With a keen focus on cutting-edge medical technologies, cultivate(MD) supports companies that show the potential to revolutionize healthcare delivery and patient care. For more information, visit: https://cultivate-md.com About the MIRA Surgical System MIRA is the world's first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room \u2013 a dedicated operating room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a legacy surgical robotic system. With MIRA, every operating room is RAS-ready. About Virtual Incision Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision's goal is to make every operating room RAS-ready. For more information, visit: https://virtualincision.com Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute \""forward-looking statements\"" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. View original content to download multimedia:https://www.prnewswire.com/news-releases/cultivatemd-announces-portfolio-company-virtual-incision-corporation-appoints-jim-alecxih-as-chief-executive-officer-302488850.html SOURCE cultivate(MD)""]"
ISRG,2025-06-25,524.3,528.14,521.26,521.63,"[""Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025? Intuitive Surgical ISRG entered 2025 with strong operational momentum, delivering 17% year-over-year growth in da Vinci procedures and a 19% rise in total revenues (to $2.25 billion) in the first quarter. Notably, day-adjusted procedure growth reached 18.5%, causing management to raise full-year guidance to 15-17%. This growth was supported by robust adoption in general surgery in the United States and accelerated utilization in emerging markets like India, Korea and the United Kingdom. The rollout of the da Vinci 5 platform continued at pace, with 147 new systems placed and over 32,000 procedures completed using the new-generation robot. However, this clinical and procedural strength faces growing financial headwinds. Gross margins declined to 66.4% in the first quarter from 67.6% a year ago due to increased depreciation, a higher mix of lower-margin platforms like Ion and da Vinci 5, and emerging cost pressures from newly implemented global tariffs. ISRG now expects tariff-driven cost of sales to erode margins by approximately 170 basis points for the full year, revising its gross margin forecast to 65-66.5%. While recurring revenues remain strong, representing 85% of the total revenues, capital expenditures, manufacturing investments and rising input costs may challenge operating leverage in the near term. Moreover, constrained hospital budgets in key markets like Germany and Japan could tamper the company\u2019s capital placement run rate, adding another layer of margin pressure. Intuitive Surgical\u2019s solid procedure growth and market adoption are commendable, but they will be tested against a backdrop of tightening margins, macroeconomic headwinds and evolving trade dynamics. Investors should watch closely whether strong volume momentum can continue to outrun inflationary and structural cost drags in the quarters ahead. In the first quarter of 2025, Stryker SYK posted strong financials, with organic sales growth of 10.1% and total revenues reaching $5.87 billion, reflecting an 11.9% year-over-year rise. This was driven by robust demand across MedSurg & Neurotechnology and Orthopaedics segments, including standout growth in trauma and extremities, and expanding Mako installations. Stryker\u2019s adjusted gross margin was 65.5%, up 190 basis points year over year, aided by manufacturing efficiencies, favorable pricing and product mix. Despite a $200 million tariff headwind expected for the year, Stryker maintained operating margin expansion of 100 basis points, reflecting strong cost control and operational leverage. In contrast, Medtronic MDT reported 3.9% year-over-year revenue growth in the fourth quarter of fiscal 2025 (to $8.93 billion), with strength in Cardiovascular (up 22% in cardiac ablation), Neuroscience, and Diabetes offsetting surgical headwinds. Medtronic\u2019s gross margin improved to 64.7% (up 19 basis points) and operating margin rose to 26.6%, buoyed by pricing strategies and cost-of-goods-sold productivity gains. However, growth remained uneven across Medtronic\u2019s portfolios. Shares of ISRG have gained 0.1% in the year-to-date period against the industry\u2019s decline of 11.4%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 62.09, above the industry average. But, it is still lower than its five-year median of 72.17. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical\u2019s 2025 earnings implies a 6.8% rise from the year-ago period\u2019s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Intuitive Surgical, Inc. (ISRG): A Bull Case Theory We came across a bullish thesis on Intuitive Surgical, Inc. (ISRG) on PitchStack Investing\u2019s Substack. In this article, we will summarize the bulls\u2019 thesis on ISRG. Intuitive Surgical, Inc. (ISRG)'s share was trading at $513 as of 12th June. ISRG\u2019s trailing and forward P/E were 76.49 and 67.11 respectively according to Yahoo Finance. Close-up of a robotic endoluminal surgery device performing a procedure in an operating room. Intuitive Surgical stands as a dominant force in the field of robotic-assisted surgery, leveraging decades of innovation to maintain a commanding 90% market share in this high-growth sector. The company continues to enhance minimally invasive care through its advanced technologies, most notably the Ion system, which delivers an 83% diagnostic yield for small lung nodules\u2014far surpassing traditional manual methods. This superior performance not only positions Ion for broader adoption in pulmonary care but also adds a meaningful growth vector to Intuitive's already robust platform. The widespread acceptance of the company\u2019s systems across hospitals worldwide reinforces its competitive moat, making it exceedingly difficult for new entrants to gain traction. Investors looking for sustained long-term growth may find the current setup compelling: analysts project a 115% stock price increase over the next five years, implying a 17% internal rate of return. This growth potential is grounded in a combination of expanding procedure volumes, continuous product innovation, and a razor-and-blade business model that ensures recurring revenue through instruments and service. Intuitive\u2019s entrenched position in hospitals, proven clinical efficacy, and ongoing investments in next-generation systems provide a strong foundation for continued leadership in surgical robotics. As healthcare systems globally prioritize better outcomes and operational efficiency, Intuitive Surgical is uniquely positioned to benefit from this secular shift, offering investors a rare blend of resilience, technological leadership, and upside. Previously, we covered a bullish thesis on ISRG by The Antifragile Investor in January 2025, focusing on its da Vinci-driven moat, IP edge, and recurring revenue. PitchStack Investing shares this view but emphasizes growth\u2014citing Ion\u2019s clinical advantage, 90% market share, and a 17% IRR forecast. Both see a leader, but one stresses defensibility, the other, accelerating upside. Intuitive Surgical, Inc. (ISRG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 106 hedge fund portfolios held Intuitive Surgical, Inc. (ISRG) at the end of the first quarter which was 95 in the previous quarter. While we acknowledge the risk and potential of ISRG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.""]"
ISRG,2025-06-26,527.01,539.634,525.84,534.19,"[""Wall Street Analysts See Intuitive Surgical (ISRG) as a Buy: Should You Invest? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about Intuitive Surgical, Inc. (ISRG) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Intuitive Surgical currently has an average brokerage recommendation (ABR) of 1.64, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 28 brokerage firms. An ABR of 1.64 approximates between Strong Buy and Buy. Of the 28 recommendations that derive the current ABR, 19 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 67.9% and 7.1% of all recommendations. Check price target & stock forecast for Intuitive Surgical here>>> While the ABR calls for buying Intuitive Surgical, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every \""Strong Sell\"" recommendation, brokerage firms assign five \""Strong Buy\"" recommendations. In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures. The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns. Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements. Looking at the earnings estimate revisions for Intuitive Surgical, the Zacks Consensus Estimate for the current year has increased 0% over the past month to $7.84. Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Intuitive Surgical. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, the Buy-equivalent ABR for Intuitive Surgical may serve as a useful guide for investors. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""ForSight Robotics raises $125M for cataract surgery platform This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. ForSight Robotics has raised $125 million as it prepares for first-in-human robotic cataract surgery clinical trials this year. The Israel-based company said this week the funds will support the next phase of growth in the development of its Oryom platform, the world\u2019s first robotic surgery platform for cataracts and other eye diseases. Participants in the Series B funding round include Eclipse, Intuitive Surgical co-founder Fred Moll, Adani Group and Reiya Ventures, among other investors. ForSight is scaling up, having identified a need to expand patient access to eye surgery amid a declining number of ophthalmologists and growing demand for vision treatment. The company cited a forecast from researchers at Vanderbilt University pointing to a 12% decline in ophthalmologists by 2035, alongside a projected 24% increase in demand. Joseph Nathan, ForSight co-founder and chief medical officer, said in a statement that the urgent global need presents an \u201cimmense\u201d opportunity for the company. \u201cWe see ophthalmology as the next frontier in the robotics revolution \u2013 much like general surgery was before the rise of Intuitive Surgical,\u201d said Nathan. Starting with cataract surgery, ForSight\u2019s platform aims to offer surgeons the dexterity, maneuverability and ergonomics to provide precise and consistent ophthalmic procedures, according to the company. The platform is designed to allow surgeons to navigate complex angles to reach any point in the eye, enabling glaucoma and retinal surgical treatment. \u201cThe company is tapping into a massive, underserved market,\u201d said Eclipse partner Seth Winterroth. ForSight said more than two dozen ophthalmic surgeons have successfully completed hundreds of procedures on animal eye models using its platform. In February, it received ISO 13485:2016 certification, an international benchmark for quality management systems in the medical device industry. The company completed a $55 million funding round in 2022, and has raised a total of $195 million to date. Recommended Reading 4 robotic surgery trends to watch in 2025""]"
ISRG,2025-06-27,536.87,544.24,533.085,533.59,"Intuitive Surgical, Inc. (ISRG) Rises Higher Than Market: Key Facts Intuitive Surgical, Inc. (ISRG) ended the recent trading session at $534.38, demonstrating a +2.44% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.8% for the day. On the other hand, the Dow registered a gain of 0.94%, and the technology-centric Nasdaq increased by 0.97%. Prior to today's trading, shares of the company had lost 5.57% lagged the Medical sector's gain of 3.12% and the S&P 500's gain of 5.12%. Investors will be eagerly watching for the performance of Intuitive Surgical, Inc. in its upcoming earnings disclosure. The company is predicted to post an EPS of $1.92, indicating a 7.87% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.35 billion, up 16.81% from the year-ago period. ISRG's full-year Zacks Consensus Estimates are calling for earnings of $7.84 per share and revenue of $9.65 billion. These results would represent year-over-year changes of +6.81% and +15.56%, respectively. Any recent changes to analyst estimates for Intuitive Surgical, Inc. should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. At present, Intuitive Surgical, Inc. boasts a Zacks Rank of #2 (Buy). From a valuation perspective, Intuitive Surgical, Inc. is currently exchanging hands at a Forward P/E ratio of 66.53. This valuation marks a premium compared to its industry average Forward P/E of 27.05. Investors should also note that ISRG has a PEG ratio of 4.4 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.25. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 181, putting it in the bottom 27% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-06-30,534.42,544.5,534.42,543.17,"[""What to Expect From Intuitive Surgical's Next Quarterly Earnings Report With a market cap of $191.3 billion, Intuitive Surgical, Inc. (ISRG) designs, manufactures, and markets advanced robotic systems that support minimally invasive surgeries. Its flagship products include the da Vinci Surgical System and the Ion endoluminal system, which enhance surgical precision and expand diagnostic capabilities. The Sunnyvale, California-based company is expected to announce its fiscal Q2 2025 earnings results on Thursday, July 17. Ahead of this event, analysts are expecting ISRG to report a profit of $1.52 per share, up 3.4% from $1.47 per share in the year-ago quarter. The company has exceeded Wall Street's bottom-line estimates in the past four quarters. In Q1 2025, Intuitive Surgical surpassed the consensus EPS estimate by 3.7%. Holiday Trading, Trade Negotiations and Other Key Things to Watch this Week Alphabet's Strong Free Cash Flow Makes GOOG Stock a Value Buy Options Flow Alert: Bulls Making Their Move in GOOGL Stock Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For fiscal 2025, analysts expect the surgical robot maker to report EPS of $6.23, down 3.9% from $6.48 in fiscal 2024. However, EPS is expected to rebound and grow nearly 18% year-over-year to $7.35 in fiscal 2026. ISRG stock has climbed 19.9% over the past year, outperforming the S&P 500 Index's ($SPX) 12.6% gain and the Health Care Select Sector SPDR Fund's (XLV) 8.2% decline over the same period. Shares of Intuitive Surgical rose 1.9% following its Q1 2025 results on Apr. 22, primarily because the company beat analysts' expectations, reporting adjusted EPS of $1.81 and revenue of $2.3 billion. The company placed 367 da Vinci systems, including 147 of its next-generation da Vinci 5 systems. Additionally, the global procedure growth of 17% and a 15% increase in the installed base to 10,189 systems reinforced investor confidence. Analysts' consensus rating on Intuitive Surgical stock is cautiously optimistic overall, with a \""Moderate Buy\"" rating. Out of 28 analysts covering the stock, 19 recommend a \""Strong Buy,\"" two have a \""Moderate Buy\"" rating, six give a \""Hold\"" rating, and one \""Strong Sell.\"" This configuration is slightly more bullish than three months ago, with 18 analysts suggesting a \""Strong Buy.\"" As of writing, ISRG is trading below the average analyst price target of $589.92. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"", ""Wolfe upgrades Medtronic as pulsed field ablation may jolt near term growth Investing.com -- Wolfe Research upgraded Medtronic plc to Peer Perform from Underperform saying that an expected ramp\u2011up of its Affera pulsed\u2011field ablation (PFA) system could add up to two percentage points to organic revenue and help the medical\u2011device maker exceed its own 5% growth target in fiscal 2026. Affera\u2019s contribution means \u201ceverything else\u201d would need to grow only about 3\u20114% to meet guidance, a level the rest of the portfolio has delivered over the past two quarters, according to analyst. Medtronic (NYSE:MDT) shares are up 1% at $86.9 on Monday, have fallen about 5% since Wolfe first put an Underperform rating on the stock three years ago, lagging the S&P 500 Health Care index by roughly 37 points over that period. The brokerage still sees structural risks, including surgical\u2011robot competition from Intuitive Surgical (NASDAQ:ISRG) and share losses in diabetes devices. It also warned that Medtronic\u2019s valuation \u2013 about 15 times projected 2026 earnings, versus 11 times for other slow\u2011growth med\u2011tech peers, could compress if execution slips. Wolfe\u2019s upgrade is not a call that \u201cthe stock is fixed forever,\u201d the note said, but reflects a more favourable skew to near\u2011term estimates thanks to Affera and \u201ca decent\u2011sized list of lesser good guys\u201d that could give the company a pulse after years of underperformance. Related articles Wolfe upgrades Medtronic as pulsed field ablation may jolt near term growth Argentina ordered to surrender YPF stake to satisfy court judgment 2 reasons why Mastercard and Visa shares are underperforming right now""]"
ISRG,2025-07-01,542.58,545.81,531.675,537.92,"Can ISRG Maintain Robotics Edge Amid Rising Rivalry & Budget Strain? Intuitive Surgical ISRG delivered a robust first-quarter 2025, with revenues rising 19% year over year to $2.25 billion and earnings per share (EPS) surpassing expectations. Yet, even as the company celebrates over 10,000 global system installs and growing da Vinci 5 adoption, it faces structural headwinds, including intensifying competition and tightening hospital capital expenditures. Despite placing 367 da Vinci systems (147 of them being da Vinci 5), management acknowledged constrained placements outside the United States, particularly in Japan, Germany and the United Kingdom, due to policy-driven hospital budget cuts. ISRG’s recurring revenues remain strong at 85% of total revenues, but tariffs and higher depreciation from facility expansion are pressuring gross margins, now forecasted to be in the 65-66.5% range for full-year 2025. The company’s ecosystem — proven outcomes, clinical training and a maturing AI-enhanced surgical suite — provides it with an edge. Force feedback tools in da Vinci 5 are showing promising clinical value, with studies suggesting improved patient recovery and reduced surgeon error. Additionally, SP and Ion platforms posted procedure growth of 94% and 58%, respectively, bolstering ISRG's multi-platform dominance. Rising Rivalry However, rivals are gaining traction. Medtronic MDT submitted Hugo for FDA urologic clearance in first-quarter 2025, a crucial step toward entering the U.S. market. MDT is conducting complementary IDE trials covering hernia, benign gynecology, and oncologic gynecology, signaling a clear strategy to broaden Hugo’s indication base. MDT may receive an FDA approval for Hugo in the second half of 2025, marking this as the first year of Intuitive Surgical facing serious U.S. competition in MIS robotics. Hugo’s modular design and open surgeon console not only promote flexible OR integration but also position it as a cost-effective alternative to Intuitive’s dominant da Vinci platform. Another rival, Globus Medical GMED, has made notable strides with its ExcelsiusGPS robotic navigation platform, widely used in spinal and cranial procedures. In late May 2025, Globus Medical showcased the system for the first time in Brazil (at GSC 2025), marking a strategic international expansion. During GSC 2025, Globus Medical also emphasized the integrated Excelsius ecosystem — comprising navigation, robotics, imaging and AI tools — which enables hospitals to flexibly adopt full robotic guidance or mix-and-match navigation-only workflows, depending on their needs. While Globus Medical’s ExcelsiusGPS isn’t competing in soft-tissue surgery, it is creating waves in oncology-related navigation and spine surgery. To maintain leadership, ISRG must counteract price-sensitive buyer behavior by leveraging leasing models, optimizing utilization of installed systems and accelerating feature adoption. While ISRG’s technological and scale advantages remain formidable, its long-term dominance will hinge on navigating a landscape shaped by value-based purchasing and global reimbursement dynamics. ISRG’s innovation pipeline and clinical credibility give it a strong lead, but sustaining leadership will require agile pricing strategies, global regulatory wins and a sharper focus on cost economics in a capital-constrained world. ISRG’s Price Performance, Valuation and Estimates Shares of ISRG have gained 4.1% in the year-to-date period against the industry’s decline of 9%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 64.35, above the industry average. But, it is still lower than its five-year median of 72.21. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 6.8% rise from the year-ago period’s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-07-02,535.34,550.7,535.34,540.82,"[""Intuitive Says da Vinci 5 Surgical System Gets European CE Mark Approval Intuitive Surgical (ISRG) said Wednesday its new robotic surgery system has received the European CE"", ""Intuitive Surgical\u2019s da Vinci 5 robot wins CE mark This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Intuitive Surgical on Wednesday said its da Vinci 5 robot received CE mark approval for adult and pediatric use in Europe across multiple minimally invasive procedures, including urologic, gynecologic and general laparoscopic. The European clearance for da Vinci 5 comes ahead of the company\u2019s projections. CEO Dave Rosa, who took the helm on July 1 from Gary Guthart, said on an earnings call in April that clearance for da Vinci 5 in Europe was expected near the end of 2025. The fifth generation system is the robotic surgery pioneer\u2019s most advanced, with updates such as force feedback technology, an enhanced vision system and more computing power that are designed to improve patient outcomes and operational efficiency. Da Vinci 5 enters the European market following the system\u2019s closely watched U.S. debut in early 2024. Intuitive is continuing to expand its launch of the system in the U.S., where it is cleared for use in urology, general, gynecology and thoracic procedures in adults. Rosa, on the April call, said Intuitive was ramping manufacturing operations and supply chain capabilities to support the broad launch of da Vinci 5 at midyear. The broad launch involves fully integrating the company\u2019s latest hardware and software and meeting customer demand, including trade-ins and dual consoles, Rosa said. The limited rollout of da Vinci 5 has gone faster than expected, driving strong system placements for the company in 2024. In Europe, surgeons used da Vinci surgical systems in more than 410,000 procedures last year. The platform has supported nearly 17 million procedures worldwide to date, Intuitive said. The European clearance comes as Intuitive prepares for increased competition in the soft tissue robotics market, with newcomers such as Moon Surgical and CMR Surgical gearing up to bring systems to the U.S. market and larger competitor Medtronic eyeing a Food and Drug Administration approval. Recommended Reading Intuitive CEO Gary Guthart to step down after 15 years"", ""Intuitive\u2019s da Vinci 5 Surgical System Receives CE Mark Fifth-generation da Vinci surgical system approved for use in Europe across multiple procedures SUNNYVALE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the da Vinci 5 Surgical System has received CE mark approval for adult and pediatric use in Europe for minimally invasive endoscopic procedures across abdominopelvic and thoracoscopic surgical procedures, including urologic, gynecologic, and general laparoscopic procedures. Da Vinci 5 is Intuitive\u2019s most advanced and integrated multiport robotic-assisted surgical system, building on the da Vinci Xi Surgical System\u2019s highly functional design. It features more than 150 enhancements and joins a portfolio of da Vinci surgical systems that surgeons have used in more than 410,000 procedures in Europe in 2024 and nearly 17 million procedures worldwide to date. \u201cWe are pleased that our da Vinci 5 Surgical System has received CE mark approval, marking its entry to Europe,\u201d said Intuitive Chief Executive Officer Dave Rosa. \u201cAt Intuitive, we\u2019re focused on providing healthcare systems across Europe and around the world with thoughtful innovation that solves problems today and into the future. After over a decade of careful development, da Vinci 5 is the most advanced and integrated platform we\u2019ve ever created \u2013 designed to enable better outcomes, efficiency, and insights for the future of minimally invasive care,\u201d said Rosa. Da Vinci 5 is designed to deliver: Enhanced surgical senses to support better patient outcomes, including first-of-its-kind Force Feedback enabled technology, the most realistic 3D da Vinci vision system to date, and an ergonomic, immersive surgeon console to support surgeon career longevity. Operational efficiency, through greater surgeon autonomy with the integration of key components that surgeons can control at their fingertips, and by streamlining workflow with an easy-to-learn system, a universal user interface for care teams, and dynamic assistance integrated into the system to automate select tasks. Actionable insights through an intelligent platform with 10,000x more computing power and new sensors, software, and advanced processors \u2013 providing surgeons with more useable data to help them quantify, understand, and improve their surgical performance for patients. \u201cWe believe that the operational efficiencies and actionable insights provided by da Vinci 5 will not only help transform surgery but also help address critical challenges faced by healthcare systems across Europe,\u201d said Dirk Barten, Intuitive senior vice president and general manager for Europe. \u201cIt's exciting that surgeons and care teams across Europe will have their choice of the full portfolio of da Vinci systems, including da Vinci 5, giving them greater choice and flexibility, and ultimately supporting quality care for more patients across the region,\u201d said Barten. In 2024, the U.S. Food and Drug Administration cleared the da Vinci 5 Surgical System for use during urology, general, gynecology, and thoracic procedures in adults. Da Vinci 5 is the fifth generation da Vinci surgical system and the latest addition to the da Vinci family. This includes multiport systems da Vinci X and da Vinci Xi, and the single port system da Vinci SP, offering surgeons and hospitals their choice of highly capable, proven solutions from Intuitive. 2025 marks Intuitive\u2019s 30th year developing robotic-assisted technology with the goal of improving patient outcomes, improving patient and care team experience, increasing access to minimally invasive care, and lowering the total cost to treat. In Intuitive's first three decades, surgeons have performed nearly 17 million procedures using our technology and nearly 90,000 surgeons have been trained to use our systems worldwide. Contact Megan Elliott, Intuitive (669) 222-9899 megan.elliott@intusurg.com About Intuitive Surgical, Inc. Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most. For more information, please visit: http://www.intuitive.com/safety About da Vinci surgical systems There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialised instrumentation, including a miniaturised surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body. Forward-Looking Statements This press release contains forward-looking statements which relate to expectations concerning matters that are not historical facts. Statements using words such as \u201cestimates,\u201d \u201cprojects,\u201d \u201cbelieves,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ctargeted,\u201d \u201cpotential,\u201d and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of Intuitive\u2019s management and involve a number of risks and uncertainties that could cause actual results or impacts on its operations, financial performance, and business position to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to, statements related to research and development of products and services, manufacturing of products, obtaining of regulatory approvals, technical, clinical, and other performance of products and services, and making products and services available to more patients and health care professionals. These forward-looking statements should be considered in light of various important factors and involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Intuitive, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include, among others, economic conditions in the geographic markets in which we operate, changes in governmental regulations, regulatory approval priorities, resources, and timelines, regulatory enforcement priorities, governmental investigations and civil litigation, and other factors discussed in Intuitive\u2019s Annual Reports and other filings with relevant securities regulators. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading \u201cRisk Factors\u201d in Intuitive\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings with the U.S. Securities and Exchange Commission. Intuitive\u2019s actual results may differ materially and adversely from those expressed in any forward-looking statements, and it undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.""]"
ISRG,2025-07-03,543.93,547.0,542.39,544.47,"[""Intuitive Surgical (NasdaqGS:ISRG) Expands Da Vinci Surgical System Presence In European Market Intuitive Surgical recently secured CE Mark approval for its da Vinci 5 Surgical System, enabling advanced robotic-assisted surgical procedures in Europe. This positive development aligns with the company's strategic push to enhance surgical technology. Over the last quarter, Intuitive's stock price increased by 9%, a movement that broadly aligns with market trends, where the S&P 500 and Nasdaq Composite experienced upward momentum, with notable gains in the tech sector. The company's innovation-driven announcements likely supported its share price performance, adding weight to the overall positive market movement. However, broader market trends, rather than singular events, seem instrumental in driving this increase. Buy, Hold or Sell Intuitive Surgical? View our complete analysis and fair value estimate and you decide. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent CE Mark approval for Intuitive Surgical's da Vinci 5 Surgical System is a significant advancement for increasing product adoption and sales, aligning with the company's growth narrative. By expanding access to robotic-assisted surgeries in Europe, this development could enhance long-term revenue potential and elevate surgical outcomes globally. The global launch and technological enhancements such as Force Feedback could drive stronger adoption rates and bolster future earnings, aligning with analyst projections of steady growth over the coming years. Over the past five years, Intuitive Surgical's total shareholder return, including stock price and dividends, has been a substantial 177.81%, reflecting strong performance in the medical equipment sector. In contrast, for the last year, the company exceeded both the broader US market and the US Medical Equipment industry. With recently reported earnings of US$2.48 billion and revenue reaching US$8.71 billion, the introduction of advanced technologies such as da Vinci 5 could continue to fuel such growth. Analysts project its revenue to grow at an approximate rate of 12.3% annually, potentially elevating its market position further. Despite its strong historical performance, the company's stock is presently trading at a higher price-to-earnings ratio compared to the industry average, indicating potential market optimism regarding its future prospects. With the current share price of US$523.08, there remains a 9.1% potential upside relative to the consensus analyst price target of US$575.49. Investors should evaluate the long-term strategic initiatives like the da Vinci 5 launch against market dynamics when considering the company's future growth trajectory. Gain insights into Intuitive Surgical's past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:ISRG. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com"", ""This $125M Israeli Startup Is Building The World's First Cataract Robot To Solve A Global Crisis: 'There Is No Human Way To Close The Gap' ForSight Robotics, an Israeli startup aiming to automate cataract and eye surgery, announced Tuesday that it raised $125 million to expand its precision robotics platform, Oryom. The round was led by Eclipse Ventures, with participation from surgical robotics legend Fred Moll, co-founder of Intuitive Surgical, and Moshe Shoham, a Technion professor and pioneer behind multiple robotics companies including Mazor, which was acquired by Medtronic for $1.6 billion, Forbes reports. Don't Miss: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs \u2014 And You Can Invest At Just $6.37/Share Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. Forbes says that more than 4 million cataract surgeries are performed each year in the U.S. alone. Yet, according to a World Health Organization report, over 1 billion people globally suffer from preventable vision loss. As the population ages and the number of ophthalmologists declines, a gap is forming that traditional medical systems can't fill. \""There is no human way to close the gap as we see it,\"" Dr. Joseph Nathan, ForSight co-founder and chief medical officer, told Forbes. \""Robotics will have to take over.\"" Cataract surgery is a highly precise procedure that involves operating within extremely small spaces, requiring steady hands and dexterous control, according to Forbes. ForSight says its Oryom platform is designed specifically to handle the complexity and consistency of ophthalmic procedures using AI-based algorithms, computer vision, and micromechanics to enhance surgical precision and reduce the physical strain on surgeons. Over the past year, more than two dozen ophthalmic surgeons have used the platform to successfully perform hundreds of procedures on animal eye models as part of the system's development and testing phase. Forbes reports that ForSight has specifically tested its robotic system on porcine eyes due to their close anatomical similarity to human eyes, a common method used in ophthalmic surgical training. Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved \u2014 Become an Investor in This $41.3M Clean Energy Brand Today The company says it has yet to perform surgery on a human patient, but expects to begin clinical trials by the end of the year. Early conversations with the Food and Drug Administration are already underway, and the new funding will carry the company through its regulatory process. ForSight was born out of Israel's Technion Institute, where Shoham, Nathan, and co-founder Daniel Glozman combined decades of expertise in medical engineering, research and development, and commercialization. Shoham's previous students have gone on to lead Medtronic's robotics division and build multi-billion-dollar exits. Moll and Shoham, often called \""the godfathers of surgical robotics,\"" now advise the company strategically, Forbes reports. \""There is only one procedure that is done more than cataract surgery and that is blood drawing,\"" Moll told Forbes. \""As far as real surgical technique [that could be helped by robotics], cataract surgery is at the top of the list.\"" With its third-generation prototype complete, ForSight is already preparing to expand its platform's capabilities beyond cataracts. Forbes says that future use cases include retinal procedures, glaucoma treatments, and complex eye surgeries that currently only a handful of surgeons in the world are qualified to perform. See Also: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey \u2013 no cost, no obligation. ForSight's Oryom system provides a potential answer to a looming global health crisis. According to the company, there are only 31.7 ophthalmologists and 14.1 cataract surgeons per million people globally, highlighting a significant gap between demand and surgical capacity. This surgeon shortage, combined with rising rates of preventable blindness, suggests that millions may not receive timely care. A 2020 study published in the British Journal of Ophthalmology, further confirms that lower-income countries average just 3.7 ophthalmologists per million people, compared to 76.2 in high-income nations, underscoring the disparity in access to eye care worldwide. By automating precision eye surgery, ForSight is betting on a future where access to vision care is no longer limited by geography or availability of human doctors. If successful, the company may become the Intuitive Surgical of ophthalmology. Read Next: Are you rich? Here\u2019s what Americans think you need to be considered wealthy. Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article This $125M Israeli Startup Is Building The World's First Cataract Robot To Solve A Global Crisis: 'There Is No Human Way To Close The Gap' originally appeared on Benzinga.com \u00a9 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.""]"
ISRG,2025-07-07,543.23,544.88,532.88,534.71,
ISRG,2025-07-08,534.0,539.59,525.665,527.3,"ISRG Expands Installed Base, But Is Utilization Keeping Pace? Intuitive Surgical ISRG continues to expand its global dominance in robotic-assisted surgery with a 15% year-over-year increase in da Vinci system installations, bringing its global installed base to more than 10,000 units. In the first quarter of 2025, the company placed 367 da Vinci systems — including 147 of the next-gen da Vinci 5 — amid strong U.S. demand. However, installations outside the country remained unchanged year over year, reflecting healthcare budget constraints in markets like Germany, Japan and the United Kingdom. While Intuitive Surgical's recurring revenues, now 85% of the total revenues, remain robust, a critical metric — utilization — reveals a key tension. Overall, procedures grew 17% year over year, yet average system utilization rose just 2% across the multiport platforms. SP and Ion platforms posted stronger utilization increases of 26% and 5% respectively, supported by focused adoption strategies and new clearances. The limited growth in core platform utilization raises questions about the ROI of hospitals post-installation, particularly in constrained capital environments. Management acknowledged this dynamic, noting efforts to drive training, site enablement, and digital adoption to boost throughput. Additionally, da Vinci 5’s Force Feedback and case insight tools, though early in rollout, are beginning to demonstrate measurable value in clinical outcomes and surgeon proficiency. ISRG’s installed base expansion remains strong, especially in the United States. However, modest system utilization growth suggests that procedural ramp-up may lag deployments in some markets. Long-term growth will require more than system placements; it hinges on improving per-system productivity, proving clinical differentiation, and navigating financial headwinds that may shift hospital ROI expectations. Stryker SYK reported record-breaking Mako installations in the first quarter of 2025, both in the United States and globally, driven by sustained momentum in orthopedics and increased procedural demand. The new Mako 4 SmartRobotics system, launched this year, features a smaller OR footprint and improved integration with its latest Q Guidance system, streamlining setup and intraoperative workflows. Management cited high utilization rates for installed units globally, particularly in knee and hip procedures, where Mako continues to drive share gains. The company also noted progress toward launching Mako Spine later in 2025 and Mako Shoulder in early 2026, expanding its robotic footprint across specialties. With a strong capital order book and robust procedural volume, Stryker expects the Mako franchise to be a key contributor to its 8.5-9.5% organic growth target. Zimmer Biomet’s ZBH ROSA robotics platform saw ongoing adoption in knee procedures, but results were more muted. While ROSA volume-based placements contributed to a mix shift versus outright sales, ROSA was mentioned as central to ZBH’s robotic strategy in 2025. The company emphasized the growing uptake of cementless knee and hip implants, including the Oxford Partial Cementless Knee, which complements robotic workflows. Though specific ROSA installation figures weren’t disclosed, the system remains integral to ZBH’s ASC and digitization strategy. Management cited increased commercial focus and expanded surgical capabilities as key growth drivers, but acknowledged tariffs and ongoing pressure on operating margins as near-term headwinds. Shares of ISRG have gained 2.4% in the year-to-date period against the industry’s decline of 7.7%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 64.35, above the industry average. But, it is still lower than its five-year median of 72.21. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 6.8% rise from the year-ago period’s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-07-09,529.82,530.71,523.16,528.13,"[""Intuitive Surgical\u2019s Da Vinci 5 System Receives CE Mark, Expands Advanced Robotic Surgery Access Across Europe Intuitive Surgical Inc. (NASDAQ:ISRG) is one of the best US stocks to buy and hold in 2025. On July 2, Intuitive Surgical announced that its latest da Vinci 5 Surgical System received CE mark approval. This regulatory milestone enables the system\u2019s use across adult and pediatric patients in Europe for a spectrum of minimally invasive endoscopic procedures, such as abdominopelvic and thoracoscopic surgeries in urology, gynecology, and general laparoscopy. The da Vinci 5 introduces 50+ enhancements on the foundational da Vinci Xi Surgical System. Key innovations include first-of-its-kind Force Feedback-enabled technology, which allows surgeons to sense pressure and tension during operations. It also features Intuitive\u2019s most realistic 3D vision system to date. The system supports 10,000x more computing power than previous models. There\u2019s also greater surgeon autonomy through integrated components controlled at the fingertips, a universal user interface for care teams, and dynamic assistance to automate select tasks. A medical team performing minimally invasive surgery with a da Vinci Surgical System. In 2024, the US FDA had already granted 510(k) clearance for the da Vinci 5 Surgical System for use in urology, general, gynecology, and thoracic procedures in adults. In 2024, surgeons performed 410,000+ procedures in Europe using da Vinci systems, contributing to ~17 million procedures performed worldwide to date with Intuitive\u2019s technology. Intuitive Surgical Inc. (NASDAQ:ISRG) develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care. While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey."", ""Evercore ISI Lifts Price Target on Intuitive Surgical to $550 From $470, Maintains In Line Rating Intuitive Surgical (ISRG) has an average rating of overweight and mean price target of $585.04, acco""]"
ISRG,2025-07-10,527.1,528.55,520.25,526.05,"[""Intuitive Surgical Says Vessel Sealer Electrosurgical Instrument Gets FDA Approval Intuitive Surgical (ISRG) said Thursday the US Food and Drug Administration approved its Vessel Seal"", ""Vessel Sealer Curved receives FDA clearance Intuitive\u2019s latest advanced energy instrument features a unique curved tip for enhanced precision Vessel Sealer Curved SUNNYVALE, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) has cleared its latest innovation in advanced energy instrumentation for use with its multiport da Vinci systems. Vessel Sealer Curved is a fully wristed, advanced bipolar electrosurgical instrument designed to seal, cut, grasp, and dissect tissue. It is the first of Intuitive\u2019s advanced energy instruments to receive FDA clearance for the transection of lymphatic vessels. Vessel Sealer Curved offers enhanced multifunctionality and precision via its slim, curved jaw designed to follow the natural contours of anatomy, helping improve visibility and control especially in tight spaces and around critical structures. The instrument\u2019s mechanical blade cuts closer to the tip, offering versatility as a dissector. \u201cWe designed Vessel Sealer Curved to give surgeons greater precision in narrow anatomical spaces,\u201d said Iman Jeddi, PhD, senior vice president and general manager, da Vinci platforms & product operations. \u201cBy combining the trusted performance of Vessel Sealer Extend with a slimmer, curved jaw profile, we\u2019re helping surgeons work more efficiently and confidently across a wide range of procedures.\u201d The FDA cleared Vessel Sealer Curved for grasping and blunt dissection of tissue, as well as bipolar coagulation and mechanical transection of blood vessels (veins and arteries) up to 7mm in diameter, lymphatic vessels, and tissue bundles that fit within the instrument\u2019s jaws. Vessel Sealer Curved is not indicated for tubal sterilization or tubal coagulation for sterilization procedures and should not be used for these procedures. 2025 marks Intuitive\u2019s 30th year developing robotic-assisted technology with the goal of improving patient outcomes, improving patient and care team experience, increasing access to minimally invasive care, and lowering the total cost to treat. In Intuitive's first three decades, surgeons performed nearly 17 million da Vinci procedures, and nearly 90,000 surgeons have been trained to use Intuitive\u2019s systems. About Intuitive Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most. About da Vinci Surgical Systems There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body. For more information, please visit the company\u2019s website at www.intuitive.com. Important Safety Information For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, visit https://manuals.intuitivesurgical.com/market. For summary of the risks associated with surgery refer to www.intuitive.com/safety. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c120cfa-0cfe-4a0e-8eb1-099c537659ca CONTACT: Contact Information: Megan Elliott megan.elliott@intusurg.com""]"
ISRG,2025-07-11,512.06,512.06,508.13,512.06,
ISRG,2025-07-14,509.88,522.1,509.88,516.44,"[""Leerink Partners Adjusts Price Target on Intuitive Surgical to $587 From $539 Intuitive Surgical (ISRG) has an average rating of overweight and mean price target of $588.04, acco"", ""BTIG Adjusts Price Target on Intuitive Surgical to $566 From $542 Intuitive Surgical (ISRG) has an average rating of overweight and mean price target of $588.04, acco"", ""Hospital Capex Headwind: Temporary Setback or Lasting Risk for ISRG? Intuitive Surgical ISRG entered 2025 with strong momentum \u2014 da Vinci system placements grew 17% year over year and procedures rose 17% globally in the first quarter. However, the company is encountering a growing challenge \u2014 capital expenditure (CapEx) constraints at hospitals, especially outside the United States. While U.S. placements increased sharply (204 units vs. 148 last year), international placements declined slightly (163 vs. 165), with Japan, Germany and the United Kingdom flagged for tightening budgets. These pressures stem from post-COVID funding tapering, defense spending reallocation (in Europe) and policy reforms (in Japan & China). Management noted that although procedure growth remains robust in many early-stage markets like India and Taiwan, longer-term growth may be capped if CapEx constraints persist. To mitigate CapEx friction, ISRG is expanding leasing and usage-based models (particularly in the United States), which now represent over 50% of placements. These models offer hospitals flexibility, bypassing the need for formal budget approvals. Still, their adoption in international markets remains nascent, and macro risks, including rising tariffs and interest rates, could amplify funding hurdles globally. Meanwhile, ISRG is focusing on increasing utilization of its existing installed base, offering operational tools like Genesis and economic modeling support to help hospitals maximize returns. Notably, utilization grew 2% for multiport platforms and 26% for SP systems. The company is also banking on clinical differentiation, like force feedback in da Vinci 5, to build long-term demand and justify investment. Hospital CapEx constraints are clearly impacting ISRG\u2019s international system placements, but strategic levers, such as flexible financing, utilization support, and differentiated technology, offer near to mid-term buffers. Whether these measures can fully offset persistent funding headwinds, especially in Europe and Asia, will determine if the current drag is temporary or a structural hurdle to Intuitive\u2019s global growth ambitions. Stryker SYK reported no sign of slowdown in capital equipment demand, with first-quarter 2025 being its best-ever quarter for Mako installations globally. Management emphasized double-digit growth across capital-intensive businesses, supported by a robust order book and high system utilization, particularly in the orthopedic robotics sector. Despite macro concerns, Stryker sees sustained strength in procedural volumes and customer interest in next-gen platforms like Mako 4, which features a smaller footprint and faster OR integration, addressing common CapEx objections. The company remains optimistic, citing no indicator of budget tightening and forecasting 8.5-9.5% organic sales growth for the year. Medtronic MDT acknowledged the impact of selective pressure in the hospital capital environment, but stressed stable U.S. purchasing trends and growth acceleration in emerging markets. The company continues to invest in its Hugo RAS platform, with FDA submission expected soon, positioning it to compete in robotic surgery without relying solely on high upfront CapEx. MDT\u2019s focus on value-based outcomes and procedural efficiency, such as in pulse field ablation and renal denervation, resonates with financially constrained systems. CEO Geoff Martha stated that Medtronic\u2019s innovation pipeline (including closed-loop neurostimulators and AI-enabled spine platforms) is expanding the total addressable market while balancing spend and margin expansion. Shares of ISRG have lost 1.9% in the year-to-date period compared with the industry\u2019s decline of 9.5%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 60.33, above the industry average. But, it is still lower than its five-year median of 72.36. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical\u2019s 2025 earnings implies a 6.8% rise from the year-ago period\u2019s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
ISRG,2025-07-15,519.21,521.28,510.84,512.23,"[""FDA Approves Intuitive Surgical (ISRG) Vessel Sealer Curved Surgical Instrument Intuitive Surgical Inc. (NASDAQ:ISRG) is one of Goldman Sachs\u2019 top healthcare stock picks. On July 10, the company secured Food & Drug Administration approval for its new Vessel Sealer Curved. The electrosurgical instrument is designed for use with multiport da Vinci systems and represents a significant development in surgical technology. A doctor in a hospital operating room using advanced surgical instruments. Vessel Sealer Curved is an Intuitive Surgical\u2019s advanced energy instrument approved for lymphatic vessel transection. It stands out due to its curved jaw design, which allows surgeons to navigate tight anatomical spaces and work around critical structures effectively. It also combines multiple functions, including sealing, cutting, grasping, and dissecting tissue. The new surgical tool aligns with the company\u2019s three-decade focus on improving minimally invasive procedures. Consequently, it should help the company maintain its leadership position in robotic surgery, having already reported over 17 million da Vinci procedures. Intuitive Surgical Inc. (NASDAQ:ISRG) is a healthcare company that develops, manufactures, and markets robotic-assisted surgical systems, primarily the da Vinci surgical system. Its primary goal is to make surgery more effective, less invasive, and easier for surgeons, patients, and their families. While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Green Energy Penny Stocks to Buy Right Now and 10 Most Popular AI Penny Stocks to Buy According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey."", ""Medtronic gets CE mark for robot-driven vessel-sealing device This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medtronic said Tuesday it received the CE mark in Europe for its LigaSure vessel-sealing technology for use in robotic-assisted surgeries. The designation increases the capabilities of Medtronic\u2019s Hugo soft tissue robotic system for gynecologic, general and urologic procedures in Europe. Hugo is not yet for sale in the U.S. Medtronic said it expects Hugo to enter the U.S. market later in the company\u2019s current fiscal year, which ends in April 2026, with an initial indication in urology. Medtronic is continuing its push into the fast-growing robotic surgery market led by Intuitive Surgical. Expansion of the Hugo platform is key to the company\u2019s strategy for improving growth in its surgical business, and the market-leading LigaSure vessel sealing technology is attracting strong surgeon adoption and taking share in the advanced energy field, CEO Geoff Martha told investors on the company\u2019s fourth-quarter earnings call in May. In its CE mark announcement at the Society of Robotic Surgeons Annual Meeting in Strasbourg, France, Medtronic said the LigaSure device reliably seals vessels in about two seconds and minimizes the spread of thermal energy to the surrounding tissue. \u201cLigaSure technology is one of the most important advances for minimally invasive surgery because it provides sealing and cutting in a way that is very, very secure for the performance of the surgeon and the security of the patient,\u201d Miguel Caceres, of the Pacifica Salud Hospital in Panama, said in Medtronic\u2019s statement. \u201cAs a robotic surgeon, we want LigaSure technology because it gives us confidence in the security of the seal.\u201d Hugo first gained the CE mark in Europe in 2021 and is now in use in more than 30 countries. In the U.S., the medical device giant submitted its application to the Food and Drug Administration for a urology indication for Hugo in the first quarter of this calendar year. Expansions into hernia and gynecology are planned. Medtronic said it also planned a live telesurgery demonstration with Hugo and would share new gynecologic data for the system at the Strasbourg meeting. Recommended Reading Medtronic training pact includes Hugo robot, cardiac ablation tech"", ""Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It Intuitive Surgical, Inc. (ISRG) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this company have returned -0.5%, compared to the Zacks S&P 500 composite's +5% change. During this period, the Zacks Medical - Instruments industry, which Intuitive Surgical falls in, has gained 0.9%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Intuitive Surgical is expected to post earnings of $1.92 per share for the current quarter, representing a year-over-year change of +7.9%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged. For the current fiscal year, the consensus earnings estimate of $7.84 points to a change of +6.8% from the prior year. Over the last 30 days, this estimate has remained unchanged. For the next fiscal year, the consensus earnings estimate of $9.05 indicates a change of +15.5% from what Intuitive Surgical is expected to report a year ago. Over the past month, the estimate has remained unchanged. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Intuitive Surgical. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. For Intuitive Surgical, the consensus sales estimate for the current quarter of $2.35 billion indicates a year-over-year change of +16.8%. For the current and next fiscal years, $9.65 billion and $11.11 billion estimates indicate +15.6% and +15.1% changes, respectively. Intuitive Surgical reported revenues of $2.25 billion in the last reported quarter, representing a year-over-year change of +19.2%. EPS of $1.81 for the same period compares with $1.5 a year ago. Compared to the Zacks Consensus Estimate of $2.18 billion, the reported revenues represent a surprise of +3.27%. The EPS surprise was +5.85%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Intuitive Surgical is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intuitive Surgical. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
ISRG,2025-07-16,512.51,515.14,506.211,512.64,"[""Intuitive demos telesurgery; SS Innovations marks 100 robot installs This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Intuitive Surgical remotely connected two surgeons for a trans-Atlantic demonstration of the telesurgery capabilities of its da Vinci 5 robotic system during a conference in Strasbourg, France. The surgeons used a dual console system to perform a procedure on an advanced tissue model to replicate the behavior of live tissue, Intuitive said Wednesday. Surgeon Doug Stoddard\u2019s console was alongside the patient cart and tissue model in Peachtree Corners, Georgia, while Andrea Pakula operated a remote console more than 4,000 miles away in Strasbourg. Stoddard is director of surgery and robotics at Christus Health in Texas. Pakula is medical director of robotic surgery at Adventist Health in California. The two passed control of surgical instruments back and forth. Both used the system\u2019s force feedback technology to feel the force exerted by instruments on the tissue model. Telesurgery is one part of collaboration efforts, including telementoring, teleproctoring and dual console surgery, that are aimed at helping clinical teams improve outcomes and reduce the cost of care, Intuitive CEO Dave Rosa said in a statement from the Society of Robotic Surgery conference. While robotic telesurgery is not a new idea, a high-performing network infrastructure and robotic system designed for remote collaboration are needed to be successful, Intuitive said. The company\u2019s telesurgery technology is still in development, and the software demonstrated is not cleared for use in the U.S. or CE marked in the European Union. \u201cOur focus is not on being first but on being rigorous in building the infrastructure to support safety, reliability, and consistent use,\u201d said Brian Miller, Intuitive\u2019s chief digital officer. Miller was an engineer who worked on Operation Lindbergh, the world\u2019s first trans-Atlantic telesurgical operation, in 2001. Medtronic on Tuesday said it also planned to conduct a telesurgery demonstration with its Hugo robot-assisted system in connection with the Society of Robotic Surgery meeting. SS Innovations International said more than 100 of its SSi Mantra surgical robotic systems have been installed in India and six other countries. More than 5,000 surgical procedures have been successfully performed to date with the system, including 240 cardiac surgeries and 32 telesurgeries, the company said Tuesday. The milestone is an increase from the 2,759 total surgeries completed at the end of 2024. \u201cWe are seeing growing demand for and acceptance of the SSi Mantra, which reflects its premium quality, innovative features, ease of use, improved patient experience, and overall cost-effectiveness,\u201d CEO Sudhir Srivastava said in a statement. SS Innovations said it expects to submit a de novo application to the Food and Drug Administration by the end of this month for approval to market the robot with multiple indications in the U.S. The company is also pursuing a European Union CE marking certification, which it said could come in late 2025. Recommended Reading Zimmer bets on autonomous surgery with Monogram purchase"", ""Intuitive demonstrates telesurgery capabilities SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, has today demonstrated its telesurgery capabilities by remotely connecting two surgeons to perform a transatlantic demonstration at the Society of Robotic Surgery (SRS) conference in Strasbourg, France. This landmark event involved Doug Stoddard, MD, located in Peachtree Corners, GA, and Andrea Pakula, MD, located remotely in Strasbourg, France. Together, using a dual console da Vinci 5 system, they performed a telesurgery procedure on an advanced tissue model developed by Intuitive to replicate the behavior of live tissue. During the demonstration, Stoddard, whose console was alongside the da Vinci 5 patient cart and tissue model, was able to pass control of surgical instruments back and forth remotely to Pakula, located at the remote surgeon console. This included Force Feedback, enabling both surgeons to feel the forces exerted on the advanced tissue model by the instruments, despite being more than 4,000 miles apart. Speaking at the SRS conference, Intuitive Chief Executive Officer Dave Rosa said: \u201cTelesurgery is an area Intuitive has been thoughtfully innovating in for many years. It is a capability that has the potential to improve patient access to minimally invasive care, but its success depends on careful development in several areas. \u201cAt Intuitive we\u2019ve built robotic surgical technology from the ground up and our focus has always been patient safety and delivering real value\u2014not technology for technology\u2019s sake. For 30 years, we\u2019ve created products that help healthcare providers deliver better care, improve clinician and care team experiences, and drive efficiencies in care delivery. \u201cTelesurgery is just one part of our telecollaboration suite, which includes telementoring, teleproctoring, and dual console surgery, that can help clinical teams to improve outcomes and reduce the total cost of care. It\u2019s exciting to see progress, but we\u2019re clear there\u2019s still a long way to go.\u201d Telesurgery \u2014 the ability of a surgeon to perform an operation remotely from the patient via a robotic surgical system \u2014 became feasible in 2001 when surgeons performed the first transatlantic procedure, dubbed Operation Lindbergh, between the U.S. and Strasbourg, France. \u201cWhile not a new idea for Intuitive, telesurgery requires a high performing network infrastructure and a robotic system designed for remote collaboration to be successful and sustainable. Our focus is not on being first but on being rigorous in building the infrastructure to support safety, reliability, and consistent use,\u201d said Brian Miller, PhD, Intuitive\u2019s executive vice president and chief digital officer, who was an engineer supporting Operation Lindbergh. This year marks Intuitive\u2019s 30th year of developing robotic-assisted technology with the goal of improving patient outcomes, improving patient and care team experience, increasing access to minimally invasive care, and lowering the total cost to treat. In Intuitive's first three decades, surgeons performed nearly 17 million da Vinci procedures, and nearly 90,000 surgeons have been trained to use Intuitive\u2019s systems. The telesurgery software on the da Vinci 5 system that was shown during this demonstration was used for demonstration purposes only. The technology is still in development, is not 510(k) cleared or CE marked, and the safety and effectiveness of the product has not been established. The technology is not currently for sale and cannot be made available nor put into service in the U.S. or in the European Union. Dr. Doug Stoddard is director of surgery and robotics at Christus Health in Texas. Dr. Andrea Pakula is medical director of robotic surgery at Adventist Health in California. About Intuitive Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most. About da Vinci Surgical Systems There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body. For more information, please visit the company\u2019s website at www.intuitive.com. Important Safety Information For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, visit https://manuals.intuitivesurgical.com/market. For summary of the risks associated with surgery refer to www.intuitive.com/safety. Forward-Looking Statements This press release contains forward-looking statements which relate to expectations concerning matters that are not historical facts. Statements using words such as \u201cestimates,\u201d \u201cprojects,\u201d \u201cbelieves,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ctargeted,\u201d \u201cpotential,\u201d and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of Intuitive\u2019s management and involve a number of risks and uncertainties that could cause actual results or impacts on its operations, financial performance, and business position to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to, statements related to research and development of products and services, manufacturing of products, obtaining of regulatory approvals, technical and other performance of products and services, and making products and services available to more patients and health care professionals. These forward-looking statements should be considered in light of various important factors and involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Intuitive, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include, among others, economic conditions in the geographic markets in which we operate, changes in governmental regulations, regulatory approval priorities, resources, and timelines, regulatory enforcement priorities, governmental investigations and civil litigation, and other factors discussed in Intuitive\u2019s Annual Reports and other filings with relevant securities regulators. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading \u201cRisk Factors\u201d in Intuitive\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings with the U.S. Securities and Exchange Commission. Intuitive\u2019s actual results may differ materially and adversely from those expressed in any forward-looking statements, and it undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law. Media Contacts In France: Peper Long +1 202-997-7373 peper.long@intusurg.com In U.S.: Megan Elliott +1 669-222-9899 Megan.elliott@intusurg.com""]"
ISRG,2025-07-17,510.83,517.67,509.25,516.16,"[""ISRG's Vessel Sealer Curved for da Vinci Systems Gets FDA Approval Intuitive Surgical ISRG recently received FDA clearance for its Vessel Sealer Curved, a multifunctional instrument designed for use with compatible da Vinci surgical systems. The Vessel Sealer Curved enables surgeons to grasp, dissect, coagulate, and transect tissue using a single, wristed tool, improving procedural efficiency in minimally invasive surgeries. The new instrument integrates Intuitive Surgical\u2019s advanced bipolar energy technology with refined mechanical design to enhance performance and precision in robotic-assisted surgeries. This clearance expands Intuitive Surgical\u2019s portfolio of surgical tools and reinforces its commitment to delivering innovative solutions that help improve outcomes and streamline operating room workflows. Following the announcement, the company's shares traded flat until yesterday\u2019s closing. Shares have lost 1.8% in the year-to-date period compared with the industry\u2019s 11.5% decline. The S&P 500 has gained 5.6% in the same time frame. The FDA clearance of the Vessel Sealer Curved enhances Intuitive Surgical\u2019s value proposition by adding a versatile, high-precision instrument to its da Vinci ecosystem. Its ability to perform multiple functions in tight anatomical spaces can increase procedural efficiency and broaden the appeal of robotic-assisted surgery across specialties. Over time, this can drive higher procedure volumes, strengthen recurring revenue from instrument sales, and deepen hospital and surgeon reliance on the da Vinci platform, supporting long-term business growth. ISRG currently has a market capitalization of $183.59 billion. It has an earnings yield of 1.45%, higher than the industry\u2019s negative 2.88%. In the last reported quarter, ISRG delivered an earnings surprise of 5.85%. Image Source: Zacks Investment Research Vessel Sealer Curved is a fully wristed, advanced bipolar electrosurgical instrument developed by Intuitive Surgical for use with compatible da Vinci systems. It is designed to seal, cut, grasp, and dissect tissue, offering multifunctionality in a single tool. It is the first advanced energy instrument from Intuitive Surgical to receive FDA clearance for the transection of lymphatic vessels, as well as its use in bipolar coagulation and mechanical transection of blood vessels up to 7mm in diameter, tissue bundles, and lymphatic structures. The device is not indicated for tubal sterilization or tubal coagulation procedures. Engineered for precision in confined anatomical spaces, the instrument features a slim, curved jaw that follows natural anatomical contours, improving visibility and control near critical structures. Its mechanical blade, positioned closer to the tip, enhances the device\u2019s versatility as a dissector. The new design builds on the trusted performance of Vessel Sealer Extend, offering improved access and surgical control. Intuitive Surgical\u2019s da Vinci platform has become a cornerstone of robotic-assisted surgery, with nearly 17 million procedures performed globally since its inception. The company has trained approximately 90,000 surgeons to operate its systems, reflecting widespread adoption and trust in its technology. With each innovation, including the addition of advanced instruments like the Vessel Sealer Curved, Intuitive Surgical continues to strengthen the capabilities of the da Vinci ecosystem, supporting its long-term mission to improve patient outcomes, enhance the surgical experience, and lower the total cost of care. Per a report by Grand View Research, the global surgical robots market size was estimated at $4.31 billion in 2024 and is projected to reach $7.42 billion by 2030, registering a CAGR of 9.42% from 2025 to 2030. Industry growth is driven by technological innovation, increasing investments from global and regional players, as well as a rise in chronic conditions and joint replacement procedures. Currently, ISRG carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Hims & Hers Health, Inc. HIMS, Cencora, Inc. COR and Integer Holdings Corporation ITGR. Hims & Hers, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 36.5%. HIMS\u2019 earnings surpassed estimates in two of the trailing four quarters, missed once and met in the other, the average surprise being 19.6%. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Hims & Hers\u2019 shares have surged 99.2% compared with the industry\u2019s 37.1% growth in the past year. Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Cencora\u2019s shares have rallied 23.9% against the industry\u2019s 16.9% decline in the past year. Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 18.4%. ITGR\u2019s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Integer Holdings\u2019 shares have gained 4.9% against the industry\u2019s 13% decline in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""BTIG Raises Intuitive Surgical (ISRG) Price Target, Maintains Buy Rating Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. BTIG analyst Ryan Zimmerman has raised the firm\u2019s price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $566 from $542 while reiterating a Buy rating ahead of the company\u2019s second-quarter earnings report. The adjustment comes as part of a broader outlook on the MedTech sector, which has faced pressure in recent months. A medical team performing minimally invasive surgery with a da Vinci Surgical System. In a research note to clients, Zimmerman highlighted that healthcare lagged the broader market in Q2, with MedTech stocks continuing to struggle early into the third quarter. Concerns over Medicaid reductions and potential hospital closures, stemming from recent legislative changes, have cast a shadow over the group, contributing to cautious investor sentiment. BTIG believes, however, that these fears may be exaggerated. While the upcoming earnings season is expected to produce uneven results, the firm sees conditions that could support a rebound. Inflation remains contained, currency exchange rates have become more favorable, and equity markets are near record highs, all of which could provide a tailwind to medical technology names. Within this mixed backdrop, Intuitive Surgical, Inc. (NASDAQ:ISRG) stands out for its consistent performance and robust fundamentals. The maker of robotic-assisted surgical systems is seen as well-positioned to weather sector-specific concerns, justifying BTIG\u2019s upward revision. Investors will be watching closely to see if the company can deliver results strong enough to reinforce its premium valuation. While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey."", ""Unlocking Q2 Potential of Intuitive Surgical (ISRG): Exploring Wall Street Estimates for Key Metrics In its upcoming report, Intuitive Surgical, Inc. (ISRG) is predicted by Wall Street analysts to post quarterly earnings of $1.92 per share, reflecting an increase of 7.9% compared to the same period last year. Revenues are forecasted to be $2.35 billion, representing a year-over-year increase of 16.8%. The consensus EPS estimate for the quarter has undergone an upward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock. While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding. Given this perspective, it's time to examine the average forecasts of specific Intuitive Surgical metrics that are routinely monitored and predicted by Wall Street analysts. Analysts forecast 'Revenue- Product (Instruments and accessories and Systems)' to reach $1.96 billion. The estimate points to a change of +15.7% from the year-ago quarter. The consensus estimate for 'Revenue- Services' stands at $368.86 million. The estimate suggests a change of +16.3% year over year. The combined assessment of analysts suggests that 'Revenue- Systems' will likely reach $516.21 million. The estimate indicates a year-over-year change of +15.2%. The average prediction of analysts places 'Revenue- Instruments and accessories' at $1.44 billion. The estimate indicates a change of +15.9% from the prior-year quarter. Based on the collective assessment of analysts, 'Total System Units Placed - Total Company' should arrive at 395 . Compared to the current estimate, the company reported 341 in the same quarter of the previous year. The collective assessment of analysts points to an estimated 'Total Number of Procedures' of 771,122 . The estimate compares to the year-ago value of 661,000 . According to the collective judgment of analysts, 'Da Vinci Surgical System Installed Base' should come in at 10,427 . The estimate compares to the year-ago value of 9,203 . It is projected by analysts that the 'Total System Units Placed - Outside of the United States' will reach 184 . The estimate is in contrast to the year-ago figure of 192 . Analysts expect 'Total System Units Placed - United States' to come in at 211 . Compared to the present estimate, the company reported 149 in the same quarter last year. The consensus among analysts is that 'Gross profit- Service' will reach $245.26 million. Compared to the current estimate, the company reported $219.50 million in the same quarter of the previous year. Analysts' assessment points toward 'Cost of revenue- Service' reaching $118.34 million. View all Key Company Metrics for Intuitive Surgical here>>> Over the past month, shares of Intuitive Surgical have returned +0.6% versus the Zacks S&P 500 composite's +4.2% change. Currently, ISRG carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Intuitive Surgical (ISRG) Showcases Transatlantic Telesurgery Capabilities in Strasbourg Conference Intuitive Surgical recently showcased its telesurgery capabilities, highlighting advancements at the Society of Robotic Surgery conference, which aligns with its commitment to innovation. The company's share price increased by 6% over the last quarter. This rise coincided with FDA clearance of the Vessel Sealer Curved for their da Vinci systems and CE mark approval of the da Vinci 5 Surgical System for minimally invasive procedures. The appointment of a new CEO, David J. Rosa, and strong earnings growth may have bolstered investor confidence. However, market stability amid political and economic volatility provided a neutral backdrop. Buy, Hold or Sell Intuitive Surgical? View our complete analysis and fair value estimate and you decide. Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The recent advancements showcased by Intuitive Surgical, including FDA and CE mark approvals for their da Vinci systems, could significantly influence the company's revenue and earnings forecasts. These product upgrades aim to enhance surgical outcomes and expand market adoption, potentially boosting revenue growth. The appointment of David J. Rosa as CEO might also reinforce strategic alignment with these innovations, fostering investor confidence. Although the company's price increased by 6% from these announcements, it still trades below the analyst consensus price target of US$581.45. This suggests room for growth if projected revenue and earnings come to fruition. Over the past three years, Intuitive Surgical\u2019s total return, encompassing share price appreciation and dividends, was 138.87%. This performance significantly exceeds its recent one-year return, where it outpaced the US Medical Equipment industry\u2019s 6.6% growth. Such long-term gains reflect strong market positioning and the anticipated success of its surgical systems. The company's enhanced product features and expanded manufacturing efforts underline expectations of future revenue growth, aligning closely with analyst projections. However, macroeconomic factors like potential trade tensions could pose risks to these positive forecasts. Learn about Intuitive Surgical's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ISRG. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com""]"
ISRG,2025-07-18,520.21,520.963,513.27,518.62,
ISRG,2025-07-21,518.185,523.09,514.955,516.12,"[""Donald Trump faces frosty reception on Aberdeen golf trip Hello and welcome to the working week.I must start with a thank you to my colleague Harvey for stepping in for me last week while I took an"", ""Intuitive Surgical Q2 Preview: Procedure Volume and Demand in Spotlight Intuitive Surgical (NASDAQ:ISRG) will report Q2 earnings after the bell on Tuesday, July 22. Street consensus expects EPS of $1.93 on revenue of $2.4 billion, up 17% YoY, supported by continued global adoption of da Vinci systems and higher procedure volumes. The stock is roughly flat year to date despite heightened volatility earlier in 2025. This earnings report could define its next directional move, signaling either renewed confidence in Intuitive Surgical's long-term growth or renewed pressure from macroeconomic risks. Warning! GuruFocus has detected 3 Warning Signs with ISRG. Investors will focus on robotic procedure volume, which grew 17% in Q1, fueling strong instrument and accessories sales. They'll also watch capital equipment placements, especially the new da Vinci 5 in North America and China, which face macroeconomic and tariff-related headwinds. Margin commentary is also key. Last quarter, management flagged about 1.7% of revenue impact from tariffs. Any reacceleration in system placements or signs of easing trade friction would bolster confidence. This article first appeared on GuruFocus."", ""Intuitive Surgical (ISRG) To Report Earnings Tomorrow: Here Is What To Expect Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be announcing earnings results this Tuesday after market hours. Here\u2019s what to look for. Intuitive Surgical beat analysts\u2019 revenue expectations by 3.1% last quarter, reporting revenues of $2.25 billion, up 19.2% year on year. It was a satisfactory quarter for the company, with a decent beat of analysts\u2019 EPS estimates but a miss of analysts\u2019 sales volume estimates. Is Intuitive Surgical a buy or sell going into earnings? Read our full analysis here, it\u2019s free. This quarter, analysts are expecting Intuitive Surgical\u2019s revenue to grow 17.1% year on year to $2.35 billion, improving from the 14.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.92 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Intuitive Surgical has only missed Wall Street\u2019s revenue estimates once over the last two years, exceeding top-line expectations by 1.6% on average. Looking at Intuitive Surgical\u2019s peers in the healthcare equipment and supplies segment, only Abbott Laboratories has reported results so far. It beat analysts\u2019 revenue estimates by 0.9%, delivering year-on-year sales growth of 7.4%. The stock was down 6.1% on the results. Read our full analysis of Abbott Laboratories\u2019s earnings results here. Debates around the economy\u2019s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.3% on average over the last month. Intuitive Surgical\u2019s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $581.45 (compared to the current share price of $519). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we\u2019ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."", ""Alphabet and Tesla Earnings, Powell Speech and More: What to Watch This Week Earnings season rolls on this week with the first of the Magnificent Seven tech names to report, Tesla and Google parent Alphabet. New economic data will shed more light on how tariffs are affecting consumer and business spending, and Federal Reserve Chair Jerome Powell is slated to speak on bank regulation.""]"
ISRG,2025-07-22,516.05,519.83,508.27,511.0,"[""Buy Now or Regret Later: This Small-Cap Stock Has Big Disruption Potential Small-cap stocks rarely receive the attention they deserve in the massive medical technology (medtech) industry, which is dominated by bigger names like Intuitive Surgical (ISRG), Medtronic (MDT), Johnson & Johnson (JNJ), and Stryker (SYK). Valued at $1.5 billion, Alphatec Holdings (ATEC), a spinal-surgery-focused medtech firm, is one such under-the-radar name that is steadily attracting Wall Street and investor attention. Its products are specifically designed to simplify complex procedures, improve reproducibility, and help surgeons treat spinal conditions more effectively. Opendoor Stock Is Surging Higher in a Frenzied Retail Rally. How Should You Play OPEN Shares Here? This Penny Stock Wants to Become the MicroStrategy of Dogecoin Robinhood Stock Stumbles as S&P 500 Inclusion Is Once Again Off the Table for HOOD Stop Missing Market Moves: Get the FREE Barchart Brief \u2013 your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Alphatec stock has gained 13% year-to-date, compared to the S&P 500 Index\u2019s ($SPX) gain of 7.7%. Let\u2019s dig in to determine why Alphatec stock is a smart buy now. Alphatec is known for using artificial intelligence (AI) to create advanced, integrated surgical systems that include implants, imaging, navigation, robotics, and biologics. The company\u2019s goal is to revolutionize spinal surgery, making it safer and more effective for patients. Some of its innovative approaches include the Anterior/Posterior Cervical Discectomy & Fusion (ACDF/PCF), Lateral, Transforaminal, Anterior Lumbar Interbody Fusion (LTP/TLIF/ALIF), corpectomy systems, and PTP (Prone TransPsoas). While ATEC is still a small-cap firm, its revenue growth, product adoption, and expanding footprint point to a company writing a strong growth story. In the first quarter, total revenue increased 22% year-over-year to $169 million, along with 24% growth in surgical revenue. The company has developed a loyal base of highly engaged surgeons, and more trained surgeons are adopting ATEC systems. Q2 saw an 18% increase in new surgeon adoption, which is a positive indicator for future growth. Alphatec is aggressively investing in R&D and surgeon training, affecting short-term profits while increasing long-term value creation. R&D expenses totaled $16.6 million in the first quarter, resulting in a net loss of $51.9 million, or $0.35 per share. However, adjusted gross margin stood at an impressive 70% for the quarter. Alphatec ended the second quarter with $153.2 million in cash and cash equivalents. Its balance sheet is currently strong enough to support growth without excessive dilution. Various factors, including aging demographics, a shift toward minimally invasive surgical methods, digitization, robotics, and surgeons demanding better tools, could drive the spine surgery market forward. Alphatec has established a strong moat by combining software, hardware, and biologics into a streamlined ecosystem focused solely on spine surgery solutions. Its rapid revenue growth, improving margins, and expanding moat indicate that the company is on track to profitability. CEO Pat Miles believes, \u201cWe are built to lead, and the best is yet to come.\u201d The company will release its second-quarter earnings on July 31. Analysts expect revenue to rise 22.5% to $178.8 million. For the full year, analysts project revenue growth of 20%, which is consistent with management\u2019s projections, with an additional 18.3% increase in 2026. Alphatec, trading at 2x forward sales, is a reasonable buy for a company with significant growth potential in the spine surgery market. The consensus on Alphatec stock is a \""Strong Buy.\u201d Of the 11 analysts covering ATEC, nine have rated it a \u201cStrong Buy,\u201d one recommends a \u201cModerate Buy,\u201d and one says it is a \u201cHold.\u201d Based on its mean price target of $18.32, Wall Street expects the stock to climb as high as 74% from current levels. Furthermore, its Street-high estimate of $22.50 implies potential upside of nearly 113.6% in the next 12 months. The global spine surgery market is massive, valued at more than $14.5 billion and expected to reach $19.1 billion by 2030. Alphatec is a small player in the medtech industry, but its focus on spine surgery solutions gives it a competitive advantage. Given this advantage, it is ahead of the competition. Alphatec, like most small-cap biotech growth stocks, is highly volatile. However, it remains an excellent choice for those seeking exposure to medical innovation with genuine long-term upside and who are willing to bear the short-term risks. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"", ""Microbot Medical\u00ae Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales Company Continues to Strengthen Organizational Infrastructure with Success-Driven Medical Device Veteran Christina Bailey, VP of Sales, Microbot Medical HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY\u00ae Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time U.S. Olympian with 20 years of medical device sales experience, Ms. Bailey has successfully led commercial teams to achieve sales goals. She will report directly to Harel Gadot, the Company\u2019s CEO, President and Chairman. Ms. Bailey has held a variety of sales leadership roles. She has worked with notable companies like Boston Scientific, Abbott, Stryker and Intuitive Surgical that have equipped her with the insights necessary to drive growth and innovation. As the Vice President of US Sales at Endologix, her leadership in building and scaling the sales team while achieving sales milestones demonstrate her capability to lead crucial product launches. Ms. Bailey serves as a Board Member for USA Hockey. As a member of the U.S.A. Women\u2019s Hockey Team, she won a gold medal at the 1998 Winter Olympics held in Nagano, Japan. \u201cChristina is a sales leader with a track record of building and working within high-performing teams across her professional and Olympic careers,\u201d commented Mr. Gadot. \u201cWe believe her leadership will strengthen our commercial efforts as she begins establishing an experienced and mission-driven sales team to support our anticipated launch of LIBERTY.\u201d LIBERTY is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world\u2019s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical\u00ae is available at http://www.microbotmedical.com. Safe Harbor Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as \u201ccontemplates,\u201d \u201ccontinues,\u201d \u201ccould,\u201d \u201cforecasts,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cestimates\u201d and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company\u2019s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical\u00ae can be found under the heading \u201cRisk Factors\u201d in Microbot Medical\u2019s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC\u2019s web site at www.sec.gov. Microbot Medical\u00ae disclaims any intent or obligation to update these forward-looking statements, except as required by law. Investor Contact: IR@microbotmedical.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/efa7e0c8-987b-4e57-8a97-2fcee0a31aa5"", ""ISRG Stock Before Q2 Earnings Release: To Buy or Not to Buy? Intuitive Surgical, Inc. ISRG is set to report second-quarter 2025 earnings on April 22. The Zacks Consensus Estimate for sales and earnings is pegged at $2.35 billion and $1.92 per share, respectively. Earnings per share estimates for ISRG have remained stable at $7.84 and $9.05 for 2025 and 2026, respectively, over the past 30 days. The company expects worldwide da Vinci procedures to increase approximately 15-17% in 2025, a trend that should have benefited the top line in the to-be-reported quarter. Intuitive Surgical\u2019s close peers, Thermo Fisher Scientific TMO and Medtronic MDT, are slated to announce their quarterly numbers in the upcoming few weeks. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.) In the last reported quarter, ISRG delivered an earnings surprise of 5.85%. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 14.64%. Image Source: Zacks Investment Research Our proven model does not conclusively predict an earnings beat for Intuitive Surgical this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below. ISRG has an Earnings ESP of 0.00% and a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The Instruments & Accessories segment is likely to report robust second-quarter results on the back of several favorable factors, especially strong da Vinci procedure growth. Procedure volume is likely to have been driven by growth in U.S. general surgery and cancer procedures in ex-U.S. markets. General surgery procedures have aided procedure growth in the U.S. market, while cancer procedures benefited ex-U.S. markets during the past two quarters. We expect this trend to have continued in the second quarter. Procedures with the Ion platform are also likely to have exhibited robust growth. However, declining demand for bariatric procedures, especially in the United States, might have partially offset the positives. Moreover, procedure growth in China improved from the prior quarter and was a little above the global average, driven primarily by urologic procedures. This trend is likely to have continued and boosted sales in the soon-to-be-reported quarter. However, tariff-related challenges are likely to have impacted sales in the country. Apart from China, rising adoption in Japan and India might have aided sales growth. The Systems segment\u2019s results are expected to reflect strong adoption of the newly launched da Vinci 5. The company\u2019s second-quarter top line is likely to have grown on the back of strong adoption of the recently launched da Vinci 5 surgical system. The company placed 147 da Vinci 5 systems during the first quarter. A similar trend is likely to have continued in the second quarter. Moreover, the first quarter reflected a higher average selling price for da Vinci 5, a trend that should have further boosted sales in the soon-to-be-reported quarter. However, the company is gearing up for a broader launch of da Vinci 5 in the second half of 2025, which should have driven expenses higher. The Services segment\u2019s quarterly results are expected to reflect strong adoption of ISRG\u2019s digital products and services, including Intuitive App and Intuitive Hub. Meanwhile, ISRG\u2019s margins are likely to have been hurt due to the launch of new da Vinci and Ion systems as well as higher depreciation related to new facilities. However, cost reductions and fixed overhead leverage might have partially offset the margin decline. Meanwhile, analysts will be asking questions on the potential impact of U.S. tariffs on China and vice versa in the upcoming quarters of 2025. The rising trade war between the world\u2019s top two economies might have hit supply chains, potentially leading to a rise in costs as well as hurting top-line growth. Intuitive Surgical\u2019s shares have declined 0.7% so far this year compared with the industry\u2019s 11.5% decline. The company\u2019s shares have underperformed the S&P 500 Index\u2019s gain of 6.5% but outperformed the Zacks Medical sector\u2019s decrease of 6.4%. ISRG has also outperformed Thermo Fisher Scientific\u2019s 20.3% decline but underperformed Medtronics\u2019 12.2% gain so far this year. YTD Price Performance Image Source: Zacks Investment Research Now, let us take a look at the value Intuitive Surgical offers to its investors at current levels. Currently, ISRG is trading at a premium compared to its industry, with a forward 12-month P/E of 60.92X compared with the industry\u2019s 27.90X. However, the current valuation came down from a five-year high of 72.39X but is higher than the five-year low of 41.90X. ISRG has traded at a premium to the industry valuation in the past five years, reflecting the company's higher growth prospects. However, the current Value score of D reflects a high valuation. ISRG's P/E F12M Graph Image Source: Zacks Investment Research Although the valuation remains high, Intuitive Surgical is likely to continue its strong performance in the rest of 2025, driven by continued growth in the company\u2019s da Vinci procedure volume and strong Ion procedure growth. Improving procedure prices should aid sales growth going forward. Increasing procedure volume, along with better system placements and services across all markets, should drive top-line growth this year. The launch of da Vinci SP in Europe and da Vinci 5 in the U.S. market should continue to drive system placements higher. However, weaknesses in bariatric procedures and challenges in China are likely to offset growth in the upcoming quarters. Meanwhile, rising trade tensions following the imposition of U.S. tariffs are likely to lead to uncertainty across the globe, which may affect ISRG\u2019s performance as well. However, the company\u2019s primary manufacturing facilities in the United States and Mexico should continue to support U.S. revenues in the upcoming quarters without any tariff risks. Meanwhile, a weak dollar can act as a tailwind for top-line growth. Although Intuitive Surgical has strong fundamental factors supporting its uptrend, we will caution investors against adding the stock to their portfolio before its earnings release. The company carries a favorable Zacks Rank; however, the Style Score of D does not reflect a major strength in the stock. The company\u2019s high valuation may have factored in the strong fundamentals, including growth in procedures and installed base. While current shareholders may hold their position, new investors should wait for the stock to release its second-quarter results and analyze the new updates before making an entry. However, valuation may continue to remain expensive as ISRG plans to expand its efforts to place systems beyond the United States, increase utilization in existing U.S. accounts and expand into additional indications in the next two years. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""ISRG vs. SYK: Which Robotic Surgery Stock Is the Stronger Buy Today? As robotic-assisted surgery continues its rising adoption in modern medicine, two industry leaders \u2014 Intuitive Surgical ISRG and Stryker SYK \u2014 are shaping the future of robotic-assisted surgery. Intuitive, renowned for its da Vinci Surgical System, continues to dominate the soft tissue surgery space. In contrast, Stryker has established a firm foothold in orthopedic procedures through its Mako robotic platform. Both companies are aggressively pursuing innovation and expanding their global reach, capturing investor attention in the rapidly evolving surgical tech market. However, their distinct clinical focuses, strategic directions and financial dynamics set them apart. In this faceoff, we explore which of these medtech powerhouses stands out as the more compelling long-term investment. Intuitive Surgical revolutionized robotic surgery with its da Vinci platform, offering the Xi system for multiport procedures and the SP system for single-port access. Both systems are equipped with 3D HD vision and EndoWrist instruments for enhanced precision. Stryker entered the robotic arena through its 2013 acquisition of Mako Surgical, leveraging the Mako system for knee and hip replacements and expanding its capabilities with Mako 4, which includes modules for hip revision, spine, and shoulder procedures. Currently, Intuitive commands nearly 80% of the global surgical robotics market by volume, while Stryker leads in orthopedic robotics, surpassing 1.5 million Mako procedures and integrating real-time analytics with its implants. While ISRG\u2019s strength lies in its wide clinical footprint, SYK has carved a specialized edge in orthopedics \u2014 underscoring their distinct positions within the surgical robotics landscape. Intuitive\u2019s first-quarter 2025 revenues rose 19% to $2.25 billion. da Vinci procedure grew 17% with 367 new system placements. Instruments and accessories revenues reached $1.37 billion (+18%), boosting recurring income. While Stryker\u2019s MedSurg/Neurotechnology sales rose 13.4% to $3.51 billion in the first quarter of 2025, Orthopaedics climbed 9.7% to $2.36 billion, fueled by robust Mako knee/hip robotics demand. The global robotic surgery market is projected to witness a 16.5% CAGR through 2029, per a report by Markets and Markets. This can be attributed to minimally invasive trends and aging populations. Intuitive\u2019s 15% installed-base growth and recurring consumables model position it to lead share gains, while Stryker\u2019s Mako orthopaedic platform and double-digit knee segment growth equips it to capture the booming joint-replacement robotics niche. The Zacks Consensus Estimate for ISRG\u2019s 2025 sales and EPS implies a year-over-year improvement of 15.6% and 6.8%, respectively. EPS estimates for 2025 have trended southward over the past 30 days but moved north 1 cent for 2026. ISRG Estimate Movement Image Source: Zacks Investment Research The Zacks Consensus Estimate for Stryker\u2019s 2025 sales and EPS implies a year-over-year improvement of 10% and 9.5%, respectively. However, EPS estimates for 2025 and 2026 have declined 2 cents each over the past 30 days. SYK Estimate Movement Image Source: Zacks Investment Research Intuitive Surgical is doubling down on next-generation innovations, led by the Ion endoluminal system for robotic bronchoscopy and peripheral lung biopsy. With a run rate exceeding 100,000 procedures, primarily in the United States, Ion was recently launched in Australia, marking the start of broader international rollout. Additionally, Intuitive Surgical received FDA 510(k) clearance for the da Vinci 5, its next-gen multiport system featuring enhanced computing power and significant design upgrades, with further da Vinci variants currently in development. Meanwhile, Stryker continues to evolve its Mako SmartRobotics platform with advanced features such as AI-driven 3D CT-based surgical planning and AccuStop haptic technology for highly precise implant placement. In late 2024, the company debuted Mako Spine and Shoulder in select markets and unveiled its fourth-generation Q Guidance modules \u2014 covering hip, knee, spine, and shoulder \u2014 at AAOS 2025. These strategic advancements reinforce Intuitive\u2019s leadership in minimally invasive thoracic and general surgery, while positioning Stryker to extend its dominance in orthopaedics into adjacent specialties through AI integration. The year-to-date price performances of both Intuitive Surgical and Stryker have been encouraging, likely due to tariff concerns and rising competition from Chinese robotic device makers. Shares of ISRG and SYK have rallied 12% and 13.1%, respectively, year to date. Image Source: Zacks Investment Research Intuitive Surgical\u2019s da Vinci dominance \u2014 nearly 80% market share, sustainable 19% revenue growth, recurring consumables and Ion lung biopsy system \u2014 underpins broad surgical robotics leadership. Stryker\u2019s Mako orthopaedic platform, AI-driven planning, haptic feedback and integrated MedSurg offerings fuel double-digit segment growth and cross-selling across care pathways. With a 10-15% market CAGR through 2030, ISRG suits growth-oriented investors seeking diversified global exposure, while SYK appeals to those targeting the fast-growing joint-replacement robotics niche. While Intuitive Surgical carries a Zacks Rank #2 (Buy) at present, Stryker has a Zacks Rank #3 (Hold), which makes ISRG a better bet for investors. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
ISRG,2025-07-23,522.5,530.35,491.855,501.95,"[""Truist Adjusts Price Target on Intuitive Surgical to $600 From $590, Maintains Buy Rating Intuitive Surgical (ISRG) has an average rating of overweight and mean price target of $597.48, acco"", ""ISRG Stock Gains on Q2 Earnings & Sales Beat, Gross Margin Contracts Intuitive Surgical ISRG reported second-quarter 2025 adjusted earnings per share (EPS) of $2.19, which beat the Zacks Consensus Estimate of $1.92 by 14.1%. The bottom line improved 23% year over year. GAAP EPS in the quarter was $1.81, up 24% from the year-ago quarter\u2019s level. This Zacks Rank #2 (Buy) company reported revenues of $2.44 billion, up 21% year over year reportedly as well as at constant currency (cc). A higher number of installed systems and growth in the da Vinci procedure volume contributed to the improvement. The top line beat the Zacks Consensus Estimate by 3.9%. Intuitive Surgical, Inc. price-consensus-eps-surprise-chart | Intuitive Surgical, Inc. Quote Instruments & Accessories Revenues from this segment totaled $1.47 billion, indicating a year-over-year improvement of 18.5%. This can be attributed to the da Vinci procedure\u2019s 17% volume growth. The sales growth also reflects approximately 52% growth in Ion procedures and 88% for the SP platform. The top-line improvement was also aided by higher system utilization, partially offset by a lower mix of bariatric procedures and a higher mix of cholecystectomy procedures. Systems This segment\u2019s revenues totaled $574.7 million, up 28.2% year over year. The robust growth was driven by a higher system placement and a rise in average selling price. Intuitive Surgical shipped 395 da Vinci Surgical Systems compared with 341 in the prior-year quarter. The company placed 216 systems in the United States and 179 in international markets. During the second quarter, ISRG placed 180 of its latest da Vinci 5 systems compared with 147 during the first quarter of 2025. Services Revenues from this segment amounted to $391.2 million, up 23.3% from the year-ago quarter\u2019s level. Adjusted gross profit was $1.66 billion, up 17.8% year over year. As a percentage of revenues, the gross margin was 67.9%, down approximately 200 bps from the prior-year quarter\u2019s figure. Selling, general and administrative expenses totaled $561.2 million, up 6.8% year over year. Research and development expenses totaled $313.3 million, up 11.9% on a year-over-year basis. Adjusted operating income totaled $946.6 million, up 25.5% year over year. As a percentage of revenues, the operating margin was 38.8%, up approximately 130 bps from the prior-year quarter\u2019s figure. Intuitive Surgical exited the second quarter with cash, cash equivalents and investments of $9.53 billion compared with $9.1 billion in the previous quarter. Total assets increased to $20.16 billion from $19.22 billion a year ago. ISRG ended the second quarter on a strong note, with earnings and revenues beating their respective estimates. Following this robust quarterly performance, the stock was up 0.3% during after-hours trading on July 22. Shares of Intuitive Surgical have lost 2.1% so far this year compared with the industry\u2019s 12.4% decline. The S&P 500 Index has increased 6.8% during the same time frame. Image Source: Zacks Investment Research The da Vinci 5 (dV5) system entered broad launch in the United States with 180 placements, bringing its total installed base to 689. The company also received regulatory approvals for dV5 in Europe and Japan, with measured rollouts planned. Utilization of dV5 surpassed the legacy Xi platform, and early clinical evidence supported the value of new features like force feedback and Case Insights. Trade-ins rose significantly, indicating early momentum in the upgrade cycle. Global da Vinci procedures rose 17% year over year, led by 14% growth in the United States and 23% outside. Strength was seen in benign general surgeries domestically and across non-urology procedures internationally, especially in India, Korea and distributor markets. Utilization improved across all platforms, with 2% growth in multiport, 30% in SP and 8% in Ion. System placements totaled 395, with U.S. demand strong but international markets pressured by budget constraints. Gross margin declined due to higher costs and tariffs (60bps drag in the second quarter). Operating margin remained strong due to favorable purchase mix and cost leverage. Tariff headwinds are expected to affect full-year margins by nearly 100bps. Medicaid-related policy uncertainty poses a potential risk, but ISRG\u2019s relatively lower exposure and strong value proposition may mitigate the impact. The company raised its 2025 procedure growth guidance to 15.5-17% (from 15-17%) and updated gross margin guidance to 66-67%. Focus remains on expanding dV5, growing Ion and SP adoption, and advancing its digital ecosystem to drive long-term value. Some other top-ranked stocks from the broader medical space that are expected to report earnings soon are Boston Scientific Corporation BSX, Cardinal Health, Inc. CAH and Cencora, Inc. COR. The Zacks Consensus Estimate for Boston Scientific\u2019s second-quarter 2025 adjusted earnings per share (EPS) is currently pegged at 72 cents. The consensus estimate for revenues is pegged at $4.89 billion. BSX currently carries a Zacks Rank #2. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Boston Scientific has an estimated long-term growth rate of 13.2%. BSX\u2019s earnings yield of 2.8% compares favorably with the industry\u2019s 1.1%. Cardinal Health currently has a Zacks Rank #2. The Zacks Consensus Estimate for fourth-quarter fiscal 2025 adjusted EPS is currently pegged at $2.03 and the same for revenues is pinned at $60.67 billion. Cardinal Health has an estimated long-term growth rate of 10.9%. CAH\u2019s earnings yield of 5.7% compares favorably with the industry\u2019s 5.5%. Cencora currently carries a Zacks Rank #2. The Zacks Consensus Estimate for third-quarter fiscal 2025 adjusted EPS is currently pegged at $3.78 and the same for revenues is pegged at $80.33 billion. Cencora has an estimated long-term growth rate of 12.8%. COR\u2019s earnings yield of 5.4% compares favorably with the industry\u2019s 4.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Alphabet and Tesla Earnings, Home Sales and More: What to Watch This Week Earnings season rolls on this week, with the first two of the Magnificent Seven tech names to report, Tesla and Google parent Alphabet. New economic data will shed more light on how tariffs are affecting consumer and business spending, and Federal Reserve Chair Jerome Powell is slated to speak on bank regulation.""]"
ISRG,2025-07-24,503.52,505.74,486.54,488.61,
ISRG,2025-07-25,492.48,497.5,490.76,495.86,"Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside? Intuitive Surgical ISRG delivered a solid second-quarter 2025 performance, with procedure volumes up 17% year over year, maintaining double-digit growth across key U.S. and international markets. The performance was led by continued strength in general surgery and gynecology, with particular momentum in hernia repair, bariatrics and colorectal procedures. China also rebounded after a soft first quarter, contributing to international growth. However, while procedure growth was robust, translating this volume into durable EPS upside presents a nuanced picture. Gross margin during the second quarter declined 200 bps year over year to 67.9%. This was due to higher component and logistics costs, foreign exchange pressure, and a higher mix of new platforms like da Vinci 5, which, while early in adoption, comes with lower margins. The company placed 395 da Vinci systems in the second quarter (up year over year), with a rising mix of operating leases that depresses near-term revenue recognition but offers long-term recurring benefits. Instruments & Accessories (I&A) revenues grew 18.5%, benefiting from strong procedure growth, and Systems revenue climbed 28.2%, indicating expanding support from an installed base that now exceeds 10,000 systems globally. Importantly, ISRG reiterated its 2025 margin guidance (66-67%) and highlighted levers to improve operating efficiency, including automation, scale, and a growing contribution from digital tools and services like My Intuitive and SmartFire. With da Vinci 5 expanding into more procedures and Ion gaining traction, particularly in the United States, margin headwinds may moderate. While strong procedure volume in the second quarter bodes well for I&A sales and long-term system utilization, near-term EPS expansion will depend on controlling margin pressures from FX, inflation and platform mix. If ISRG can drive operational efficiencies while scaling adoption of its newer platforms, durable EPS upside could follow its procedure strength. Globus Medical GMED delivered a strong first-quarter 2025 performance with net sales of $598.1 million and adjusted EPS of 68 cents. The integration with NuVasive continues to yield benefits, with synergy capture and operational scale supporting margin expansion. The company saw volume-driven growth across its musculoskeletal solutions, particularly in Enabling Technologies and Imaging, with demand for robotic-assisted surgeries sustaining momentum. GMED also reaffirmed its 2025 guidance, indicating confidence in execution. Overall, robust procedural growth and operational leverage position GMED favorably as they continue to scale its combined platform. Zimmer Biomet ZBH reported first-quarter 2025 sales of $1.91 billion, up 2.3% at cc, while adjusted EPS was $1.81, down from $1.94 a year ago. U.S. Hips led growth with a 3.7% increase, driven by new launches like the Z1 stem and OrthoGrid. While U.S. Knees remained flat, it is expected to gain traction through expanded adoption of cementless and partial options. The company reaffirmed its 3-5% constant currency organic growth guidance, supported by ongoing product rollouts and channel optimization. Despite modest EPS pressure from tariffs and acquisition costs, ZBH’s procedural volume and innovation cycle remain key tailwinds. Shares of ISRG have lost 6.4% in the year-to-date period compared with the industry’s decline of 7.7%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-sales ratio of 16.7, above the industry average. But, it is still lower than its five-year median of 17.1. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 6.8% rise from the year-ago period’s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-07-28,498.0,502.81,493.22,493.95,"[""ISRG's Gross Margin Falls on Product Transition and Trade Pressures Intuitive Surgical ISRG reported a second-quarter 2025 gross margin of 67.9%, down from 70% in the prior-year period. While the company's top-line performance was solid, the margin compression highlights structural shifts underway within its operations and product mix. A key driver of the margin contraction is the increasing contribution of newer, lower-margin platforms, specifically the da Vinci 5 and Ion systems. Although these technologies are central to ISRG\u2019s next growth chapter, they come with elevated manufacturing and service costs, particularly in the early phases of commercialization. The da Vinci 5, in broad launch across the United States, requires more complex support infrastructure, pushing service costs higher. Another notable factor is the impact of depreciation from recent capacity investments. ISRG's ongoing expansion, including the opening of a 187,000 sq. ft. facility in Bulgaria, adds incremental overhead even before full operational efficiency is realized. This strategic buildout reflects management\u2019s commitment to scale production globally but creates short-term margin headwinds. Tariff-related expenses added further pressure, reducing gross margin by approximately 60 basis points in the second quarter alone. The broader trade environment, especially U.S.-China tariff dynamics, is expected to exert an approximate 100 basis points annual drag on gross margin. While these challenges are largely transitional, they reflect ISRG\u2019s evolving business model. Management anticipates that over time, scale efficiencies, maturing service operations, and increased procedure volumes on da Vinci 5 and Ion systems will help recover margins. However, in the near term, investors should expect continued volatility in gross profitability as the company navigates this shift from a legacy high-margin portfolio to a broader, innovation-driven ecosystem. Boston Scientific BSX reported an adjusted gross margin of 69.4% in second-quarter 2025, down 100 basis points year over year. The decline was primarily due to inventory charges related to the discontinuation of the ACURATE valve. Despite this headwind, the company benefited from a favorable product mix and continued operational productivity, which helped partially offset the impact. GAAP gross margin was 67.7%. Management remains confident in its ability to expand gross margin over the long term, supported by ongoing cost-efficiency programs, manufacturing optimization, and the strength of high-growth, high-margin portfolios across its structural heart and neuromodulation segments. Thermo Fisher\u2019s TMO second-quarter 2025 adjusted gross margin was 41.3%, down about 80???bps from the year-ago level. Management said tariffs and FX shaved roughly 150???bps off this margin (about a 5% drag on operating profit), partly offset by nearly 70???bps of productivity gains. CFO Stephen Williamson noted these headwinds translate to roughly a 140???bps hit to reported margins. In short, trade-related costs and mix shifts narrowed gross margins, though strong cost-control measures (productivity improvements) helped cushion the decline. Shares of ISRG have lost 5% in the year-to-date period compared with the industry\u2019s decline of 6.8%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 56.6, above the industry average. But, it is still lower than its five-year median of 72.4. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical\u2019s 2025 earnings implies a 11.3% rise from the year-ago period\u2019s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Intuitive Surgical Insider Sold Shares Worth $2,216,160, According to a Recent SEC Filing Myriam Curet, Executive Vice President & Chief Medical Officer, on July 25, 2025, sold 4,500 shares"", ""Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know Intuitive Surgical, Inc. (ISRG) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this company have returned -7.1% over the past month versus the Zacks S&P 500 composite's +4.9% change. The Zacks Medical - Instruments industry, to which Intuitive Surgical belongs, has gained 3.3% over this period. Now the key question is: Where could the stock be headed in the near term? While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Intuitive Surgical is expected to post earnings of $2.00 per share for the current quarter, representing a year-over-year change of +8.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.2%. The consensus earnings estimate of $8.17 for the current fiscal year indicates a year-over-year change of +11.3%. This estimate has remained unchanged over the last 30 days. For the next fiscal year, the consensus earnings estimate of $9.2 indicates a change of +12.6% from what Intuitive Surgical is expected to report a year ago. Over the past month, the estimate has changed +1.7%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Intuitive Surgical. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. In the case of Intuitive Surgical, the consensus sales estimate of $2.41 billion for the current quarter points to a year-over-year change of +18.2%. The $9.78 billion and $11.16 billion estimates for the current and next fiscal years indicate changes of +17.1% and +14.2%, respectively. Intuitive Surgical reported revenues of $2.44 billion in the last reported quarter, representing a year-over-year change of +21.4%. EPS of $2.19 for the same period compares with $1.78 a year ago. Compared to the Zacks Consensus Estimate of $2.35 billion, the reported revenues represent a surprise of +3.93%. The EPS surprise was +14.06%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Intuitive Surgical is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intuitive Surgical. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
ISRG,2025-07-29,497.25,502.42,496.17,496.88,"[""Cushman & Wakefield Welcomes Conor Flannery as Executive Vice Chair in Silicon Valley Veteran Tenant Rep Broker Joins Cushman & Wakefield from JLL SAN JOSE, Calif., July 28, 2025--(BUSINESS WIRE)--Cushman & Wakefield announced today that the real estate services firm has hired Conor Flannery as Executive Vice Chair. Bringing more than 20 years of experience in occupier services and tenant representation, Flannery will further strengthen the firm's capabilities in offering innovative real estate solutions to clients across the Bay Area. Flannery will be based out of Silicon Valley. Flannery joins Cushman & Wakefield with a proven track record of negotiating complex real estate transactions globally. During his tenure at JLL, Flannery closed over 1,200 leases valued at more than $2B and structured more than 50 acquisitions totaling $3B. With expertise in corporate real estate purchases and P&L navigation, Flannery has guided key transactions for clients like Intuitive Surgical, Netgear, Nova and Ichor Systems, spanning intricate headquarters, manufacturing sites and R&D locations. \""We are so excited to welcome Conor to Cushman & Wakefield, as he is the epitome of the industry-leading talent we\u2019re recruiting,\"" said Tom McDonnell, Executive Regional Director, Northwest. \""This strategic hire reinforces our dedication to our clients in Silicon Valley. Conor\u2019s values align perfectly with our culture and his deep expertise will be invaluable as we focus on delivering the next iteration of global real estate advisory and services. By continuously recruiting exceptional professionals like Conor, we remain at the forefront of providing end-to-end solutions to our clients.\"" Cushman & Wakefield is always advancing its advisory model to meet occupier business challenges and support decision-making. \""We\u2019re committed to embedding a consulting-led approach across our platform,\"" said Matt Chatham, President of Occupier Advisory Services. \""The evolution of our business is always building on our current success, creating better tactical process to support clients. The use of more data and insights empowers our professionals to operate with greater efficiency and deliver stronger advisory solutions.\"" \""I have always been impressed with the Cushman & Wakefield team, and I am thrilled to become a part of it. With a strong foundation in Silicon Valley, I\u2019m looking forward to contributing to the team\u2019s continued growth. We see immense potential in today\u2019s market and we\u2019re eager to deliver exceptional solutions for our occupier clients,\"" added Flannery. About Cushman & Wakefield Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In 2024, the firm reported revenue of $9.4 billion across its core service lines of Services, Leasing, Capital markets, and Valuation and other. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit www.cushmanwakefield.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20250728406513/en/ Contacts Media Contact: Jayden Lapin Communications Manager, West Region 212-841-5052 Jayden.LapinTatman@cushwake.com"", ""5 Must-Read Analyst Questions From Intuitive Surgical\u2019s Q2 Earnings Call Intuitive Surgical\u2019s second quarter results were marked by strong procedure growth and robust capital equipment placements, which together helped the company exceed Wall Street\u2019s top- and bottom-line expectations. Management attributed the quarter\u2019s momentum to continued adoption of the da Vinci 5 robotic surgical system, particularly in the United States, as well as solid execution in expanding its installed base across key international markets. CEO Dave Rosa highlighted that \u201cbenign general surgery led U.S. procedure growth with a strong contribution from after-hours procedures, while international growth was led by non-urology procedures.\u201d Is now the time to buy ISRG? Find out in our full research report (it\u2019s free). Revenue: $2.44 billion vs analyst estimates of $2.35 billion (21.4% year-on-year growth, 3.7% beat) Adjusted EPS: $2.19 vs analyst estimates of $1.92 (14.2% beat) Adjusted EBITDA: $1.09 billion vs analyst estimates of $965.2 million (44.6% margin, 12.8% beat) Operating Margin: 30.5%, up from 28.2% in the same quarter last year Sales Volumes rose 15.8% year on year (3% in the same quarter last year) Market Capitalization: $177.1 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Travis Lee Steed (Bank of America Securities) asked about margin sustainability after a strong quarter, with CFO Jamie Samath clarifying that current margins benefited from favorable purchase mix and lower OpEx growth, but should not be viewed as a new baseline. Travis Lee Steed (Bank of America Securities) inquired about Intuitive\u2019s strategy regarding third-party instrument reprocessing, to which CEO Dave Rosa responded that the company is focused on continuous innovation, reliability, and cost reduction to provide value versus remanufactured alternatives. David Harrison Roman (Goldman Sachs) questioned the impact of Medicaid coverage policy changes on U.S. hospital capital spending; Samath said it is too early to assess the effect, but noted economic challenges could influence hospital budgets and capital allocation. Robert Justin Marcus (JPMorgan) asked if productivity gains have been observed with da Vinci 5 compared to prior models. Management cited anecdotal improvements in efficiency and utilization but emphasized the need for more robust evidence. Lawrence H. Biegelsen (Wells Fargo) sought clarity on the pace of international system placements following recent regulatory approvals, with Samath stating the rollout will be measured and dependent on customer readiness and infrastructure development. In coming quarters, the StockStory team will closely track (1) adoption rates and clinical feedback from the broader da Vinci 5 rollout in the United States, Europe, and Japan, (2) utilization trends and feature adoption for SP and Ion platforms in new markets, and (3) the impact of evolving tariff and policy environments on margins and capital placements. Additional attention will be paid to ongoing product innovation and manufacturing scale-up efforts. Intuitive Surgical currently trades at $493, down from $511.63 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it\u2019s free). Trump\u2019s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines. Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."", ""Jim Cramer on Intuitive Surgical: \u201cI\u2019m Inclined to Recommend the Stock\u201d Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the stocks that Jim Cramer weighed in on. In response to a caller\u2019s query about the company, Cramer commented: Stock market data on a laptop screen. Photo by Alesia Kozik on Pexels Intuitive Surgical (NASDAQ:ISRG) develops robotic systems for minimally invasive procedures. The company\u2019s main products include the da Vinci Surgical System and Ion platform, along with training, support services, and digital tools for healthcare providers. While discussing the best performers of the last 20 years in May, Cramer mentioned the stock and said: While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey."", ""One Buy-Rated Stock With an Unbreakable Moat That You Can\u2019t Ignore Intuitive Surgical (ISRG), valued at $177 billion, is a medical technology company best known for its da Vinci Surgical System. It has long held a monopoly on the robotic surgery market with the da Vinci systems, a robotic platform that helps surgeons perform minimally invasive surgeries. Its success is based on a two-decade-old ecosystem of surgeon loyalty, hospital dependency, and technological supremacy. During the same period, the stock returned more than 6,330%. With advancements in artificial intelligence (AI), Intuitive can now further develop its system, solidifying its unbreakable moat. Let us see if the stock is currently a buy. Warren Buffett Warns Inflation Turns Business Into \u2018The Upside-Down World of Alice in Wonderland\u2019 But Weeds Out \u2018Bad Businesses\u2019 Why GOOGL Stock May Be the Market\u2019s Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Intuitive\u2019s da Vinci system is an advanced robotic system that allows surgeons to operate through small incisions using robotic arms and a 3D high-definition camera, giving them greater precision, control, and vision. These minimally invasive surgeries result in fewer complications, shorter hospital stays, and faster recovery times. Intuitive\u2019s business model includes not only selling these systems but also earning recurring revenue from sales of system-related instruments and accessories, as well as surgeon training programs. In the most recent second quarter, global da Vinci procedures increased 17% year over year. The company installed 395 da Vinci systems in Q2, including 180 da Vinci 5 systems, its fifth-generation robotic system, which the company launched in 2024. Total revenue increased by 21% to $2.44 billion, with adjusted earnings up 23% to $2.19 per share. Despite an increase in the average selling price (ASP) of da Vinci systems from $1.44 million to $1.5 million, systems revenue increased by 28% due to increased placements and demand for the company\u2019s latest da Vinci platforms. This reveals that hospitals are prioritizing investments in Intuitive\u2019s cutting-edge surgical platforms, despite broader capital expenditure constraints in some global markets. Additionally, instruments and accessories revenue also rose by 18% YoY to $1.47 billion. One standout performer in the quarter was the SP (Single Port) platform, which grew procedures by 88% year on year. It is used in confined anatomical spaces and complex cases such as colorectal or head and neck surgeries, where traditional multiport robotic systems may fail to function. In the second quarter, Intuitive placed 23 SP systems. Additionally, the Ion system, Intuitive\u2019s robotic-assisted platform for minimally invasive lung biopsies, saw a 52% increase in procedures to 35,000, with an installed base of 905 systems. Despite macroeconomic uncertainty and rising trade tensions, gross margins remained at 67.9%. The company repurchased $181 million worth of shares and spent $155 million in capex, yet grew its cash reserves to $9.5 billion. Looking ahead, the company intends to launch da Vinci 5 globally. Intuitive is well-positioned to execute, with a healthy balance sheet, recurring revenue model, and strong free cash flow. Intuitive has a two-decade headstart in the field of robotic surgery. According to GlobalData, Intuitive held 60% of the global robotic surgery market in 2024. This market, which was valued at $2.9 billion in 2024, is expected to reach $9.2 billion by 2034. Intuitive has installed over 11,000 da Vinci systems across 74 countries. Bringing a robotic system to market requires years of research and development, surgeon partnerships, billions of dollars, and regulatory hurdles. Even if a new entrant or an established player attempts to enter this space, they must show clinical efficacy, safety, and training scalability at a level that matches Intuitive. Rivals with deep pockets have developed alternatives. Notably, Medtronic (MDT) with its Hugo system, Johnson & Johnson (JNJ) with its Ottava surgical system, and Stryker (SYK) with its Mako system have all attempted but failed to gain market share. This is due in part to hospitals and surgeons being locked into the da Vinci ecosystem, where they have invested a significant amount of money to purchase these systems and train their surgeons. Once trained, switching platforms is costly and risky. That\u2019s what makes the moat so unbreakable. Besides the da Vinci, Intuitive has expanded its reach into pulmonology, colorectal, thoracic, and head-and-neck surgeries with Ion, SP, and staplers, creating a diversified model. Overall, Intuitive is a growth stock with decades of innovation, operational excellence, and a moat based on technological superiority and clinical outcomes that competitors will find difficult to replicate. On Wall Street, overall, Intuitive stock is a \u201cModerate Buy.\u201d Out of the 28 analysts that cover the stock, 18 rate it a \u201cStrong Buy,\u201d two suggest a \u201cModerate Buy,\u201d seven rate it a \u201cHold,\u201d and one says it is a \u201cStrong Sell.\u201d The average target price of $602.96 is 21% above current levels. The high price estimate of $675 implies 36% upside over the next 12 months. Despite its unbreakable moat and excellent long-term growth prospects in the robotic surgery market, ISRG stock is currently trading at a premium of 60x forward earnings. Risk-averse investors can start accumulating shares around the $400 level to invest with a margin of safety. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"", ""Cathie Wood Goes Shopping: 3 Stocks She Just Bought Cathie Wood added to her existing positions in Nvidia, DoorDash, and Intuitive Surgical to kick off this trading week. Nvidia shares have more than doubled since their April lows, but the stock is trading at a reasonable 30 times next year's earnings target. DoorDash and Intuitive Surgical have very different stock charts, even though the one that is going the wrong way is the one serving up accelerating growth. 10 stocks we like better than Nvidia \u203a Cathie Wood is built for rallying markets. The co-founder, CEO, and chief investment officer of Ark Invest is crushing the market this year, proving that she can catch 2020 in a bottle again. Ark's daily transactions are announced at the end of the day. Like a tribute band on tour, Wood is mostly playing her hits. Ark bought shares of Nvidia (NASDAQ: NVDA), DoorDash (NASDAQ: DASH), and Intuitive Surgical (NASDAQ: ISRG) on Monday, adding to existing positions. Nvidia and DoorDash are rolling these days, but Intuitive Surgical has been a market laggard. Let's take a closer look. Nvidia is hitting fresh highs. The world's most valuable company by market cap has now more than doubled since bottoming out in early April. The lead horse in the artificial intelligence (AI) revolution has earned its upticks, and it's easy to kick yourself for missing the near-term bottom a little more than three months ago. Resist the urge to take it out on yourself. Nvidia was in bad shape heading into April's rally. Between a Chinese start-up bragging about delivering generative AI without springing for Nvidia's priciest chips and export restrictions into China costing it billions in suspended sales, it was easy to wonder if one of the market's best performers over the past five years was done as a bellwether. Is it ever too late to buy a dynamic growth stock? Buying Nvidia right now for 55 times trailing earnings doesn't seem cheap, especially for the handful of people who nailed the bottom on April 7. Now look at it through the windshield instead of the rearview mirror. Nvidia is trading for just 30 times next year's projected profit of $5.84 a share, a target that keeps rising. Nvidia has consistently exceeded bottom-line expectations. You don't want to bet against the market's lone $4 trillion company. Nvidia won't report its fiscal second-quarter numbers for another four weeks. It should be another strong performance, even with the impact of restrictions for its H20 chips into China during the period. Analysts see revenue soaring 52% to $46.7 billion with earnings per share rising 47%. If this is Nvidia when there are headwinds to deal with, what will happen when it's business as usual? As hot as Nvidia has been lately, DoorDash brings a strong one-year chart to the table. The leading third-party app for restaurant delivery has seen its shares soar 135% over the past 12 months, more than double Nvidia's haul in that time. It's a different story if you stretch out the timeline. DoorDash is up just 35% in the last five years. Nvidia is a 17-bagger. Revenue growth is decelerating for the fifth consecutive year at DoorDash, but it's holding up a lot better than other pandemic-boosted businesses that saw their business prospects dry up when things returned to normal. The app operator's revenue rose 21% to $3 billion in the first quarter, fueled by an 18% jump in orders. Bears would knock DoorDash when it was growing much faster for its lack of profitability, but that's no longer the case. DoorDash turned profitable last year, cranking out positive reported earnings in its last three quarters. DoorDash is now enjoying the merits of its model's scalability. The bottom line should outpace the top line for the next couple of years at this point. Not every stock on Wood's shopping list on Monday is crushing the market. Intuitive Surgical is actually trading lower in 2025. It still has a good story to tell. Intuitive Surgical is a leader in robotic surgical arms that can help improve precision and recovery times in the procedures it has regulatory clearance to lend a hand in. Unlike DoorDash, revenue is accelerating for the third year in a row. Its trailing earnings is also a new record. The stock isn't cheap despite its year-to-date pullback. Intuitive Surgical is fetching a forward earnings multiple north of $50. It revolutionized the way many surgical procedures get done aided by its da Vinci platform, but now it faces competitive threats to its lucrative model. The business is still in better shape than its recent stock activity. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now\u2026 and Nvidia wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you\u2019d have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you\u2019d have $1,083,392!* Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 1,046% \u2014 a market-crushing outperformance compared to 183% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks \u00bb *Stock Advisor returns as of July 29, 2025 Rick Munarriz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends DoorDash, Intuitive Surgical, and Nvidia. The Motley Fool has a disclosure policy. Cathie Wood Goes Shopping: 3 Stocks She Just Bought was originally published by The Motley Fool""]"
ISRG,2025-07-30,497.71,503.215,496.948,500.51,
ISRG,2025-07-31,497.24,498.965,479.6,481.09,"[""1 Healthcare Stock to Consider Right Now and 2 That Underwhelm From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry\u2019s returns - over the past six months, healthcare stocks have collectively shed 14.2%. This drawdown is a noticeable divergence from the S&P 500\u2019s 5.4% return. Only some companies are subject to these dynamics, however, and a handful of high-quality businesses can deliver earnings growth in any environment. With that said, here is one healthcare stock poised to generate sustainable market-beating returns and two best left ignored. Market Cap: $8.46 billion Founded in 1989 to solve the \""unsolvable problem\"" of accurate pulse oximetry during patient movement, Masimo (NASDAQ:MASI) develops and manufactures noninvasive patient monitoring technologies, including its breakthrough pulse oximetry systems that accurately measure blood oxygen levels even during patient movement. Why Do We Avoid MASI? At $156.02 per share, Masimo trades at 28.9x forward P/E. Check out our free in-depth research report to learn more about why MASI doesn\u2019t pass our bar. Market Cap: $21.88 billion With over 600 million tests performed annually and involvement in 90% of FDA-approved drugs in 2023, Labcorp (NYSE:LH) provides laboratory testing services and drug development solutions to doctors, hospitals, pharmaceutical companies, and patients worldwide. Why Does LH Give Us Pause? Labcorp is trading at $263.91 per share, or 15.7x forward P/E. To fully understand why you should be careful with LH, check out our full research report (it\u2019s free). Market Cap: $179.4 billion Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Why Is ISRG on Our Radar? Intuitive Surgical\u2019s stock price of $497 implies a valuation ratio of 59.8x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it\u2019s free. When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that\u2019s already erased most losses. Don\u2019t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."", ""Intuitive Surgical (ISRG) Soared on Solid Financial Results Baron Funds, an investment management company, released its \u201cBaron Health Care Fund\u201d second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund\u2019s top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Intuitive Surgical, Inc. (NASDAQ:ISRG). Intuitive Surgical, Inc. (NASDAQ:ISRG) manufactures and markets products that help physicians and healthcare providers improve the quality of and access to minimally invasive care. The one-month return of Intuitive Surgical, Inc. (NASDAQ:ISRG) was -8.07%, and its shares gained 10.99% of their value over the last 52 weeks. On July 30, 2025, Intuitive Surgical, Inc. (NASDAQ:ISRG) stock closed at $500.51 per share, with a market capitalization of $179.421 billion. Baron Health Care Fund stated the following regarding Intuitive Surgical, Inc. (NASDAQ:ISRG) in its second quarter 2025 investor letter: A medical team performing minimally invasive surgery with a da Vinci Surgical System. Intuitive Surgical, Inc. (NASDAQ:ISRG) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 106 hedge fund portfolios held Intuitive Surgical, Inc. (NASDAQ:ISRG) at the end of the first quarter, which was 95 in the previous quarter. Intuitive Surgical, Inc.'s (NASDAQ:ISRG) reported total revenue of $2.44 billion in the second quarter of 2025, representing 21% growth over the prior year. While we acknowledge the potential of Intuitive Surgical, Inc. (NASDAQ:ISRG) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Intuitive Surgical, Inc. (NASDAQ:ISRG) and shared the list of stocks Jim Cramer weighed in. In the previous quarter, Baron Health Care Fund noted that Intuitive Surgical, Inc. (NASDAQ:ISRG) faced a stock decline due to investor rotation and tariff concerns. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.""]"
ISRG,2025-08-01,475.46,486.06,473.24,483.025,"[""United States Surgical Robots Market Competition, Forecast & Opportunities Report 2025-2030, with Medtronic, Intuitive Surgical, Stryker, Medrobotics, TransEnterix, Think Surgical, Accuray, and More The U.S. Surgical Robots Market offers significant growth opportunities driven by technological advancements, a shift to minimally invasive procedures, and expanding applications in oncology. The deployment in outpatient centers and strong institutional support further boost market prospects, despite cost barriers. U.S. Surgical Robots Market Dublin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The \""United States Surgical Robots Market, By Region, Competition, Forecast & Opportunities, 2020-2030F\"" has been added to ResearchAndMarkets.com's offering. The United States Surgical Robots Market was valued at USD 2.35 Billion in 2024 and is expected to reach USD 4.14 Billion by 2030, rising at a CAGR of 9.85%. As one of the most technologically advanced and commercially mature healthcare markets, the U.S. continues to lead the global adoption of surgical robotics. The demand is driven by rapid technological innovation, increased preference for minimally invasive procedures, and the expansion of robotic applications across a broad range of clinical specialties. The market benefits from strong institutional investment and widespread adoption in hospitals, academic centers, and private health systems, positioning the U.S. as a central hub for both development and deployment of robotic surgical technologies. Surgical robotics is transitioning from being a high-end specialty tool to becoming an integral part of standard surgical care. Demographic shifts, rising surgical caseloads, and healthcare priorities centered on precision, safety, and efficiency are further propelling market momentum. Companies that focus on platform innovation, scalability, and measurable clinical benefits are set to capture substantial opportunities in this rapidly evolving space. Key Market Drivers: Increasing Use of Surgical Robots in Treatment of Cancer: A primary growth catalyst in the U.S. Surgical Robots Market is the expanding use of robotic-assisted technologies in oncology. Robotic systems are increasingly employed in cancer surgeries such as prostatectomy, hysterectomy, colorectal resections, and thoracic operations due to their superior precision, minimal invasiveness, and favorable patient recovery outcomes. With around 1.9 million new cancer diagnoses reported annually in the U.S. (excluding certain skin cancers), hospitals are turning to robotic platforms to improve procedural outcomes in complex oncologic cases. These systems help reduce complications, preserve surrounding tissues, and support faster recovery, especially in delicate procedures like radical prostatectomy. The increase in robotic installations across cancer centers and tertiary care hospitals is directly linked to rising surgical volumes in oncology, reinforcing the technology's clinical and economic value. Key Market Challenges: High Capital and Operational Costs: The significant upfront and ongoing costs associated with surgical robots remain a barrier to broader market penetration. System acquisition costs typically range from $1 million to $2.5 million, not including maintenance, consumables, and staff training. Smaller hospitals and outpatient centers often lack the financial flexibility to adopt such platforms, particularly when return on investment is uncertain or slow. Recurring expenses related to single-use instruments, software upgrades, and service agreements further increase the financial burden. These cost constraints limit robotic adoption to well-funded institutions, hindering accessibility in community hospitals and rural areas where the need for advanced care is equally pressing. Budget-conscious facilities may struggle to justify these investments despite the long-term clinical and operational advantages. Key Market Trends: Expansion into Outpatient and Ambulatory Surgery Centers (ASCs): A key trend reshaping the market is the increasing deployment of surgical robots in outpatient and ambulatory surgery centers. The healthcare industry is shifting toward same-day, minimally invasive procedures that reduce hospital stays and lower costs. Manufacturers are responding by developing compact, mobile, and cost-efficient robotic systems designed specifically for ASC environments. These next-generation platforms require smaller space, faster setup, and simpler workflows, aligning well with ASC operations. Robotic-assisted surgeries in orthopedics, gynecology, and urology are increasingly performed in these settings due to their minimally invasive nature and quicker recovery times. This trend not only expands patient access to robotic surgery but also opens new avenues for growth among device manufacturers and service providers targeting the ASC segment. Key Market Players: Medtronic USA, Inc Intuitive Surgical, Inc. Stryker Corporation Johnson & Johnson Medrobotics Corporation TransEnterix, Inc. Zimmer Biomet Holdings, Inc. Think Surgical, Inc. Accuray Incorporated Globus Medical, Inc. Report Scope: In this report, the United States Surgical Robots Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: United States Surgical Robots Market, By Product: Orthopedics Neurology Urology Gynecology Others United States Surgical Robots Market, By End User: Inpatient Outpatient United States Surgical Robots Market, By Region: North-east Mid-west West South Key Attributes: For more information about this report visit https://www.researchandmarkets.com/r/rxqsyg About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Surgical Robots Market CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900"", ""Intuitive Surgical, Inc. (ISRG) Installs 395 da Vinci Systems in Q2, Forecasts 17% Procedure Growth We recently compiled a list of the 13 Best Major Stocks to Invest in Now. Intuitive Surgical, Inc. is placed first on our list. Intuitive Surgical, Inc. (NASDAQ:ISRG) tops our list for being one of the best major stocks. It is known for its da Vinci robotic surgical systems and reported strong Q2 2025 results, highlighting continued growth and innovation in minimally invasive surgery. Revenue rose 21% year-over-year to $2.44 billion, driven by a 17% increase in procedure volumes and record placements of 395 da Vinci systems globally. Of these, 180 were the newer da Vinci 5 systems, up from 70 a year earlier. The total installed base expanded to 10,488 systems, a 14% increase. The da Vinci 5 rollout is central to the company\u2019s momentum. It recently received EU certification for adult and pediatric procedures across multiple specialties, and clearance in Japan for nearly all previously approved surgical areas, excluding cardiac. Additional approval for the system\u2019s force feedback technology is being pursued in Europe. A surgical prosthesis developed by the company on display in a medical laboratory. Intuitive Surgical, Inc. (NASDAQ:ISRG) updated its 2025 gross margin outlook to 66%, adjusting for tariff effects. The company also reaffirmed expectations for 15\u201317% global procedure growth this year, reflecting strong demand as hospitals address surgical backlogs and broaden access to robotic procedures. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.""]"
ISRG,2025-08-04,486.75,489.99,478.82,483.36,
ISRG,2025-08-05,483.22,486.51,476.75,477.0,"ISRG's Ion Platform Sees Uptick in Utilization, Eyes Efficiency Intuitive Surgical’s ISRG Ion platform continues to build momentum, posting a robust 52% year-over-year improvement in procedures (to approximately 35,000) for second-quarter 2025. However, the real story lies beneath the headline growth — system utilization for Ion increased 8% year over year, a critical metric that underscores the company’s sharpened focus on workflow optimization and operational efficiency. While system placements dipped to 54 units from 74 a year ago, management remains committed to scaling Ion’s usage within its existing installed base. The emphasis is now on enhancing procedural workflows, streamlining clinical adoption and optimizing product costs — all aimed at accelerating Ion's path to profitability. Intuitive Surgical’s near-term priorities for Ion include bolstering utilization growth in the United States, while strategically expanding into international markets, notably with first commercial procedures completed in Australia and Korea. As competition intensifies in the robotic-assisted bronchoscopy space, Ion’s growing procedural throughput offers a key competitive edge. Higher utilization not only improves return on investment for hospitals but also enhances recurring revenue streams through instrument and accessory sales. Moreover, as ISRG navigates macroeconomic challenges and tariff pressures, workflow efficiency gains and product cost optimizations in Ion could serve as vital levers to protect margins. Given the growing demand for minimally invasive lung biopsy solutions, Ion's capacity to improve procedural throughput and drive operational excellence will be pivotal. The platform’s 8% utilization growth may seem incremental, but in a high-mix capital equipment business, such gains could compound significantly over time, enhancing both customer stickiness and long-term value proposition. Investors should closely watch how workflow enhancements translate into higher adoption rates, especially as Intuitive Surgical scales Ion across new geographies and care settings. Stryker’s SYK Mako platform continues to gain traction, with management highlighting strong global utilization growth alongside record installations in second-quarter 2025. As hospitals maximize their existing Mako systems, the surge in procedure volumes is driving higher recurring revenues through consumables and software services. This utilization-driven growth is increasingly important as Stryker navigates tariff pressures and cost headwinds. With expanded applications like hip revision, spine, and soon shoulder procedures, Mako’s procedural throughput is poised to accelerate further, enhancing the platform's long-term revenue visibility and margin resilience. Mako is quietly becoming Stryker’s high-value recurring revenue engine. Zimmer Biomet’s ZBH ROSA robotics platform saw ongoing adoption in knee procedures, but results were more muted. While ROSA volume-based placements contributed to a mix shift versus outright sales, ROSA was mentioned as central to ZBH’s robotic strategy in 2025. The company emphasized the growing uptake of cementless knee and hip implants, including the Oxford Partial Cementless Knee, which complements robotic workflows. Though specific ROSA installation figures weren’t disclosed, the system remains integral to ZBH’s ASC and digitization strategy. Management cited increased commercial focus and expanded surgical capabilities as key growth drivers, but acknowledged tariffs and ongoing pressure on operating margins as near-term headwinds. Shares of ISRG have lost 7.4% in the year-to-date period compared with the industry’s decline of 10.7%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 55.05, above the industry average. But, it is still lower than its five-year median of 72.26. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies an 11.3% rise from the year-ago period’s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-08-06,477.04,480.991,473.26,474.06,
ISRG,2025-08-07,478.42,479.133,463.9,469.82,"Q2 Earnings Highs And Lows: Intuitive Surgical (NASDAQ:ISRG) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at surgical equipment & consumables - specialty stocks, starting with Intuitive Surgical (NASDAQ:ISRG). The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 3.2% while next quarter’s revenue guidance was in line. In light of this news, share prices of the companies have held steady. On average, they are relatively unchanged since the latest earnings results. Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Intuitive Surgical reported revenues of $2.44 billion, up 21.4% year on year. This print exceeded analysts’ expectations by 3.7%. Overall, it was a very strong quarter for the company with a solid beat of analysts’ EPS estimates. “We’re pleased with our solid performance this quarter, highlighted by continued customer adoption of our newer and existing platforms, including da Vinci 5,” stated Dave Rosa, Intuitive CEO. “We are committed to advancing care, and helping our customers provide better patient outcomes, better patient and care team experiences, broadening access to care and decreasing the total cost of care.” Intuitive Surgical achieved the fastest revenue growth of the whole group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 7.5% since reporting and currently trades at $473.51. Is now the time to buy Intuitive Surgical? Access our full analysis of the earnings results here, it’s free. With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide. Teleflex reported revenues of $780.9 million, up 2.3% year on year, outperforming analysts’ expectations by 1.3%. The business had a very strong quarter with a solid beat of analysts’ full-year EPS guidance estimates and an impressive beat of analysts’ EPS estimates. Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 1.6% since reporting. It currently trades at $112.07. Is now the time to buy Teleflex? Access our full analysis of the earnings results here, it’s free. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Integra LifeSciences reported revenues of $415.6 million, flat year on year, exceeding analysts’ expectations by 5.2%. It was a satisfactory quarter as it also posted a solid beat of analysts’ organic revenue estimates. Integra LifeSciences delivered the biggest analyst estimates beat but had the slowest revenue growth and weakest full-year guidance update in the group. The stock is flat since the results and currently trades at $12.31. Read our full analysis of Integra LifeSciences’s results here. Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions. LeMaitre reported revenues of $64.23 million, up 15% year on year. This print beat analysts’ expectations by 2.6%. It was a very strong quarter as it also logged a solid beat of analysts’ full-year EPS guidance estimates and a solid beat of analysts’ organic revenue estimates. LeMaitre delivered the highest full-year guidance raise among its peers. The stock is up 8.7% since reporting and currently trades at $93.38. Read our full, actionable report on LeMaitre here, it’s free. Thanks to the Fed’s rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn’t send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump’s November win lit a fire under major indices and sent them to all-time highs. However, there’s still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."
ISRG,2025-08-08,470.74,474.08,469.11,470.08,"[""Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock Intuitive Surgical, Inc. (ISRG) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this company have returned -10.7%, compared to the Zacks S&P 500 composite's +1.9% change. During this period, the Zacks Medical - Instruments industry, which Intuitive Surgical falls in, has lost 1.3%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Intuitive Surgical is expected to post earnings of $2.00 per share, indicating a change of +8.7% from the year-ago quarter. The Zacks Consensus Estimate has changed +2% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $8.17 points to a change of +11.3% from the prior year. Over the last 30 days, this estimate has changed +5%. For the next fiscal year, the consensus earnings estimate of $9.2 indicates a change of +12.6% from what Intuitive Surgical is expected to report a year ago. Over the past month, the estimate has changed +1.7%. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Intuitive Surgical is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. For Intuitive Surgical, the consensus sales estimate for the current quarter of $2.41 billion indicates a year-over-year change of +18.2%. For the current and next fiscal years, $9.78 billion and $11.16 billion estimates indicate +17.1% and +14.1% changes, respectively. Intuitive Surgical reported revenues of $2.44 billion in the last reported quarter, representing a year-over-year change of +21.4%. EPS of $2.19 for the same period compares with $1.78 a year ago. Compared to the Zacks Consensus Estimate of $2.35 billion, the reported revenues represent a surprise of +3.93%. The EPS surprise was +14.06%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Intuitive Surgical is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intuitive Surgical. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Leerink Partners Raised the Firm\u2019s PT on Intuitive Surgical (ISRG), Kept a Buy Rating Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the Best Stocks to Invest in for High Returns. On July 23, Leerink Partners analyst Mike Kratky raised the firm\u2019s price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) from $587 to $593, while maintaining a Buy rating on the stock. The analyst noted that the company delivered robust results in the fiscal second quarter of 2025. Both revenue and earnings per share exceeded expectations by 4% and 14%. Kratky noted that this was driven by strong revenue growth in all segments and a rise in da Vinci system placements in the United States. A medical team performing minimally invasive surgery with a da Vinci Surgical System. Moreover, Intuitive Surgical, Inc. (NASDAQ:ISRG) also saw greater-than-expected global procedure growth and raised its full-year guidance for procedure growth and gross margin. It now expects international da Vinci procedure growth of approximately 15.5% to 17% in 2025, compared to 17% in 2024. Intuitive Surgical, Inc. (NASDAQ:ISRG) is a medical technology company that develops robotic-assisted surgical systems, including the da Vinci surgical system and the Ion endoluminal system. While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.""]"
ISRG,2025-08-11,468.16,475.825,468.05,471.7,"Apreo raises $130M for pivotal trial of emphysema device This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Apreo Health has raised $130 million to fund a pivotal trial and early commercialization of a device for treating severe emphysema, the company said Thursday. If approved, the device will compete with Pulmonx’s Zephyr Valve. Apreo has designed its device to work in a broader patient population than Zephyr and has seen a lower rate of collapsed lungs than its rival in studies to date. Physicians implant Apreo’s device using a bronchoscope. The venture capital wing of Intuitive Surgical, which sells a robotic bronchoscopy platform, is among the investors in Apreo. Patients with emphysema, a severe form of chronic obstructive pulmonary disease, can suffer damage to their lung’s air sacs. The damage can cause air to become trapped and the lungs to expand beyond their normal size, a condition called hyperinflation that is associated with poor exercise capacity, diminished quality of life and other negative outcomes. Apreo is developing its Breathe Airway Scaffold to release trapped air and relieve hyperinflation. When implanted, the scaffolds expand to open and reinforce the patient’s airways. Apreo designed the device to allow trapped air to leave via the airways, thereby reducing hyperinflation and alleviating symptoms. The company generated clinical data to support the device in two early-phase trials. A pooled analysis of the 60 emphysema patients in the studies linked the implant to statistically significant improvements in residual volume, a measure of air trapping, three and six months after treatment. Apreo also reported improvements on measures of lung function, exercise capacity and quality of life. No patients had a pneumothorax, the medical term for a collapsed lung, during the follow-up period. The finding provides a potential advantage over Pulmonx’s Zephyr. The valve, which was approved by the Food and Drug Administration in 2018, was associated with a 26.6% rate of pneumothorax in a study. The Zephyr study limited enrollment to patients with little or no collateral ventilation, meaning they lack airways that bypass the normal airflow routes. Apreo’s first and second studies lacked that restriction. The authors of the paper about Apreo’s trials said the dependence on emphysema distribution and the degree of collateral ventilation means only a small proportion of patients benefit from existing devices. Apreo started a pivotal trial of its scaffold last month. The study is designed to enroll 250 patients to test if the device is better than current optimal medical management at improving a lung function measure. New investors Bain Capital Life Sciences and Norwest are supporting Apreo’s trial by co-leading the $130 million investment in the company. Fellow new investors F-Prime and Intuitive Ventures, the investment wing of Intuitive Surgical, also participated. Returning investors Lightstone Ventures and Santé Ventures contributed as well. Recommended Reading GT Medical closes $53M round to commercialize brain tumor device"
ISRG,2025-08-12,473.57,479.465,473.0,478.415,"ISRG's Post-Earnings Slide: Margin Worries Overshadow Growth Story Intuitive Surgical ISRG posted second-quarter fiscal 2025 results on July 22. It delivered a solid top-line beat and healthy procedure growth, but shares have lost more than 7% since the release. While operational execution remained strong, investors zeroed in on margin pressures, cost headwinds, and certain demand risks that overshadowed the positives. ISRG has lost 7.7% since July 22 against the industry’s growth of 0.7%. It has also underperformed its peers like Medtronic MDT and Zimmer Biomet ZBH over this period. While MDT has gained 1.1%, ZBH improved 3.6%. The S&P 500 Index was up 1.4% in the same period. Image Source: Zacks Investment Research Tariff and Cost Inflation Weigh on Margins: Management acknowledged that recently enacted tariffs will have a roughly 100-basis-point negative impact on cost of sales in 2025, with the effect likely to increase each quarter as higher-cost inventory moves through the system. The tariffs compound existing pressure from higher facilities costs, increased service costs related to the da Vinci 5 rollout, and a greater mix of lower-margin Ion systems and da Vinci 5 platforms. Pro-forma gross margin slipped to 67.9% from 70% a year ago. International and Domestic CapEx Headwinds: The company noted ongoing budgetary and financial constraints in international markets such as Japan, China, and parts of Europe, which could slow hospital capital spending. There is also a possibility for U.S. CapEx risk if macro or policy pressures intensify. These dynamics raise concerns about sustaining placement momentum. Procedure Mix Shift Dampening Revenue per Case: ISRG cited downward pressure from fewer bariatric procedures, which tend to drive higher instrument and accessory (I&A) revenues. Moreover, higher cholecystectomy procedures, which typically yield lower per-procedure revenue, are also adding to the pressure. Shifts in Transaction Structure: A higher mix of trade-in transactions, alongside expectations for leasing to increase over time, may weigh on near-term capital sales. Operational Expense Growth: Rising headcount and increased depreciation from newly commissioned facilities and other investments are driving operating expenses higher, limiting near-term operating leverage. Medicaid Coverage Uncertainty: Management also flagged the potential for loss of coverage for Medicaid patients, introducing an element of U.S. demand uncertainty. The top and bottom-line estimates for 2025 and 2026 suggest continued growth for both the metrics. However, the estimates imply a slower growth rate for ISRG going forward as compared to 2024. A slower growth in 2025, especially for EPS, reflects ongoing pressure on gross margin due to increasing depreciation, a higher product mix of low-margin Ion and da Vinci 5, and tariff risks. Both its peers, Medtronic and Zimmer Biomet, are also anticipated to have a weaker EPS growth rate, primarily due to ongoing macro headwinds similar to ISRG. Image Source: Zacks Investment Research Intuitive Surgical is currently trading at a forward 12-month price-to-earnings of 53.61X, significantly higher than the industry average of 27.98X. However, the current valuation is lower than its five-year median of 72.19X. The company currently carries a Zacks Value Score of ‘D.’ Meanwhile, Medtronics and Zimmer Biomet are trading at a significantly cheaper valuation of 16.35X and 12.3X. MDT and ZBH are also trading below their industry-average, reflecting an attractive valuation with a Zacks Value Score of ‘B’. Image Source: Zacks Investment Research Promising da Vinci 5 Adoption: Despite near-term margin pressure, the da Vinci 5 platform is gaining traction, with procedures and placements increasing. The company is enhancing its value proposition through clinical and workflow features, although force-feedback instruments remain supply-constrained until at least the first quarter of 2026. Encouraging Approvals for New Instruments and Procedures: ISRG secured approval for multiple new instruments — such as the SP stapler, vessel sealer curved, and 50-use endoscope — and new procedures, including tracheal bronchoplasty, transanal local excision and resection. These additions expand the addressable market and offer opportunities for higher I&A utilization per case over time. International Expansion Bolstering Growth: Despite budget pressures in certain regions, the company continues to expand its footprint across Europe, Japan, China, India, Australia and Korea. Management emphasized that procedure growth in several of these markets is contributing meaningfully to the top line. During the earnings call, management reiterated its commitment to developing Intuitive Telepresence, a platform designed to enable surgeons to perform operations remotely using ISRG’s robotic systems. This technology could dramatically extend the reach of skilled surgeons beyond the physical confines of a single hospital, potentially addressing critical shortages of surgical expertise in underserved or rural areas. From a strategic standpoint, telesurgery has the potential to redefine ISRG’s addressable market. By decoupling surgeon location from patient location, the company could tap into hospitals that currently lack on-site access to specialized procedures. This not only expands the customer base but also increases the frequency of complex, high-value surgeries performed using ISRG’s platforms. Management noted that Intuitive Telepresence remains in early development stages, with ongoing work to ensure reliability, precision, and compliance with stringent regulatory and data-security requirements. While commercialization is still some years away, the initiative aligns with broader healthcare trends toward telemedicine and remote care delivery. If successful, telesurgery could become a multi-billion-dollar incremental opportunity, opening up licensing, subscription, and service revenue streams alongside traditional system sales. Intuitive Surgical, Inc. price | Intuitive Surgical, Inc. Quote The post-earnings pullback reflects a clear investor concern — margin resilience in the face of tariffs, cost inflation and an evolving procedure mix. The combination of lower-margin platform sales, rising operating expenses, and international CapEx constraints has introduced uncertainty into what had been a consistently high-margin growth story. Yet, the structural tailwinds remain compelling. The da Vinci 5’s clinical differentiation, an expanding portfolio of approved instruments and procedures, and ongoing international market penetration provide avenues for growth. Longer term, telesurgery could open entirely new revenue streams. For now, investors will likely key in on three near-term milestones –visibility on tariff mitigation strategies, signs of gross-margin stabilization, and progress in easing supply constraints for high-value da Vinci 5 instruments. We caution investors against taking any new position in the stock. However, existing investors may continue to hold it at present. ISRG carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-08-13,481.63,482.69,474.906,482.34,"ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue? Intuitive Surgical’s ISRG Ion platform continued its steep growth trajectory in the second quarter of 2025, with procedures surging 52% year over year to roughly 35,000. This performance underscores the system’s increasing role in minimally invasive lung diagnostics and interventions, an area with significant long-term potential. The quarter marked Ion’s first commercial procedures in Australia and Korea, expanding the platform’s global footprint. While the installed base grew to 905 systems, capital placements fell to 54 from 74 in the prior-year period, reflecting the challenge of scaling hardware sales even as utilization improves. Average system utilization climbed 8% year over year, signaling stronger engagement from existing customers. The Ion’s trajectory draws inevitable comparisons to the early adoption curve of Intuitive Surgical’s flagship da Vinci system. If Intuitive can replicate that success in pulmonary care, Ion could open a multi-billion-dollar opportunity by transforming the standard of care for early lung cancer diagnosis and other thoracic procedures. However, the slowdown in system placements highlights a near-term bottleneck. Hospital capital budgets, particularly outside the United States, remain under pressure from macroeconomic and trade headwinds, potentially affecting expansion. The focus will likely remain on deepening utilization and demonstrating economic value to support broader uptake. Still, with strong procedural momentum, expanding international presence and a growing body of clinical validation, Ion remains one of Intuitive Surgical’s most promising growth vectors. The next test will be whether the company can turn rising case volumes into sustained capital demand, setting the stage for Ion to follow in da Vinci’s footsteps as a transformative platform in its field. Competing Robotic Surgery Updates At the 2025 AAOS Annual Meeting, Stryker SYK introduced its fourth-generation Mako SmartRobotics system, Mako 4, featuring the first FDA-cleared robotic hip revision capability. With this advancement, Stryker enhances surgical planning and execution across hip, knee, spine and shoulder procedures. Mako 4 integrates Stryker’s Q Guidance System, offering improved intraoperative visibility and streamlined workflows. Simultaneously, Globus Medical GMED showcased its ExcelsiusFlex robotic navigation system for Total Knee Arthroplasty. Globus Medical’s system offers both CT-based and imageless registration options, providing surgeons with ergonomic control and procedural flexibility. Globus Medical’s ExcelsiusFlex is designed to enhance surgical precision and accommodate diverse patient needs and surgeon preferences. ISRG’s Price Performance, Valuation and Estimates Shares of ISRG have lost 8.3% in the year-to-date period compared with the industry’s decline of 10.2%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-sales ratio of 16.13, above the industry average. However, it is still lower than its five-year median of 26.91. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies an 11.3% rise from the year-ago period’s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-08-14,482.5,483.6,473.81,477.08,
ISRG,2025-08-15,480.02,482.035,476.5,480.26,
ISRG,2025-08-18,480.84,487.2,479.66,481.189,
ISRG,2025-08-19,480.985,485.53,476.8,479.2,"[""Evercore ISI Lowered the Firm\u2019s PT on Intuitive Surgical (ISRG), Kept an In Line Rating Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On July 23, Evercore ISI lowered the firm\u2019s price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) from $550 to $535, while keeping an In Line Rating on the stock. The rating follows the company\u2019s fiscal second-quarter earnings call for 2025. The company exceeded both revenue and EPS expectations during the quarter, driven by improved system sales. Intuitive Surgical, Inc. (NASDAQ:ISRG) posted $2.44 billion in revenue, up 21.4% year-over-year and ahead of expectations by $87.21 million. The EPS of $2.19 also came in ahead of consensus by $0.27. A medical team performing minimally invasive surgery with a da Vinci Surgical System. Despite these impressive sales figures, the firm remains uncertain regarding the company\u2019s potential to sustain the momentum gained in the second quarter, thus maintaining a Hold rating on the stock. Intuitive Surgical, Inc. (NASDAQ:ISRG) develops and markets advanced robotic-assisted surgical systems, including the da Vinci surgical systems and the Ion endoluminal system. While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey."", ""Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know Intuitive Surgical, Inc. (ISRG) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this company have returned -6.8% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Medical - Instruments industry, to which Intuitive Surgical belongs, has gained 5.4% over this period. Now the key question is: Where could the stock be headed in the near term? While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Intuitive Surgical is expected to post earnings of $2.00 per share, indicating a change of +8.7% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.9% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $8.17 points to a change of +11.3% from the prior year. Over the last 30 days, this estimate has changed +4.9%. For the next fiscal year, the consensus earnings estimate of $9.2 indicates a change of +12.6% from what Intuitive Surgical is expected to report a year ago. Over the past month, the estimate has changed +1.5%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Intuitive Surgical. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. For Intuitive Surgical, the consensus sales estimate for the current quarter of $2.41 billion indicates a year-over-year change of +18.2%. For the current and next fiscal years, $9.78 billion and $11.16 billion estimates indicate +17.1% and +14.1% changes, respectively. Intuitive Surgical reported revenues of $2.44 billion in the last reported quarter, representing a year-over-year change of +21.4%. EPS of $2.19 for the same period compares with $1.78 a year ago. Compared to the Zacks Consensus Estimate of $2.35 billion, the reported revenues represent a surprise of +3.93%. The EPS surprise was +14.06%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Intuitive Surgical is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intuitive Surgical. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""ISRG's International Push for Ion: Strategic Bet or Overstretch? Intuitive Surgical ISRG is doubling down on its Ion platform\u2019s global prospects, marking its first commercial system sales in Australia and Korea during the second quarter of 2025. The expansion comes as Ion continues its remarkable momentum, with procedures surging 52% year over year to nearly 35,000 in the quarter. Yet, the international push raises the question: Is this a carefully calculated growth play, or could it stretch resources at a time when macro headwinds weigh on key Asian markets? Japan and China remain challenging for Intuitive Surgical. Both are grappling with constrained hospital capital budgets and lingering trade frictions, limiting system placements. Against this backdrop, Australia and Korea may look like lower-risk testbeds \u2014 markets with relatively advanced healthcare infrastructures, established robotic adoption in da Vinci, and strong physician interest in minimally invasive innovation. By planting early Ion footprints here, Intuitive Surgical could seed referral centers that drive regional adoption and generate clinical data critical for broader Asia-Pacific traction. The strategic intent seems clear \u2014 replicate the U.S. playbook, where Ion\u2019s rapid adoption was underpinned by strong utilization growth (8% YoY) and expanding clinical evidence. Korea, in particular, has already emerged as a hotspot for SP platform adoption, suggesting it could be a fertile ground for the Ion platform as well. Australia, meanwhile, offers a gateway into the broader Asia-Pacific, with its regulatory pathways often influencing neighboring markets. Still, execution risks loom. Capital constraints in Asia, combined with intensifying competition and tariff uncertainties, could slow the Ion platform\u2019s scale-up. Moreover, Intuitive will need to balance resources between sustaining U.S. growth and nurturing nascent international markets. For now, Ion platform\u2019s early international sales are more symbolic than material. But, if Intuitive Surgical can leverage its success in the United States to establish clinical and commercial credibility in Asia-Pacific, this could prove to be a strategic beachhead rather than a costly overreach. Johnson & Johnson\u2019s JNJ Monarch robotic-assisted bronchoscopy has received an FDA 510(k) clearance in March for its Monarch Quest software, which integrates NVIDIA-accelerated AI navigation and GE Healthcare\u2019s 3D mobile imaging, boosting real-time computational power by around 260% to enhance targeting of peripheral lung nodules. Additionally, the results from the Johnson & Johnson\u2019s TARGET multicenter study (679 patients across the United States., Canada, and Hong Kong) published in CHEST show the Monarch system reached nodules in 98.7% of cases, achieving an 83.2% diagnostic yield. Johnson & Johnson\u2019s Monarch also demonstrated a safety profile compared to non-robotic bronchoscopy. Medtronic\u2019s MDT Hugo robotic-assisted surgery (RAS) system has made significant advances \u2014 the Expand URO IDE study in the United States met both safety and effectiveness endpoints, showing a 98.5% surgical success rate across urologic procedures, outperforming the 85% benchmark. Medtronic has submitted Hugo to the FDA for urologic indication in early 2025, with additional trials underway in hernia and benign gynecology, and preparation for oncologic gynecology studies. In Europe, Medtronics\u2019 Hugo achieved a CE Mark for its LigaSure vessel-sealing technology last month, expanding its utility in various surgical specialties. ISRG\u2019s Price Performance, Valuation and Estimates Shares of ISRG have lost 7.8% in the year-to-date period compared with the industry\u2019s decline of 7.5%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 54.56, above the industry average. However, it is still lower than its five-year median of 72.16. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical\u2019s 2025 earnings implies an 11.3% rise from the year-ago period\u2019s level. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""CMR Surgical hires Chris O\u2019Hara to drive US robot expansion This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. CMR Surgical has hired Chris O\u2019Hara as commercial president and general manager for the U.S. The appointment comes as the surgical robotics company prepares to scale up in the U.S. market after receiving Food and Drug Administration authorization in October for its Versius multiport soft tissue robot. With FDA marketing authorization secured, \u201cthis is a pivotal moment for CMR,\u201d the company wrote in a LinkedIn post announcing the hire. O\u2019Hara joined CMR in the new role on Monday. He previously served as senior vice president of sales and marketing at Virtual Incision and has also held senior roles at Intuitive Surgical and Globus Medical. At CMR, O\u2019Hara will lead commercial strategy as a member of the executive team, reporting to CEO Massimiliano Colella. \u201cHis proven track record in building successful commercial teams and driving strategic growth will be instrumental as we expand in the [U.S.],\u201d the company said. CMR said its Versius system has now been used in more than 36,000 clinical procedures globally. The Cambridge, U.K.-based robot developer is among a batch of young companies preparing to challenge market leader Intuitive Surgical in surgical robotics. CMR recently closed a $200 million financing round intended to fund the commercial expansion of Versius, with a focus on the U.S. market. At the time, CMR said Versius was the world\u2019s second most utilized soft tissue surgical robot, used in a range of procedures across more than 30 countries. Recommended Reading CMR Surgical secures $200M for US robot rollout""]"
ISRG,2025-08-20,479.39,483.635,478.08,480.45,"BTS and clients recognized with 59 Brandon Hall Group Excellence Awards in 2025 SAN FRANCISCO, August 20, 2025--(BUSINESS WIRE)--BTS GROUP AB (publ), a global leader in strategy implementation, has earned 59 Brandon Hall Group Excellence Awards in 2025 alongside its clients. These awards recognize some of BTS’s most innovative and effective solutions, created through close collaboration with their clients. Advantage Performance Group, a BTS company, proudly received three Brandon Hall Awards, including two golds and one silver. Below is a list of the winning projects and partnerships that achieved recognition: Ajinomoto Co., Inc. Amgen Asito AstraZeneca Aurecon Beiersdorf Bound and Beyond Public Company Limited (""BEYOND"") Clariant DBS Emirates Global Aluminium Ericsson Estee Lauder Companies Exclusive Networks Gilead Sciences Grifols, S.A. Haleon Harbour Energy plc HDFC Bank Holcim Indorama Ventures Intuitive Surgical Kasikornbank Public Company Limited (KBank) Linde Plc Mercado Libre MICHELIN Mitsui Chemicals Mondelez Naturgy Energy Group S.A. Nexans Philip Morris International (PMI) PT Sinar Mas Agro Resources and Technology Tbk QIC Roche Diagnostics Spain Salesforce Scotiabank Shiseido APAC Six Group AG Syngenta Tennant Company Thanachart Insurance (TNI) Vertex Pharmaceuticals Wildlife Conservation Society ""This recognition comes at a time when leaders everywhere are being tested,"" said Jessica Skon, CEO of BTS. ""Our clients are not only rising to meet those challenges, they’re turning them into opportunities to lead differently, innovate with new thinking, and galvanize their teams to transform."" These awards include 43 gold, 13 silver, and 3 bronze covering categories ranging from Best Unique or Innovative Leadership Development Program to Best Learning Program Supporting a Change Transformation Business Strategy. Find the full list of winners here. Entries were evaluated by a panel of veterans, independent senior industry experts, Brandon Hall Group analysts, and executives based on these criteria: Alignment to their business need and environment. Program design, functionality and delivery. Adoption, integration, user experience, innovation and creativity. Overall effectiveness, impact, and measurable benefits. ""This has been a year of headwinds for many organizations, yet our clients continue to lead with vision and transform with resilience,"" said Roanne Neuwirth, CMO of BTS. ""These awards honor the boldness to challenge the status quo, the creativity to find new ways forward, and the commitment to making a lasting difference."" Excellence Award winners will continue to be honored at Brandon Hall Group’s HCM Excellence Conference, February 9-12, 2026, at the Hilton West Palm Beach, Florida. Select winners will also serve as presenters in breakout sessions, sharing their leading practices during the conference. About BTS BTS is a global consultancy that helps organizations turn strategy into action by equipping their people with the skills, mindsets, and behaviors to lead, sell, and perform when it counts. We partner with senior leaders and teams to build leadership, drive transformation, and create lasting business impact from the C-suite to the front line. BTS is publicly traded on the Nasdaq Stockholm under the symbol BTS B. About Brandon Hall Group Brandon Hall Group is an HCM research and advisory firm empowering excellence in organizations globally through research and tools for over 20 years. Areas of expertise include Learning and Leadership Development, Talent Management and Acquisition, and HR/Workforce Management. View source version on businesswire.com: https://www.businesswire.com/news/home/20250820969733/en/ Contacts Roanne Neuwirth CMO +1 (339) 222-4112"
ISRG,2025-08-21,478.22,479.32,461.25,469.88,"[""A Rise In Surgical Robotics Could Send These 2 Healthcare Stocks Soaring The robotic-assisted surgery market is expected to grow significantly in the coming years. Intuitive Surgical is the leader in this space and should profit from its rapid growth. Relative newcomer Medtronic could also cash in as it launches its Hugo device. 10 stocks we like better than Intuitive Surgical \u203a The use of robotics in surgery is on the rise. The market was valued at $800 million in 2015, and has since risen to over $3 billion. One reason behind this rapid growth is that these robot systems utilize flexible, highly maneuverable instruments along with tiny cameras, allowing surgeons to perform complex procedures, often of the minimally invasive type. Compared to open surgeries, they result in less skin cutting, less bleeding, and less scarring. However, according to one survey, while 78% of U.S. surgeons are interested in the technology, many still aren't using it, leaving significant white space ahead. The increased adoption of surgical robotics could prove to be a massive tailwind for some healthcare leaders, including Intuitive Surgical (NASDAQ: ISRG) and Medtronic (NYSE: MDT). Intuitive Surgical is currently the leader in robotic surgery, thanks to a lineup of products that includes the Ion system, which aids in performing lung biopsies, and the renowned da Vinci system, indicated for a range of procedures in general surgery and many other areas. The da Vinci system is perhaps the best-known robot device on the market. It was first approved in 2000. Intuitive Surgical has since launched several newer versions of this product; the fifth generation was introduced last year. Having a first-mover advantage will help Intuitive Surgical in at least three ways as the market expands significantly. First, the company has established a brand name among physicians, who, like everyone else, tend to gravitate toward brands they trust, especially when lives are at stake. Second, since the da Vinci system has been in use for so long, a substantial amount of data from clinical trials and real-world applications demonstrates its efficacy. That's always an advantage in the healthcare industry. Third, Intuitive Surgical has a significant existing installed base. It ended the second quarter with 10,488 installed da Vinci systems, for a 14% year-over-year increase. These are expensive devices, so healthcare facilities won't switch unless they have a very strong incentive, which grants Intuitive Surgical a strong moat thanks to high switching costs. Meanwhile, the company has routinely recorded excellent financial results: Intuitive Surgical is facing some headwinds, including increased costs resulting from tariffs. Even with those, shares should perform well over the long run as the company's products continue to gain traction in the underpenetrated and rapidly growing robotic surgery industry. Despite its underperformance in the market this year, the stock still looks like a buy today. Medtronic is inching closer to making its grand entrance in the U.S. surgical robotics industry. Earlier this year, it reported that its device, the Hugo system, had been successful in clinical trials for urologic procedures. The company is now awaiting clearance from the U.S. Food and Drug Administration in that indication. Medtronic decided to pursue this opportunity precisely because it saw massive white space. A couple of years ago, management pointed out that less than 5% of procedures that could be performed with robotic assistance actually were at the time. The company is likely to seek additional approvals for its Hugo system. While it will take some time to have a meaningful impact, Medtronic's venture into this market could be an important addition over the long run for a company that has been struggling to grow its revenue at a satisfactory rate. Medtronic has made other changes to its business recently, including deciding to spin off its only consumer-facing segment, diabetes care, whose margins were lower than those of the rest of the business. Medtronic also faces tariff-related challenges, but the decision to separate from its diabetes unit should help. Furthermore, the company consistently delivers strong financial results despite economic and other challenges. That's due to its extensive and diversified portfolio of products across several therapeutic areas, and significant presence in 150 countries worldwide. Lastly, the company has a brilliant dividend track record; having increased its payouts for 48 consecutive years, it's closing in on Dividend King status. Medtronic's stock remains a top choice for income seekers, particularly given the significant growth opportunity its launch of the Hugo system is expected to provide. Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now\u2026 and Intuitive Surgical wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you\u2019d have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you\u2019d have $1,076,588!* Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 1,055% \u2014 a market-crushing outperformance compared to 183% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks \u00bb *Stock Advisor returns as of August 18, 2025 Prosper Junior Bakiny has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. A Rise In Surgical Robotics Could Send These 2 Healthcare Stocks Soaring was originally published by The Motley Fool"", ""2 Reasons to Like ISRG (and 1 Not So Much) Over the last six months, Intuitive Surgical\u2019s shares have sunk to $480, producing a disappointing 18.9% loss - a stark contrast to the S&P 500\u2019s 6.4% gain. This may have investors wondering how to approach the situation. Following the drawdown, is now a good time to buy ISRG? Find out in our full research report, it\u2019s free. Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful Surgical Equipment & Consumables - Specialty company because there\u2019s a ceiling to what customers will pay. Intuitive Surgical\u2019s system placement punched in at 395 in the latest quarter, and over the last two years, averaged 11.4% year-on-year growth. This performance was impressive and shows its offerings have a unique value proposition (and perhaps some degree of customer loyalty). We track the long-term change in earnings per share (EPS) because it highlights whether a company\u2019s growth is profitable. Intuitive Surgical\u2019s astounding 17.7% annual EPS growth over the last five years aligns with its revenue performance. This tells us its incremental sales were profitable. A company\u2019s ROIC, or return on invested capital, shows how much operating profit it makes compared to the money it has raised (debt and equity). We like to invest in businesses with high returns, but the trend in a company\u2019s ROIC is what often surprises the market and moves the stock price. On average, Intuitive Surgical\u2019s ROIC decreased by 3.1 percentage points annually over the last few years. Only time will tell if its new bets can bear fruit and potentially reverse the trend. Intuitive Surgical has huge potential even though it has some open questions. After the recent drawdown, the stock trades at 57.4\u00d7 forward P/E (or $480 per share). Is now a good time to buy? See for yourself in our comprehensive research report, it\u2019s free. Trump\u2019s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines. Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."", ""Analysts Intuitive Surgical (ISRG) Boost Price Target on Da Vinci 5 Launch Intuitive Surgical, Inc. (NASDAQ:ISRG) ranks among the top robotics to buy according to analysts. As the company\u2019s da Vinci 5 surgical system moves into its global launch phase, Bernstein SocGen Group maintained its Outperform rating on Intuitive Surgical, Inc. (NASDAQ:ISRG) and increased its price target from $675 to $685 on July 23. With revenue of $2.44 billion, the company reported impressive second-quarter earnings, outpacing consensus projections by 4% and indicating 21% growth. Even though worldwide da Vinci systems placements missed estimates by 4%, adjusted earnings per share increased by 23% to $2.19. During the quarter, Intuitive Surgical\u2019s da Vinci 5 placements increased to 180 units, up from 147 in the first quarter, and procedures gained 17% globally, which was slightly higher than the consensus estimate. In the United States, Intuitive Surgical, Inc. (NASDAQ:ISRG) is moving from a limited to a broad launch after da Vinci 5 was approved in March 2024. This will let clients to upgrade their current fleets to the new system. Intuitive Surgical, Inc. (NASDAQ:ISRG) is dedicated to developing, manufacturing, and marketing robotic products that utilize minimally invasive surgery to improve clinical outcomes for patients. While we acknowledge the potential of ISRG to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ISRG and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds. Disclosure: None. This article is originally published at Insider Monkey."", ""Baird Lifts PT on Intuitive Surgical (ISRG) to $600 From $590, Keeps an Outperform Rating Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best stocks to invest in for the long term. On July 23, Baird raised the firm\u2019s price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $600 from $590, keeping an Outperform rating on the shares. A medical team performing minimally invasive surgery with a da Vinci Surgical System. The firm told investors that it remains a buyer of the stock, as its key performance indicators \u201ccontinue to fire on all cylinders.\u201d The same day, Leerink Partners analyst Mike Kratky also reiterated a bullish stance on Intuitive Surgical, Inc. (NASDAQ:ISRG), giving the stock a buy rating. The analyst expressed optimism about the company\u2019s multiple growth drivers and commercial execution, raising the EPS estimates for the upcoming years to reflect confidence in Intuitive Surgical, Inc.\u2019s (NASDAQ:ISRG) ability to sustain its momentum. Intuitive Surgical, Inc. (NASDAQ:ISRG) has an elaborate ecosystem of services and products that provide robotic-assisted surgical solutions and invasive care. Its products include the Ion Endoluminal and the Da Vinci Surgical systems. While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.""]"
ISRG,2025-08-22,473.0,478.97,469.845,476.16,"[""Intuitive Surgical Stock: Analyst Estimates & Ratings Valued at a market cap of $168.4 billion, Intuitive Surgical, Inc. (ISRG) is the global leader in robotic-assisted, minimally invasive surgery, best known for its da Vinci Surgical System and Ion endoluminal platform. Founded in 1995 and headquartered in Sunnyvale, California, the company has maintained dominance in the robotic surgery space for over two decades through continuous innovation, most recently with the da Vinci 5 system, featuring enhanced computing power and force feedback. Should You Buy the Dip as Palantir Stock Falls for 7 Straight Days? George Soros Is Betting Big on Beaten-Down UnitedHealth Stock. Should You? 2 \u2018Strong Buy\u2019 Stocks Offering Fat Yields of Over 7.5% in August 2025 Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! This healthcare giant has struggled to keep up with the broader market over the past 52 weeks. Shares of Intuitive Surgical have rallied 3.6% over this time frame, while the broader S&P 500 Index ($SPX) has gained 13.3%. Moreover, on a YTD basis, the stock is down 10%, compared to SPX\u2019s 8.3% return. Zooming in further, ISRG has also considerably lagged behind the SPDR S&P Health Care Equipment ETF\u2019s (XHE) 7.2% decline over the past 52 weeks and 8.9% downtick on a YTD basis. On Jul. 22, Intuitive Surgical delivered its Q2 2025 earnings, and its shares dipped 1.8% in the next trading session. Its revenue rose 21% year-over-year to $2.44 billion, driven by a 17% increase in da Vinci procedures, higher system placements, and a 14% expansion of its installed base to over 10,400 systems. Non-GAAP net income reached $798 million and $2.19 per share. Instrument and accessory sales grew 18% to $1.47 billion, and the company ended the quarter with $9.53 billion in cash and investments. Intuitive also gained key regulatory clearances for its da Vinci 5 system in Europe and Japan, and raised its full-year 2025 outlook, projecting da Vinci procedure growth of 15.5%\u201317% and strong margins. For the current fiscal year, ending in December, analysts expect ISRG\u2019s EPS to rise marginally year over year to $6.54. The company\u2019s earnings surprise history is promising. It exceeded the consensus estimates in each of the last four quarters. Among the 29 analysts covering the stock, the consensus rating is a \u201cModerate Buy,\u201d which is based on 18 \u201cStrong Buy,\u201d two \u201cModerate Buy,\u201d eight \u201cHold,\u201d and one \u201cStrong Sell\u201d rating. This configuration is slightly bearish than a month ago, with 20 analysts suggesting a \u201cStrong Buy\u201d rating. On July 23, RBC Capital raised its price target on Intuitive Surgical to $615 from $605, maintaining an \u201cOutperform\u201d rating after the company delivered strong quarterly results. The mean price target of $597.12 represents a 27.1% premium from ISRG\u2019s current price levels, while the Street-high price target of $685 suggests an upside potential of 45.8%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"", ""Box, Intuitive Surgical, and Surgery Partners Stocks Trade Down, What You Need To Know A number of stocks fell in the afternoon session after markets continued to decline, as investors grew cautious ahead of a key speech by Federal Reserve Chair Jerome Powell. The move came as U.S. equity markets recorded a fifth consecutive day of losses for major indexes like the S&P 500, with technology stocks experiencing the largest declines. Investors have grown wary that the sharp rally in the tech sector since April may have advanced too far. The market-wide caution is largely driven by the upcoming Jackson Hole symposium, a meeting of central bankers, where traders are anxiously awaiting Fed Chair Powell's speech on Friday for guidance on the future path of interest rates. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Document Management company Box (NYSE:BOX) fell 3.5%. Is now the time to buy Box? Access our full analysis report here, it\u2019s free. Surgical Equipment & Consumables - Specialty company Intuitive Surgical (NASDAQ:ISRG) fell 4%. Is now the time to buy Intuitive Surgical? Access our full analysis report here, it\u2019s free. Outpatient & Specialty Care company Surgery Partners (NASDAQ:SGRY) fell 4.1%. Is now the time to buy Surgery Partners? Access our full analysis report here, it\u2019s free. Surgery Partners\u2019s shares are somewhat volatile and have had 13 moves greater than 5% over the last year. In that context, today\u2019s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 8 days ago when the stock gained 3.2% on the news that markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings. Surgery Partners is up 7.8% since the beginning of the year, but at $22.96 per share, it is still trading 31.9% below its 52-week high of $33.69 from August 2024. Investors who bought $1,000 worth of Surgery Partners\u2019s shares 5 years ago would now be looking at an investment worth $1,290. Unless you\u2019ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.""]"
ISRG,2025-08-25,475.25,477.865,467.8,468.44,"[""2 Growth Stocks With Sky-High Potential to Hold for Decades Intuitive Surgical's procedure-led, recurring-revenue model keeps strengthening as da Vinci 5 rolls out. Amazon's multiple profit engines -- AWS, retail, and advertising -- continue to scale together. Both businesses are investing aggressively today to unlock years of compounding ahead. 10 stocks we like better than Amazon \u203a Investors searching for long-duration compounders don't need to overcomplicate things. One approach is to look for market-leading, platform-like business models with recurring economics and management teams investing for the next era of growth. Two standouts fit that bill today: minimally invasive robotic surgery specialist Intuitive Surgical (NASDAQ: ISRG) and cloud-computing and online retailer juggernaut Amazon.com (NASDAQ: AMZN). Intuitive's latest quarterly update reinforced the strength of its model, while Amazon's second\u2011quarter numbers highlighted a business that keeps scaling across multiple profit engines. Neither is cheap, but the durability of their growth stories makes them worthy buy\u2011and\u2011hold candidates for decades. And if you're looking for something you can hold onto for the long haul, quality (which rarely trades at cheap valuations) is arguably more important than your entry points anyway. Intuitive posted a strong Q2, with revenue up 21% year over year to $2.44 billion and non\u2011GAAP diluted earnings per share (EPS) of $2.19 -- up 23%. Growth was broad-based across its different key sales drivers -- instruments, accessories, and systems placements. This momentum reflects rising procedure volume and continued adoption of the company's latest minimally invasive surgical platform: the da Vinci 5. The lifeblood of Intuitive Surgical's business has always been procedure growth -- a key performance indicator that is looking outstanding lately. Management now expects worldwide da Vinci procedure expansion of about 15.5% to 17% for 2025, essentially tracking last year's robust pace. Importantly, Intuitive placed 395 da Vinci systems in Q2, including 180 da Vinci 5 units, expanding the installed base that fuels high\u2011margin recurring revenue on instruments and accessories. That mix supports a compounding engine that is difficult for rivals to disrupt. Profitability is holding up even as the company rolls out new platforms and navigates tariff headwinds. Intuitive guided to a 2025 non-GAAP gross margin of 66% to 67% (a figure that management says includes the estimated impact of tariffs) and continues to generate substantial cash, giving it ample flexibility to invest, expand indications, and support customers through usage-based models. The outcome is a virtuous cycle: A larger installed base begets more procedures, which funds more innovation, which then drives more placements -- and so on. Amazon's Q2 results underscored the advantage of owning multiple engines that reinforce each other over time. Net sales rose 13% year over year to $167.7 billion; operating income climbed to $19.2 billion; and each of the company's major segments contributed. Its online stores segment saw 11% year-over-year growth. Other revenue (this is primarily driven by Amazon's advertising business) grew 19% year over year. Additionally, Amazon's high-margin, cloud-computing business, Amazon Web Services (AWS) saw sales rise 17% year over year. These pieces work together, with Prime membership demand and an ever\u2011denser logistics network supporting retail economics, while AWS and advertising benefit from growing scale and provide higher\u2011margin revenue streams. AWS, of course, remains the company's crown jewel. Segment revenue increased 17.5% year over year to $30.9 billion, with the high-margin segment's operating profit helping to power companywide earnings even as Amazon steps up capital spending to support artificial intelligence (AI) workloads. Advertising is another quiet but powerful engine, rising at a healthy clip and benefiting from closed-loop performance data only Amazon can provide at this scale. The combination of AWS, ads, and a more efficient retail network give Amazon multiple ways to grow EPS over a very long horizon. Yes, capital expenditures are heavy as the company builds data centers and invests for the AI era (Amazon spent $31.4 billion on capex during Q2 alone). The question, however, isn't the spending itself; it's whether the returns justify it. Fortunately, Amazon has a long track record of front-loading investment to capture decades of utility, and the current cycle looks similar. With multiple profit centers throwing off cash, Amazon can fund growth internally while still improving margins over time. Both companies have built enviable, self-funding, platform-like business models, creating virtuous flywheels for themselves that seem to constantly expand their competitive advantages over peers. Intuitive's installed base and recurring procedure economics should compound for years as robotics penetrates more procedures and geographies. Amazon's diversified engines -- retail, advertising, and AWS -- reinforce one another, creating operating leverage as scale increases. Sure, with Intuitive Surgical and Amazon's price-to-earnings ratios sitting at 65 and 34, respectively, these growth stocks are not cheap -- and that does bring some risk to the table, making it important for investors to keep their allocations to these stocks small. But these two companies' potent combinations of durable competitive advantages, recurring revenue characteristics, and large addressable markets make them both compelling candidates to buy and hold for decades. Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now\u2026 and Amazon wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you\u2019d have $649,657!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you\u2019d have $1,090,993!* Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 1,057% \u2014 a market-crushing outperformance compared to 185% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks \u00bb *Stock Advisor returns as of August 18, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Intuitive Surgical. The Motley Fool has a disclosure policy. 2 Growth Stocks With Sky-High Potential to Hold for Decades was originally published by The Motley Fool"", ""4 medtech topics to watch for the rest of 2025 This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Halfway into the year, medical device companies are getting more clarity about what the rest of 2025 will hold. After a slowdown in dealmaking in the spring, acquisitions are picking back up. Medtech companies are preparing for significant launches, with Medtronic ramping up its challenge to Intuitive Surgical\u2019s robots and Medicare broadening coverage of a device-based treatment for high blood pressure. Meanwhile, the Food and Drug Administration, under new leader Martin Makary, is starting to outline its regulatory approach and negotiate how much it will collect in fees from the industry in the coming years. While there are still plenty of questions ahead, such as what tariffs will look like in the fall, device firms are moving ahead with their growth plans. Here are four developments MedTech Dive is watching in the second half of 2025: Dealmaking is always a topic to watch in the medtech space as acquisitions fuel the industry. However, the M&A environment has been uneven this year. After several big acquisitions were executed in the opening months, such as Stryker\u2019s nearly $5 billion pick-up of Inari Medical, dealmaking then came to a near standstill as companies grappled with a volatile market marked by back-and-forth tariff policies from the Trump administration. For months, few notable deals were executed. Still, experts told MedTech Dive that the second half of the year would see more spending \u2014 and those predictions quickly came true. In July, BD and Waters agreed to a $17.5 billion merger that would combine BD\u2019s biosciences and diagnostic solutions business with Waters. The deal would be the industry\u2019s largest of the year, and it kicked off a run of announcements. July 14 BD and Waters announce $17.5 billion merger July 14 Zimmer Biomet announces $177 million proposed acquisition for Monogram Technologies July 21 ZimVie agrees to be sold to Archimed for about $730 million July 22 Labcorp agrees to buy certain lab assets from Community Health Systems for $195 million August 5 Alcon proposes to buy STAAR Surgical for $1.5 billion With roughly four months left in 2025, M&A remains a key topic to watch. RBC Capital Markets analyst Shagun Singh, speaking with MedTech Dive in June, said that companies would be opportunistic, regardless of market uncertainty. \u201cM&A is just going to continue. I think it\u2019s the lifeblood of medtech,\u201d Singh said. \u201cYou\u2019re not going to pass up an opportunity because of tariffs if you can get into a multibillion dollar market and you have an asset right in front of you.\u201d Singh added that dealmaking is likely wide open in the space, with multiple attractive markets and technologies to gamble on. \u201cIt\u2019s going to be all over the place,\u201d Singh said. \u201cI really think that it\u2019s going to be diverse.\u201d A Medicare national coverage determination, or NCD, for a treatment called renal denervation will expand access to the minimally invasive procedure for people with uncontrolled hypertension, and help determine the scope of an important new market for Medtronic. The potential market for the procedure is sizable: Nearly half of American adults have high blood pressure, but only 1 in 4 have it under control. \u201cThe final NCD will clearly define the Medicare reimbursable population, and that has significant implications on the total available market opportunity,\u201d said Mizuho analyst Anthony Petrone. Medtronic has predicted renal denervation will be one of its fastest growth drivers, once the Centers for Medicare and Medicaid Services\u2019 reimbursement policy is in place. The final NCD memorandum is expected in October. With the deepest clinical data set and a large salesforce to support its efforts, \u201cMedtronic will be the biggest game in town,\u201d said Petrone. The FDA approved two renal denervation systems in late 2023 as treatment options for patients when lifestyle changes and medications fail to lower blood pressure. Medtronic\u2019s Symplicity Spyral system won the FDA\u2019s backing despite resistance from the agency\u2019s panel of outside advisers, who raised questions about the device\u2019s effectiveness and which patients might benefit from the procedure. Medtronic\u2019s device uses radiofrequency energy to ablate overactive nerves around the renal arteries that supply blood to the kidneys. The other FDA-approved technology, Recor Medical\u2019s Paradise system, uses ultrasound energy. Recor is a subsidiary of Otsuka Medical Devices. While Medtronic and Recor have a head start in the market, more medtech companies are pursuing renal denervation. Boston Scientific this spring acquired SoniVie, which is developing an ultrasound-based system called Tivus. Boston Scientific, which owned a 10% stake in SoniVie, agreed to pay up to $540 million to buy the remainder of the company. South Korea\u2019s DeepQure and precision diagnostics company Geneticure are also investing in renal denervation technologies. Remarks from healthcare providers received by the CMS during its public comment period show support for expanding access to the procedure. The American College of Cardiology and American Heart Association also recently incorporated renal denervation into their high blood pressure management guidelines for the first time. Still, clinical adoption could take time to ramp up as doctors are trained on the procedure and referral pathways are developed, said Needham analyst Mike Matson. \u201cIt's definitely going to be a high-growth market. It's going to be a little bit slow at first because even though they'll have the reimbursement, it's a completely new type of procedure,\u201d said Matson. \u201cBut it should gain momentum and become a pretty meaningful market and growth driver for Medtronic, as well as Otsuka.\u201d The FDA\u2019s device center began the first steps to determine how much funding the agency will receive from the medtech industry from 2027 to 2032. The FDA held the first public hearing in early August to reauthorize the Medical Device User Fee Amendments, also known as MDUFA, which allows the agency to supplement appropriations from Congress with industry fees over a five-year period. Steven Grossman, a regulatory consultant with HPS Group, wrote in an email that the meeting was the first in a process that is likely to take 15 months. \u201cThe most important takeaway is that there is widespread support for renewal,\u201d Grossman wrote. \u201cThe details were useful in terms of what different stakeholders want, but nobody was giving away their bottom line.\u201d The current MDUFA V agreement, which expires in September 2027, allocated between $1.78 billion and $1.9 billion for the FDA\u2019s Center for Devices and Radiological Health, depending on if the center met certain hiring goals. By comparison, the FDA received approximately $1.1 billion in the previous five-year term. For MDUFA VI, the agency is seeking more funds as the Trump administration has proposed cutting funding to the FDA and other health agencies. Michelle Tarver, director of the CDRH, made the case for additional funds in the meeting. \u201cWe\u2019ll need critical resources in MDUFA VI,\u201d Tarver said. \u201cA modern CDRH that is driven by gold standard science requires talented experts.\u201d The future of the MDUFA program was a concern raised during the meeting. Diana Zuckerman, president of the National Center for Health Research, said the FDA is required to spend at least the equivalent amount of money in appropriations as when the user fee law began. If that doesn\u2019t happen, then the industry could cut its fees. \u201cWe don\u2019t want that to happen,\u201d Zuckerman said in an interview. \u201cThen there\u2019s not enough money for anything.\u201d Zuckerman and other patient advocates called for more user fee funding, and for some of the funds to be allocated to postmarket safety for medical devices. They also called for more transparency in the user fee process. The FDA is seeking public comments through Sept. 4 before kicking off a series of meetings to reach an agreement with the medical device industry. Zuckerman said she expects more comments from outside stakeholders, such as patients and medical groups. \u201cDevices have flown under the radar for decades,\u201d Zuckerman said. \u201cWill this be the year when people are paying more attention?\u201d Medtronic will become the first big medtech company in the U.S. to challenge Intuitive Surgical\u2019s nearly 25-year lead in soft tissue robotic surgery if it secures the FDA\u2019s nod to launch its Hugo system this year. The company submitted a filing to the FDA in the first quarter of the year for use of the Hugo robot in urology procedures. It also completed enrollment in studies to support U.S. indications in hernia and benign gynecology, and received the go-ahead to start a trial in oncologic gynecology. Analysts expect Medtronic will win some healthcare systems as Hugo customers, but they are skeptical about how much market share it can take from the industry leader. \u201cWe're not expecting Intuitive to lose meaningful share with the launch of Hugo in the U.S.,\u201d said BTIG analyst Ryan Zimmerman. With the rollout of its technologically advanced da Vinci 5 robot, first introduced in early 2024 and now launching broadly, Intuitive has \u201cleapfrogged\u201d the competition, said Zimmerman. \u201cThe ecosystem around DV5 is so strong that it's very hard to break that monopoly,\u201d he said. Many surgeons are trained on the da Vinci system, which has a large installed base, and the technology is backed by years of clinical data, noted Needham\u2019s Matson. When Medtronic finally enters the U.S. market, said the analyst, \""it's going to be an uphill battle.\u201d Hugo could wrangle market share from hospitals looking to retire older da Vinci systems, and the robot will be attractive to surgeons who are loyal to Medtronic\u2019s suite of surgical instruments, said Mizuho\u2019s Petrone. Da Vinci\u2019s growing adoption has eroded Medtronic\u2019s instruments business, as more procedures shift to robotics. Speaking at an investor conference in May, Medtronic CEO Geoff Martha said Hugo is expected to support a rebound in growth in the surgical business. When the company announced in July that it gained the CE mark for use of its LigaSure vessel-sealing device in robotic-assisted surgeries with Hugo in Europe, Medtronic said it expected the robot to enter the U.S. market later in its current fiscal year, which ends in April 2026. Recommended Reading Will medtech M&A pick back up in the second half?"", ""Should You Buy Intuitive Surgical Stock Today, or Wait for a Better Price? Intuitive Surgical's underlying business looks strong. It may face increased competition, tariff-related impacts, and valuation concerns. Given the company's moat and a significant runway for growth in its market, the stock remains a buy. 10 stocks we like better than Intuitive Surgical \u203a One of famed investor Warren Buffett's principles is to buy shares of wonderful companies at fair prices to hold for the long term. Let's try to use it to decide whether Intuitive Surgical (NASDAQ: ISRG), a medical device specialist, is worth investing in today. The healthcare giant certainly appears to be a wonderful company. Intuitive Surgical is helping revolutionize medicine through innovations in robotic surgery. The company's da Vinci system, the first robotic-assisted surgery (RAS) device to be cleared in the U.S., is the runaway market leader. Intuitive Surgical generates consistent revenue, profits, and cash flow. It even benefits from a moat thanks to intangible assets (patents that grant it some degree of pricing power) and switching costs -- its devices are expensive to buy and to train medical staff on, making the prospects of switching to a competitor almost prohibitively expensive. Strong cash generation and a moat are two key attributes that Buffett loves. However, bears might point out several other aspects that make the stock appear less attractive. Intuitive Surgical is facing several headwinds. First, tariffs are already affecting its financial results. We can't be sure that President Donald Trump's aggressive trade policies will remain in place even after he leaves office, but currently, they pose a threat to the company's prospects. Second, Intuitive Surgical will face increased competition in the years to come. Medtronic is close to launching its RAS device, the Hugo system, in the U.S., and it will compete directly with the da Vinci system in urologic procedures. Johnson & Johnson is testing its Ottava system in gastric bypass, another indication where the da Vinci system is already cleared. Third, despite the company's underperformance this year, Intuitive Surgical's shares appear expensive based on some traditional valuation metrics: For context, the average forward price-to-earnings (P/E) ratio for the healthcare sector is 16.6. Also, I often look for a forward price-to-sales (P/S) of 2 or below to consider a healthcare stock undervalued. At these levels, and given the challenges Intuitive Surgical is currently facing and may face in the future, can the company still deliver superior returns to investors who initiate positions today? It's worth noting that Intuitive Surgical's valuation seems more reasonable when considering its price-to-earnings-to-growth (PEG) ratio of approximately 2.2. While it's still above the S&P 500's average of 1.5, a stock performing as well as Intuitive Surgical deserves a premium. And despite the threat of tariffs, the company continues to post excellent financial results. In the second quarter, revenue increased by 21% year over year to $2.44 billion. Non-GAAP (adjusted) earnings per share came in at $2.19, 23% higher than the year-ago period. Trailing-12-month free cash flow soared by 240% to almost $2 billion. Intuitive Surgical delivered second-quarter results of this caliber, and should also post strong earnings for the full calendar year despite an expected 1% impact from tariffs on its top line. What about the company's other challenges? While competition will become more fierce, there's more than enough room for multiple winners in the RAS market; the industry is severely underpenetrated. Thanks to RAS devices, surgeons can perform minimally invasive procedures that benefit everyone. For patients, this means less skin cutting, less bleeding, and fewer scars. For both patients and hospital systems, this can translate into shorter hospital stays. Despite these advantages, robotic procedures are still far from achieving widespread adoption for eligible indications. This means there's massive long-term growth potential. Intuitive Surgical's moat should allow it to remain the leader here. Its first-mover advantage counts for something: The company already has a long list of approved uses for its devices -- which competing RAS systems will take time to catch up to, even after they hit the market -- and a large installed base of more than 10,000 da Vinci systems. So what's the verdict? Intuitive Surgical's shares aren't exactly cheap. But the stock is worth the premium and can still deliver above-average returns, so long as investors stay the course for at least five years. Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now\u2026 and Intuitive Surgical wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you\u2019d have $649,657!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you\u2019d have $1,090,993!* Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 1,057% \u2014 a market-crushing outperformance compared to 185% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks \u00bb *Stock Advisor returns as of August 18, 2025 Prosper Junior Bakiny has positions in Intuitive Surgical and Johnson & Johnson. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends Johnson & Johnson and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Should You Buy Intuitive Surgical Stock Today, or Wait for a Better Price? was originally published by The Motley Fool"", ""What Intuitive Surgical (ISRG)'s Expected Earnings Growth and System Placements Mean for Shareholders Intuitive Surgical recently saw heightened investor attention ahead of its latest earnings report, with analysts expecting growth in earnings per share and revenue versus the previous year. While system placements showed strong average growth over the last two years and EPS has increased at a robust pace, a yearly decrease in return on invested capital has become a point of focus for some observers. Now, we'll explore how analyst optimism about continued revenue and earnings expansion, driven by rising system placements, shapes the company's investment narrative. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. To be a shareholder in Intuitive Surgical, belief in the long-term adoption of robotic-assisted surgery, strong procedure growth, and expanding recurring revenue streams is essential. The latest surge in investor attention ahead of earnings may reinforce the near-term focus on revenue and EPS growth, but the most important short-term catalyst remains continued system placements, while a declining return on invested capital stands out as a non-trivial risk. Recent earnings results have not materially shifted these near-term priorities or threats. Among the company's announcements, the July 2, 2025, CE mark approval for the da Vinci 5 Surgical System in Europe directly supports the recurring catalyst of broadening global adoption. This regulatory milestone may help drive further system placements and procedure volume expansion, directly feeding into Intuitive Surgical\u2019s recurring growth narrative even as investors watch for issues like margin compression and adoption hurdles. However, in contrast to these growth trends, investors should be aware that intensifying competition from third-party suppliers threatens the predictability of high-margin recurring revenue... Read the full narrative on Intuitive Surgical (it's free!) Intuitive Surgical's outlook anticipates $13.4 billion in revenue and $3.7 billion in earnings by 2028. To achieve this, the company would need to deliver 13.5% annual revenue growth and an increase in earnings of $1.1 billion from the current $2.6 billion. Uncover how Intuitive Surgical's forecasts yield a $583.64 fair value, a 23% upside to its current price. Simply Wall St Community members contributed 12 fair value estimates for Intuitive Surgical, ranging from US$266 to US$584 per share. While opinions vary greatly, the ongoing risk from international financial pressures could influence long-term performance expectations and highlights the importance of reviewing multiple viewpoints. Explore 12 other fair value estimates on Intuitive Surgical - why the stock might be worth as much as 23% more than the current price! Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your Intuitive Surgical research is our analysis highlighting 3 key rewards that could impact your investment decision. Our free Intuitive Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intuitive Surgical's overall financial health at a glance. Our top stock finds are flying under the radar-for now. Get in early: The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free. Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ISRG. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com""]"
ISRG,2025-08-26,468.64,474.585,464.8,474.26,"Wall Street Analysts Think Intuitive Surgical (ISRG) Is a Good Investment: Is It? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Intuitive Surgical, Inc. (ISRG). Intuitive Surgical currently has an average brokerage recommendation (ABR) of 1.76, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 29 brokerage firms. An ABR of 1.76 approximates between Strong Buy and Buy. Of the 29 recommendations that derive the current ABR, 18 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 62.1% and 6.9% of all recommendations. Check price target & stock forecast for Intuitive Surgical here>>> The ABR suggests buying Intuitive Surgical, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation. Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five ""Strong Buy"" recommendations for every ""Strong Sell"" recommendation. This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision. In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures. The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns. There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices. Looking at the earnings estimate revisions for Intuitive Surgical, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $8.17. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Intuitive Surgical. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Intuitive Surgical. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-08-27,471.35,475.598,470.13,471.14,"[""SP Platform's 88% Procedure Growth: The Next Frontier for ISRG? Intuitive Surgical\u2019s ISRG second-quarter 2025 results highlighted an impressive 88% year-over-year surge in single-port (SP) procedures, underscoring the platform\u2019s accelerating momentum within the company\u2019s broader portfolio. While da Vinci multiport systems remain the backbone of Intuitive\u2019s installed base, SP\u2019s performance \u2014 particularly outside the United States \u2014suggests it may be emerging as the next meaningful growth driver along with Ion platform. Korea stood out with a 112% procedure increase, fueled by highly efficient, high-utilization programs that continue to expand across multiple surgical specialties. Europe and Japan are progressing steadily, albeit at earlier stages of adoption. This global spread signals not just geographical diversification but also rising confidence among surgeons in SP\u2019s clinical utility. A key factor in SP\u2019s expanding adoption is its broadening clinical footprint. Initially centered on urology, the platform is now gaining traction in colorectal, thoracic and transanal procedures. The rollout of the SP stapler \u2014 viewed as a critical enabler for complex colorectal and thoracic surgeries \u2014 further strengthens its potential for case volume expansion. Financially, SP placements were modest at 23 systems in the second quarter, yet utilization rose 30%, indicating that installed systems are seeing higher throughput. Strong uptake in Korea and increasing European and Japanese usage point to SP\u2019s ability to drive procedure growth even without large-scale system placements. The question for investors is whether SP can replicate the multiport da Vinci\u2019s trajectory and evolve into a core volume engine for Intuitive Surgical. With rising adoption beyond urology and early evidence of efficiency gains, SP appears well-positioned to be more than just an adjunct platform. Its sustained growth could mark the next frontier in Intuitive Surgical\u2019s long-term expansion story. PROCEPT BioRobotics PRCT markets the AquaBeam Robotic System, which performs image-guided, heat-free waterjet aquablation for benign prostatic hyperplasia (BPH). PROCEPT BioRobotics\u2019 AquaBeam delivers highly precise, automated tissue removal under ultrasound guidance, appealing to urology practices and overlapping with Intuitive Surgical\u2019s early SP urology use cases. PROCEPT BioRobotics\u2019 targeted platform may thus rival SP by capturing procedural volume in urology with a technology-specific advantage. Last year, PRCT launched its next-generation, AI-powered platform for Aquablation therapy, HYDROS Robotic System, for treating BPH. Simultaneously, Globus Medical GMED showcased its ExcelsiusFlex robotic navigation system for Total Knee Arthroplasty. Its system offers both CT-based and imageless registration options, providing surgeons with ergonomic control and procedural flexibility. Globus Medical\u2019s ExcelsiusFlex is designed to enhance surgical precision and accommodate diverse patient needs and surgeon preferences. Shares of ISRG have lost 9.2% in the year-to-date period compared with the industry\u2019s decline of 8.6%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 53.65, above the industry average. But, it is still lower than its five-year median of 72.05. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical\u2019s 2025 earnings implies an 11.3% rise from the year-ago period\u2019s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report PROCEPT BioRobotics Corporation (PRCT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Intuitive to lay off 331 employees in California This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Intuitive Surgical plans to lay off 331 people in California, according to a Worker Adjustment and Retraining Notification filed with the state. The layoffs are expected to take effect by Oct. 27, and will take place at a facility in Sunnyvale, California. In the WARN notice, Intuitive stated that the company \u201cwill cease operations for graveyard and weekend shifts for Ion Instruments & Accessories (I&A) production, as well as related logistics and quality operations activities in Sunnyvale. All roles supporting these shifts will be eliminated.\u201d The majority of the positions affected are for assembly technicians. California\u2019s database classifies the layoffs as \u201cmanufacturing.\u201d \u201cMore specifically, as part of creating a global \u2018hub model,\u2019 we are permanently ending graveyard and weekend shift effective October 23 and 24, 2025, respectively, as well as transitioning our work model effective October 27, 2025,\u201d Intuitive said in the WARN letter. An Intuitive spokesperson said in an emailed statement that the company is transitioning to a new shift schedule to allow its manufacturing teams to coordinate more efficiently. \u201cAs part of this change, we have informed employees of planned adjustments ahead of their implementation,\u201d the spokesperson said in the statement. \u201cOur goal is to retain these employees in roles on the standard shift schedule, however, we understand that roles on the standard shift schedule may not be suitable for some of these employees and we are committed to assisting their transition to alternate employment.\u201d The cuts come as Intuitive Surgical has reported solid growth and a successful launch of its latest soft tissue robotic system, the da Vinci 5, which has convinced Wall Street that the new product will help the company maintain its dominance over the space despite the emergence of competing robots. In the first six months of the year, Intuitive reported revenue of $4.69 billion, representing 20% growth year over year. The medtech industry has experienced tens of thousands of layoffs in recent years as companies grappled with macroeconomic factors. While not a major participant in the mass layoffs, Intuitive did cut 72 employees in North Carolina in 2023. Editor\u2019s note: This story was updated to include a statement from Intuitive Surgical. Recommended Reading Intuitive Surgical tempers tariff impact expectations""]"
ISRG,2025-08-28,470.86,474.24,468.0,473.84,"ISRG vs. MDT: Which MedTech Titan Is the Stronger Investment Choice Now? Both Intuitive Surgical ISRG and Medtronic MDT reported solid financial results, but their businesses diverge. Intuitive, known for its Da Vinci surgical robots, delivered 21% revenue growth for the second quarter of 2025 ($2.44 billion), fueled by a 17% jump in da Vinci procedures. Medtronic, a diversified medtech giant, posted first-quarter fiscal 2026 sales of $8.6 billion (up 8.4% on a reported basis and 4.8% organically). Below we compare their financial performance, growth drivers and key product updates – notably Intuitive’s new Da Vinci 5 and Ion platforms versus Medtronic’s Hugo surgical robot. Year to date, shares of ISRG have lost 9.8% compared to MDT’s 15.2% gain. Image Source: Zacks Investment Research Intuitive Surgical is trading at a forward 12-month price-to-sales of 15.8X, costlier than Medtronics’ forward sales multiple of 3.3X. Image Source: Zacks Investment Research ISRG posted a 21% jump in second-quarter revenues and a pro forma operating margin of 39%. Its installed base of da Vinci systems grew 14% (to nearly 10,500 worldwide), driving a 17% rise in da Vinci procedures. Including the newer Ion bronchoscopy platform, total robotic procedure volume was up 18%. Procedure growth was broad-based, with the U.S. benign general surgery (e.g. cholecystectomy, appendectomy) and new international markets (India, Korea) being the major contributors. The company rolled out its Da Vinci 5 system nationally, placing 180 da Vinci 5 units in the second quarter and crossing 100,000 total da Vinci 5 procedures in the launch phase. Intuitive Surgical also shipped 54 Ion systems, with Ion procedures surging 52% to nearly 35,000, as the company expands in Korea and Australia. Single-port (SP) robot use nearly doubled (88% growth) in the quarter, aided by new clearances (like 50-use endoscopes) and expanded GI indications. Recurring revenues (instruments, accessories, services) remain a strength, accounting for nearly 85% of total sales, with average instrument???and???accessory revenue per procedure of around $1,800. Non-financially, Intuitive is pushing innovation. It received new FDA clearances (e.g. curved vessel sealer, tracheal bronchoplasty surgery) and demonstrated force-feedback and telepresence features of da Vinci 5 at surgical conferences. Management emphasized building manufacturing scale and quality as the company fully launches Da Vinci 5 globally. Intuitive raised its 2025 da Vinci procedure growth guidance to 15.5-17%, implying confidence in continued adoption of its robots. ISRG’s Sales & EPS Growth Estimate Image Source: Zacks Investment Research Medtronic’s first-quarter fiscal 2026 performance was led by its large cardiovascular, diabetes and neurosurgery businesses. Total revenues were $8.58 billion (organic +4.8%), roughly in line with its guidance. Cardiovascular portfolio sales grew 7%, driven by Cardiac Ablation (Pulsed Field Ablation), which was up nearly 50% (especially in the United States and Japan). Structural heart (TAVR) was up 6%, and Cardiac Rhythm Management rose 3% (with strong adoption of new ICD and leadless pacer products). Neuromodulation (pain stimulators) grew 10% along with mid-single digits growth for the Cranial & SpinalTechnologies business, helping overall Neuroscience to grow 3.1%. Medtronic’s Diabetes unit grew 7.9%, aided by new glucose sensors (CE-marked Simplera Sync in Europe) and expanded 780G pump labeling (type 2, young children). Management reiterated plans to spin off the MiniMed diabetes business — a move expected to be margin-accretive. In Medtronic’s Surgical (Medical-Surgical) division, revenues were up just 2.4%. Growth was backed by Advanced Energy (LigaSure) instruments — a market share gainer — but offset by a shift from conventional to robotic surgery. Critically, Medtronic is ramping up its Hugo robotic surgery system. Internationally, Hugo is gaining share (growing procedures outside the U.S. market), and Medtronic won the CE Mark for LigaSure on Hugo last month. The company filed for U.S. FDA approval and expects a U.S. launch in late fiscal 2026. Management says Hugo’s rollout should be “accretive to growth” once it begins. In the meantime, Medtronic is investing heavily in R&D (nearly 8% YoY) across cardiovascular, diabetes and neuromodulation, and pushing cost efficiencies in materials and SG&A. Medtronic’s margins held steady (adjusted gross of 65.1%) despite mix headwinds. Its outlook remains modest — roughly 5% organic growth for fiscal 2026, with an expectation of growth accelerating in the second half. Foreign exchange tailwinds (recent dollar weakness) and lower-than-anticipated tariffs should provide a lift, and management is confident about driving scale from its large installed base. MDT’s Sales & EPS Growth Estimate Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surigcal’s 2025 EPS implies year-over-year growth of 11.3% to $8.17. Estimates have shown an upward trend in the past 60 days, improving 4.2%. Image Source: Zacks Investment Research Meanwhile, the consensus estimate for Medtronic’s fiscal 2026 EPS is pinned at $5.61, suggesting an increase of 2.2% year over year. Analyst estimates have moved north 1.1% in the past 60 days. Image Source: Zacks Investment Research Intuitive’s pure-play robotic focus is yielding double-digit growth and improving leverage, with robust procedure growth and raised guidance. Medtronic, by contrast, is a broad platform. Its mid-single-digit growth is supplemented by very high growth devices (like ablation devices) and an upcoming Hugo robot launch. We note that Intuitive is winning on outsized growth in a niche (robotic surgery) with premium margins, while Medtronic offers stability and scale across many markets with new catalysts (like Hugo and spun-off diabetes) on the horizon. While both companies currently carry a Zacks Rank #3 (Hold), MDT seems attractive compared to ISRG due to its cheaper valuation. Moreover, ISRG carries a Zacks VGM Score of ‘D’ while MDT has a score of ‘B’, making MDT a better bet as of now. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
ISRG,2025-08-29,474.23,475.4,468.775,473.295,
ISRG,2025-09-02,470.56,472.565,464.75,469.07,"Is Intuitive Surgical Stock Underperforming the S&P 500? With a market cap of $169.7 billion, Intuitive Surgical, Inc. (ISRG) designs, manufactures, and markets advanced robotic-assisted surgical systems and related products. The company also provides instruments, accessories, digital solutions, and comprehensive service support to enhance surgical precision and hospital performance worldwide. Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Intuitive Surgical fits this criterion perfectly. Its flagship da Vinci Surgical System enables minimally invasive procedures, complemented by the Ion endoluminal system for diagnostic lung biopsies. Trump Claims ‘$8 Trillion in Tariff Revenue’ Amid ‘Hundreds of Thousands of New Jobs’ in Confusing Labor Day Post ‘You Sleep Like You're Rich. I'm Up Like I'm Broke’: Billionaire Grant Cardone Says Most People Are Too Complacent To Become Rich This Quantum Computing Stock Is Poised to Dominate. Why Analysts Think You Should Buy It Here. Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Shares of the Sunnyvale, California-based company have pulled back 23.2% from its 52-week high of $616. ISRG stock has fallen 14.8% over the past three months, underperforming the broader S&P 500 Index’s ($SPX) 9.3% gain over the same time frame. In the longer term, shares of Intuitive Surgical have decreased 1.9% over the past 52 weeks, lagging behind the 15.5% return of the SPX over the same time frame. Moreover, the stock is down 9.3% on a YTD basis, compared to SPX’s 9.8% rise. Despite a few fluctuations, ISRG stock has been trading below its 50-day and 200-day moving averages since early June. Shares of ISRG fell 1.8% following its Q2 2025 results on Jul. 22 despite beating expectations, as investor concerns focused on slowing international system placements, which declined to 179 due to budgetary pressures in Japan, China, and Europe. While Q2 sales rose 21% to $2.4 billion and adjusted EPS jumped 23% to $2.19, the cautious tone on global growth overshadowed these positives. However, rival Becton, Dickinson and Company (BDX) stock has shown a more pronounced decline than ISRG stock. BDX stock has dropped 14.9% on a YTD basis and 19.2% over the past 52 weeks. Despite the stock’s weak performance over the past year, analysts remain moderately optimistic about its prospects. ISRG stock has a consensus rating of “Moderate Buy” from 29 analysts in coverage, and the mean price target of $597.12 is a premium of 26.2% to current levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"
ISRG,2025-09-03,470.11,471.0,434.8,441.18,"[""ISRG's SP Stapler: A Game Changer for Colorectal and Thoracic Procedures? Intuitive Surgical\u2019s ISRG early rollout of the da Vinci SP stapler marks a pivotal development in expanding the procedural mix of its single-port (SP) platform. While the SP has gained traction in urology and select general surgery, its broader adoption has been limited by the absence of critical enabling technologies. The introduction of a stapler directly addresses this gap, particularly for colorectal and thoracic procedures \u2014 two high-volume categories where stapling is essential. In second-quarter 2025, management highlighted that the stapler rollout remains in its early phase, with a measured approach focused on building clinical experience and key opinion leader engagement. Nonetheless, SP procedures surged 88% year over year, with Korea leading utilization and Europe and Japan showing early momentum. Utilization rose 30%, signaling a strong appetite for broader indications once the full instrument ecosystem matures. The stapler, coupled with new procedure clearances such as transanal resections, materially expands SP\u2019s reach into complex colorectal surgeries, while thoracic adoption remains a logical next step. The SureForm 45 SP stapler had received FDA clearance during the first quarter, followed by management positioning it as a catalyst for thoracic and colorectal use. Now, early commercialization validates its role as a critical enabler. As Intuitive Surgical builds clinical data and surgeon proficiency, the stapler is expected to accelerate SP\u2019s adoption curve, transitioning the platform from a niche solution to a versatile system capable of competing across high-value surgical categories. Ultimately, the stapler could become the next key driver that shifts SP from promising to indispensable. By unlocking access to colorectal and thoracic procedures, Intuitive Surgical is positioning SP not just as a complementary system, but as a core driver of growth within its multi-platform ecosystem. Medtronic MDT is emerging as a strong competitor to Intuitive Surgical with its Hugo RAS system \u2014 a modular and portable robotic platform designed to provide greater surgical flexibility at a potentially lower cost of ownership than da Vinci. By using distributed arm carts and an open-console design, Hugo is well-positioned to attract hospitals in colorectal and general surgery where adaptability and cost efficiency are critical, while complementing areas where the SP system already excels. At the same time, Stereotaxis STXS has carved out leadership in robotic magnetic navigation with its Genesis RMN and next-generation GenesisX systems, which enable highly precise cardiac and electrophysiology procedures. Although Stereotaxis does not directly overlap with SP\u2019s colorectal or thoracic applications, its success underscores how specialized robotic platforms can dominate targeted clinical niches. Together, Medtronic, with its broad multipurpose system, and Stereotaxis, with its specialized precision technology, represent distinct but meaningful rivals in the shifting surgical robotics landscape. ISRG\u2019s Price Performance, Valuation and Estimates Shares of ISRG have lost 8.1% in the year-to-date period compared with the industry\u2019s decline of 10.1%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 52.93, above the industry average. But, it is still lower than its five-year median of 71.95. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical\u2019s 2025 earnings implies an 11.3% rise from the year-ago period\u2019s level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Stereotaxis Inc. (STXS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""SoFi launches new AI-themed ETF as skepticism grows By Suzanne McGee (Reuters) -SoFi Technologies jumped back into the exchange-traded fund business on Wednesday with its first launch in nearly two years, betting on artificial intelligence, the hottest theme in retail investing. The new fund, SoFi Agentic AI ETF, will target what SoFi calls \u201cnext-generation AI\u201d companies, such as those developing self-driving vehicles, autonomous technology and cybersecurity networks, as well as AI stalwarts such as semiconductor and cloud computing firms. The debut comes as enthusiasm for all things AI faces a test, with investors asking tougher questions about sky-high valuations of AI leaders like Nvidia and Palantir Technologies, as well as AI's ability to generate outsize productivity and profitability gains. SoFi's ETF will track the performance of a new tailor-made index from Solactive, the BITA USA Agentic AI Select Index, and will levy a fee of 0.69%. Brian Walsh, head of advice and planning at SoFi, told Reuters that the index's current 30 components range from some of the most-owned AI investments, such as Nvidia, to more unusual ways to play the theme, such as Intuitive Surgical and Deere & Co., firms which are integrating AI into robotic surgery products and farm equipment. Solactive screens potential holdings to identify companies that derive \""a meaningful portion of their revenue\"" from deploying AI. \""This goes above and beyond what first-generation AI exposure can provide,\"" said Walsh, adding that he expects the composition of the underlying index to alter as the theme evolves. SoFi, a digital financial services platform, has backed five other ETFs, the most recent of which, the SoFi Enhanced Yield ETF, debuting in November 2023. Roxanna Islam, head of sector and industry research at VettaFi, noted the AI-themed ETF market is becoming \""crowded\"", as asset managers rush to roll out more products. Some 190 single-stock leveraged and inverse ETFs now offer investors a way to bet on outsize moves in underlying stocks like Nvidia, Tesla and Palantir that are linked to the AI theme. \""It's going to be hard to stand out from the crowd and gather assets at this point,\"" she said. The most recent AI-themed ETF to launch was the Janus Henderson Global Artificial Intelligence ETF on August 19. That fund has seen inflows of $1.9 million since its debut. Steve Sosnick, market strategist at IBKR, said that in spite of the profit-taking on big AI stocks like Nvidia in recent days, \""the enthusiasm for this theme is still driving the bus.\"" (Reporting by Suzanne McGee, Editing by Nick Zieminski)""]"
ISRG,2025-09-04,440.69,455.28,437.41,454.52,"[""Ashes to Alpha: Why Intuitive Surgical\u2019s (ISRG) Fallout is a Legit Upside Opportunity Thanks to its nearly 6% drop during the midweek session, Intuitive Surgical (ISRG) graced \u2014 for lack of a better word \u2014 the rankings of Barchart\u2019s \u201cAll US Exchanges Percent Change Declines\u201d screener. As you can tell from the name, this list provides a breakdown of the day\u2019s biggest percentage losers. Let\u2019s just be honest here: most of the time, you\u2019re going to find straight up junk by default. But occasionally, you come across gems that have the potential of rising above the muck. I\u2019m not just going to argue that ISRG stock is one such candidate; I have compelling, scientific evidence to back it up. Lucid Motors Could Be Foreshadowing What\u2019s Coming Next for Over-Hyped AI Stocks. Here\u2019s the Ugly Truth. This VIX Butterfly Spread has a 9 to 1 Reward to Risk Ratio Large Unusual Options Activity in Alphabet Options Shows the Stock Is Undervalued Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Too often, Wall Street is full of well-meaning advice that says a lot but says nothing. One of my \u201cfavorites\u201d is from legendary investor Warren Buffett: \u201cBe fearful when others are greedy, and greedy when others are fearful.\u201d This statement, while seemingly profound, raises the obvious question: how do you know which red-stained names to buy and which ones to avoid? The answer: out-of-sample testing. In the financial publication space, virtually every single article (to my knowledge) that has been published in the mainstream ecosystem presents an in-sample argument. Put another way, the conclusion and the evidence to support said conclusion stem from the same dataset. For ISRG stock, the common argument is the Trump administration\u2019s tariffs and the negative impact that they have on the business caused the security to tank. However, the bulls would counter that because Intuitive now trades for a lower multiple, the strength of the company\u2019s fundamentals would eventually lead to a positive market rerating. As reasonable as this logic may sound, the conclusion (that ISRG stock is undervalued) and the evidence to support said conclusion (the reduced multiple relative to historical or prior averages) come from the same dataset. Here\u2019s a red-pill moment for you. This trope of an analysis is no different than claiming that the Flying Spaghetti Monster (FSM) exists because you prayed to it and it helped you find your keys. The conclusion (that the FSM exists) and the evidence to support it (helping you find your keys) come from the same source. Everybody should be familiar with the phrase, correlation does not imply causation. This is especially relevant on Wall Street, where the ginormous leap from correlation to causation is baked into almost every headline, argument and \u201cundervalued\u201d call. I\u2019m guilty of this thought process as well. But with the shifting environment in the multimedia space, this is an opportunity to bring about meaningful change. Because in-sample arguments are inherently self-referential, there\u2019s no way to falsify the claim. Further, any wisdom, any guidance that stems from such circular logic is bound to be fragile \u2014 with success stories more often than not hailing from survivorship bias, not actual methodology. In sharp contrast, out-of-sample testing controls for outside factors. Stated differently, by conducting such tests, we are seeking to determine the probability of causality: does the thing being asserted legitimately work in other contexts? For me, what makes ISRG stock so intriguing is that in the trailing 10 weeks, it printed a 3-7-D sequence: three up weeks, seven down weeks, with an overall downward trajectory. Based on my dataset, which covers January 2019 through a little over the halfway point this year, the 3-7-D has a tendency of skewing the range of prices toward the upside over the next 10 weeks. Unfortunately, if I leave the argument as so, it would be very much an in-sample assertion. To create an out-of-sample test, I conducted three regime experiments: a post-Great Recession test, a pre-COVID-19 test and a post-COVID-19 test: What I discovered was that in the post-recession test, the skew eventually tilted negatively following the 3-7-D sequence. However, in the other out-of-sample tests (as well as the in-sample dataset), the expected forward skew is positive. So long as the overall sentiment regime doesn\u2019t shift into \u201crecession mode,\u201d the 3-7-D signal reliably represents an upside opportunity. Of course, reliability doesn\u2019t guarantee results. However, with the out-of-sample tests, we have quantitative confidence that ISRG stock could move higher over the next two months. Given that upside may be a higher probability than what market makers believe, it\u2019s fair to assert that ISRG stock options are mispriced. Those who want to get aggressive may consider the 460/470 bull call spread expiring Oct. 17. The above transaction involves buying the $460 call and simultaneously selling the $470 call, for a net debit paid of $410 (the most that can be lost in the trade). Should ISRG stock rise through the short strike price ($470) at expiration, the maximum profit is $590, a payout of nearly 144%. As with anything market-related, there\u2019s always going to be risk. For a more probabilistically comfortable trade, setting the short leg at $460 may be ideal (in exchange for a lower payout). However, based on multiple regime tests, I\u2019m confident that ISRG stock is a discount \u2014 not just a cheapened name. On the date of publication, Josh Enomoto did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"", ""S&P 500 Robotics Titan Intuitive Surgical Dives As CFO Warns Of 'Dynamic' Tariffs Environment Intuitive Surgical stock dropped Wednesday after the robotic surgery titan's CFO suggested the impact of tariffs could be steeper in 2026."", ""1 Cash-Producing Stock to Consider Right Now and 2 That Underwhelm A company that generates cash isn\u2019t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not all companies are created equal, and StockStory is here to surface the ones with real upside. Keeping that in mind, here is one cash-producing company that leverages its financial strength to beat its competitors and two that may face some trouble. Trailing 12-Month Free Cash Flow Margin: 6.6% With roots dating back to 1944 and a significant acquisition of Kimball International in 2023, HNI (NYSE:HNI) manufactures and sells office furniture systems, seating, and storage solutions, as well as residential fireplaces and heating products. Why Are We Hesitant About HNI? At $45.53 per share, HNI trades at 12.2x forward P/E. Read our free research report to see why you should think twice about including HNI in your portfolio, it\u2019s free. Trailing 12-Month Free Cash Flow Margin: 48.1% Formerly known as Alliance Data Systems until its 2022 rebranding, Bread Financial (NYSE:BFH) provides credit cards, installment loans, and savings products to consumers while powering branded payment solutions for retailers and merchants. Why Are We Out on BFH? Bread Financial\u2019s stock price of $65.87 implies a valuation ratio of 8.6x forward P/E. To fully understand why you should be careful with BFH, check out our full research report (it\u2019s free). Trailing 12-Month Free Cash Flow Margin: 21.8% Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Why Does ISRG Catch Our Eye? Intuitive Surgical is trading at $442 per share, or 52.8x forward P/E. Is now the right time to buy? Find out in our full research report, it\u2019s free. Trump\u2019s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines. Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.""]"
ISRG,2025-09-05,454.83,467.99,454.78,466.86,"[""Medtronic trial of Hugo robot in hernia repair hits primary endpoints This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. A clinical trial of Medtronic\u2019s Hugo robot has met its primary effectiveness and safety endpoints, the company said Thursday. Physicians used the robotic-assisted surgery system to treat 193 patients. All of the surgeries were successfully completed. Two people had surgical safety events in the 30 days after treatment that were resolved without complication. Medtronic has filed for authorization of the system in a urology indication and plans to expand into hernia repair later. The company will compete with Intuitive Surgical for the hernia market. Medtronic\u2019s attempt to ease Intuitive\u2019s grip on the robotic surgery market centers on a system designed to be more versatile than existing products. Hugo has a modular design, giving surgeons the flexibility to use the number of arms needed for a procedure and resulting in a system that can be moved between operating rooms. The company has identified hernia repairs as procedures that do not typically require four arms and may benefit from the flexibility of the Hugo system. To validate Hugo in the indication, Medtronic enrolled 193 patients, split roughly evenly between people undergoing inguinal and ventral hernia repair. Medtronic reported a 100% surgical success rate in the trial, beating the pre-specified 85% performance goal to meet the primary effectiveness endpoint. The trial defined surgical success as a procedure that was completed without switching to laparoscopy, open surgery or an alternative robotic-assisted system. Intuitive received 510(k) clearance for its da Vinci system in inguinal hernia repair in 2017 and added ventral hernia repair to the list of authorized indications in 2018. The label expansions were supported by a retrospective clinical study and real-world evidence. Medtronic reported no surgical site events in the 92 inguinal hernia repair patients who were available for analysis. The trial defined an event as a surgical-site occurrence or infection related to the device or procedure from the first incision through 30 days post-procedure. There were two events in the cohort of 94 ventral hernia patients. The 2.1% event rate was below the pre-specified 30% performance goal. The mean length of hospital stay was 4.7 hours for inguinal patients and 6.7 hours for ventral patients. Using the data, Medtronic plans to expand the label for Hugo to cover hernia procedures after winning its first authorization in urology. Targeting hernia will move Medtronic into an indication that is central to Intuitive\u2019s business. In each of the past three years, more than half of the da Vinci procedures were for benign conditions, most notably hernia repairs, hysterectomies and cholecystectomies. Intuitive said strong growth in general surgery procedures, notably cholecystectomies, hernia repair and appendectomies, drove 14% growth in U.S. da Vinci procedures in the second quarter. The company named gynecological procedures, another setting targeted by Medtronic, as an additional growth driver. Recommended Reading The robotic surgery market battle is heating up"", ""Intuitive Surgical Stock Has Been Plummeting. Is It Time to Buy? Despite the stock's downward trend lately, the company is growing at an impressive pace. Management recently warned investors about some of the key risks and pressures the robotics company faces. Drawdowns in the stock prices of great companies like Intuitive Surgical don't always last long. 10 stocks we like better than Intuitive Surgical \u203a Intuitive Surgical (NASDAQ: ISRG) fell about 6% on Wednesday, following remarks at a healthcare conference, where management flagged tariff and international-market pressures. Shares of the minimally invasive surgical robotics company were already choppy after July earnings. Wednesday's slide, therefore, worsened a sell-off and pushed the stock back to lows last seen in April during a market sell-off amid tariff scares. For investors, the question is whether the headlines reflect a deterioration in fundamentals or just near-term noise. Despite the stock's huge decline of about 20% over the last three months, the core business looks incredibly strong. Still, management's recent comments are worth some consideration as investors decide whether this is a good time to buy shares or not. At a Wells Fargo healthcare investor conference this week, Intuitive Surgical chief financial officer Jamie Samath reminded investors that some year-ago demand in Japan was boosted by lingering COVID funds, and that several international markets are now dealing with budget constraints. He also highlighted pricing pressure in China and rising domestic competition. These factors, of course, could negatively affect demand and temper system orders. To help customers navigate tighter budgets, Intuitive plans to lean more on leasing in international markets. Leasing currently only accounts for about 30% to 40% of placements outside the U.S. -- far below the U.S. mix. None of this is new to the surgical-robotics market. But hearing it plainly can rattle a stock after a big multi-year run. Tariffs added to the nerves. Management has previously quantified a roughly 1-point gross-margin headwind from tariffs in 2025, with the final impact dependent on how policies evolve. But Samath said that the impact of tariffs could be higher next year. Investors should keep in mind the sort of company we're talking about here. A slowdown and some margin headwinds are permissible given the company's backdrop of impressive growth. In Q2, Intuitive Surgical's revenue rose 21% to $2.44 billion as worldwide da Vinci procedures increased roughly 17%. Placements of da Vinci surgical systems during the quarter climbed to 395 units, including 180 da Vinci 5s, and the installed base reached 10,488. Non-GAAP earnings per share (EPS) was $2.19, up from $1.78 a year ago. Management also guided for 2025 procedure growth of about 15.5% to 17%, a range that implies continued, though moderating, expansion. These are not the numbers you typically see from a business in trouble. The investment case in Intuitive Surgical still rests on procedure growth, an expanding installed base, and higher-value platforms. Q2's 17% procedure growth and a 14% larger installed base support a resilient annuity stream from instruments and accessories, which made up about $1.47 billion of quarterly revenue. Meanwhile, the da Vinci 5 rollout should drive incremental utilization and mix over time as features are adopted and trade-ins flow through the system. Investors following the medical devices industry will recognize how critical these adoption cycles can be to sustaining growth. The growth stock's valuation, even after its recent pullback, remains premium -- but not unworkable for a durable compounder. At roughly $440, the stock trades near 50 times an annualized run-rate of Q2 non-GAAP EPS ($2.19 x 4). This isn't too bad for a market leader growing as rapidly as Intuitive Surgical is. The flip side, however, is straightforward: if procedure growth slows meaningfully below management's expectations -- or if international pricing pressure intensifies, the valuation multiple has a lot of room to compress. Overall, I'd argue that -- for investors accustomed to buying high-quality growth stocks -- the risk/reward balance is solid after the stock's recent drawdown. One final nuance: Intuitive's management team is notoriously conservative. They consistently highlight risks, often baking in buffers to their outlook. That trait can be frustrating in the moment, but it has also built credibility over decades of execution. Against that backdrop, this week's sober commentary reads more like a noteworthy warning -- not a red flag. For patient investors, this is likely a great time to buy shares of an incredible company with a long runway. Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now\u2026 and Intuitive Surgical wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you\u2019d have $661,268!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you\u2019d have $1,045,818!* Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 1,047% \u2014 a market-crushing outperformance compared to 184% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks \u00bb *Stock Advisor returns as of August 25, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool has a disclosure policy. Intuitive Surgical Stock Has Been Plummeting. Is It Time to Buy? was originally published by The Motley Fool""]"
ISRG,2025-09-08,466.7,470.28,462.62,469.96,
ISRG,2025-09-09,470.0,472.69,464.36,467.54,
ISRG,2025-09-10,467.99,468.04,446.53,449.98,
ISRG,2025-09-11,451.155,463.05,449.75,455.85,
ISRG,2025-09-12,453.19,454.15,448.15,449.68,
ISRG,2025-09-15,449.29,450.58,433.02,433.99,
ISRG,2025-09-16,433.65,437.17,429.72,434.5,
ISRG,2025-09-17,434.6,438.785,430.59,433.67,
ISRG,2025-09-18,435.0,436.33,429.8,435.64,
ISRG,2025-09-19,439.46,440.5,434.74,438.49,
ISRG,2025-09-22,438.12,447.13,433.81,444.55,
ISRG,2025-09-23,444.75,450.985,443.17,447.75,
ISRG,2025-09-24,450.94,451.337,443.55,443.99,
ISRG,2025-09-25,440.39,442.17,433.43,438.12,
ISRG,2025-09-26,441.43,443.455,438.5,441.12,
ISRG,2025-09-29,442.06,443.26,437.765,439.22,
ISRG,2025-09-30,439.0,448.19,438.0,447.18,
ISRG,2025-10-01,447.0,448.31,430.34,438.04,
ISRG,2025-10-02,437.12,443.36,433.01,443.01,
ISRG,2025-10-03,443.845,456.59,443.49,452.35,
ISRG,2025-10-06,459.71,460.3,449.08,449.69,
ISRG,2025-10-07,449.24,451.0,439.47,440.94,
ISRG,2025-10-08,442.305,450.53,439.42,448.09,
ISRG,2025-10-09,447.76,450.29,443.26,443.76,
ISRG,2025-10-10,444.06,446.99,429.25,429.59,
ISRG,2025-10-13,432.43,438.1,430.0,435.73,
ISRG,2025-10-14,430.3,439.205,427.836,436.39,
ISRG,2025-10-15,437.0,440.82,432.78,435.79,
ISRG,2025-10-16,438.47,439.49,433.81,434.62,
ISRG,2025-10-17,437.17,449.09,434.57,446.13,
ISRG,2025-10-20,452.5,461.83,451.35,458.47,
ISRG,2025-10-21,459.47,466.9799,456.31,462.74,
ISRG,2025-10-22,543.0,549.85,522.1656,527.03,
ISRG,2025-10-23,525.37,552.5,525.0845,551.3,
ISRG,2025-10-24,547.625,552.45,541.46,546.51,
ISRG,2025-10-27,544.75,551.63,538.75,551.25,
ISRG,2025-10-28,546.62,552.2,539.0,545.39,
ISRG,2025-10-29,543.0,544.95,534.45,537.59,
ISRG,2025-10-30,534.37,538.0,529.308,529.94,
ISRG,2025-10-31,528.625,538.14,526.2,534.41,
ISRG,2025-11-03,532.055,544.84,527.6016,544.191,
ISRG,2025-11-04,545.09,546.0,535.4,538.82,
ISRG,2025-11-05,538.0,552.0,536.15,548.55,
ISRG,2025-11-06,547.03,548.55,538.07,547.78,
ISRG,2025-11-07,543.24,562.65,541.74,560.0,
ISRG,2025-11-10,560.0,578.3,560.0,576.17,
ISRG,2025-11-11,575.06,579.22,570.5,572.24,
ISRG,2025-11-12,574.13,580.47,569.71,572.45,
ISRG,2025-11-13,566.86,573.3221,561.0,565.65,
ISRG,2025-11-14,559.5,560.02,548.92,549.83,
ISRG,2025-11-17,546.57,554.35,544.11,546.71,
ISRG,2025-11-18,546.055,549.21,538.83,546.77,
ISRG,2025-11-19,544.925,566.86,544.19,564.47,
ISRG,2025-11-20,566.92,574.45,550.0,552.25,
ISRG,2025-11-21,551.165,564.0,548.042,561.65,
ISRG,2025-11-24,562.93,570.77,560.0,568.6,
ISRG,2025-11-25,564.44,580.0,561.29,578.87,
ISRG,2025-11-26,579.85,582.4147,573.75,574.21,
ISRG,2025-11-28,571.41,574.0,568.2737,573.48,
ISRG,2025-12-01,568.99,573.535,566.63,567.37,
ISRG,2025-12-02,568.6,570.75,561.39,567.72,
ISRG,2025-12-03,569.48,571.77,563.04,569.71,
ISRG,2025-12-04,571.98,574.23,564.72,568.63,
ISRG,2025-12-05,569.5,576.88,569.43,575.34,
ISRG,2025-12-08,576.15,576.15,562.67,566.97,
ISRG,2025-12-09,566.5,569.0,557.5,558.13,
ISRG,2025-12-10,557.76,560.05,546.55,555.97,
ISRG,2025-12-11,545.465,553.39,542.71,547.36,
ISRG,2025-12-12,546.0,548.99,537.69,542.32,
ISRG,2025-12-15,546.05,561.62,546.05,559.52,
ISRG,2025-12-16,559.05,559.69,546.1301,554.58,
ISRG,2025-12-17,554.68,561.455,554.0,556.86,
ISRG,2025-12-18,557.29,566.85,557.255,561.85,
ISRG,2025-12-19,561.63,574.57,561.31,572.53,
ISRG,2025-12-22,576.0,583.45,573.295,579.83,
ISRG,2025-12-23,577.135,579.2,573.67621,577.34,
ISRG,2025-12-24,577.34,579.85,575.03,577.15,
ISRG,2025-12-26,578.21,579.4,575.96,577.81,
ISRG,2025-12-29,577.81,580.5,574.215,575.4,
ISRG,2025-12-30,572.21,574.77,570.45,572.63,
ISRG,2025-12-31,572.5,573.28,565.77,566.36,
ISRG,2026-01-02,566.78,567.39,555.4,561.98,
ISRG,2026-01-05,561.15,567.08,558.0,566.37,
ISRG,2026-01-06,565.0,594.54,564.345,592.64,
ISRG,2026-01-07,592.89,603.88,590.8,592.27,
ISRG,2026-01-08,582.685,589.95,582.685,585.08,
ISRG,2026-01-09,587.32,589.58,579.62,586.24,
ISRG,2026-01-12,581.97,582.19,566.8,572.745,
ISRG,2026-01-13,571.45,572.59,556.04,561.82,
ISRG,2026-01-14,533.96,551.0,528.0,546.76,
ISRG,2026-01-15,553.74,553.74,535.69,541.34,
ISRG,2026-01-16,542.0,543.0,532.6301,535.068,
ISRG,2026-01-20,527.0,532.605,525.23,527.26,
ISRG,2026-01-21,527.59,530.05,518.64,523.69,
ISRG,2026-01-22,526.68,532.0,522.74,525.81,
ISRG,2026-01-23,530.0,540.0,521.18,523.99,
ISRG,2026-01-26,523.945,533.97,518.65,528.81,
ISRG,2026-01-27,532.61,535.0,523.54,525.04,
ISRG,2026-01-28,523.91,529.36,520.24,522.04,
ISRG,2026-01-29,521.17,522.0,502.48,507.55,
ISRG,2026-01-30,506.775,511.03,501.385,504.22,
ISRG,2026-02-02,502.0,504.2,496.15,496.56,
ISRG,2026-02-03,495.21,499.0,476.79,478.88,
ISRG,2026-02-04,480.105,481.0,465.689,478.41,
ISRG,2026-02-05,482.78,489.51,475.17,476.32,
ISRG,2026-02-06,482.165,491.65,480.07,488.0,
ISRG,2026-02-09,486.05,493.54,483.9,492.86,
ISRG,2026-02-10,494.22,500.3756,493.5258,495.15,
ISRG,2026-02-11,492.75,500.34,490.66,495.81,
ISRG,2026-02-12,496.12,497.84,475.83,478.6,
ISRG,2026-02-13,480.5,495.57,479.61,485.8,
ISRG,2026-02-17,481.215,495.19,481.215,493.45,
ISRG,2026-02-18,494.1,502.88,490.6401,500.76,
ISRG,2026-02-19,496.49,503.73,495.25,499.53,